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Prologue
Breast cancer is among the most well-known and researched public health 
problems in the world. In the last decades, increasing numbers of women have 
been diagnosed with breast cancer. This has led to an extensive increase in medical 
interventions, mostly in high-income countries (HICs), where more resources and 
infrastructure are available. These medical interventions (e.g., screening, surgery, 
and systemic therapy) have had a positive effect on the chances of surviving breast 
cancer 1,2. Currently, women who are diagnosed with breast cancer in an early 
stage of the disease can reasonably expect to be cured and to have a disease-free 
future 3. Although a diagnosis of breast cancer in HICs is still extremely disturbing 
for patients and their relatives, breast cancer is no longer the death sentence it 
was decades ago. However, for many women living in low- and middle-income 
countries (LMICs), the prognosis still is very poor 1,4. At the same time, the 
incidence of breast and other cancers and the costs for controlling these diseases 
have continued to increase in both LMICs and HICs toward disproportionately 
high levels 5,6. Resource constraints are a major factor in the complex discussion 
on how to best control the breast cancer, which is an ongoing issue that requires 
continual intensive research and collective efforts on a global scale. As part of 
these efforts, this thesis provides information for LMICs on the breast cancer 
control interventions that give the greatest value for money.
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A short history of breast cancer
It is important to set forth a history of breast cancer to understand how human beings 
dealt with breast cancer in the past as well as how some people still perceive breast 
cancer in certain (remote) parts of the world. The history of breast cancer is full of 
attempts to understand the nature of the disease and to control it by physical removal 
(surgery), burning (cautery), cell destruction (chemo and radiotherapy), and therapy 
targeted to cell receptors (bio-modulation) 7. It is also important to note that most 
medical discoveries relating to cancer control were only made in the last decades.
Some of the earliest evidence of cancer can be found among fossilized bone tumors, 
human mummies from ancient Egypt, and ancient manuscripts. The oldest description 
of breast cancer is in the Egyptian Edwin Smith Papyrus, which dates to about 1600 
BC 8. The papyrus describes eight cases of ulcers of the breast that were treated by 
cauterization with a tool called the “fire drill.” Egyptian physicians wrote also that there 
was no treatment for the mysterious disease 9. It took another 2000 years before the 
disease was given a name, karkinos, the Greek word for crab.
Ancient physicians and medical researchers posited several theories as to the cause 
of breast cancer. The “imbalance of humors” (blood, phlegm, yellow bile, and black 
bile) theory of Hippocrates (400 B.C.) and Galen (200 A.D.) was widely accepted for 
almost two millennia 10,11. Other imagined causes included divine punishment, lack of 
(or too much) sexual activity, physical injuries, fear of breast cancer, and the cessation of 
menstruation. Only in the eighteenth century was the “black bile” of the “imbalance of 
humors” theory replaced with “lymph” in the understanding of breast cancer. Infectious 
diseases were quite common in the eighteenth century, and numerous new theories 
as to the cause of breast cancer were then proposed, ranging from inspissated milk, 
trauma, personality type, exposure to bad air, and infection 7. 
In the nineteenth century, when improvements in sanitation and infectious disease 
control increased the lifespans of women, breast cancer became more common, 
and the disease then received increased attention from the medical community 
12. This led to the first successful method for treating breast cancer, surgical removal 
of lymph nodes, breast tissue, and chest muscle (together with the widespread usage 
of disinfectant and sterile gloves). While surgical removal of ulcers was proposed by 
Hippocrates in the Greek era (400 B.C.) and was done in the Islamic world (the tenth 
through twelfth centuries), surgery was considered barbaric in European Christendom 
(the fifth through fifteenth centuries) 7. Around 1882, surgeon William Stewart Halsted 
began performing and perfecting mastectomies 4. Halsted’s mastectomies were invasive, 
requiring the removal of breasts, lymph nodes, and underlying muscle, and this radical 
procedure often left patients with long-term pain and disability.
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Almost a century later, the lumpectomy was introduced in the 1970s, a much 
less invasive surgical procedure that removed only the cancerous tumor and the 
surrounding affected tissue 11. In 1985, breast cancer patients receiving a lumpectomy 
followed by radiation treatment were found to have equal survival outcomes to those 
undergoing a more invasive mastectomy 13. Around this time, chemotherapy also 
became available. Chemotherapy could also be used to shrink tumors before surgery 
as well as to treat metastasized cancer and prevent recurrences after surgery. Many 
other medical interventions were introduced during the twentieth century, including 
hormonal therapies, staging systems, mammography, breast reconstruction following 
surgery, and new diagnostic methods (e.g., magnetic resonance imaging, sentinel lymph 
node biopsy, frozen section) 14. 
In the past three decades, scientists have experimented with combinations of 
treatments to improve the outcomes of breast cancer patients. This has led to a better 
understanding of the disease and to the development of less invasive, more targeted 
treatments and new options to diagnose and manage the disease (see Controlling 
breast bancer below). Despite these advances, however, breast cancer remains an 
important health problem, and one that continues to require intensive research and 
intense discussions on how to best control it.
Clinical manifestation and staging of breast 
cancer
Initially, breast cancer may not cause any symptoms. A lump may be too small for a 
woman to feel or to cause any noticeable changes. In some cases, the first noticeable 
symptom of breast cancer is a new lump or mass in the breast or thickened breast 
tissue that can be detected by a woman or a doctor. A lump that is painless, hard, and 
has uneven edges is more likely to be cancerous. However, cancers can be tender, soft, 
and rounded, and thus it is important for women to have anything unusual checked by 
a physician.
According to the American Cancer Society, any of the unusual changes in the breast 
shown in the figure below can be a symptom of breast cancer (Figure 1).
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Figure 1. Symptoms of breast cancer
Source: the American Cancer Society 15.
However, these changes are most often related to less serious conditions that are 
not cancerous, such as infections or cysts. Invasive breast cancer is diagnosed in only 
about one in 20 women who go to their physicians with breast cancer symptoms 
16,17, although this number generally depends on the level of awareness of signs and 
symptoms in the population.
In countries with well-established breast cancer screening programs, abnormal breast 
changes are often found by a screening mammogram, leading to further testing. 
However, up to 15% of women eligible for screening are diagnosed with a cancerous 
breast mass not detected by the mammogram (mammographically occult disease), and 
another 30% are found to have a breast mass in the interval between mammograms 
(interval cancers). Therefore, regardless of the availability of a breast cancer screening 
program, women should be generally aware of the early signs of breast cancer 
described above.
If breast cancer is confirmed through further testing, the extent of the cancer can 
be described by stage. Breast cancer staging is the process of determining how 
widespread the cancer is; it depends on whether the cancer is invasive or non-invasive, 
the size of the tumor, how many lymph nodes are involved, and whether it has spread 
to other parts of the body (metastasis). The staging process usually comprises physical 
examination, biopsy, imaging tests (clinical staging), and surgery (pathologic staging). The 
most commonly used system to describe the stages of breast cancer is the American 
Joint Committee on Cancer’s (AJCC) TNM system, which classifies breast cancers into 
four invasive stages (stages I to IV) (Figure 2).
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Figure 2. The American Joint Committee on Cancer’s (AJCC) TNM staging system
Source: figure created by author.
Breast cancer stage is one of the most important factors in determining the prognosis 
of the disease and the options for treatment. It therefore plays a key role in this thesis.
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Risk factors of breast cancer
The first large-scale case-control study among women with breast cancer was 
performed in 1923 by Janet Lane-Claypon, one of the founders of modern 
epidemiology 18. The aforementioned “imbalance of humors” theory had been 
discarded by this time 19, and this new research identified several breast cancer risk 
factors relating to age at menopause, parity, age at first birth, and duration of lactation 
that are still considered valid today. Since this important epidemiological review, several 
risk factors for breast cancer have been investigated and documented (Table 1). 
However, for the majority of women presenting with breast cancer, it is not possible to 
identify specific risk factors 20,21.
Many of the documented risk factors are linked to estrogens—more specifically, to 
reproductive factors associated with prolonged exposure to endogenous estrogens 22. 
Early menarche, late menopause, and late age at first childbirth are among the most 
important risk factors for breast cancer, while breastfeeding seems to have a protective 
effect 20, 21. Exogenous hormones, such as oral contraceptives and hormonal therapy for 
menopause, cause a small increase in breast cancer risk, and this risk seems to decrease 
once use stops 23. A familial history of breast cancer increases the risk of breast cancer 
by a factor of two or three. Mutations in certain genes (particularly in BRCA1, BRCA2, 
and p53) greatly increase the risk of breast cancer, but these mutations are uncommon 
and only account for a small number of breast cancer cases.
Modifiable risk factors - that is, lifestyle factors, such as alcohol use, obesity, and physical 
inactivity, have also been documented for breast cancer. Danaei et al. reported that 
21% of global breast cancer mortality is attributable to the joint hazard of alcohol 
use, overweight and obesity, and physical inactivity 24. The percentage of attributable 
cancer deaths of these risk factors together differed by almost 10% between low- and 
middle-income countries (LMICs) and high-income countries (HICs) (18% and 27%, 
respectively).
The differences between LMICs and HICs in breast cancer incidence can partly be 
explained by dietary effects in combination with later first childbirth, lower parity, and 
shorter breastfeeding 25. The increasing adoption of a western lifestyle in LMICs is an 
important determinant in the increase of breast cancer incidence in these countries 26.
Chapter 1
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Table 1. Overview of breast cancer risk factors
Risk factor type Relative risk
≥ 4,00
Relative risk
2,00 > 4,00
Relative risk
1,25 > 2,00
Relative risk
≥ 0,80
Sex, age and residence o Female
o Increasing age (>50 years)
o High income country
Family history and genetics o BRCA1 gene
o BRCA2 gene
o ATM or TP53 gene (p53) mutation 
carrier
o Two or more first-degree relatives 
with breast cancer CHEK2 mutation 
carriers
o One first-degree relative
o multiple second-degree relatives 
with breast cancer
Breast conditions o DCIS in same breast
o LCIS
o High breast density
o Atypical deuctal hyperplasia o DCIS in opposite breast
o Proliferate BBD without atypia
Reproductive and menstrual history o Age at first period (<12 years)
o Age at menopause (>55 years)
o Parity
o Four births or more
o Age at first birth <25 years
o Breastfeeding > 12 months 
Endogenous hormones o High circulating levels of oestrogen a o High circulating levels of androgens
o High circulating levels of IGF-1 and 
IGFBP-3 a
Exogenous hormones o Use of contraceptives within past 
10 years
o Use of combined hormone 
replacement therapy
o Use of tamoxifen for more than 
5 years
o Use of raloxifene
Body size and lifestyle behaviors o Height>175 cm a
o BMI>25 kg/m2 a
o Daily intake of 3 or more alcoholic 
drinks
o Obesity b
o Physical inactivity
o Smoking
Medical history or treatment o Radiation treatment for Hodgkin’s 
disease before age 30 years
o History of breast cancer in 
opposite breast
o History of cancer in other organs
o Treatment with high-dose ionising 
radiation
o In utero exposure to DES
Environmental o High-dose ionising radiation, espe-
cially before age 20
o Light at night/shift work
Table adapted from the National Breast and Ovarian Cancer Centre (NBOCC) and printed with their permission 27. DCIS = Ductal carcinoma in situ; LCIS = Lobular carcinoma in situ. BBD = Benign breast disease; IGF= Insuline-like growth factor ; 
IGFBP = Insuline-like growth factor binding protein; BMI = Body mass index; DES = diethylstilbestrol. a Post-menopausal breast cancer only. b Pre-menopausal breast cancer only.
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The global burden of breast cancer
Even though risk factors for breast cancer have been identified and documented 
(as described in the previous section), breast cancer remains a major public health 
problem throughout the world. Among women, it is the most common cancer in both 
HICs and LMICs. It ranks second when both sexes are considered (below lung cancer) 
and accounts for ten percent of all new cancer diagnoses worldwide each year 28. 
Although breast cancer is a very common and recognizable disease throughout the 
world, outcomes of breast cancer patients vary significantly between HICs and LMICs. 
In 2012, an estimated 1.67 million new breast cancer cases were diagnosed worldwide, 
about 25% of all female cancer cases. Of all these new breast cancer cases, about 
883,000 (53%) were diagnosed in LMICs, compared to 794,000 cases in HICs 
(47%) 29. Breast cancer incidence rates vary about fivefold around the world and are 
generally higher in most HICs. However, incidence rates are increasing in countries 
with low rates of the disease 30. As mentioned in the previous section, this can partly 
be explained by dietary effects in combination with later first childbirth, lower parity, 
shorter breastfeeding, and the adoption of a western lifestyle 25. Studies of migrants 
from low-risk to high-risk countries show that incidence rates increase and eventually 
become similar to those among the rest of the population in the new country 23. 
Breast cancer is also one of the most common causes of death from cancer among 
women globally. With 522,000 deaths in 2012, the disease ranks as the fifth-leading 
cause of death from cancer overall. Most women diagnosed with breast cancer in HICs 
can reasonably expect to be cured and enjoy a long life expectancy. Such progress 
has been made possible by screening programs that enable early detection and by 
the use of multiple modality treatments 29. However, in LMICs, under-resourced and 
underperforming health services continually fail to deliver adequate screening and 
treatments, leading to poor outcomes for patients with breast cancer31. This seems to 
be confirmed by the 2012 mortality numbers: with 324,000 deaths, breast cancer was 
still the most frequent cause of cancer death in women in LMICs (62%), but it was the 
second-leading cause of cancer death in HICs (198,000 deaths, 38%) 29. 
The global differences in mortality rates, from 6 per 100,000 in Eastern Asia to 20 per 
100,000 in Western Africa, are less marked than the differences in the incidence rates 
(see Figure 3) 29. This is because of the more favorable survival rates for breast cancer 
in high-incidence countries (lower mortality-to-incidence ratios). The mortality-to-
incidence ratio of breast cancer, which indicates breast cancer survival or case fatality, 
has a worldwide average of 31.1%. However, the differences in the ratios between 
HICs and LMICs are enormous; in the United States and in Africa, these rates are 
18.9% and 49.0%, respectively. The bulk of the high mortality-to-incidence ratios in 
LMICs can be explained by the high proportion of women presenting with breast 
cancer in late stages. Late-stage breast cancer has a poor prognosis and outcome even 
in HICs.
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About 16.6 million Disability Adjusted Life Years (DALYs) were lost because of breast 
cancer worldwide in 2011 32. When considering DALYs lost, breast cancer ranks fifth 
compared to all other cancers and accounts for about 7.5% of all DALYs lost because 
of cancer. About 55% of the global breast cancer burden is currently experienced 
in HICs. The European region accounts for 25.2% of all breast cancer DALYs lost 
worldwide, whereas the African and Eastern Mediterranean regions account for 
9.6% and 8.1%, respectively 32. Although much of the breast cancer burden is still 
experienced in HICs, breast cancer is the top cancer in women worldwide. 
In spite of the numbers provided above and the improved prognosis of breast cancer 
in the last decades, the initial diagnosis of breast cancer is still perceived by many 
patients as a life-threatening event, and more than 35% of these patients experience 
anxiety and depression33. Breast cancer and cancer in general can be equally—if not 
more—distressing for patients’ relatives, greatly affecting their daily functioning and 
their economic situation. 
General introduction 19
1
Figure 3. Incidence and mortality rates in different world regions (2012, age standardized)
Source: GLOBOCAN 29.
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Controlling breast cancer 
The previous section explained that the burden of breast cancer is increasing, 
particularly in LMICs. In these countries, relatively more breast cancer cases are fatal 
(higher mortality-to-incidence ratios) because most of these cases are diagnosed 
in late stages 22. Effective and straightforward options for controlling the disease are 
available and could mitigate much of the breast cancer burden in these countries.
Although some risk reduction might be achieved through controlling breast cancer 
risk factors, these preventive strategies cannot eliminate the majority of breast 
cancers and breast cancer burden throughout the world. A wide range of non-
preventive interventions for breast cancer control exist, particularly in HICs, ranging 
from mammography screening to expensive monoclonal antibody therapy (with 
trastuzumab) for palliation. In LMICs, where breast cancer incidence is relatively low 
and the majority of women are diagnosed in late stages, health systems are generally 
weak, and these countries often have to opt for less advanced breast control strategies.
The aim of breast cancer control is to reduce the incidence and mortality of the 
disease as well as to improve the quality of life with breast cancer 33. A comprehensive 
breast cancer control program involves prevention, early detection, diagnosis and 
treatment, rehabilitation, and palliative care, and should be equitable and make the best 
use of available resources 22. Comprehensive breast cancer control involves all of the 
above-mentioned control components. An overview of non-preventive interventions is 
provided in Table 2, and the most important control components are discussed in the 
following.
Prevention
Prevention aims at eliminating or reducing the exposure to breast cancer risk 
factors and could eventually have an impact in reducing the incidence of breast and 
other cancers in the long term. Preventive control strategies include the promotion 
of a healthy diet, physical activity, and the control of alcohol intake, overweight, and 
obesity. Some women who are at higher breast cancer risk (often genetic) prefer to 
remove their breasts as a preventive action. As mentioned, lifestyle choices may not be 
sufficient to eliminate the majority of breast cancers in the world. Future preventive 
strategies may improve this and could involve genetic testing to individualize patient 
treatment or techniques to repair or replace harmful genes before breast cancer 
occurs. 
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Table 2. Interventions along the continuum of care to control breast cancer (prevention excluded)
Control component Sub-component Intervention options purpose
Early detection Breast health awareness
(education ± self-examination)
o Outreach
o Basic awareness raising media campaign (BAR)
o Mass awareness raising media campaign (MAR)
Early diagnosis through recognition of early signs and 
symptoms in symptomatic populations
Opportunistic screening /
Population-based screening
o CBE combined with usual diagnostic test
o CBE combined with FNA
o Analogue mammography
o Digital mammography
o Three-dimensional mammography 
o MRI*
o Ultrasound*
o Full field ultrasound*
o Tactile imaging*
o VOC breath tests*
o Tomosynthesis*
o Breast Computerized Tomography*
o Multistatic Array Processing for Radiowave Image Acquisition*
Use of a screening test in a presumably asymptomatic 
population, to identify individuals with an abnormality 
suggestive of cancer
Diagnosis Clinical diagnosis o History
o Physical examination
o CBE
o Surgical biopsy
o FNA 
o Core needle biopsy
o Imaged-guided sampling
o Preoperative needle localization under mammographic or ultrasound guidance
o Stereotactic biopsy
o Sentinel node biopsy
Identify and classify the patient’s condition or disorder 
allowing medical decisions on treatment and prognosis. 
It should help in selecting the most appropriate 
therapy
Pathology diagnosis o Cytology/pathology report
o ER/PR status
o Margin status
o Her-2/neu status
o IHC staining
Lab/radiologic diagnosis o Ultrasound
o Mammogram
o Chest radiography
o Liver ultrasound
o Renal status
o CBC
o Bone scan
o MRI
o PET scan
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Control component Sub-component Intervention options purpose
Treatment Surgery o Total mastectomy
o Modified radical mastectomy
o Breast conserving therapy (lumpectomy)
o Sentinel node biopsy
o Reconstructive surgery
Improve the survival, recurrence rates or quality of life 
of breast cancer patients
Radiotherapy o Post-mastectomy irradiation of the chest wall and regional nodes
o Breast-conserving whole-breast irradiation
Chemotherapy o Classical CMF
o Anthracycline monotherapy or in combination 
o Taxanes 
o Capecitabine
o Growth factors 
o Vinorelbine
o Gemcitabine
o Carboplatin
Hormonal and other therapy o Selective ER Modifiers (tamoxifen)
o Aromatase inhibitors
o Swith therapy
o Trastuzumab
o Fulvestrant
Follow-up and 
rehabilitation
o Imaging
o Fysiotherapy
o Physical examination
Regularly monitor if the cancer might return. Help the 
person regain control over the many aspects of their 
lives as independent and productive as possible
Palliative Pain treatment, inpatient based 
or home based care
o Non-opioid and opioid analgesics
o Bisphosphonates
o Anti emulsives
o Anti depressants
o Boost radiotherapy
o Emotional support
o Inpatient based care
o Home based care
Relief of suffering. Improve quality of life of patients 
and relatives
Source: Table created by author. CBE = Clinical breast examination; FNA = Fine needle aspiration; MRI = Magnetic resonance imaging; VOC = Volatile organic compounds; ER = Estrogen receptors; PR = Progesterone receptors; IHC = Immunohistochemical; 
CBC = Complete blood count; PET = positron emission tomography; CMF = Cyclophosphamide Methotrexate Fluorouracil. *These techniques could, for example, complement mammography in a screening program, or could be used as standalone screening 
techniques; however, they are still controversial.
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Early detection
Early detection aims at finding breast cancer in an earlier stage when treatment is 
more effective. The early detection component of breast cancer control programs can 
comprise a breast health awareness sub-component to raise awareness of the early 
signs and symptoms of breast cancer in symptomatic populations. This may lead to the 
earlier recognition of breast cancer signs and symptoms so that women will seek care 
and have an earlier diagnosis (this is also called “early diagnosis”). However, most early 
detection components include the screening of asymptomatic populations (also called 
“secondary prevention”). Screening was first proposed in the 1950s 34, and it remains 
the cornerstone of breast cancer control for improving breast cancer outcomes and 
survival22. 
Mammography screening is widely used for early detection in HICs and is generally 
applied to women between 50 and 70 years of age. The exact benefits and harms 
of mammography screening are still under discussion, but according to the latest 
discussions, the impact of mammography screening on breast cancer mortality 
in HICs is about 20% to 30% 35–37. The harms of screening include undergoing an 
uncomfortable or painful test, experiencing anxiety, and undergoing biopsies from 
false positive test results. However, the most debated harm of breast cancer screening 
is over-diagnosis (i.e., the detection of harmless tumors that would never have been 
detected in the absence of screening). 
Discussions on the kind of screening test and the population that should be targeted 
for screening are complex. LMICs could, for example, base screening strategies on 
mammography, clinical breast examination (CBE), ultrasound, tactile imaging, or breath 
tests 38, 39. Thus far, however, the impact and practicability of these screening tests are 
largely unknown in LIMCs because of a lack of cancer registries and experimental 
studies 39–42. In addition, the impact of screening and the population that should be 
targeted for screening in LMICs also depend on diversity in epidemiology, socio-
cultural aspects, and the organization of health care. Moreover, the available budget for 
breast cancer control is often limited in LMICs.
Diagnosis, treatment, and palliative care
Irrespective of the early detection intervention used, continuity and quality of actions 
across the entire continuum of care (diagnosis, treatment, follow-up) are essential for 
a well-functioning control program. After the detection of a breast abnormality, the 
next important determinant of an effective control program is the diagnostic process, 
which is a combination of careful assessment and investigations determined by three 
sub-components: clinical diagnosis, pathology tests, and diagnosis by laboratory and 
imaging tests. Various techniques exist throughout these three sub-components; they 
are presented in Table 2. Nevertheless, at the basic level, a clinical exam and biopsy 
(open or FNA), a cytological report of the biopsy (size, grade, TNM, stage), a diagnostic 
imaging test (mammogram or ultrasound), and an ER/PR test are required to select an 
effective treatment strategy 43.
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A wide range of treatment options exist for breast cancer patients. Treatment can 
be divided into three sub-components: surgery, radiation, and systemic treatment 
(chemotherapy and hormonal therapy). Basic-level therapies involve the removal of 
the tumor and lymph nodes (lumpectomy or modified mastectomy), chest wall and 
regional lymph node irradiation, AC (doxorubicin and cyclophosphamide) or CMF 
chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil), and tamoxifen 
for those eligible 43. The choice of the treatment schedule and its effectiveness 
vastly depend on the number of axillary lymph nodes involved, the tumor size, 
histological grade, hormonal receptor status, and the age and preferences of the 
patient 44. In addition, treatment approaches should include psychosocial support and 
rehabilitation. Therapy schedules including taxanes, trastuzumab, aromatase inhibitors, 
or bisphosponates are expensive, and could require much of the available resources in 
LMICs 43.
Palliative care is an approach that improves the quality of life of patients and their 
relatives facing problems with life-threatening diseases. It can prevent or relieve 
suffering through early identification and careful assessment and treatment of pain and 
physical, social, and spiritual suffering 22,33. Palliative care can be provided by inpatient 
care, home-based care, or a combination of the two. Breast cancer patients with 
metastatic disease or with recurrent breast cancer are generally incurable. Depending 
on the localization of the metastases, mastectomy, hormonal therapy, chemotherapy, 
bisphosphonates, or a combination can be used. Most patients also benefit from non-
opioid and opioid analgesics (morphine) and radiotherapy (boost). In most of the 
world, the majority of breast cancer patients present with advanced disease. For them, 
the only realistic treatment option is pain relief and palliative care. Effective approaches 
to palliative care are available and should be considered for implementation. This is 
particularly important for LMICs, in which most breast cancer patients are diagnosed in 
advanced stages of the disease.
With better control of infectious diseases and improvements in living conditions and 
health care, life expectancy has increased worldwide. However, at the same time, the 
number of cancers and other non-communicable diseases has increased significantly 45, 
with breast cancer as the most prevalent female cancer. Much is currently known about 
the causes of breast cancer and effective means by which to control the disease. The 
establishment of national breast cancer control strategies could facilitate controlling the 
disease in LMICs even if their resources are severely limited 33. 
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The economic burden of breast cancer
In the previous sections, the health burden of breast cancer and options for controlling 
the disease were presented. However, breast cancer not only represents a large health 
burden, but also a significant economic burden to societies. Substantial healthcare costs 
are associated with the early detection, diagnosis, and management of the disease. 
Moreover, some patients are unable to continue working, and many rely on friends and 
family for support during treatment or in the last phases of the disease. 
The economic burden of breast cancer is not well documented, and comprehensive 
estimates on the cost of breast cancer are limited. A study by Luengo-Fernandez et 
al. estimated the economic burden of cancer across the 27 EU countries in 2009, 
as well as the specific proportions of the total cost attributable to breast, colorectal, 
lung, and prostate cancers 46. Across the EU population, the healthcare costs of all 
cancers were equivalent to €102 per citizen in 2009. Lung cancer had the highest 
total economic cost (€18.8 billion, 15% of overall cancer costs), followed by breast 
cancer (€15.0 billion, 12%). When the total economic costs for breast cancer (€15.0 
billion) are broken down into their various cost components, healthcare costs account 
for 45% of the total costs for breast cancer (€6.7 billion), productivity losses account 
for 34% (€5.0 billion), and informal care accounts for 21% (€3.2 billion) of the total 
costs for breast cancer. Most interesting is that drugs were the largest component of 
breast cancer healthcare costs (€3.1 billion, 46% of healthcare costs). Moreover, the 
healthcare costs per EU member (per capita) varied greatly for breast cancer, ranging 
between €2 (Malta) and €2,342 (Germany).
The global economic costs of breast cancer were estimated in another study (the 
Economist Intelligence Unit) and were reported in 2009 47. Although the estimates in 
this report cannot be compared with the study of Luengo-Fernandez et al. and are less 
detailed, the estimated global economic costs for breast cancer were US$28.4 billion. 
The healthcare costs accounted for 46% ($13.1 billion) of the total costs, and the non-
direct healthcare costs ($7.6 billion) and productivity losses ($7.7 billion) each account 
for 27% of the total breast cancer costs. One striking feature of the estimated US$28.4 
billion breast cancer costs is that 96% of these global costs were spent by HICs. This 
seems disproportionate since only 15% of the world’s population lives in HICs 47. 
The global economic burden of breast cancer seems substantial in terms of both 
medical and non-medical costs. The medical health care costs attributable to breast 
cancer vary greatly between countries, reflecting differences in total health care 
spending. Non-medical costs, however, seem generally higher (account for more or 
less 55% of all costs) than medical costs. This is possibly because of the reproductive 
age of breast cancer patients: many cases occur in women below 65 years, especially 
in LMICs. These breast cancer cases correspond to relatively high productivity losses of 
ill-health and seeking and undergoing care.
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Breast cancer consumes resources at an astonishing rate and, while high-income 
countries account for 96% of total spending on breast cancer, the impact of the disease 
is felt around the world 47. However, studies on the economic burden of breast cancer 
that consider both healthcare and non-healthcare costs are sparse. Such studies are 
important because they can complement studies on the health burden and support 
decisions on efficient resource allocation for breast cancer control. 
Health economics and cost-effectiveness analysis 
(CEA) for breast cancer control
Given the impact of breast cancer on healthcare costs and the financial constraints 
faced by most LMICs, identifying breast cancer control interventions that can 
significantly reduce the burden of the disease at low costs is extremely important. The 
scientific discipline of health economics connects health with the resources consumed 
in promoting it. The underlying problem with health economics is that people have 
nearly infinite healthcare needs, but there are finite (limited) resources with which 
to satisfy them. Therefore, choices have to be made about which healthcare needs 
are most important and how best to use the available resources. The field of health 
economics attempts to illuminate these choices 48.
A principal analytic tool that is often used within the field of health economics is 
cost-effectiveness analysis (CEA). This method is used to compare different health 
interventions by assessing the gains in health relative to the costs of each intervention. 
CEA supports decision making by identifying the areas of action in which the greatest 
health gains can be achieved within the available budget.
The basic calculation in CEAs involves dividing the cost of an intervention in monetary 
units (e.g., US dollars, Euros, or local currencies) by the expected health gain measured 
in natural units (e.g., number of life-years, Disability Adjusted Life Years (DALYs), or 
Quality Adjusted Life Years (QALYs). The result is summarized in the cost-effectiveness 
ratio (CER) of the intervention and the incremental cost-effectiveness ratio (ICER) of 
the intervention (relative to another intervention). For example, assume that a certain 
breast cancer medicine costs $120 dollars per patient for the entire regimen. Because 
of this medicine, the patient is able to live three years longer. This corresponds to a 
CER of $40 dollars per life-year saved ($40 dollars per LYS). Assume that another 
regimen costs $300 dollars and that patients taking the medicines in this regimen 
generally live six years longer. The CER of this more expensive regimen is then $50 
dollars per life-year saved ($50 dollars per LYS).
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However, in this case, the incremental cost-effectiveness ratio (ICER), which is defined 
as the ratio of the change in the costs of intervention B (compared to alternative 
A) to the change in the effects of intervention B (compared to alternative A) is 
$60 additional dollars per life-year saved ($60 per LYS). The ICER should be used 
to compare the differences between the costs and health outcomes of the two 
alternative interventions since they compete for the same resources. 
These ratios correspond to a pure form of utilitarianism, the concept of maximizing 
health value for the available money. Hence, CEAs provide the clearest and simplest 
way to promote value for money in health and allow comparisons throughout the 
health sector. To use CERs and ICERs to choose what to buy, decision makers must 
determine a maximum willingness to pay for units of health gain (e.g., the World Bank 
has described health interventions that cost less than $100 dollars per life-year saved 
as highly cost-effective for poor countries) unless other criteria are considered to 
justify buying something with relatively poor cost-effectiveness. The calculations of the 
CERs and ICERs by themselves do not monetize the intrinsic value of health 49. 
Various health economic studies on breast cancer screening, genetic testing, drug 
treatments, and follow-up have been conducted and reviewed 50–56. Prior health 
economic studies typically report the costs and effects of an intervention given an 
existing level of control in a specific country and are aimed at a specific group of 
breast cancer patients. For example, many of the CEAs have focused on comparing 
different strategies (e.g., comparing age ranges, screening tests, and screening 
frequencies) for screening in HICs 56. Costs per life-year saved range from $2,450 to 
$14,790 in Europe, and from $28,600 to $47,900 in the United States 49. This indicates 
that the cost-effectiveness of breast cancer interventions varies greatly by country and 
depends on many factors, including disease epidemiology, health care systems, costs, 
and compliance rates. Moreover, the majority of studies have been conducted in HICs 
and cannot be directly translated to low-resource settings.
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Thesis rationale and objective
The sustainability of health care systems and the need to prioritize efficient health 
investments are at the top of many national political agendas. Economic evaluations 
generate essential information to support decisions on alternative health policy 
options. Data on the cost-effectiveness of a particular control strategy are very 
powerful in showing how much health benefit can be obtained for a given investment 
relative to other possible strategies. 
Current information on the cost-effectiveness of breast cancer control interventions 
for LMICs is very limited because most cost-effectiveness studies in this area have been 
conducted in HICs. Considering the differences in incidence rates, age at diagnosis, and 
constrained resources compared to Western populations, LMICs require different 
solutions than the more conventional strategies to control breast cancer. Breast cancer 
control interventions that appear to be cost-effective in HICs may not be cost-effective 
in LMICs even when the lower cost of providing health services is taken into account. 
Therefore, it is necessary to identify breast cancer control interventions in LMICs that 
are effective and efficient in averting deaths and improving quality of life at low costs.
The aim of this thesis is: To provide evidence-based information on the value for 
money of breast cancer control interventions in LMICs, to guide LMICs in planning or 
improving their national breast cancer control programs.
Thus, the specific research question of this thesis is: What is the cost-effectiveness 
of a range of breast cancer control interventions along the continuum of care in a 
number of LMICs? 
To comprehensibly guide LMICs in improving breast cancer control, this thesis also 
focuses on other considerations next to cost-effectiveness.
Unfortunately, it is not possible to include all low- and middle- income countries within 
the scope of this thesis. The LMICs for which cost-effectiveness estimates for breast 
cancer control were assessed in this thesis are Ghana, Mexico, Costa-Rica, India, and 
Peru. These countries were selected on the basis of the national importance of breast 
cancer control as expressed by the Ministries of Health of these countries in addition 
to the interest in cost-effectiveness in these countries.
To understand the approach used throughout this thesis, it is important to first discuss 
the general WHO-CHOICE approach applied and the mathematical model developed 
to analyze the general cost-effectiveness of various breast cancer control interventions. 
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Approach used in this thesis
WHO-CHOICE approach
To allow for meaningful comparisons across different LMICs, the generalized cost-
effectiveness (GCEA) analysis approach proposed by WHO-CHOICE is used in this 
thesis 57. WHO-CHOICE is a program of the World Health Organization that helps 
countries set priorities with consideration for impact and cost-effectiveness 58. The 
WHO-CHOICE tools involve disease models and costing tools, which are preset 
with regional average data (default settings). For a GCEA in a specific country, data for 
epidemiology, intervention impacts, and prices can easily be replaced with data that are 
more appropriate for the country in question. 
The WHO-CHOICE methodology proposes the evaluation of all interventions that 
may be considered policy-relevant, either because they are highly cost-effective or 
highly cost-ineffective. All interventions, including those that are independent and 
those that are mutually exclusive, are compared to a common comparator, which is a 
situation in which the impacts of currently implemented interventions are removed. It 
is commonly designated as the “counterfactual null.” This counterfactual null represents 
a more comparable reference across populations than the current intervention (or 
mix of interventions) used in standard cost-effectiveness analysis. This approach enables 
the comparison of interventions across diseases and populations.
In economic analyses, the costs and benefits are recorded and assessed from a certain 
perspective. The choice of this perspective must be derived logically from the research 
question posited by the country under investigation. WHO-CHOICE usually considers 
an extensive healthcare perspective and generally does not include non-health costs. In 
addition to the cost of interventions as determined from best practice guidelines, this 
perspective includes the costs of administration, training, and program elements 57.
In addition, to interpret CERs and ICERs for choosing what to purchase and what not 
to, decision makers must determine a set of cost-effectiveness thresholds (different 
willingness to pay levels for units of health). WHO-CHOICE denotes an intervention 
as “cost-effective” if it produces a healthy year of life for less than three times the 
gross domestic product (GDP) per capita. If an intervention produces a healthy year 
of life for less than the GDP per capita, it is denoted as “very cost-effective” 57. As 
mentioned before, calculation of the CERs and ICERs by itself does not monetize the 
intrinsic value of health. The maximum willingness to pay per unit of health should be 
determined by local decision makers, and the proposed WHO-CHOICE thresholds 
are rules of thumb that should not be interpreted overly strictly. 
Using the WHO-CHOICE methodology, the impact of a certain intervention on the 
population health of a specific population of interest gives the estimate of effectiveness. 
This effectiveness is applied to a population level model (a tool called PopMod) to 
project the likely impact in Disability Adjusted Life Year (DALYs) over a period of 100 
years. 
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It is of critical importance that the different intervention scenarios are described 
accurately using all essential information to interpret the estimated costs and benefits. 
This includes the strict definition of the treatment pathway for clinical interventions 
as well as which procedures are incorporated and which are not. However, studying 
different interventions in the field of breast cancer immediately reveals a vast number 
of early detection, diagnosis, and treatment options (see Table 2). In recent decades, 
the diagnosis and treatment of breast cancer has become increasingly complex with 
specified diagnoses and tailored treatment combined with surgery, radiotherapy, 
chemotherapy, and hormonal therapy regimens. Although the aim of WHO-CHOICE 
is to include all interventions of interest, it would be impossible to include all possible 
single and mutually exclusive breast cancer intervention scenarios. Therefore, in this 
thesis, intervention scenarios are incorporated that consider AJCC stages I, II, III, and 
IV 59 and conform to the most common clinical practice guidelines  established in 
LMICs 43. Although this is much less specific than the approaches described in many 
diagnostic guidelines or common practices, it offers the possibility of using population-
level data. Moreover, it is in line with the aim of this thesis - to evaluate the cost-
effectiveness of breast cancer control strategies to support national-level decisions. 
Overview of the mathematical modeling approach
Figure 4 represents a simplified sketch of the model used to estimate the cost-
effectiveness of breast cancer interventions. As can be seen in this figure, the 
population modeled includes three categories: the healthy, the sick, and the dead. 
The healthy population (or population at risk) in this model is equivalent to the 
total number of women without breast cancer in the country under study. The sick 
population consists of the number of prevalent and incident breast cancer cases, 
and this category is divided into the four AJCC breast cancer stages (stages I to IV). 
Each AJCC stage in this category has a corresponding health state valuation (HSV, or 
disability weight) and case fatality rate.
The estimated effectiveness of interventions is expressed in terms of changes in case 
fatality rates (treatment interventions), health state valuations (treatment interventions), 
or stage distribution (awareness raising and screening interventions). Interventions are 
implemented for a period of ten years, after which the epidemiological rates return to 
their counterfactual level in the null scenario. As such, modeling a specific intervention 
involves using evidence-based, country-specific data to address the intervention’s 
impact on these factors. 
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Figure 4. Applied breast cancer model
Graphical representation of the model showing the relationships between the different health states through the incidence rates of breast cancer (i
x
 I-IV), 
the different stage specific case fatality rates (f
x
 I-IV), and the background mortality (m
x
). Stage specific relapse rates (r
x
 I-III), to stage IV were used to 
correct the disability weights (HSV I-IV).
Thesis outline
The overarching goal of this thesis is to provide evidence-based information for LMICs 
on the breast cancer control interventions that give the greatest value for money. The 
provision of this information will be presented through various scientific studies over 
eight chapters (Chapters Two to Nine).
In chapter two, a systematic review is presented on previous economic analyses of 
breast cancer control in LMICs. As previously mentioned, the international literature 
on the costs and health effects of breast cancer control focuses mainly on HICs, and 
there is little information on the cost and effectiveness of breast cancer interventions 
in LMICs. This systematic review provides an overview of what economic information 
from LMICs is currently available and discusses the relevant considerations for future 
economic analyses. 
Chapter three discusses the development of a simple model to predict the stage 
distribution of different breast cancer screening alternatives in diverse populations. 
With the scarcity of studies on screening methods in LMICs, it seems difficult to 
estimate the effectiveness of breast cancer screening in LMICs. The developed model 
can assist in estimating the impact of CBE screening and mammography screening in 
LMICs. 
Breast cancer population 
 
 Stage I 
Stage IV 
Death 
Healthy 
population 
(at risk) 
Births 
Stage II 
Stage III 
mx 
ix (I-IV) fx (I-IV) 
HSV (I-IV) 
rx (I-III) 
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In chapter four to seven a number of case studies are presented that provide the 
costs, effects and cost-effectiveness of different breast cancer control options in five 
individual LMICs (Ghana, Peru, Mexico, Costa-Rica, and India). The results of these case 
studies could possibly be used for the development or improvement of national breast 
cancer control strategies in these countries.
In chapter eight, the cost-effectiveness of different cancer control interventions for 
cervical, colorectal, and breast cancer in two different world sub-regions (Southeast 
Asia and Sub-Saharan Africa) are presented. This can guide resource allocation 
decisions in LMICs with relatively similar resources and overall mortality. The study 
provides general insights into the comparative cost-effectiveness of control strategies 
across and beyond individual cancers. 
This thesis also focuses on other considerations than just cost-effectiveness, as cost-
effectiveness is only one of the multiple criteria relevant to priority setting. In chapter 
nine, a multi-criteria decision analysis (MCDA) method specifically for breast cancer 
control is discussed. If we want policy makers to make good use of the results from 
CEAs, other criteria should be considered and assessed simultaneously. MCDA is also 
able to account for all the important considerations relating to equity, feasibility, budget, 
health level, and responsiveness. This last study therefore presents the development of 
a simple MCDA rating tool, which can be used in the priority-setting process. This tool 
may improve the consideration of multiple relevant criteria, including CEA results, to 
support comprehensive breast cancer control strategies in LMICs.
Chapter ten concludes the thesis. In this chapter, the contributions and limitations of 
this thesis are discussed. A number of important next steps in the field of global breast 
cancer control and recommendations for future research are proposed in this chapter.
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A good place to start is where you are now
Sten G Zelle, Rob M Baltussen
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Abstract
Background
To support the development of global strategies against breast cancer, this study 
reviews available economic evidence on breast cancer control in low- and middle-
income countries (LMICs).
Methods
A systematic article search was conducted through electronic scientific databases, 
and studies were included only if they concerned breast cancer, used original 
data, and originated from LMICs. Independent assessment of inclusion criteria 
yielded 24 studies that evaluated different kinds of screening, diagnostic, and 
therapeutic interventions in various age and risk groups. Studies were synthesized 
and appraised through the use of a checklist, designed for evaluating economic 
analyses.
Results
The majority of these studies were of poor quality, particularly in examining costs. 
Studies demonstrated the economic attractiveness of breast cancer screening 
strategies, and of novel treatment and diagnostic interventions.
Conclusions
This review shows that the evidence base to guide strategies for breast cancer 
control in LMICs is limited and of poor quality. The limited evidence base suggests 
that screening strategies may be economically attractive in LMICs – yet there 
is very little evidence to provide specific recommendations on screening by 
mammography versus clinical breast examination, the frequency of screening, or 
the target population. These results demonstrate the need for more economic 
analyses that are of better quality, cover a comprehensive set of interventions and 
result in clear policy recommendations.
Keywords
Breast cancer control, economic evaluation, systematic review, low- and middle-
income countries, cost-effectiveness, noncommunicable diseases.
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Background
Noncommunicable diseases (NCDs) have become increasingly important in low- and 
middle-income countries (LMICs). Once considered a problem only in high-income 
countries (HICs), more and more patients who suffer from cancers and other NCDs 
are now observed in LMICs 1. This is mainly due to the ageing populations and changing 
lifestyles in LMICs 2. The global importance of NCDs has recently been acknowledged 
through the UN Summit on NCDs, held by the UN General Assembly in September 
2011. As highlighted in the summit, the most prominent cause of cancer death among 
women in LMICs is breast cancer, accounting for 269,000 deaths (12.7% of all cancer 
deaths) in 2008 3,4.
In HICs, many efforts have been undertaken to control breast cancer, leading to various 
improvements in breast cancer outcomes 5,6. Strategies for breast cancer control are 
geared towards early detection and early treatment, and although its benefits are still 
open to discussion 7-9, mammography screening has been widely implemented 10-12. In 
these countries, the selection of breast cancer control strategies has often been guided 
by economic analyses, demonstrating the value of alternative interventions 13-16.
In contrast to the established breast cancer control strategies in HICs, breast cancer 
is often neglected in LMICs and control strategies lack evidence-based information 
17-20. Policy-makers in LMICs cannot adopt similar breast cancer control strategies as 
implemented in HICs because most LMICs rely on much smaller budgets, and both the 
costs and effectiveness of control strategies are highly dependent on the population 
characteristics and the functioning of the health system 11,20,21.
Against this background, the present review provides an inventory of economic 
analyses of breast cancer control in LMICs. The paper’s objectives are to present the 
available economic evidence from LMICs and to assess the methodological quality of 
the analyses. This research could improve the evidence base on cost-effective breast 
cancer interventions and could strengthen breast cancer control policy in LMICs.
Methods
Search strategy and selection criteria
In this review, we analyzed publications from the MEDLINE index using PubMed, the 
Web of Science, Scopus, and Google Scholar. We searched the literature using the 
keyword ‘breast cancer’, combined with the keywords: ‘developing countries’, ‘Asia’, 
‘USSR’, ‘Middle-East’, ‘Eastern Europe’, ‘West-Indies’, ‘China’, ‘Russia’, ‘India’, ‘Africa’, or 
‘limited resource’, or combined with: ‘cost-benefit’, ‘cost-effectiveness’, ‘costing’, or ‘cost 
analysis’. Additionally, we searched these indexes using ‘breast neoplasms’, ‘developing 
countries,’ and ‘economics’ in MeSH terms. Our search took place in January 2013, and 
was limited to publications in English. Studies were included only if they concerned 
breast cancer and originated from LMICs as listed by The World Bank 22.
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The selection process is shown in Figure 1. In step 1, articles found by our search in the 
various indexes were merged in a database, which was then corrected for duplications 
(in Google Scholar, because of the large number of articles founds, we screened 
titles until the point that we did not find any further relevant title among the last 500 
screened titles; in total, we screened 800 titles in this database). In step 2 we screened 
the titles of these articles, in step 3 the abstracts and in step 4 the remaining articles 
were read completely. We excluded publications for which no full-text article versions 
were available, or those not published in English. Furthermore, we excluded articles 
that only mentioned costs or cost-effectiveness without presenting original data.
Figure 1. Selection process of analyzed publications
Study characteristics
We documented the following characteristics from the reviewed articles: country or 
region, base year of cost data, study population, and breast cancer stage(s) considered. 
The stage was categorized as stage I to IV according to the American Joint Committee 
on Cancer 23.
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We documented the following methodological characteristics: type of economic 
evaluation –cost analysis or cost of illness analysis, separately reported costs and 
effects, cost-effectiveness analysis, cost–benefit analysis, and cost–utility analysis; study 
design – experimental, observational (cohort, case control, or cross-sectional), model 
based, and other designs; study perspective – non-healthcare perspective (for example, 
productivity loss, travel costs, co-payments), healthcare perspective (for example, 
hospital administration costs, treatment costs), and societal perspective including non-
healthcare and healthcare costs; time horizon; and outcome measure for effectiveness 
(disability-adjusted life years, quality-adjusted life years, life years saved, lives saved, and 
intermediate outcome measures).
The following qualitative characteristics were documented: sources for estimation 
of effectiveness, sources for estimation of resource utilization, discount rates used, 
sensitivity analysis for assumptions, and reported incremental analysis. We classified 
sources for estimation of effectiveness and resource utilization by primary data 
collection (for example, patients, questionnaires), secondary data collection (for 
example, records), literature based, expert opinion, and other. We also noted whether 
discount rates were used on costs, effects, both costs and effects, or not at all.
We also registered the study objective, the evaluated interventions, and the main study 
conclusions for each reviewed article.
Study evaluation
We used an established checklist by Drummond and Jefferson to judge the quality 
of the economic evaluations 24,25. A three-point response scale was added, similar 
to Gerard and colleagues 25, to more specifically grade the quality of each item on 
the checklist. Scores on this scale ranged from 0 (not considered), to 1 (partially 
considered) to 2 (fully considered). A few adjustments to the checklist by Drummond 
and Jefferson were necessary to create a more responsive scoring system for our 
particular set of economic studies. We removed those items that were not applicable 
to any of the reviewed studies (for example, on productivity changes), and combined 
some items that were otherwise putting too much emphasis to certain domains in the 
overall score (for example, on health state valuations and discount rates). The adapted 
checklist is provided in Table 1. We summed up all scores, and compared this with 
the maximum attainable score to calculate the mean quality score of a study (as a 
percentage of the maximum attainable score). We accounted for items that were not 
relevant to the study under scrutiny (for example, studies that studied costs and effects 
in a single year were not criticized for not applying any discount rate in the analyses).
Two reviewers (SGZ and RMB) evaluated each publication for conformance with 
this checklist, and consensus was reached when scores differed. We followed PRISMA 
guidelines for reporting this systematic review.
Chapter 2
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Table 1. Checklist for quality of economic evaluations
Item Fully Partial Not at all Not appropriate
Original checklist 2 points 1 point 0 points NA
Study design
1. The research question is stated
2. The economic importance of the research question is stated
3. The viewpoint(s) of the analysis are clearly stated and justified (relating to a particular decision-making context)
4. The rationale(s) for choosing the alternative programs or interventions which are compared is stated
5. The alternatives being compared are clearly described
6. All relevant alternatives are included
7. The choice of economic evaluation is justified in relation to the questions addressed
Effectiveness estimation
8. The primary outcome measure for the economic evaluation is clearly stated
9. The source(s) of effectiveness estimates used is clearly stated
10. Details of the design and results of the effectiveness study are given (if based on a single study)
11. Details of the methods of synthesis or meta-analysis of estimates are given (if based on multiple studies)
12. Data and methods used to value health states and other benefits are stated and justified.
Cost estimation
14. Indirect non-healthcare costs are included or discussed
15. Quantities of resources are reported separately from their unit costs
16. Methods for the estimation of quantities and unit costs are described and justified.
17. Details of currency of price adjustments for inflation or currency conversion are given
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Item Fully Partial Not at all Not appropriate
Original checklist 2 points 1 point 0 points NA
Analysis
18. Time horizon of costs and benefits are stated
18. Details of any model used are given
19. The choice of model used and the key parameters on which it is based are justified
20. The discount rate(s) is stated
21. The choice of rate(s) is justified
22. Details of statistical tests and confidence intervals are given for stochastic data
23. Sensitivity analysis is performed:
 2) Probabilistic (bootstrap/Monte Carlo)
 1) Deterministic (one way /multiple way)
24. The choice of variables in sensitivity analysis and the range over which these variables are varied is justified
25. Incremental analysis is performed and reported
Interpretation of results
26. Major outcomes are presented in a disaggregated as well as aggregated form
27. The answer to the study question is given
28. Relevant alternatives are compared
29. Conclusions follow from the data reported
30. Conclusions are accompanied by the appropriate caveats such as generalizability, equity, feasibility, and implementation
This checklist was adapted from Drummond and Jefferson 24.
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Results
Search results
The stepwise selection of articles by our selection criteria is presented in Figure 1. 
Our search strategy resulted in a total of 6,816 studies: 679 studies from PubMed, 
328 studies from Web of Science, 5,009 studies from Scopus, and 800 from Google 
Scholar, respectively. In step 1, by merging the results of all individual search strategies 
and excluding duplication, the total number of hits was reduced to almost 4,400. Upon 
screening of titles (step 2), abstracts (step 3) and full texts (step 4), we eventually 
identified 24 articles that met our inclusion criteria.
Study characteristics
Table 2 describes the baseline characteristics of the 24 included studies. We found 
eight studies from Asia, most concerning China, India and Iran. Five studies were on 
a global or sub-regional level, while there were five studies from Africa, three from 
Europe and three from Latin America. A total of 10 studies evaluated breast cancer 
screening in combination with treatment (n = 10), assessing mammography screening 
(n = 9), clinical breast examination (CBE) (n = 3), magnetic resonance imaging 
(n = 1), ultrasound (n = 1), biopsy (n = 1), elasticity imaging (n = 1), and tactile 
imaging (n = 1), respectively 26-36. These studies evaluated a variety of age groups and 
screening frequencies (Table 2). One study reported on a mass-media intervention 
to improve the early detection of breast cancer in Ghana 35. Seven studies evaluated 
only treatment interventions including drug therapy (n = 4), oophorectomy (n = 1), 
radiotherapy (n = 1), and treatment in general (n = 1) 37-42. Other studies examined 
the costs of diagnostic interventions (n = 3) or did not consider a specific intervention 
(n = 2) 43-48.
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Table 2. Characteristics of reviewed studies, ordered by base year of cost data
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Groot and 
colleagues, 
2006 28
World 
sub-regi-
ons
2000 Female population at 
risk, in AfrE, AmroA, 
SearD
All Cost-effective-
ness analysis
Model 
based
Health-
care
100 
years
DALYs Literature 
based
Secon-
dary data 
collection
On both 
costs and 
effects
Yes Yes
Okonkwo and 
colleagues, 
2008 30
India 2001 Female population 
at risk
All Cost-effective-
ness analysis
Model 
based
Health-
care
25 
years
Life years 
saved
Secondary 
data
collection
Secon-
dary data 
collection
On both 
costs and 
effects
Yes Yes
Munshi, 
2009 41
World-
wide
Varying 
from 2002 
to 2007
Breast cancer patients 
in general
All Report on 
costs and 
effects sepa-
rately
Other Health-
care
NA Intermedia-
te outcome 
measures
Literature 
based
Literature NA NA NA
Sarvazyan and 
colleagues, 
2008 32
World-
wide
Varying 
from 2003 
to 2007
Female population 
at risk
All Cost-effective-
ness analysis
Other Not 
stated
1 year Life years 
saved
Literature 
based
Literature NA Yes No
Fonseca and 
colleagues, 
2009 38
Brazil 2005 Hypothetical cohort 
of 64-year-old post-
menopausal women
All Cost-effective-
ness analysis
Model 
based
Health-
care
Life-
time
Life years 
saved
Literature 
based
Expert 
opinion
On both 
costs and 
effects
Yes Yes
Ginsberg and 
colleagues, 
2012 27
Sub-Saha-
ran Africa 
and South 
East Asia
2005 Female population at 
risk, in SearD and AfrE
All Cost-effective-
ness analysis
Model 
based
Health-
care
100 
years
DALYs Literature 
based
Secon-
dary data 
collection
On both 
costs and 
effects
Yes Yes
Salomon and 
colleagues, 
2012 31
Mexico 2005 Female population 
at risk
All Cost-effective-
ness analysis
Model 
based
Health-
care
100 
years
DALYs Literature 
based
Secon-
dary data 
collection
On both 
costs and 
effects
Yes Yes
Pakseresht 
and colleagues, 
2011 48
India 2006/2007 103 women with pri-
mary breast cancer in a 
tertiary hospital
All Cost analysis/
cost of illness
Obser-
vational
Non- 
health-
care
2 years NA NA Primary 
data col-
lection
NA NA NA
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Yazihan and 
Yilmaz, 2006 34
Turkey 2007 Female population 
at risk
All Cost-effective-
ness analysis
Other Health-
care
6 years DALYs Secondary 
data col-
lection
Secon-
dary data 
collection
None No No
Bastani and 
Kiadaliri, 
2012 49
Iran 2008 Patients younger than 
75 with node-positive 
breast cancer
All Cost-utility 
analysis
Experi-
mental
Health-
care
8 
months
QALYs Primary 
data col-
lection
Primary 
data col-
lection
NA No NA
Liubao and 
colleagues, 
2009 39
China 2008 Model cohort of 1,000 
51-year-old operable 
breast cancer patients
All Cost-effective-
ness analysis
Model 
based
Health-
care
Life-
time
QALYs Secondary 
data col-
lection
Secon-
dary data 
collection
On both 
costs and 
effects
Yes Yes
Astim, 2011 36 Turkey 2010 Female population at 
risk older than 30
All Report on 
costs and 
effects sepa-
rately
Model 
based
Health-
care
10 
years
Intermedia-
te outcome 
measures
Secondary 
data col-
lection
Literature Yes No No
Zelle and 
colleagues, 
2012 35
Ghana 2010 Female population 
at risk
All Cost-effective-
ness analysis
Model 
based
Health-
care
100 
years
DALYs Literature 
based
Primary 
data col-
lection
On both 
costs and 
effects
Yes Yes
Bai and collea-
gues, 2012 42
China 2012 Model cohort of 
women aged 51.7, with 
early stage breast can-
cer after lumpectomy
1 
and 
2
Cost-effective-
ness analysis
Model 
based
Health-
care
Life-
time
QALYs Literature 
based
Literatu-
re/expert 
opinion
On both 
costs and 
effects
Yes Yes
Arredondo 
and colleagues, 
1995 43
Brazil Not clear Hypothetical breast 
cancer case
All Cost analysis/
cost of illness
Obser-
vational
Health-
care
NA NA NA Expert 
opinion
NA No No
Boutayeb and 
colleagues, 
2010 37
Morocco Not clear Early-stage breast 
cancer patients in 
Morocco
Not 
clear
Cost-effective-
ness analysis
Obser-
vational
Health-
care
1 year Life years 
saved
Literature 
based
Secon-
dary data 
collection
NA No No
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Denewer and 
colleagues, 
2010 26
Egypt Not clear Female population at 
risk between 25 and 
65 years
All Report on 
costs and 
effects sepa-
rately
Experi-
mental
Health-
care
2 years Intermedia-
te outcome 
measures
Primary 
data col-
lection
Not clear None No No
Guggisberg 
and colleagues, 
2011 46
Cameroon Not clear Women who under-
went FNA in a rural 
hospital
All Report on 
costs and 
effects sepa-
rately
Obser-
vational
Health-
care
5 
weeks
Intermedia-
te outcome 
measures
Primary 
data col-
lection
Not clear NA No No
Kobayashi, 
1988 44
World-
wide
Not clear NA NA Cost analysis/
cost of illness
Obser-
vational
Health-
care
NA Intermedia-
te outcome 
measures
Primary 
data col-
lection
Primary 
data col-
lection
NA NA NA
Love and 
colleagues, 
2002 40
Vietnam 
and China
Not clear Premenopausal Viet-
namese and Chinese 
breast cancer patients, 
considered for surgery
2 Cost-effective-
ness analysis
Experi-
mental
Health-
care
15 
years
Life years 
saved
Primary 
data col-
lection
Not clear On both 
costs and 
effects
No Yes
Mousavi and 
colleagues, 
2008 29
Iran Not clear Female population at 
risk between 35 and 69
All Report on 
costs and 
effects sepa-
rately
Other Health-
care
1 year Life years 
saved
Expert 
opinion
Expert 
opinion
NA No No
Nasrinossadat 
and colleagues, 
2011 47
Iran Not clear 51 patients that under-
went surgical excision 
of nonpalpable breast 
masses
All Report on 
costs and 
effects sepa-
rately
Obser-
vational
Health-
care
3 to 4 
years
Intermedia-
te outcome 
measures
Primary 
data col-
lection
Not clear None No No
Thomas and 
colleagues, 
1999 45
Nigeria Not clear Patients who received 
FNA between 1994 
and 1997
All Report on 
costs and 
effects sepa-
rately
Obser-
vational
Patient NA Intermedia-
te outcome 
measures
Primary 
data col-
lection
Not clear NA NA NA
DALYs = disability-adjusted life years; FNA = fine needle aspiration; NA = not applicable; QALY = quality-adjusted life year.
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The methodological study characteristics of the reviewed studies are presented in 
Table 2. The base year of cost data in the included studies was generally not from 
before year 2000, and could not be identified in eight studies. The majority of studies 
combined both costs and effects in a single cost-effectiveness estimate (n = 13), and 
the majority of these were based on mathematical models (n = 9). Most studies used 
a healthcare perspective (n = 19), and only one study included non-healthcare costs 
48. Studies used a time horizon varying between 5 weeks and the lifetime of the study 
population. Most reviewed studies used intermediate outcome measures (that is, 
clinical effects n = 8), life years saved (n = 6), or disability-adjusted life years (n = 5) as 
their main effectiveness outcome, while quality-adjusted life years were less frequently 
used (n = 3).
Study quality
Table 2 summarizes the quality of the included studies, as indicated by the percentage 
score. The quality of all studies ranges from 23 to 86%. Studies by Ginsberg and 
colleagues, Zelle and colleagues, and Bai and colleagues had the highest total average 
scores, and these were all modeling studies 27,35,42.
Studies generally scored poorly on the domain ‘estimation of costs’, at an average 34% 
of the maximum obtainable score across all studies. The average score for ‘study design’ 
was 73%, while the quality of the domains ‘estimation of effectiveness’, ‘analysis’, and 
‘interpretation of results’ was scores as 70%, 51%, and 68%, respectively.
Study findings
As described earlier, most studies evaluated breast cancer screening in combination 
with treatment. Studies in Mexico, Poland, Turkey identified mammography screening 
as a cost-effective intervention 31,33,34,36, whereas studies in India, Ghana and Egypt 
found other strategies (such as CBE screening or mass-media awareness raising) to 
be economically more attractive (Table 3) 26,30,35. Sarvazyan and colleagues proposed 
another breast cancer screening option: tactile imaging as an alternative to several 
other interventions 32.
Econom
ic analyses of breast cancer control in low- and m
iddle-incom
e countries: a system
atic review
492
Table 3. Interventions compared, study objectives, and main study conclusions of reviewed articles
Authors Interventions compared Study objective Conclusions by authors
Groot and colleagues, 
2006 28
Combinations of individual stage I to IV treatment and 
an extensive mammography screening control program
To assess the cost-effectiveness of breast cancer 
control that covers various interventions in different 
settings
Stage I treatment and an extensive screening control 
program are the most cost-effective interventions
Okonkwo and collea-
gues, 2008 30
Mammography screening, CBE screening among diffe-
rent age groups and in different frequencies
To assess which screening program should be imple-
mented in India
CBE screening in India compares favorably with mam-
mography screening in developed countries
Munshi, 2009 41 Several treatment interventions To present pragmatic cost-saving breast cancer 
interventions
Intelligent use of knowledge about the disease can help 
us to exploit new techniques for maximum therapeutic 
gain with minimal investment
Sarvazyan and collea-
gues, 2008 32
CBE, mammography, ultrasound, magnetic resonance 
imaging, biopsy, elasticity imaging, tactile imaging
To review the diagnostic accuracy, procedure cost, and 
cost-effectiveness of currently available techniques for 
breast screening and diagnosis.
Tactile imaging has the potential to provide cost-effec-
tive breast cancer screening and diagnosis
Fonseca and collea-
gues, 2009 38
Anastrozole vs. tamoxifen in the adjuvant setting of 
early breast cancer
To determine cost-effectiveness of anastrozole, compa-
red with tamoxifen, in the adjuvant treatment of early 
stage breast cancer in Brazil
Anastrozole is more cost-effective than tamoxifen in 
the adjuvant setting of early breast cancer
Ginsberg and collea-
gues, 2012 27
Stage 1 to 4 treatment individual, treatment of all 
stages, biennial mammography screening 50 to 70 vs. 
null scenario
To determine the cost-effectiveness of 81 interventions 
to combat breast, cervical and colorectal cancer at 
different geographic coverage levels, to guide resource 
allocation decisions in LMICs
For breast cancer, although expensive, mammography 
screening in combination with treatment of all stages is 
cost-effective in both regions (I$2,248 to 4,596/DALY). 
Treating early-stage breast cancer is more cost-effec-
tive than treating late-stage disease
Salomon and collea-
gues, 2012 31
Stage 1 to 4 treatment individual, treatment of all sta-
ges, screening (annual CBE >25 years + mammography 
annual >50 years + mammography biennial >40 to 49 
years) vs. null scenario
Analyze the cost-effectiveness of 101 intervention 
strategies directed at nine major clusters of NCDs 
in Mexico (including breast cancer), to inform decisi-
on-makers
Treatment of all stages is cost-effective and treatment 
of early stages is more cost-effective than late stage 
treatment. Nationwide screening has an incremental 
CEA of I$22,000/DALY and is potentially cost-effective
Pakseresht and collea-
gues, 2011 48
NA To estimate the expenditure audit of women with 
breast cancer in a tertiary hospital in Delhi
Expenditure on treatment for breast cancer depends 
on many factors, including the size and stage of the 
cancer, the woman's age, use of private hospitals and 
insurance
Szynglarewicz and 
Matkowski, 2011 33
Polish screening program costs vs. other countries To show preliminary results of the Polish screening 
program
Population-based mammographic screening conforming 
the European quality standards is cost-effective even 
for middle-income countries
Yazihan and Yilmaz, 
2006 34
Mammography screening in age group 50 to 69 vs. 
treatment only
To determine the efficiency of resource usage in mam-
mography screenings and the impact on breast cancer 
stages in Turkey
Mammography screening is economically attractive for 
Turkey
Chapter 2
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Authors Interventions compared Study objective Conclusions by authors
Bastani and Kiadaliri, 
2012 49
Docetaxel, doxorubicin and cyclophosphamide (TAC) 
vs. 5-fluorouracil, doxorubicin, cyclophosphamide 
(FAC) in node-positive breast cancer patients
To evaluate the cost-utility of TAC and FAC in no-
de-positive breast cancer patients
FAC was a dominant option versus TAC in the short 
term. In this study, TAC resulted in higher costs and 
lower QALYs over the study period
Liubao and colleagues, 
2009 39
AC (doxorubicin/cyclophosphamide) vs. TC (docetaxel/
cyclophosphamide)
To estimate the cost-effectiveness of AC (doxorubicin/
cyclophosphamide) vs. TC (docetaxel/cyclophospha-
mide)
TC appears to be more effective and more costly 
than AC. TC may be viewed as cost-effective using the 
general WHO threshold
Astim, 2011 36 Annual and biennial mammography screening in various 
age groups (40+, 45+, 50+, 55+, 60+ years) vs. no 
screening
To evaluate the cost-effectiveness, optimal minimum 
age and screening interval for a screening program in 
Turkey
Results of the simulation suggests that women over 
40 in Turkey should be screened by mammography 
biennially
Zelle and colleagues, 
2012 35
Treatment interventions, biennial mammography and 
CBE screening interventions, awareness raising inter-
ventions, palliative care interventions vs. null scenario
To analyze the cost, effects and cost-effectiveness of 
breast cancer control interventions in Ghana, and 
identify the optimal mix of interventions to maximize 
population health
Both screening by clinical breast examination and mass 
media awareness raising seem economically attractive 
interventions ($1,299 and $1,364/DALY). Mammograp-
hy screening is not cost-effective
Bai and colleagues, 
2012 42
Radiotherapy vs. no radiotherapy after surgery To assess the cost-effectiveness of additional radi-
otherapy for women with early breast cancer after 
breast-conserving surgery
In health resource-limited settings, the addition of 
radiotherapy is a very cost-effective strategy (–$420/ 
QALY) in comparison with no-radio therapy in women 
with early breast cancer
Arredondo and colle-
agues, 1995 43
Case management costs for infrastructure, human 
resources, laboratory, hospital stay, drugs, mastectomy, 
disposable material, curing material
To develop a system for monitoring costs of case ma-
nagement for each disease (breast cancer, cardiac calve 
disease and enteritis and bronchopneumonia)
Economic analyses hold important information for 
decision-making
Boutayeb and collea-
gues, 2010 37
Three chemotherapy regimes, AC, AC + taxanes, AC + 
taxanes + trastuzumab
To evaluate the total cost of chemotherapy in early 
stage breast cancer
Moroccan health authorities need to devote between 
US$13.3 to 28.6 million to treat women by chemothe-
rapy every year
Denewer and collea-
gues, 2010 26
CBE-based screening with selective mammography vs. 
no screening
To evaluate the disease pattern of screen-detected 
cancers and determine the effectiveness of CBE-based 
screening
CBE-based screening with selective mammography is 
feasible, effective and improves the results of breast 
cancer management in Egypt
Guggisberg and colle-
agues, 2011 46
On-site FNA clinic vs. shipping of specimens To assess the feasibility of an on-site cytopathology 
clinic in a rural hospital in Cameroon
Cytopathology (FNA) is a reliable alternative for tissue 
diagnosis in low-resource settings
Kobayashi, 1988 44 Costs and performance of breast echography in diffe-
rent institutions
To analyze the economics and cost performance of 
breast echography in various institutions
The best cost performance, internationally, can be 
achieved by mechanical and real-time electronic linear 
scanners
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Authors Interventions compared Study objective Conclusions by authors
Love and colleagues, 
2002 40
Adjuvant oophorectomy and tamoxifen vs. oophorec-
tomy and tamoxifen for recurrence after observation.
To evaluate costs, disease-free and overall survival 
after surgical oophorectomy and tamoxifen in pre-
menopausal Vietnamese women with operable breast 
cancer
Vietnamese and Chinese women with hormone 
receptor-positive operable breast cancer benefit from 
adjuvant treatment with surgical oophorectomy and 
tamoxifen
Mousavi and collea-
gues, 2008 29
Mammography screening in age groups 35 to 69 and 50 
to 69 and no screening
To decide whether mammography screening should 
be established in Iran or whether other options are 
needed
Benefits of other policies than mammography scree-
ning need to be explored
Nasrinossadat and 
colleagues, 2011 47
Methylene blue dye injections vs. wire localization To report experience in marking nonpalpable breast 
masses by injection of methylene dye
Marking with methylene blue dye is a simple, effective 
and low-cost method for localization of nonpalpable 
breast masses
Thomas and collea-
gues, 1999 45
FNA cytology vs. surgical tissue biopsy To assess the results and limitations of a Nigerian FNA 
clinic
FNA cytology can help improve the management and 
cost of care of patients with palpable masses
CEA = cost-effectiveness analysis; CBE = clinical breast examination; DALY = disability-adjusted life year; FNA = fine needle aspiration; LMIC = low- and middle-income country; NCD = noncommunicable disease; QALY = quality-adjusted life year; WHO 
= World Health Organization. 
Table 4. Summary of quality assessment and domain scores of reviewed studies
Authors Scored domains Summary scores
Study 
design
Effectiveness 
estimation
Cost
estimation
Analysis Interpretation 
of results
Number of 
items scored
Sum of 
scores
Total average 
score
Groot and colleagues, 2006 28 Score granted 12 7 6 16 9 29 50 1.72
% of maximum (domain) score 86% 88% 75% 89% 90% 86
Okonkwo and colleagues, 2008 30 Score granted 12 6 3 16 10 28 47 1.68
% of maximum (domain) score 86% 100% 38% 100% 100% 84%
Munshi, 2009 41 Score granted 7 7 0 1 4 21 19 0.90
% of maximum (domain) score 50% 70% 0% 50% 40% 45%
Sarvazyan and colleagues, 2008 32 Score granted 7 7 0 1 4 21 19 0.90
% of maximum (domain) score 50% 70% 0% 50% 40% 45%
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Authors Scored domains Summary scores
Study 
design
Effectiveness 
estimation
Cost
estimation
Analysis Interpretation 
of results
Number of 
items scored
Sum of 
scores
Total average 
score
Fonseca and colleagues, 2009 38 Score granted 14 6 1 13 10 28 44 1.57
% of maximum (domain) score 100% 100% 13% 72% 100% 79%
Ginsberg and colleagues, 2012 27 Score granted 12 8 8 18 10 29 52 1.79
% of maximum (domain) score 86% 100% 75% 89% 100% 90%
Salomon and colleagues, 2012 31 Score granted 12 6 5 14 8 29 45 1.55
% of maximum (domain) score 86% 75% 63% 78% 80% 78%
Pakseresht and colleagues, 2011 48 Score granted 7 1 4 3 5 15 20 1.33
% of maximum (domain) score 88% 50% 50% 75% 63% 67%
Szynglarewicz and Matkowski, 
2011 33
Score granted 5 3 2 1 5 24 15 0.625
% of maximum (domain) score 88% 50% 50% 75% 63% 33%
Yazihan and Yilmaz, 2006 34 Score granted 12 0 3 2 5 28 22 0.79
% of maximum (domain) score 86% 0% 38% 13% 50% 40%
Bastani and Kiadaliri, 2012 49 Score granted 13 8 4 7 8 25 40 1.6
% of maximum (domain) score 93% 100% 50% 70% 80% 80%
Liubao and colleagues, 2009 39 Score granted 13 7 4 16 10 29 50 1.72
% of maximum (domain) score 93% 88% 50% 89% 100% 86%
Astim, 2011 36 Score granted 9 5 3 8 7 28 32 1.14
% of maximum (domain) score 64% 63% 38% 50% 70% 57%
Zelle and colleagues, 2012 35 Score granted 14 7 7 14 10 29 52 1.79
% of maximum (domain) score 100% 88% 88% 78% 100% 90%
Bai and colleagues, 2012 42 Score granted 13 8 5 18 8 29 52 1.79
% of maximum (domain) score 93% 100% 63% 100% 80% 90%
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Authors Scored domains Summary scores
Study 
design
Effectiveness 
estimation
Cost
estimation
Analysis Interpretation 
of results
Number of 
items scored
Sum of 
scores
Total average 
score
Arredondo and colleagues, 1995 43 Score granted 10 NA 1 0 7 18 18 1.00
% of maximum (domain) score 71% NA 13% 0% 70% 50%
Boutayeb and colleagues, 2010 37 Score granted 12 4 4 1 6 25 27 1.08
% of maximum (domain) score 86% 50% 50% 13% 60% 54%
Denewer and colleagues, 2010 26 Score granted 10 4 0 2 5 25 21 0.84
% of maximum (domain) score 71% 50% 0% 20% 50% 42%
Guggisberg and colleagues, 2011 46 Score granted 3 6 2 1 5 25 24 0.96
% of maximum (domain) score 21% 75% 25% 13% 50% 35%
Kobayashi, 1988 44 Score granted 4 4 1 NA 3 19 12 0.63
% of maximum (domain) score 29% 67% 13% NA 30% 32%
Love and colleagues, 2002 40 Score granted 9 6 1 10 8 27 34 1.26
% of maximum (domain) score 64% 100% 13% 63% 80% 63%
Mousavi and colleagues, 2008 29 Score granted 5 1 0 1 3 22 10 0.45
% of maximum (domain) score 36% 25% 0% 13% 30% 23%
Nasrinossadat and colleagues, 
2011 47
Score granted 75 5 0 0 5 25 17 0.68
% of maximum (domain) score 50% 63% 0% 0% 50% 34%
Thomas and colleagues, 1999 45 Score granted 7 4 0 0 6 21 17 0.81
% of maximum (domain) score 50% 67% 0% 0% 60% 41%
Total average domain score (%) 73% 73% 70% 34% 51% 68%
If items were not applicable (NA) for a reviewed paper, the maximum obtainable (domain) score was reduced with 2 points per item. 
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Studies evaluating treatment interventions typically favored the novel interventions. 
Anastrozole was more cost-effective than tamoxifen in a Brazilian study 38, 
oophorectomy and tamoxifen after recurrence was shown to be favorable in 
Vietnamese and Chinese patients 40, additional radiotherapy after breast-conserving 
surgery was very cost-effective in China 42, and chemotherapy consisting of a 
docetaxel and cyclophosphamide regimen was more attractive compared with an 
doxorubicin and cyclophosphamide regimen also in Chinese patients 39. There was 
only one study with a negative suggestion for the novel and more costly intervention 
docetaxel, doxorubicin, cyclophosphamide, as compared with the more conventional 
5-fluorouracil, doxorubicin, dyclophosphamide regime 49.
Studies that only assessed costs and did not include effectiveness estimates, reported 
on costs of breast cancer for patient management in Brazil (US$1,646 per patient) 43, 
and the costs of patient expenditure (US$242 per patient) in India 48.
The three studies evaluating diagnostic interventions demonstrated the economic 
attractiveness of inexpensive interventions; that is, fine-needle aspiration cytology and 
methylene blue dye injections 45-47. These interventions could be especially relevant for 
diagnosing breast cancer in rural settings and settings with low resources.
Discussion
This study shows that there is limited economic evidence on breast cancer control 
in LMICs. Only 24 economic evaluation studies were found in this review, and their 
quality was generally poor. Furthermore, the study populations were very diverse, as 
most studies examined different kinds of screening and therapeutic interventions in 
various age and risk groups. Owing to this poor availability, quality, and comparability, 
we conclude that the economic evidence base to guide strategies for breast cancer in 
LMICs is currently insufficient.
Our review raises a few discussion points. First, there is mixed evidence on the 
economic attractiveness of mammography screening. Studies in Mexico, Poland and 
Turkey demonstrate the intervention to be cost-effective, whereas studies in India, 
Ghana, and Egypt suggests that other forms of screening – for example, by CBE – 
provide more value for money. The evidence base is too small to generalize these 
findings to other LMICs, and to draw general conclusions. Also, most of the studies 
evaluating therapeutic interventions seem to favor the more novel – and often more 
expensive – therapy. These findings may be explained by many reasons, including 
the higher effectiveness of the novel interventions but possibly also the association 
between funding sources and pro-industry conclusions 50.
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Second, in general, we found that the quality of the reviewed articles was poor. The 
majority of studies failed to score at least 50% on every domain (‘study design’, 
‘estimation of effectiveness’, ‘estimation of costs’, ‘analysis’, and ‘interpretation of results’). 
These domain scores further show that most emphasis was given to the design of 
the studies and the interpretation of results, whereas costs, in particular, were poorly 
evaluated. This calls for better adherence of studies to methodological standards 
for economic analyses, or the development of such standards specifically for breast 
cancer research. Future studies could be improved by using a checklist, and through 
transparent reporting of the items in checklists 25,51.
Third, the current evidence base leaves many LMICs with the difficult task of 
extrapolating results from other countries. The transferability of economic evaluations 
across countries is complicated, as clinical practice patterns, healthcare systems, and 
cultural and ethical practices differ across countries 52,53. Standardized ways of adopting 
economic evaluations, with the help of available checklists and guidelines 24,25,51,54-58, 
may improve this lack of transferability. Alternatively, modeling studies could play an 
important role in extrapolating results from one context to another. Modeling studies, 
however, rely on the availability of costing and effectiveness data, and this emphasizes 
the need for more primary data collection on these aspects in LMICs. With data from 
such studies, researchers would not have to continue to rely on sensitivity analyses or 
extrapolating cost estimates from data in HICs. National cancer registries, mortality 
databases, hospital registries, and accessible publications would be essential for 
providing such information 59.
Fourth, and closely related, we generally advocate the use of modeling studies 
in the economic analysis of breast cancer control in LMICs. In addition to their use 
in the extrapolation of study findings, they generally appeared to be of high quality, 
are sufficiently flexible to include important methodological characteristics such 
as adequate time horizon, and seem also appropriate to evaluate a broad array of 
interventions across different groups.
Fifth, the most adopted type of economic evaluation was cost-effectiveness analysis, 
using a healthcare perspective and life years saved as the primary outcome. Although 
cost-effectiveness analyses using a healthcare perspective contribute very important 
information, productivity losses for patients suffering from breast cancer – and most 
probably other NCDs – can be substantial 60,61. So far, there is no methodological 
consensus on estimating productivity loss and the cost of illness can vary greatly 
between different costing approaches (for example, human capital approach vs. friction 
cost approach) and also between gender, age and the type of job of patients 62. Further 
research should account for economic and social characteristics of the population 
under study, and should try to investigate productivity losses. Additionally, life years 
saved may be a less appropriate outcome when palliative or preventive interventions 
are investigated, and the use of disability-adjusted or quality-adjusted life years may be 
more appropriate.
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Sixth, there is currently very little economic evidence on less established interventions 
such as tactile imaging, awareness raising, CBE screening, or preventive and palliative 
interventions. Economic studies, especially in LMICs, should aim to evaluate these 
interventions more often (and thereby including broad target populations) and they 
have the potential to be economically attractive 26,30,32,35.
Finally, guidance in decision-making and recommendations for implementation are 
generally underemphasized in economic evaluations. By reflecting on the health system 
characteristics of the particular country and considering them in implementation 
recommendations, economic evaluations could improve their use in breast cancer 
policy development.
Our study has a number of limitations. Primarily, the number of articles reviewed is 
very limited, possibly the result of our search strategy. Besides a possible publication 
bias – studies with negative outcomes are less likely to be published – we searched 
only for articles published in English. This may explain the relatively small number of 
articles found, for instance, from Spanish-speaking regions or from countries where 
there is less emphasis on publishing research (for example, in Africa). Also, the studies 
included in our review vastly differed with regard to their methodology, objectives, 
characteristics, and study populations and hence are difficult to compare. In addition, 
our quality assessment of the reviewed articles was based on a checklist that gives 
highest scores to a full reporting of all domains. However, short reports in the form of, 
for example, editorials may not include all these details but may nevertheless be valid 
for the goals they serve. Hence, the scores for these studies should be interpreted 
with caution.
Conclusions
To conclude, our findings indicate that research on the costs and cost effectiveness 
of breast cancer control in LMICs is still in its infancy. The limited evidence base 
suggests that screening strategies may be economically attractiveness in LMICs – 
yet there is very little evidence to provide specific recommendation (on screening 
by mammography vs. CBE, the frequency of screening, or the target population). 
These results demonstrate the need for more economic analysis that are uniform, of 
better quality, cover a comprehensive set of interventions and result in clear policy 
recommendations.
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Abstract
Objective
To provide proof of concept for a simple model to estimate the stage shift as a 
result of breast cancer screening in low- and middle-income countries (LMICs). 
The amount of stage shift is an essential early detection indicator and an important 
proxy for the performance of screening programmes and their possible further 
impact. Our model could help LIMCs to decide on which control strategies to 
implement.
Methods
We assessed the concept of our model in three steps. First, we calculated the 
proportional performance rates (i.e. index number Z) based on 16 screening 
rounds of the Nijmegen Screening Program (384,884 screened women). Second, 
we used linear regression to assess the association between Z and the amount of 
stage shift observed in the  Nijmegen Screening Program. Third, we hypothesized 
how Z could be used to estimate the stage shift as a result of breast cancer 
screening in LMICs. 
Results
Our results show that stage shifts can be estimated by the proportional 
performance rates (Zs) using linear regression. The Zs, calculated for each screening 
round, are highly associated with the observed stage shifts in the Nijmegen 
Screening Program (Pearson’s R: 0.798, R square: 0.637). 
Conclusions
This study confirms that our model can predict the stage shifts in the Nijmegen 
Screening Program, and provides proof of concept that the model could 
theoretically be applied to other settings with different characteristics. This is a 
promising and important step, although our model should not be straightforwardly 
used to estimate the impact on mortality and further research should investigate 
the extrapolation of our model to other settings. As the amount of stage shift is 
an essential screening performance indicator, our model could provide important 
information on the performance of breast cancer screening programmes that 
LMICs consider implementing.
Key words
Breast cancer control, breast cancer screening, stage distribution, developing 
countries, model, validation, CBE screening.
Abbreviations used
LMICs: low- and middle-in income countries; CBE: clinical breast examination; MSTs: 
mean sojourn times; AJCC: American Joint Committee on Cancer; DCIS: ductal 
carcinomas in situ.
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Introduction
Breast cancer is the most frequent cancer occurring in women in both high-income 
countries (HICs) and low- and middle-income countries (LMICs), and is a major public 
health problem. In 2008, breast cancer was responsible for about 485,000 deaths 
worldwide, and some 1.4 million new cases of breast cancer were diagnosed. The 
incidence and mortality rates of breast cancer are expected to rise in most LMICs in 
the coming years 1.
Early detection, followed by appropriate treatment, is currently the most effective 
strategy to reduce breast cancer mortality 2. Mammography screening is widely used 
for early detection in high income countries (HICs) and is generally applied to women 
aged between 50 and 70 years. Although the benefits and harms of mammography 
screening are still being debated, the impact of mammography screening on breast 
cancer mortality in HICs seems to be about 20% to 30% 3-5.
LMICs could also establish early detection strategies based on mammography 
screening or perhaps clinical breast examination (CBE) screening 6. So far, however, 
the impact and practicability of screening strategies in LMICs is largely unknown due 
to a lack of cancer registries and experimental studies 6-9. In addition, extrapolating 
the impact of screening programs from Western populations to populations in LMICs 
is not a straightforward process due to the diversity in epidemiology, socio-cultural 
aspects, and the differences in the organization of health care systems. 
While actions to control breast cancer seem essential in LMICs, it is not easy to make 
well-informed decisions on how to control the disease in these countries. For this 
reason, we propose a simple model to assess the performance of different modalities 
of breast cancer screening in LMICs and possibly their further impact. The model 
estimates the shift in the proportion of early vs. late stage breast cancers (i.e., stage 
shift) based on the expected performance rates in the screened population. Although 
the amount of stage shift cannot be straightforwardly linked to breast cancer mortality, 
it can be regarded as an important proxy for the performance of early detection 
programmes 8, 10-16. Particularly in LMICs where the stage distribution of newly 
diagnosed breast cancer cases is often poor, the amount of stage shift is an essential 
performance indicator that could help LIMCs to decide on which breast cancer control 
programmes to implement.
The objective of this study was to provide a proof of concept for our model, to explain 
the model parameters and assumptions and to provide an example of its application 
to a LMIC. Our model is based on data from the Nijmegen Screening Program 17 
and established screening theories 18, 19. The model can assess the stage shift related to 
mammography and clinical breast examination (CBE) screening with different screening 
frequencies and age groups, relies on accessible data 20, and could be easily adopted in 
LMICs. The model could provide important information for LMICs on the potential 
performance and further impact of a breast cancer screening program.
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Methods
Our model requires three steps to estimate the shift in the proportion of early vs. 
late stage breast cancers (i.e., stage shift) related to mammography screening. Firstly, 
we calculate the proportional performance rates (i.e. index number Z) based on 
observations from the Nijmegen Screening Program 17, 21
.
 Secondly, we assess the 
association of Z and the amount of stage shift observed in the Nijmegen Screening 
Program. Thirdly, we hypothesize how Z could be used to estimate the stage shift as a 
result of breast cancer screening in other countries. 
Step one – calculating the detection rates and ”Z”
This step involves calculating the age-specific proportional detection rates (5-year 
age groups) 18
.
 These detection rates will then be used to calculate Z, a theoretical 
measure for the proportion of screen-detected breast cancers out of the total 
number of incident breast cancer cases per year (proportional performance rate) 
in a certain area or country. We hypothesize that Z, which accounts for the local 
screening and population characteristics, can be used to estimate the stage shift (shift 
in the proportion of early vs. late stage breast cancers), and can thus predict screening 
performance.
Mathematical framework 
We used the following parameters to calculate proportional performance rates; 
targeted age groups, age-specific incidence, frequency of screening, age-specific mean 
sojourn times, age-specific sensitivity of the test, age-specific attendance rates, and age-
specific population (Box 1). These parameters are explained in more detail below and 
in Appendix A, and relate to each other according to equations 1 through 4. These 
equations were adopted from Duffy et al 18
.
 and adjusted for the addition of the 
parameters attendance, coverage by invitation, and the fraction of prevalent screens 
(i.e., A, C and ps) in equations 2 and 3. The summation of proportional performance 
rates of each 5-year age group will eventually result in a Z,  (Equation 4). 
Predicting the stage shift as a result of breast cancer screening in low- and middle-income countries: a proof 
of concept
67
3
Box 1. Parameters used
Equation 1: Detection rate at prevalent (first) screens (P);
Equation 2: Detection rate at incident (subsequent) screens (Q); 
Equation 3: Total 1-year detection rate (T);
Equation 4: Proportional performance rate (Index number Z);
Estimates of input parameters
Most parameters used to calculate Z are true observations from the Nijmegen 
Screening Program. Detailed information on the Nijmegen Screening Program was 
retrieved from the department for Health Evidence of the RadboudUMC, Nijmegen. 
Essential information on this screening program has been recorded since 1975, 
including the age-specific target groups, attendance, referrals, incident and prevalent 
screens, and invitation intervals 21, 22
.
 The observed age-specific variables from each 
Nijmegen screening round (incidence [I], sensitivity of mammography [Sm], frequency 
[r], attendance [A], fraction of prevalent screens [ps]), were used in our equations to 
calculate Z for each screening round (n=16) (Table 1). 
Parameters: 
MST = Mean sojourn time of mammography (MST1) or CBE (MST2) 
S = Sensitivity of mammography (Sm) or CBE (Scbe) 
r = Screening frequency 
λ = Transition rate from preclinical to clinical disease (1/MST) 
I = Background incidence in situation without screening 
A = Attendance rate 
C = Coverage by invitation rate 
ps= Fraction of prevalent screens 
Z = Proportional performance rate (Index number) 
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Not all parameters could be derived from the Nijmegen Screening Program. The mean 
sojourn times (MST1, MST2) and the sensitivity of CBE screening (Scbe) were based 
on the international literature 16, 18, 23-28
.
Other unobserved parameters, such as the sensitivity of mammography (Sm) in age 
groups that were not included in the Nijmegen Screening Program, were derived from 
an assumed parameter distribution (Table 1). More detailed information on these 
parameters can be found in Appendix A. For the unobserved parameters that were 
predominantly based on the literature and were used in our model (MST1, Sm), we 
performed univariate sensitivity analyses.
Table 1. Average age-specific parameters over 16 screening rounds (1975-2005)
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0-14 19.13% - - - - - - -
15-19 6.96% - - - - - - -
20-24 7.28% 0.04% 0.92 2.99% 1.16 0.80 0.31 - 0.58 0.00
25-29 7.51% 0.23% 0.87 7.28% 1.35 0.78 0.36 – 0.68 0.00
30-34 7.56% 0.91% 0.84 13.36% 1.57 0.75 0.42 - 0.79 0.00
35-39 7.33% 1.94% 0.82 17.55% 1.83 0.72 0.49 – 0.92 0.54
40-44 6.89% 3.79% 0.82 32.28% 2.13 0.69 0.57 – 1.07 0.36
45-49 6.32% 5.69% 0.82 43.84% 2.48 0.64 0.66 - 1.24 0.47
50-54 5.88% 7.10% 0.82 53.16% 2.89 0.60 0.77 - 1.45 0.18
55-59 5.37% 7.51% 0.82 60.82% 3.37 0.55 0.90 - 1.68 0.08
60-64 4.83% 8.49% 0.80 67.24% 3.92 0.50 1.05 - 1.96 0.08
65-69 4.27% 9.80% 0.76 72.70% 4.56 0.44 1.22 – 2.28 0.10
70-74 3.75% 9.43% 0.70 77.39% 5.31 0.37 1.42 – 2.66 0.08
75-79 3.06% 10.65% 0.60 81.47% 6.19 0.31 1.66 - 3.09 0.09
80-84 2.16% 10.83%  0.47 85.05% 7.21 0.23 1.93 - 3.60 0.09
85-89 1.17% 9.81% 0.30 88.21% 8.39 0.19 2.25 – 4.19 0.00
90-94 0.43% 8.29% 0.08 91.03% 9.77  0.15 2.62 – 4.88 0.00
95+ 0.10% 5.49% 0.00† 92.83% 10.87 0.13 2.92 - 5.42 0.00
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Step two - relating the calculated Z with the shift in breast cancer stage 
distribution
The second step relates the calculated Z, with the stage shift (i.e., the proportion of 
early vs. late stage breast cancers) as observed in the population of the Nijmegen 
Screening Program. For stage distribution, we followed the American Joint Committee 
on Cancer (AJCC) definition of cancer stages 29
.
 We outline our main assumptions 
below and explain the use of a linear regression model to assess the relationship 
between Z and the stage shift.
Hypothesis on stage shift – equal Z’s, equal stage distributions
Our main hypothesis is that the calculated Z is related to the magnitude of the stage 
shift (i.e., the shift in the proportion of early vs. late stage breast cancer). If Z is related 
to these stage shifts, it can be used to estimate the potential stage shift of a certain 
breast cancer screening program that a LMIC considers for implementation. Figure 1 
illustrates a hypothetical example of a country where no screening is applied and in 
which the current stage distribution is poor (about 25% of breast cancers detected 
in early stage [stages I and II]) 30
.
 When breast cancer screening is implemented, we 
expect a shift in stage distribution with more breast cancer patients presenting in the 
early stages I and II (85%) by following the experience from the Nijmegen Screening 
Program. The extent of this stage shift depends on the local screening and population 
characteristics, which are included in calculating Z. 
We hypothesize that a country with an equal Z, as calculated in the Nijmegen 
Screening Program (i.e., equal proportional performance rates), will arrive at the same 
stage distribution as observed in the Nijmegen Screening Program (i.e., equal Z’s - 
equal stage distributions). By adjusting the screening and population characteristics 
corresponding to the country under evaluation, we can calculate the countries’ Z, and 
hence the extent of stage shift in this country when screening is applied (Figure 1). 
Linear regression
We hypothesize that Z is linearly associated with the shift in breast cancer stage 
distribution (i.e., the proportion of early vs. late stage breast cancers). We use linear 
regression to predict the proportion with early stage breast cancer in the population 
(y), with Z as a single predictor (i.e., y = intercept + ß-coefficient * Z). 
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Figure 1. Hypothetical stage shift assumptions 
When Z1 and Z2 are equal, both screening programmes perform equally well and the stage distribution is expected to be the same.
Step three – interpretation and use of regression coefficients 
In the last step, we will use the linear regression model, but adjust the regression 
coefficients according to the conditions of a particular LMIC. 
Adjusting regression coefficients to the context of a particular country
The linear regression model and its coefficients can be used to estimate the stage 
shift for a given Z. As explained above, we hypothesize that a country with a Z equal 
to that observed in the Nijmegen Screening Program will also have the same stage 
distribution as observed in the Nijmegen Screening Program (equal Z’s - equal stage 
distributions). However, the countries’ current stage distribution is likely different from 
the stage distribution in which the Nijmegen Screening Program started. The current 
stage distribution is represented by the intercept of our regression model. This means 
that the intercept of our regression model can vary by country, and we need to 
adjust the ß-coefficient according to these different intercepts. When the country has 
a Z equal to the Nijmegen Screening Program, the ß-coefficient should theoretically 
change to arrive at the same stage distribution. By changing the intercept (e.g., based 
on the current stage distribution of a country) while leaving the stage distribution 
unchanged, we can estimate the adjusted ß-coefficient for that country.
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Results
Step one – calculating the detection rates and “Z” of the Nijmegen 
Screening Program
A total of 384,884 women were screened during the period from 1975 to 2005, and 
the breakdown of screening indicators and outcomes are presented in Table 2. The 
average attendance rate of this entire period was about 65%, with lower attendance 
rates during the period from 1979 to 1991 (attendance <60%). During this period, 
the targeted age groups for screening were relatively high. Of those who were 
screened, about 1% (0.95%) were recalled for further diagnosis and about one-third 
of these referred women were diagnosed with invasive breast cancer (0.36% of those 
screened). Of all screened women, about 0.06% were diagnosed with non-invasive 
carcinomas (DCIS), representing 15% of all screen-detected carcinomas (invasive 
and non-invasive). Over the entire screening period, 489 interval carcinomas were 
diagnosed in the participating women, representing about one-third (32%) of the total 
carcinomas that were found in the target population. The interval carcinomas also 
determined the screening sensitivity of roughly 65% for the entire screening period. In 
1981, 1985, 1987, and 1989, the screening sensitivity was less than 55%. 
Table 2 shows the estimated Z’s per screening round in relation to the actual observed 
outcomes from the Nijmegen screening dataset. These Z’s equal the proportional 
performance rates (Equation 4 in the methods section) and were calculated using 
the observed age-specific outcomes from the Nijmegen screening dataset. The start 
of the screening programme in 1975 and 1977 is represented by high Z’s  (99% and 
67%, respectively) and high actual observed outcomes (95% and 93% in early stages, 
respectively).
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Table 2. Observed screening outcomes (1975-2005) of the biennial Nijmegen Screening Program 
1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 Total/
Average
Round no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 16
Age groups targeted 36-65 38+ 40+ 42+ 40+ 40+ 40+ 40+ 45-70 47-70 49-70 49-70 49-75 49-75 49-75 49-75 N.A.
Women in target 
group
23,210 30,547 29,003 28,034 29,977 30,595 30,196 28,954 26,380 17,925 15,600 16,200 19,124 19,414 19,881 19,844 384,884
Women invited 23,210 30,547 29,003 28,034 29,977 30,595 30,196 28,954 26,380 17,925 15,600 16,200 19,124 19,414 19,881 19,844 384,884
Coverage by invita-
tion (C)
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
Women screened 19,703 19,786 16,632 15,111 16,173 16,484 16,483 15,222 13,203 12,613 11,249 11,726 13,205 14,189 14,913 15,183 241,875
% prevalent screens 
(ps)
100% 20.49% 3.72% 2.54% 18.87% 8.88% 8.21% 3.07% 2.25% 2.51% 3.15% 14.03% 14.96% 16.24% 13.78% 12.76% 15.34%
 Attendance rate (A) 84.89% 64.77% 57.35% 53.90% 53.95% 53.88% 54.59% 52.57% 50.05% 70.37% 72.11% 72.38% 69.05% 73.09% 75.01% 76.51% 64.65%
Recalled 254 192 134 127 105 87 86 97 91 84 91 138 172 124 289 236 2,307
% recalled 1.29% 0.97% 0.81% 0.84% 0.65% 0.53% 0.52% 0.64% 0.69% 0.67% 0.81% 1.18% 1.30% 0.87% 1.94% 1.55% 0.95%
Invasive screening 
carcinomas
66 67 48 40 45 44 45 51 51 48 34 52 71 59 71 73 865
% invasive 0.33% 0.34% 0.29% 0.26% 0.28% 0.27% 0.27% 0.34% 0.39% 0.38% 0.30% 0.44% 0.54% 0.42% 0.48% 0.48% 0.36%
Non-invasive 
screening carcinomas 
(DCIS)
9 8 9 8 11 17 6 10 10 8 10 5 12 7 12 11 153
% non-invasive 
(DCIS)
0.05% 0.04% 0.05% 0.05% 0.07% 0.10% 0.04% 0.07% 0.08% 0.06% 0.09% 0.04% 0.09% 0.05% 0.08% 0.07% 0.06%
Interval carcinomas 32 35 30 35 26 34 41 42 28 22 16 24 33 27 35 29 489
Screening sensitivity 
(S)
67.35% 65.69% 61.54% 53.33% 63.38% 56.41% 52.33% 54.84% 64.56% 68.57% 68.00% 68.42% 68.27% 68.60% 66.98% 71.57% 63.74%
Cancers in women 
not invited)
69 50 51 58 51 53 70 71 84 67 91 99 118 110 119 103 1264
Programme sensi-
tivity
39.52% 44.08% 37.21% 30.08% 36.89% 33.59% 28.85% 31.10% 31.29% 35.04% 24.11% 29.71% 31.98% 30.10% 31.56% 35.61% 33.17%
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1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 Total/
Average
Stage I 69% 63% 52% 41% 47% 36% 38% 42% 35% 43% 38% 43% 42% 43% 37% 47% 45%
Stage II 26% 31% 32% 41% 42% 43% 46% 42% 38% 40% 46% 40% 39% 42% 46% 40% 40%
Stage III 4% 6% 13% 17% 12% 21% 14% 15% 24% 15% 16% 15% 18% 14% 16% 12% 15%
Stage IV 1% 1% 4% 0% 0% 0% 3% 1% 3% 2% 0% 1% 1% 1% 0% 1% 1%
% in early stage 95% 94% 83% 83% 88% 79% 83% 85% 73% 83% 84% 84% 81% 85% 83% 88% 84%
Index Z* 0.95 0.86 0.34 0.26 0.32 0.29 0.26 0.27 0.26 0.40 0.36 0.36 0.40 0.42 0.36 0.40 0.41
Screening sensitivity = (invasive screening carcinomas/[invasive screening carcinomas + interval carcinomas]); Programme sensitivity = (invasive screening carcinomas/[invasive screening carcinomas + interval carcinomas + cancers in women not invited]); 
Stage I to IV: breast cancer stages are based on AJCC staging atlas.29 N.A. = not applicable.
*Index Z was calculated according to formulas as described in our methods section.
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Step two - relating the calculated Z with the shift in breast cancer stage 
distribution
The estimated Z’s start to decrease in 1979 and remain at the same level until 1993, 
with some fluctuations. The observed outcomes during this same period, however, 
remain relatively high, which indicates a low correlation between Z and observed 
outcomes during these screening rounds. Nevertheless, the overall linear correlation 
between the Z’s and the observed outcomes over the entire screening period (1975-
2005) is significant (Pearson’s r = 0.798). The results of our simple linear regression 
model are visualized in Figure 2. Our selected model has an explained variance (R 
square) of 0.637 and can estimate the proportion of breast cancers early stage (y) 
using Z with the following equation: y =0.761 + 0.202 * Z (p=0.000).
Figure 2. Correlation of ‘Z’ and the percentage of early stage cases of screening rounds 1975–2005 and the 
corresponding regression function (values per round are presented in Table 2)
Step three – interpretation and use of regression coefficients 
Our results show that the proportional performance rates (Z’s) are associated with 
stage shifts, and can therefore be used to estimate the stage shift (proportion of early 
vs. late breast cancer stages) as a result of breast cancer screening. In order to calculate 
the stage shift corrected for the current stage distribution of a country (i.e., different 
intercepts), the ß-coefficients will change according to the values in Table 3. Based 
on this table, countries could use the ß-coefficient depending on their current stage 
distribution. This ß-coefficient could then be used to estimate the stage shift resulting 
from a screening program based on the regression function and the calculated Z.  A 
hypothetical example on how our model can be applied in a LMIC is available in the 
next section.
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Table 3. Regression coefficients under different starting conditions
Intercept Regression coefficient (ß) Proportion in early stage (y) Confidence interval (CI) of estimate*
0.7500 0,2270 y = 0.75 + 0.2270 x Z ± 0.0611
0.7000 0,3404 y = 0.70 + 0.3404 x Z ± 0.0611
0.6500 0,4539 y = 0.65 + 0.4539 x Z ± 0.0611
0.6000 0,5674 y = 0.60 + 0.5674 x Z ± 0.0611
0.5500 0,6809 y = 0.55 + 06809 x Z ± 0.0611
0.5000 0,7944 y = 0.50 + 0.7944 x Z ± 0.0611
0.4500 0,9079 y = 0.45 + 0.9079 x Z ± 0.0611
0.4000 1,0213 y = 0.40 + 1.0213 x Z ± 0.0611
0.3500 1,1348 y = 0.35 + 1.1348 x Z ± 0.0611
0.3000 1,2483 y = 0.30 + 1.2483 x Z ± 0.0611
0.2500 1,3618 y = 0.25 + 1.3618 x Z ± 0.0611
0.2000 1,4753 y = 0.20 + 1.4753 x Z ± 0.0611
0.1500 1,5888 y = 0.15 + 1.5888 x Z ± 0.0611
0.1000 1,7022 y = 0.10 + 1.7022 x Z ± 0.0611
The proportion of breast cancer cases diagnosed in stage I and II in a particular country where no screening is in place can be interpreted as the intercept. 
*95% confidence interval based on ± 2x standard deviation.
Application of our model, example Colombia
The Ministry of Health (MoH) of Colombia, a middle-income country, is interested in 
providing an organized breast cancer screening programme as part of their national 
cancer control strategy. The country faces an increase of breast cancer incidence, with 
most women arriving in late stage (15%, 30%, 35%, 20% in stage I to IV respectively) 
having a vast impact on their budget for cancer treatment. The country is particularly 
interested in a biennial mammography screening or biennial CBE screening program, 
for women aged 40 to 65. The MoH would like to know the impact of these two 
screening options, in terms of stage shift, over a period of 10 years.
Step 1
Colombian population registers are used for populating our model 31, and incidence 
information is obtained from GLOBOCAN 20. These GLOBOCAN incidence rates 
are increased with an overall rate of 3% per year, and projected over their documented 
population to calculate the age-specific number of incident cases (I). The MoH of 
Colombia assumes that the sensitivity (S) of both mammography and CBE screening 
is generally 10% lower compared to the Nijmegen Screening Program, because of 
the relatively undertrained radiologists and practitioners They also expect the overall 
attendance to be about 10% lower (A) but assume no differences in natural history 
of the disease (MST, A). The number of prevalent screens (ps), those women that are 
eligible for their first screening round, is calculated from the population register. 
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The original parameters provided in table 1 were adjusted according to these local 
differences and, for a biennial screening frequency (r=2), the country estimates five 
index numbers (Z) (one for each screening round). The calculations of Z for the first 
two screening rounds (2010, 2012) are provided in table 4, using the formula’s for P, Q, 
T and Z. 
Step 2 and 3
Next, the Zs of all screening rounds (2010, 2012, 2014, 2016, 2018) are used to 
estimate the proportion of early vs. late breast cancer stages, according to the 
regression coefficients in table 3. As the current breast cancer condition of Colombia 
can be characterized by 45% of the patients presenting in early stage (15 % stage 
I + 30% stage II), the MoH uses the regression coefficients corresponding to the 
45% intercept (0.9349). Hence, the regression formula is defined by: y =0.45 + 
0.9349*index Z. The proportions of early breast cancer stages per screening round 
(y) can now be estimated using this regression formula. These estimations (Zs and 
percentage of early stage cases) are presented in Table 5. 
Besides the proportions of early breast cancer stages, Table 5 also presents 
rough estimates of the possible stage distributions as a result of the two screening 
programmes. Further explanation on this optional calculation (Step 4) is provided in 
Appendix B.
Sensitivity analysis on parameter assumptions
Whereas most of the parameters used in our proposed model are based on actual 
observations, we investigated different mathematical functions for our key unobserved 
parameters in the Nijmegen Screening Program. These unobserved parameters are 
the age-specific mean sojourn times  for mammography (MST1), and the sensitivity of 
mammography (Sm) in age groups that were not targeted by the program (i.e., under 
age 30 years and above age 75 years). The overall impact of varying these functions 
on our regression model can be found in Appendix Table C1. When using a logistic 
or S-curve function for MST1 (model B, E and F), the explained variance (R square) 
of our regression model is relatively high. For sensitivity (Sm), a combined S-curve 
and inverse function (model F) results in the highest R square. In our selected model, 
we therefore used a logistic function for estimating MST1, and combined an S-curve 
and inverse function for estimating mammography sensitivity (Sm). Age-specific mean 
sojourn times and sensitivity for CBE screening (MST2, Scbe), could not be analyzed 
in a sensitivity analysis because CBE screening is not part of the Nijmegen Screening 
Program and therefore observations are lacking.
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Table 4. Estimated index numbers (Z) for Colombia for (first two screening rounds only) 
Screening 
ages
Popu-
lation33
Inci-
dence20
Attendance 
rate (A)*
Sensitivity 
(S) mammo-
graphy*
Mean Sojourn 
Time (MST)  
mammography
Sensiti-
vity (S) 
CBE
Mean So-
journ Time 
(MST)  CBE
Fraction of
prevalent 
screens (ps)
P
mammo-
graphy
P CBE Q mam-
mography
Q CBE Index Z 
mammo-
graphy
Index Z 
CBE
2010, first screening round
0-14 5,877 - NA NA NA NA NA NA
14-39 8,959 636 NA NA NA NA NA NA
40-44 1,606 707 0.74 0.30 2.13 0.71 1.07 1 334 394 0 0
45-49 1,459 909 0.74 0.41 2.48 0.64 1.24 1 676 533 0 0
50-54 1,237 985 0.74 0.49 2.89 0.58 1.45 1 1,031 613 0 0
55-59 971 892 0.73 0.56 3.37 0.53 1.68 1 1,234 579 0 0
60-64 735 744 0.72 0.62 3.92 0.48 1.96 1 1,294 499 0 0
65-69 549 717 NA NA NA NA NA NA
70-74 409 688 NA NA NA NA NA NA
75+ 957 1,545 NA NA NA NA NA NA
∑ 22,759 ∑ 7,822 ∑ 4,568 ∑ 2,618 ∑ - ∑ - ‘Z’= 0.584 ‘Z’= 0.335
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Screening 
ages
Popu-
lation33
Inci-
dence20
Attendance 
rate (A)*
Sensitivity 
(S) mammo-
graphy*
Mean Sojourn 
Time (MST)  
mammography
Sensiti-
vity (S) 
CBE
Mean So-
journ Time 
(MST)  CBE
Fraction of
prevalent 
screens (ps)
P
mammo-
graphy
P CBE Q mam-
mography
Q CBE Index Z 
mammo-
graphy
Index Z 
CBE
2012, second screening round
0-14 5,794 - NA NA NA NA NA NA
14-39 9,108 666 NA NA NA NA NA NA
40-44 1,616 732 0.68 0.30 2.13 0.72 1.07 0.398 138 163 87 109
45-49 1,523 977 0.67 0.41 2.48 0.65 1.24 0 0 274 247
50-54 1,320 1,082 0.66 0.50 2.89 0.59 1.45 0 0 380 282
55-59 1,069 1,011 0.65 0.56 3.37 0.53 1.68 0 0 414 267
60-64 806 841 0.63 0.62 3.92 0.48 1.96 0 0 379 222
65-69 602 809 NA NA NA NA NA NA
70-74 439 760 NA NA NA NA NA NA
75+ 1,139 1,895 NA NA NA NA NA NA
∑ 23,414 ∑ 8,773 ∑ 138 ∑ 163 ∑ 1,533 ∑ 1,289 ‘Z’= 0.190 ‘Z’= 0.157
P: Detection rate at prevalent screens ( ). Q: Detection rate at prevalent screens   Total 1-year detection rate T = . Proportional performance rate Z = . Screened age groups are 40 to 64 with biennial interval. * These parameters were reduced with 10% of 
the original values listed in Table 1.
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Table 5. Interpretation of index numbers (Z) using our proposed model for Colombia
Year of
screening
‘Z’
mammo-
graphy
Outcome of model* Estimate of stage shift as 
a result of mammography 
screening
Rough estimate of stage 
distribution as a result 
of mammography scree-
ning**
‘Z’ 
CBE
Outcome of model* Estimate of stage shift as a 
result of CBE screening
Rough estimate of 
stage distribution as a 
result of mammography 
screening**
% of cases
in early 
stage (I &II)
% of cases
in late stage
(III &IV)
I II III IV % of cases
in early 
stage (I &II)
% of cases
in late stage
(III &IV)
I II III IV
Before screening 45% 55% 15% 30% 35% 20% Before screening 45.0% 55.0% 15% 30% 35% 20% 
2010 0.584 (0.45 + 0.9079*0.58) 
= 0.9766
97.3% 2.3% 54% 44% 2% 1% 0.335 (0.45 + 0.9079*0.335) 
= 0.7541
75.4% 24.6% 41% 34% 16% 9%
2012 0.190 (0.45 + 0.9079*0.190)
= 0.6225
62.2% 37.8% 34% 28% 25% 13% 0.147 (0.45 + 0.9079*0.147) 
= 0.5835
58.3% 41.7% 32% 26% 27% 15%
2014 0.186 (0.45 + 0.9079*0.186) 
= 0.6189
61.9% 38.1% 34% 28% 25% 13% 0.142 (0.45 + 0.9079*0.142) 
= 0.5789
57.9% 41.1% 32% 26% 27% 15%
2016 0.180 (0.45 + 0.9079*0.180) 
= 0.6134
61.3% 38.7% 34% 28% 25% 14% 0.136 (0.45 + 0.9079*0.136) 
= 0.5734
57.3% 42.7% 32% 26% 28% 15%
2018 0.220 (0.45 + 0.9079*0.220) 
= 0.6497
65.0% 35.0% 36% 29% 23% 12% 0.156 (0.45 + 0.9079*0.156) 
= 0.5916
59.2% 40.8% 33% 27% 27% 14%
*Screened age groups are 40 to 64, with biennial screening interval. **Allocation of proportion in stage I & II: 0.55 (stage I), 0.45 (stage II). Allocation of proportion in stage III & IV: 0.65 (stage III), 0.35 (stage IV). Further explanation is provided in Appendix B.
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Discussion
We provide the first proof of concept for a model to estimate the potential 
impact of screening on the stage distribution of breast cancer. Our model is based 
on a comprehensive mathematical framework that employs important screening 
performance parameters. These parameters were, to the extent possible, derived 
from observations from the Nijmegen Screening Program comprising over 30 years 
of screening data (1975-2005) in various age groups. In this study, we propose a three 
step approach to assess the potential impact of biennial mammography screening on 
breast cancer stage shifts. This approach could also possibly be used to predict the 
stage shifts from CBE screening programs and mammography screening programs 
with alternative screening frequencies and age groups, for which we provided an 
example (Colombia). Our model could provide important information on the 
possible performance of breast cancer screening programs that LMICs could consider 
implementing.
Our results confirm that our model can be used to estimate the stage shifts 
(proportion of early vs. late breast cancer stages) based on proportional performance 
rates (Z’s), using linear regression. Our regression model explains a high proportion 
of the variability in our data (R square: 0.637), and the observed stage shifts in the 
Nijmegen Screening Program are highly associated with the Z’s (Pearson’s  R: 0.798). 
This provides a conceptual proof for the first two steps of our model, although these 
steps should also be confirmed in other countries with different screening datasets. 
Based on the hypothesis that countries with screening programs that perform equally 
well will have an equivalent stage distribution (equal Z’s - equal stage distributions), 
any country could use the regression model (step three). Theoretically, the regression 
coefficients of this model should be selected according to the current stage 
distribution of the country under study. However, whether our hypothesis (equal Z’s 
- equal stage distributions) can be accepted and, hence, whether it is valid to use step 
three of our model to extrapolate this regression model and use it for any country 
(external validity) is not proven by this study. Further research in other settings should 
be performed to verify this hypothesis. 
Our model can also be used to assess the impact of CBE screening as well as other 
low-cost screening modalities that might become available 9, 32, 33
.
 However, although 
CBE screening trials are executed in a number of LMICs such as India, Peru, and 
Vietnam 15, 28, 34, 35, these trials currently lack estimates on important screening 
outcomes, therefore, the estimated impact of CBE screening by our model should be 
interpreted carefully. In our model, we based the mean sojourn time (MST2) of CBE 
screening on an exponential growth model and assumed a range of preclinical- and 
clinical -detection sizes. Yet, these preclinical- and clinical -detection sizes and growth 
models are still being debated 36-38
.
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Also, the age-specific sensitivity of CBEs (Scbe) were adopted from Bobo et al. and 
corrected according to Sankaranarayanan et al. 25, 28, and the findings from these studies 
cannot be generalized to CBEs performed in other settings. Despite these differences, 
our CBE sensitivity estimates have been used in other modelling studies 39, and could 
initially be used to assess the impact of CBE screening in developing countries. Future 
research should investigate the MSTs and the sensitivity of CBEs and mammograms in 
LMICs.
Our model is based on the use of accessible data. Population registries exist in most 
LMICs, and population estimates could otherwise be obtained from other sources 31
.
 If 
appropriate cancer registries are lacking, LMICs could use GLOBOCAN estimates to 
acquire age-specific breast cancer incidence rates 1
.
 While the quality of GLOBOCAN 
information from most of the LMICs might not be of sufficient quality, this data often 
remains the only relatively unbiased source of information available on the profile 
of cancer. As in our example in Colombia (Appendix B), LMICs could also assume 
different estimates based on their current stage distribution, sensitivity, or attendance 
rates, and adjust the age-specific estimates provided in this study (Table 2). Although 
LMICs could easily adopt our model and adapt the estimates we  provide, we suggest 
that when our model is used different assumptions on these estimates should be 
addressed through uncertainty analyses.
There are some important limitations of this study and our proposed model. 
First, although the Nijmegen Screening Program comprises data from over 30 years, 
our results are based on 16 screening rounds. This may impact the overall accuracy 
of our model (internal validity) and the inclusion of data from more screening rounds 
may improve our regression model. 
Second and mentioned previously, the Nijmegen Screening Program only includes 
a population screened by mammography with a biennial screening interval, and the 
extrapolation of our model to other settings (external validity) is not yet proven 
by this study. In addition, although there is no clear evidence of this, natural history 
parameters could differ in the breast cancer populations of LMICs 40. 
Third, our model is based on average, age-specific parameters, and does not allow 
dynamic modelling or simulation of individual patients. Since we use averaged 
parameters, we may have less precise estimates compared with more advanced 
models. Nevertheless, advanced models rely on difficult mathematical approaches and 
require advanced information at the expense of their usefulness for policy makers 39, 41, 
42, and few of these models have been tested or applied in LMICs. 
Fourth, not all factors relating to health care access are accounted for in our 
mathematical model. The insurance status, level of poverty, rate of obesity, and the 
method of detection could also impact screening performance 43, 44, although these 
factors should be partly covered by selecting locally relevant attendance rates. 
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Fifth, our model does not provide much more insight on the harms and benefits of 
screening (e.g., impact on mortality, over-diagnosis, survival, false positives) 3, and can 
only be used for estimating stage distributions. An improved stage distribution can 
be the result of diagnosing additional stage I cancers, but does not necessarily mean 
a reduction of the absolute numbers of stage III-IV cancers and, correspondingly, a 
reduction of mortality from the disease. Higher proportions of breast cancers detected 
in the early stages are, hence, not straightforwardly linked to higher levels of averted 
breast cancer mortality. Moreover, if early detection is not followed by appropriate 
treatment, which could often be the case in LMICs, the indirect impact of screening 
on breast cancer mortality would also decrease. The impact of screening on breast 
cancer mortality should therefore not (directly) be assessed through our proposed 
model, specifically in LMICs were appropriate breast cancer treatment could be lacking. 
Despite this, estimating the stage distribution as a result of screening is nevertheless 
helpful for the selection of early detection programmes as the amount of stage shift is 
a useful performance indicator for a screening programme. This information could be 
of particular interest for LMIC’s were stage distributions are often poor, the continuum 
of early detection, treatment and follow-up services is not always available, and hence 
the eventual impact of screening on breast cancer mortality is difficult to estimate. 
Sixth, whether a proposed screening program is beneficial to a particular country, 
cannot merely be based on the outcomes of our model (i.e. the estimated stage 
shift). Multiple criteria such as effectiveness, budget impact, cost-effectiveness, safety, 
accessibility of disadvantaged populations or other equity considerations, are often 
considered in deciding this 45
.
 The trade-off between, for example, the costs and effects 
of the proposed screening program depends on the willingness to pay for a unit of 
effect (e.g. QALY/DALY) of a country and - even more - on the available budget. 
Previous experiences indicate that the budget for controlling breast cancer may 
increase two- or three-fold due to a screening program. The effectiveness, however, will 
increase between zero- and five-fold, dependent on the current stage distribution of a 
particular country 46
.
 Our model can be used to support this discussion, by estimating 
the potential stage shift of a proposed programme so the potential costs or effects 
of this program can be estimated. The interpretation of the amount of stage shift as a 
result of breast cancer screening is therefore not straightforward, though we believe 
that 60% of breast cancer cases in early stage should nominally be obtained through a 
breast cancer screening program.
The above limitations fit within our aim to provide broad indications on the 
performance and the potential impact of different screening options in LMICs, rather 
than providing very precise estimates. 
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In conclusion, we have developed a three step model to estimate the potential impact 
of screening on the stage shift of breast cancer. Our results show that our model can 
be used to estimate the stage shifts of the Nijmegen Screening Program, and provides 
proof of concept that it could theoretically be adapted to other settings with different 
characteristics. This is a promising and important step, although further research 
should investigate the extrapolation of our model to other settings and investigate the 
assumptions used in our parameters.
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APPENDIX A
Parameter estimates
Most parameters used to calculate the proportional performance rate per screening 
round (index number Z) were based on true observations from the Nijmegen 
Screening Program, whereas other parameters were derived from the international 
literature (i.e. mean sojourn time [MST]) 1-3
.
 These parameters are discussed below.
Detailed information on the Nijmegen Screening Program was retrieved from  the 
RadboudUMC, department for Health Evidence. Essential information on this 
screening programme has been recorded since 1975, including the age specific target 
groups. attendance, recalls, incident and prevalent screens, and invitation interval. 
The observed age specific screen detected carcinomas 4-8, interval carcinomas and 
residual carcinomas were for instance used to calculate age specific sensitivity for 
mammography (Table 1 of main document).
Natural history parameters (MST, A)
When describing the general natural history of breast cancer, we consider two 
important parameters in our equations; the mean sojourn time and lead time of breast 
cancer 9-11. Both parameters are age-dependent and hence relate to the age-group 
in which screening takes place 12, 13. The onset of breast cancer is dependent on the 
(natural) incidence in different age groups, while the mean sojourn time depends on 
both the aggressiveness (doubling time) of a tumour and the sensitivity of a test to 
detect the tumour. The lead time is also dependent on the ability to detect a cancer in 
the pre-clinically detectable phase (i.e. relates to the sensitivity of the test used) (Figure 
A1.1). 
Figure A1.1. Natural history representation of mean sojourn time (MST), lead time and sensitivity in non-screened 
vs. screened breast cancer populations 14.
The age-specific sojourn time is the average time that it takes the cancer to grow from a size at which it becomes detectable by screening (Sm) to a size 
detectable clinically (Sp) (pre-clinical detectable phase). It depends on the average doubling time of the tumor in a certain age group and the ability of the 
screening test to detect the cancer. The lead time represents the earlier moment of detection due to screening with respect to the moment on which a 
tumor becomes clinically manifest (Sp). The ability of a screening instrument to detect cancer affects the sojourn and lead time. A survival gain is expected 
due to this earlier detection.
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In future analyses, we could also use estimates of the MST(x) of clinical breast 
examination (CBE) by assuming that the growth rate of breast cancer can be 
described by an exponential function and by assuming standard average estimates of 
preclinical and clinical detection thresholds (i.e. the size of the cancer when it can be 
pre-clinically detected or clinically manifests) per age group. If we take for example 
a screening age of 40 to 49 years, which has a preclinical detection threshold (y) of 
5 mm for mammography, and a MST (40-49) of 2.4 years. Then, let the preclinical 
detection threshold of for CBE be 10 mm and the  clinical detection threshold 20 
mm 3. With these parameters we can estimate the MST (40-49) also for CBE, which 
has a preclinical detection threshold of 10 mm (y). Using the exponential formula for 
the preclinical detection threshold (y) of 10 mm: , gives us a MST (40-49) of 1.2 years 
for CBE (Figure A1.2, Table 1 of main document). However, multiple assumptions can 
be made on the preclinical detection thresholds of mammography (i.e. between 0.15 
and 0.5 centimetre) and also the growth model for the growth rate of breast cancer 
(e.g. logistic, Gompertz, exponential functions)12, 14. When we would use a preclinical 
detection threshold for mammography of 0.15 centimetre, the exponential function 
would be y=  This gives us, for a given preclinical detection threshold (y) of 10 mm, a 
MST of 0.64 years for CBE.
Figure A1.2. Calculation of Mean sojourn time (MST) of CBE screens assuming a preclinical detection threshold of 
1.0 cm. a clinical detection threshold of 2.0 cm. and an exponential growth rate 14
Demographical Parameters (I, population)
The annual number of breast cancer patients in a certain age-group can be estimated 
by using the age-specific incidence rate and the population at risk within the specific 
age-group (e.g. based on life tables). In our model we used the Dutch population and 
incidence statistics available from the Netherlands Statistics Institute (CBS) and the 
Dutch Cancer Registry (IKCnet) (Table 1 of main document) 15
.
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Chapter 388
Health System Parameters (A, C) 
We use two health system parameters that relate to the size of the implemented 
screening programme and the behaviour of the target population. The first indicator 
consists of the proportion of the target population invited with respect to the total 
target population (i.e. coverage by invitation rate, C). It could be possible for health 
program managers to implement a screening program only in a certain part of the 
country, for instance a single province. On a national basis, the potential impact of the 
screening program is then smaller as only a fraction of the total population is covered 
by this program. Our parameter C, accounts for this. The second parameter is based 
on the proportion of the population screened with respect to the total population 
invited (i.e., attendance rate A) (Table 2 of main document). This is an important 
parameter, which directly influences the potential impact of a screening program. 
Screening Parameters (S, r, ps) 
As outlined earlier, the sensitivity and specificity of a screening test are imperative for 
the efficiency of a screening program. Specificity is relating to the number of false-
positives, thus more important when evaluating the harms of screening or screening 
costs-effectiveness. The sensitivity of a screening test can vary between settings 
because of differing machines and their calibration, reading experience and recall 
policies. The age-specific sensitivity estimates for mammography used in this study, 
were based on the interval and screen detected cancers of each screening round as 
observed in the Nijmegen Screening Program. The targeted age groups, proportion 
of prevalent screens and coverage by inviation were derived from the same dataset. 
The frequency of screening (e.g., annually, biennially or triennially) and the age groups 
targeted for screening will also impact the sensitivity and the overall effectiveness of 
the screening programme (Figure A1.3). 
Figure A1.3. Hypothetical influence of screening frequency (interval) in relation to mean sojourn time (MST) and 
sensitivity of a screening programme 14
40‐49 50‐59 60‐69 70‐74
3 i t l
Mean Sojourn Time (MST)
# i t l C 25%y  n erva   n erva   ancers = 
1 i t l # i t l C 12%y  n erva   n erva   ancers = 
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Non-observed parameters
The observed age-specific variables from each Nijmegen screening round (sensitivity 
(S), frequency (r), attendance (A), fraction of prevalent screens [ps]), were used in our 
equations to calculate the Z of each screening round (n=16). As not all parameters 
were available or reliable for each age group (i.e. values for non-screened age groups 
or values years based on few observations), we estimated non-observed parameters 
using mathematical functions describing the distribution of the specific parameter, for a 
given age. The mathematical functions, derived from curve estimation models in SPSS, 
were selected according to the greatest R square and were based on the average 
age specific parameters of the entire screening period (i.e. grand means of the 16 
screening rounds) (Table 1 of main document). For our unobserved parameters that 
were predominantly based on the literature and derived from an assumed parameter 
distribution (e.g., mathematical functions describing MST), we performed univariate 
sensitivity analysis (Table 4 of main document).
Additionally, we based the sensitivity of CBE screening on two studies. First, we 
obtained age-specific sensitivity estimates from Bobo et al16. Yet these age-specific 
sensitivity are based on an annual opportunistic screening program in the United 
States, and are therefore not representative for LMICs. We therefore reduced these 
estimates with 7.1%, according to the reported sensitivity of a large triennial CBE 
screening program in India 17. The average difference in CBE sensitivity between these 
two studies used was 7.1% (58.8% vs. 51.7%). 
Stage distribution
For stage distribution, we follow the American Joint Committee on Cancer (AJCC) 
definition of cancer stages. The original TNM breast cancer stage classification, derived 
from the entire population of the Nijmegen Screening Program, was reclassified to the 
AJCC stage distribution (stage  I, II, III, and IV) 18. This includes the invasive screening 
carcinomas. interval carcinomas and the carcinomas of non-targeted and non-
participants (Table 2 of main document). This table also presents the proportions of 
early stage (AJCC stage I and II) and late stage (AJCC stages III and IV) breast cancers 
per screening round. 
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APPENDIX B
Step 4: optional
Distribution of stage I to IV among estimated stage shift
Besides using our model for estimating stage shifts, it could also be used to estimate 
the breast cancer stage distribution (I, II, III and IV breast cancer stages). The average 
proportion of stage I and II among early stage (53% stage I, 47% stage II) and stage III 
and IV among late stage breast cancers (93% stage III, 7% stage IV) from the Nijmegen 
Screening Program (table 1 of main document), could hypothetically be used to 
reallocate stage I to IV over the proportions of late vs. early stages as estimated by 
our model. However, this distribution probably different in other countries based on 
variations in breast density, screening frequencies and referral policies of the adopted 
screening program 1-4. If we would base this distribution on the several other countries 
that adopt organized screening programs, we could generally expect about 55% of 
the early breast cancer stages in stage I and 45% in stage II. For the late stages, this 
is probably 65% in stage III and 35% in stage IV, respectively (Appendix table B1). 
Although this is a rough approach, LMICs could use these approximated distribution 
rules to further estimate the stage distribution resulting from their screening activities 
(see Table 5 of main document). 
Appendix table B1. Stage distribution of breast cancer cases based on mammography screening in a number of 
high-income countries
Early Late
Stage I Stage II Stage III Stage IV
Nijmegen (this study) 53% 47% 93% 7%
NCDB (2010) 3 63% 37% 69% 31%
New Hampshire 1998-2004 5 61% 39% 69% 31%
Germany (1996-2007)1* 71% 29% - - 
BCSC (1994-2008) 6 72% 28% - - 
Netherlands 2003-2009 7* 50% 50% 74% 26%
Norway 1996-2005  1* 64% 36% 45% 55%
Belgium (Flemish) 2008 8* 62% 38% 56% 44%
Switzerland. Ticino 1996-2007 9* 50% 50% 66% 34%
Czech Republic. 2010 10* 53% 47% 71% 29%
France 2004-2008  11* 56% 44% 64% 36%
Slovenia 2009 12* 55% 45% 86% 14%
England. Northern. Yorkshire 1998-2000 13 45% 55% 61% 39%
East England 2006-2009 14 48% 52% 64% 36%
Scotland 2010-2011 15 53% 47% 64% 36%
Expected based on 2 year screening interval programs only (*)
(rounded off)
55% 45% 65% 35%
NCDB = National Cancer Data Base; BCSC = Breast Cancer Surveillance Consortium. Stage distributions of NCDB and BCSC (United States) are based 
on opportunistic screening programmes and therefore not taken into account. Data from the United Kingdom are based on triennial screening programmes.
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If things are getting easier, maybe you’re headed downhill
(Ghanaian proverb)
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Abstract
Objective
Breast cancer control in Ghana is characterized by low awareness, late stage 
treatment and poor survival. In settings with severely constrained health resources, 
there is a need to spend money wisely. To achieve this and to guide policy makers in 
their selection of interventions, this study systematically compares costs and effects 
of breast cancer control interventions in Ghana. 
Methods
We used a mathematical model to estimate costs and health effects of breast 
cancer interventions in Ghana from the healthcare perspective. Analyses were 
based on the WHO-CHOICE methodology, with health effects expressed in 
disability-adjusted life years (DALYs), costs in 2009 United States dollars (US$), and 
cost-effectiveness ratios (CERs) in US$ per DALY averted. Analyses were based on 
local demographic, epidemiological and economic data, to the extent this data was 
available. 
Results
Biennial screening by clinical breast examination (CBE) of women aged 40-
69 years, in combination with treatment of all stages, seems the most cost-
effective intervention (costing $1,299 per DALY averted. The intervention is also 
economically attractive according to international standards on cost-effectiveness. 
Mass media awareness raising (MAR) is the second best option (costing $1,364 
per DALY averted). Mammography screening of women of 40-69 years (costing 
$12,908 per DALY averted) cannot be considered cost-effective. 
Conclusions
Both CBE screening and MAR seem economically attractive interventions. Given the 
uncertainty on the effectiveness of these interventions, only a phased introduction 
of these interventions, together with a careful monitoring and evaluation, is 
warranted. Moreover, their implementation is only meaningful if the capacity of 
basic cancer diagnostic, referral and treatment and possibly palliative services is 
simultaneously improved. 
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Introduction
Breast cancer is a major public health problem in Ghana. It is the most common type 
of cancer among Ghanaian women in terms of mortality and prevalence and over 
20,000 disability adjusted life years (DALYs) are lost every year due to breast cancer 1. 
Ghana is facing a relatively high mortality to incidence ratio and it is expected that the 
incidence will increase in Ghana in the years to come 2, 3. (Table 1)
Currently, Ghana lacks a formal breast cancer control policy. Breast cancer treatment 
guidelines are absent and treatment involving radiotherapy is only available in Ghana’s 
two largest cities creating important geographic barriers to access. Also financial 
barriers exist: although breast cancer diagnosis and treatment are covered by 
Ghana’s National Health Insurance (NHIS), only 34% of the Ghanaian population was 
enrolled in 2010 4. Available studies on breast cancer in Ghana typically report poor 
stage distribution, survival and awareness. They furthermore indicate that knowledge, 
beliefs and social stigma of Ghanaians are important determinants of the late stage 
presentation of breast cancer 5-8. These poor conditions point out the need to improve 
breast cancer control policy in Ghana, and address the needs of Ghana’s relatively 
young female population.
Given its limited health care resources, Ghana needs to spend money wisely and only 
fund those interventions that provide value for money. Cost-effectiveness analysis 
(CEA) is a tool that systematically compares costs and effects of health interventions 
and that can guide policy makers in these decisions. However, the evidence base on 
cost-effectiveness of cancer control in Ghana – or any other low-income country – 
is scarce 9, 10. International literature on the costs and health effects of breast cancer 
control focuses mainly on high-income countries and is difficult to extrapolate to 
low-income countries due to differences in context. Screening programs in African 
countries, could for example use different tools and target different age groups than 
programs in Western settings.
This paper responds to the following research question: ‘From the healthcare 
perspective, what are the costs, health effects, and cost-effectiveness of breast cancer 
control interventions in Ghana, and what is the optimal mix of interventions to 
maximize population health?’ We used an established and previously published model 
by Groot et al. (2006) on the cost-effectiveness of breast cancer control in six world 
sub-regions, and adapted it to reflect the demographic, epidemiological and economic 
context of Ghana to the extent possible. 
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Table 1. Age distribution of breast cancer incidence and mortality in Ghana 
Age groups Female
population*
Incidence
(/100,000)
Number of
incident cases (%)
Mortality
(/100,000)
Number of
deaths (%)
Mortality/
incidence ratio
0 to 14 4.605.974 0.1 5 (0.2%) 0.0 0 (0.0%) n/a
15 to 29 3.145.512 1.0 31 (1.1%) 0.4 13 (0.7%) 0.40
30 to 44 2.013.112 31.7 638 (22.5%) 11.3 227 (12.3%) 0.36
45 to 59 1.231.140 80.1 986 (34.8%) 53.2 655 (35.3%) 0.66
60 to 69 482.535 104.5 504 (17.8%) 84.4 407 (22.0%) 0.81
Source: WHO Global Burden of Disease data, 2004 update. 
*Based on population Ghana in 2009. 
Methods
General approach
We used WHO-CHOICE standardized methods in cost-effectiveness analysis - 
described in detail elsewhere - as a basis of our analysis 10, 11. This approach compares 
all possible interventions to a situation where no interventions are available. This 
counterfactual acts as a reference to compare the cost and effects of existing and new 
interventions. The standardized method enables us to make comparisons of the costs 
and health effects across a wide range of competing interventions such as HIV/AIDS, 
malaria, and mental disorders 12.
Country adaptation
WHO-CHOICE has made a number of tools and methods available to adapt its 
regional results to the country level 13. A study team, established in 2009, served as 
an expert panel to assess the mathematical model for its relevance in Ghana, define a 
meaningful set of interventions, identify data sources for the collection of country data, 
analyze results and interpret findings. The study team included representatives from 
the Ministry of Health (MoH), Ghana Health Services (GHS), breast cancer specialists, 
public health specialists and health economists. 
Mathematical model
The model structure is presented in Figure 1 10. This state transition population model 
simulates the development of the Ghanaian population and accounts for births, 
background mortality and breast cancer epidemiology of Ghana 14. The model includes 
a healthy state, a deceased state, and stage I to IV breast cancer states following the 
American Joint Committee on Cancer (AJCC) 15. The effectiveness of interventions 
is based on their effect on health state valuations (HSVs) and case fatality (treatment 
interventions), or stage distribution (awareness raising and screening interventions). 
Each intervention, individually and in combination, is then implemented for 10 years. 
Next, the model-population is followed over its life-time to include all health effects 
that occur after these 10 years.
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Since the interventions are affecting both mortality (case fatality) and morbidity, 
intervention effectiveness is expressed in disability adjusted life years (DALYs). The 
difference in the total number of healthy years lived by the population between each 
scenario and the null-scenario gives the population health gains in DALYs averted.
We improved the initial model of Groot et al. (2006) by correcting HSVs for 
relapse, assuming that patients could only have relapse to stage IV at a constant rate. 
Additionally, we corrected stage-specific case fatality estimates, derived from the 
original study, for the addition of chemotherapy in stage I-II and mastectomy in stage 
IV according to the most recent Breast Health Global Initiative (BHGI) guidelines 16-19.
Figure 1. Graphical representation of the model
Graphical representation of the model showing the relationships between the different health states through the incidence rates of breast cancer (Ix1–Ix4), 
the different stage-specific case-fatality rates (corrected for progression) (Fx1–4) and the background mortality (M). Stage-specific relapse rates to stage 
IV were used to correct health state valuations only (Rx1–Rx3).
Interventions
The expert panel identified a set of 11 interventions that are relevant to breast cancer 
control in the Ghanaian context, all related to awareness raising, screening, treatment 
and palliative care (Table 2). 
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Table 2. Definition and classification of individual interventions for breast cancer control in Ghana
Treatment of individual stages Down-staging interventions § Palliative Care||
Stage I treatment: lumpectomy with axillary dissection and 
radiotherapy.* Eligible patients receive tamoxifen† or chemo-
therapy.‡ 10, 16, 17
Basic Awareness Raising (BAR): community nurses training pro-
gram + opportunistic outreach activities by community nurses 
to raise breast cancer awareness and educate on breast self 
examination techniques (BSE) + enhanced media activities. 20
Basic Palliative Care (BPC): palliative care-volunteers training 
program + home based visits by volunteers every fortnight + 
pain treatment through morphine, laxatives and palliative radio-
therapy (8 Gy in 1 fraction) for eligible patients. 17, 20-22
Stage II treatment: lumpectomy with axillary dissection and 
radiotherapy.* Eligible patients receive tamoxifen† or chemo-
therapy.‡ 10, 16, 17
Mass-media awareness raising (MAR): BAR + mass media 
campaign. 20
Extended Palliative Care (EPC): BPC apart from community 
nurses instead of palliative care-volunteers, pain treatment 
strengthened with anti-depressants, anti-emetics and zelodronic 
acid. 17, 20-24
Stage III treatment: modified mastectomy followed by adjuvant 
chemotherapy‡ and radiotherapy.* Eligible patients receive 
tamoxifen.† 10, 17
Biennial clinical breast examination (CBE) screening in asympto-
matically women aged 40-69 years: community nurses training 
program + active outreach screening by community nurses + 
limited media activities. 20, 22
Stage IV treatment: adjuvant chemotherapy‡ and radiotherapy 
(10 Gy) + end of life hospitalization. Eligible patients receive 
total mastectomy and/or tamoxifen.† 17, 19
Biennial mammography screening in asymptomatic women aged 
50-69 years + limited media activities. 10
Biennial mammography screening in asymptomatic women aged 
40-69 years + limited media activities. 10
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Some of these interventions do not yet exist in Ghana (e.g. mammography screening) 
but the expert panel judged them to be of potential benefit. The specific definition of 
interventions was based on consultations with the expert panel, WHO experts, BHGI 
guidelines, and the scientific literature 17, 18, 20, 21, 25. 
The 11 interventions were combined to construct a total of 17 intervention 
scenarios. This includes the current Ghanaian situation in which patients of stages I to 
IV are treated at a 10% coverage level (as estimated by the expert panel). All other 
interventions are evaluated at a geographic coverage level of 80% (i.e. reaching 80% 
of those people who need services) according to the expert panel and standard 
CHOICE methodology. 
Data sources 
Health effects
Key components in the mathematical model are demography, breast cancer 
epidemiology, stage distribution, case-fatality and health state valuations. Data used to 
fill in these components are discussed in turn. 
Demographic data was based on formal 2009 data from the government of Ghana 26. 
We used Global Burden of Disease (GBD) estimates from 2004 for Ghana (personal 
communication), in the absence of more recent or detailed information. Information 
on the present stage distribution of breast cancer in Ghana was derived from records 
of the Korle Bu Teaching Hospital in Accra. The impact of the various screening 
interventions on this stage distribution was estimated on the basis of a simple model 
following Duffy et al. (2005) by using proportional detection rates and stage shifts from 
Groot et al. (2006). We calculated stage shifts in Ghana while accounting for locally 
relevant attendance rates (60% for screening programs), sensitivity of tests, sojourn 
time (reducing sojourn times for CBE by one-third), and incidence and prevalence 
in different age groups 27-30. The effectiveness of the mass media awareness raising 
intervention was based on the study by Devi et al. (2007) whereas we assumed that 
the basic awareness raising intervention (BAR) caused a 10% down-staging of late 
stage breast cancer cases. In the absence of reliable Ghanaian data, data on case-
fatalities of breast cancer were based on Groot et al. (2006) and relapse rates on the 
literature 10, 16, 18, 19. Health state valuations were based on the Global Burden of Disease 
study, and corrected for relapse to stage IV 1, 10, 16. We assumed that the palliative care 
interventions affect health state valuations only 19, 21, 31, 32 – its effect was determined by 
the expert panel. The assumed impact of each intervention is listed in Table 3.
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Table 3. Case fatality rates, disability weights and stage distributions used for individual interventions
Intervention Case fatality rates* Disability weights† Stage distribution‡
Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV % in stage I % in stage II % in stage III % in stage IV
Untreated 0.020 0.063 0.15 0.30 0.068 0.071 0.073 0.090 2.3% 20.5% 50.0% 27.3%
Stage I treatment 0.006 0.068 2.3%
Stage II treatment 0.039 0.070 20.5%
Stage III treatment 0.093 0.072 50.0%
Stage IV treatment 0.227 0.0730 27.3%
Basic Palliative Care (BPC) 0.227 0.0720 27.3%
Extended Palliative Care (EPC) 0.227 0.0715 27.3%
Current country specific situation 0.006 0.039 0.093 0.227 0.068 0.070 0.072 0.073 2.3% 20.5% 50.0% 27.3%
Basic Awareness Raising (BAR) 0.006 0.039 0.093 0.227 0.068 0.070 0.072 0.073 10.2% 20.1% 44.8% 24.8%
Mass media Awareness Raising (MAR) 0.006 0.039 0.093 0.227 0.068 0.070 0.072 0.073 21.1% 41.5% 24.1% 13.3%
Biennial CBE screening (40-69) 0.006 0.039 0.093 0.227 0.068 0.070 0.072 0.073 39.5% 30.2% 19.2% 11.1%
Biennial mammography screening (50-69) 0.006 0.039 0.093 0.227 0.068 0.070 0.072 0.073 42.0% 32.1% 16.4% 9.4%
Biennial mammography screening (40-69) 0.006 0.039 0.093 0.227 0.068 0.070 0.072 0.073 47.8% 36.5% 10.0% 5.7%
Current country specific situation: Current situation in Ghana with treatment coverage of 10%. 
* Original estimates (Groot et al) were corrected for the addition mastectomy in stage IV and chemotherapy in stage I and II. 10, 16-19 
† Original estimates (Groot et al) were corrected for relapse to stage IV. Relapse rates were derived from Adjuvant Online. 10, 16, 17 
‡ Present stage distribution is based on Korle Bu hospital registry. 
Effects of MAR derived from Devi et al. 20. Effects of screening interventions were based on stage shifts from baseline 10 to the stage distribution in the USA 18. Stage shifts were adapted by calculating relative differences in detection rates between USA 
and Ghana 25. Calculations included age specific incidence, prevalence 1, sojourn time 25, sensitivity 24 and attendance rates (75% in USA vs. 60% in Ghana). 
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Costs
Following standardized WHO-CHOICE methodology on CEA, we distinguished 
between patient-level and program-level costs 13. We used an ingredients approach to 
costing analysis, in which quantities and prices are separately reported. 
Unit costs of patient services were as much as possible based on the principles of 
micro-costing, including detailed resource utilization patterns and prices. Estimates 
of these were based on Ghanaian treatment practices and/or expert opinion and 
local inventories of prices (personal communication). In some instances, no detailed 
estimates were possible and costs were based on NHIS fees charged for services 
from public hospitals. As a last resort, where no local resource utilization patterns 
were known or fees were available, on e.g. lumpectomy, we used the WHO-CHOICE 
database on standard medical procedures 33. From this database we obtained the 
standard procedure for lumpectomy, including a series of standardized quantities on 
supplies and equipment needs, clinician time, and protocols of care. These quantities 
were then multiplied by Ghanaian unit prices (salaries, drugs and equipment). Prices of 
traded (international) goods were based on the WHO-CHOICE database, and were 
marked-up for transportation and distribution. To estimate the total patient costs of 
interventions, we multiplied the costs of patient services with the number of patients 
requiring these services (Table 4). The total number of patients requiring treatment is 
an output of the mathematical model, whereas the proportion of patients that make 
use of stage specific services (e.g. diagnostics, surgery, systemic therapy) was estimated 
by the expert panel. 
Program-level costs capture management, administrative, media and law-enforcement 
costs, and costs for training of healthcare personnel. These costs were based on 
interviews with program managers from GHS. Media and operating costs (i.e. prices 
for broadcasting, flyers, and posters) were based on local inventories of prices. 
For all interventions, we also included costs of diagnostic tests for women presenting 
without breast cancer (i.e. the tested negatives of all stages) and assumed the ratio 
of tested negatives vs. tested positives to be 16.4:1 34. Single treatment scenarios also 
include the costs of diagnosing all other stages and, regarding screening interventions, 
we included costs for evaluating false positives 22, 34-37.
All costs were estimated in 2009 local currency (Ghana Cedis) and converted to U.S. 
dollars (US$) using the 2009 exchange rate (1 GHC = 0.701 US$). Both health effects 
(DALYs) and costs (US$) were discounted at an annual rate of 3%. 
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Table 4. Average utilization of diagnosis and treatment services and unit costs per patient
Procedure Ingredients Stage I Stage II Stage III Stage IV Relapse PC Unit cost per patient 
(US$)
Initial diagnosis and evaluati-
on during treatment
No. of health centre visits 1 1 1 1 0 3.51*
No. of hospital visits 3 3 3 3 3 5.26*
Bilateral Mammography 1 1 2 0 - 54.88*
Complete blood count 7 7 7 7 6 14.21*
FNA or core needle biopsy 1 1 1 1 - 38.78*
Liver function tests 8 8 8 8 7 6.20†
Ultrasonography 1 1 1 1 20.69*
Renal function tests 8 8 8 8 7 7.01*
Bone scan 0 0 1 1 - 109.94*
Chest X-ray 1 1 1 1 - 23.93*
ECG 1 1 1 1 - 13.46*
Non-breast cancer  
evaluation
No. of health centre visits 2 2 2 2 3.51*
Bilateral Mammography 1 1 1 1 54.88*
Ultrasonography 0.28 0.28 0.28 0.28 20.69*
FNA or core needle biopsy 0.02 0.02 0.02 0.02 38.78*
Treatment No. of hospitalization days 2 2 6 6 6 6 10.52*
No. of end of life hospitalization days 7 7 4.7 10.52*
No. of OPD visits radiotherapy 30 30 30 30 30 1 5.26*
No. of OPD visits chemotherapy 6 6 6 6 5.3 - 5,26*
% receiving surgical intervention Lumpectomy 
40%
Lumpectomy 
30%
Lumpectomy 
10%
Lumpectomy - Lumpectomy - Lumpectomy - 156.38†
Mastectomy 
60%
Mastectomy 
70%
Mastectomy 
90%
Mastectomy 
5%
Mastectomy 
5%
Mastectomy
5%
604.45†
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Procedure Ingredients Stage I Stage II Stage III Stage IV Relapse PC Unit cost per patient 
(US$)
% receiving anesthesia 100% 100% 100% 5% 5% 5% 136.77†
% receiving radiotherapy 40% 30% 100% 10% 60% - 37.48 per 2Gy†
% receiving endocrine treatment 100% 100% 100% 40% 40% - 0.28/day*
% receiving chemotherapy 0% 20% 60% 60% 80% - 405.71* (per 4 cycles)
% receiving boost radiotherapy 41% 37.48†
% receiving home based visits 75% 3.51/visit*
% receiving morphine 84% 1.47/day*
% receiving laxative 50% 4.91/day*
% receiving Ondansetron 36% 3.51/day*
% receiving Amitriptyline 41% 0.02/day*
% receiving Zelodronic Acid 30% 108.71/day*
PC: Palliative care (substitutes stage IV treatment). Chemotherapy: 4 cycles of doxorubicin and cyclophosphamide , supplemented with dexamethasone (AC regimen). Endocrine treatment: daily dose of 20 mg. Tamoxifen for 5 years. Radiotherapy: 50 Gy given 
in 25 fractions of 2 Gy. Boost radiotherapy: 1 fraction of 10 Gy. Morphine: 40ml/54sdays. Laxatives: 35mg/54 days. Ondansetron: 8mg/day. Amitriptyline: 75mg/day. Bisphosphonates: 5 mg zelodronic acid/day. 
* Unit costs derived from different sources. Local unit prices derived from public (university) hospital, combined with information from WHO-CHOICE (South African ) database 30.
† Unit costs completely derived from WHO-CHOICE (South African ) database in 2000 US$. First corrected for IMF (world) inflation 2000-2009 (1.423) , then the 2009 GHC/US$ exchange rate was used (0.701)
Note: Program costs and costs for follow-up and screening procedures are not presented in this table.
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Cost-effectiveness analysis
Average cost-effectiveness ratios (ACERs) are calculated for each intervention by 
dividing its total number of DALYs averted by its total costs. Using a standard approach, 
we identified the set of interventions a region should purchase to maximize health 
gains for different budget levels. The order in which interventions would be purchased 
is called an expansion path and is based on the incremental costs and health effects of 
each intervention compared to the last intervention purchased. Only interventions that 
are both more effective and less costly than other (combinations of) interventions are 
considered on this expansion path – and these are labelled ‘dominant’ interventions. 
The incremental cost-effectiveness ratios (ICER) for those interventions are calculated 
by dividing the incremental costs by the incremental health effects. WHO-CHOICE 
defines interventions that have a cost-effectiveness ratio of less than one time the 
gross domestic product (GDP) per capita as very cost-effective, and those with a ratio 
that falls between one time and three times the GDP per capita as cost-effective 38. 
In Ghana, this means that interventions that cost less than $649 per DALY averted 
can be considered very cost-effective, and interventions that cost between $649 and 
$1,947 can be considered as cost-effective. 
Sensitivity Analysis
We performed a deterministic sensitivity analysis to assess the impact of key 
parameters on cost-effectiveness results. The baseline case fatality rates and HSVs 
were varied +/- 25%, the effect of down-staging interventions was reduced by 25%, 
and for CBE screening we also used effectiveness estimates from other studies 22, 39-
41. Furthermore, we used different sources for Ghana’s current stage distribution 
and varied costs for outpatient visits and hospitalization (+/- 25%). In addition, we 
lowered attendance rates of screening interventions (-10%), the sensitivity of CBE and 
mammography tests (-25%), and the capacity utilization of machinery (-25%). 
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Results
Table 5 shows costs, effects and cost-effectiveness of the 17 intervention scenarios. The 
annual number of DALYs saved by the individual stage I to IV breast cancer treatments 
vary between 365 (treatment of stage I) and 1,860 (treatment of stage III). Combined 
together, these interventions can avert almost 3,800 DALY’s. The addition of a palliative 
care program only adds very few DALYs.
Interventions to raise awareness, combined with treatment of all stages, avert between 
5,600 and 9,500 DALYs. Biennial CBE screening averts around 12 500 DALYs, whereas 
biennial mammography screening can save between 13,185 and 14,580 DALYs 
(depending on the targeted age-group), all in combination with treatment of all stages.
With increasing intervention effectiveness, costs increase as well. The individual 
treatment interventions cost between $5.1 million (stage I) to $10.3 million (stage III) 
annually, and are among the least costly interventions. Basic and extensive palliative 
care cost $6.0 million and $8.3 million, respectively. With an annual cost of over $42.4 
million, biennial mammography screening of women between ages 40 to 69 years, 
combined with treatment of all stages, is the most costly intervention.
The cost-effectiveness ratios (CERs) of the individual treatment interventions range 
between $5,012 (stage II treatment) and $16,824 (stage IV treatment) per DALY 
averted. Extended palliative care costs almost $22,000 per DALY averted. 
Interventions to raise awareness and screening interventions, combined with treatment 
of all stages, are more cost-effective than the treatment interventions. The most cost-
effective intervention for breast cancer control in Ghana is biennial CBE screening in 
women aged 40-69 years combined with treatment of all stages, which costs $1,299 
per DALY averted. Mass media awareness raising ($1,364 per DALY averted) is slightly 
less cost-effective than CBE screening. Mammography screening interventions, in 
combination with treatment of all stages, cost between $2,163 and $2,907 per DALY 
averted. 
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Table 5. Costs (US$), effects and cost-effectiveness of breast cancer control in Ghana
Intervention scenarios* Patients 
per year
Annual treatment 
costs†
Annual program 
costs†
Annual training 
costs†
Annual total 
costs† 
DALYs averted 
a year‡
ACER ICER
1 Current country specific situation (10% coverage) 445 1,449,828 135,222 52,786 1,637,836 437 3,745 NA
2 Stage I treatment 81 4,794,800 353,406 25,843 5,174,049 365 14,173 NA
3 Stage II treatment 727 5,984,201 353,406 25,843 6,363,450 1,270 5,012 NA
4 Stage III treatment 1,778 9,936,648 353,406 25,843 10,315,897 1,860 5,547 NA
5 Stage IV treatment 970 5,893,621 353,406 25,843 6,272,870 373 16,824 NA
6 Basic Palliative Care (BPC) 970 4,979,912 1,011,392 45,225 6,036,528 374 16,133 NA
7 Extended Palliative Care (EPC) 970 7,202,892 1,024,824 45,225 8,272,941 375 22,032 NA
8 Treatment of stage I to IV 3,556 11,684,609 446,962 51,685 12,183,257 3,785 3,219 NA
9 Basic awareness raising (BAR)+ treatment of stage I to IV 3,556 11,532,296 1,324,972 64,607 12,921,875 5,624 2,298 NA
10 Mass media awareness raising (MAR)+ treatment of stage I to IV 3,556 11,010,702 1,844,944 64,607 12,920,252 9,473 1,364 NA
11 Biennial CBE screening (40-69) + treatment of stage I to IV 3,556 14,795,753 1,435,919 79,374 16,311,046 12,560 1,299 1,299
12 Biennial mammography screening (50-69) + treatment of stage I to 
IV
3,556 26,682,513 1,691,896 141,533 28,515,941 13,185 2,163 NA
13 Biennial mammography screening (40-69) + treatment of stage I to 
IV
3,556 40,499,576 1,751,124 141,533 42,392,234 14,580 2,907 12,908
14 MAR + BPC + treatment of stage I to III 3,556 10,538,750 2,582,414 83,989 13,205,153 9,521 1,387 NA
15 Biennial CBE screening (40-69) + BPC + treatment of stage I to III 3,556 14,389,915 2,124,102 98,756 16,612,773 12,561 1,323 NA
16 Biennial mammography screening (40-69) + BPC + treatment of 
stage I to III
3,556 27,114,060 2,721,859 194,608 30,030,527 13,187 2,277 NA
17 Biennial mammography screening (50-69) + EPC + treatment of 
stage I to III
3,556 40,290,127 2,455,957 194,608 42,940,693 14,581 2,945 553,616
ACER = Average cost-effectiveness ratio compared to the do nothing-scenario (US$ per DALY averted). ICER = Incremental cost effectiveness ratio, ratio of additional cost per additional life-year saved when next intervention is added to a mix (additional 
US$ per additional DALY saved). NA = Not applicable because intervention is less cost-effective than others.
* Intervention scenarios are implemented at 80% coverage levels, except for scenario 1.
† In 2009 US$ (1 GHC = 0.701 US$)
‡ DALYs, disability-adjusted life-years (age weighted, discounted)
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Figure 2 shows the expansion path of breast cancer control, i.e. the order in which 
interventions should be implemented at different levels of resource availability. This 
path shows that biennial CBE screening of women aged 40-69 is the optimal choice 
(incremental cost per DALY of $1,299) at a cost of around $16 million, followed by 
mammography screening of women of 40-69 years (with an incremental CER of 
$12,908 per DALY saved) at a cost of $42 million, both in combination with treatment 
of all stages. The addition of basic palliative care to mammography screening and 
treatment of all stages would incur an incremental cost of $553,616 per DALY saved. 
The dotted line corresponds to three times the Ghanaian GDP per capita per DALY 
averted, and represents the suggested cost-effectiveness threshold as explained above. 
Both CBE screening and MAR plus treatment of all stages, combined with or without a 
basic palliative care program, are beneath this threshold. Note that MAR, because it is 
slightly less cost-effective than CBE, is not on the expansion path and would – strictly 
interpreted – not be a candidate for implementation. Yet, as these small differences 
are likely not policy relevant, we nevertheless consider MAR as a candidate for 
implementation. 
Figure 2. Cost-effectiveness of breast cancer interventions and expansion path according to ICER (Incremental 
cost-effectiveness ratio) 
Dotted line represents the cost-effectiveness threshold of 3*GDP/capita/DALY averted (1,947 US$/DALY). In 2009 the Ghanaian GDP per capita was 
US$649.
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Sensitivity Analysis
Sensitivity analysis showed that our model is sensitive to alternative assumptions on 
case fatality rates and stage distribution, and to a smaller extent on sensitivity of tests, 
capacity utilization and attendance rates (Table 6). If higher case-fatality rates were 
assumed, representing poorer survival, the CER of awareness-raising and screening 
interventions would increase 14-46%. Lower case-fatality rates would result in a 
12 to 44% decrease of these CERs. As our assumptions on current Ghanaian stage 
distribution are based on hospital records, we also considered alternative sources and 
these affected the CER of treatment stage I mostly (CER range -47% to +16%) and 
also the CER of awareness raising and screening interventions (CER ranges -26% to 
+22%). 
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Table 6. Results of sensitivity analysis on average cost-effectiveness ratio (ACER)
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1 Current country specific situation (10% coverage) 3,745 4,694 3,297 6,522 4,325 3,825 3,885 - - -
2 Stage I treatment 14,173 6,714 4,208 16,427 16,000 14,466 15,056 - - -
3 Stage II treatment 5,012 10,175 7,467 10,181 5,797 5,138 5,282 - - -
4 Stage III treatment 5,547 8,675 5,523 11,078 6,280 5,745 5,793 - - -
5 Stage IV treatment 16,824 7,527 24,130 61,173 19,774 17,303 17,707 - - -
6 Basic Palliative Care (BPC) 16,133 6,028 24,258 58,388 16,032 16,536 16,992 - - -
7 Extended Palliative Care (EPC) 22,032 11,359 30,321 79,159 21,895 22,461 22,948 - - -
8 Treatment of stage I to IV 3,219 3,256 2,937 6,197 3,681 3,297 3,348 - - -
9 Basic Awareness Raising (BAR)+ treatment of stage I to IV 2,298 1,701 2,805 3,344 2,542 2,352 2,387 - - 2,656
10 Mass media Awareness Raising  (MAR)+ treatment of stage I to IV 1,364 1,077 1,577 1,681 1,468 1,390 1,415 - - 1,503
11 Biennial CBE screening (40-69 years) + treatment of stage I to IV 1,299 1,047 1,478 1,499 1,385 1,351 1,352 1,451 1,409 1,274 -1,462
12 Biennial mammography screening (50-69 years) + treatment of stage I to IV 2,163 1,751 2,454 2,488 2,303 2,197 2,304 2,360 2,328 -
13 Biennial mammography screening (40-69 years) + treatment of stage I to IV 2,907 2,373 3,279 3,303 3,088 2,950 3,118 3,081 3,048 -
14 MAR + BPC + treatment of stage I to III 1,387 1,093 1,605 1,716 1,451 1,412 1,437 NA NA -
15 CBE screening (40-69) + BPC + treatment of stage I to III 1,323 1,066 1,505 1,528 1,380 1,374 1,376 1467,26 1,427 1,323-1,478
16 Mammography screening (40-69) + BPC + treatment of stage I to III 2,277 2,804 2,584 2,620 2,375 2,311 2,419 2,496 2,460 -
17 Mammography screening (50-69) + EPC + treatment of stage I to III 2,945 2,404 3,322 3,346 3,068 2,987 3,155 3,115 3,083 -
* Alternative stage distribution A, reflecting present Ghanaian situation, derived from breast clinic Kumasi (4% stage I, 7% stage II, 18% stage III, 70% stage IV). 
† Alternative stage distribution B, reflecting present Ghanaian situation, according to Groot et al. (9.4% stage I, 14.2% stage II, 58.0% stage III, 18.4% stage IV)10. 
‡ Mechanical equipment (e.g. mammography machines, CT, X-ray)
§ Alternative assumptions on effectiveness of awareness interventions (-25%), sensitivity of CBE 39, and stage shifts of CBE screening 35, 38, 39. 
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Discussion
Our analysis indicates that screening by CBE, in combination with treatment of all 
stages, seems the most cost-effective intervention for breast cancer control in Ghana. 
The intervention can detect cancer in an early stage and therefore allows early 
treatment with relatively high effects at low costs. The intervention costs around $1,300 
per DALY averted, and seems cost-effective according to international thresholds on 
cost-effectiveness. MAR can also be considered cost-effective according to the same 
threshold, but mammography screening not. 
Our study confirms the findings by Groot et al. (2006) that screening interventions 
are cost-effective and that early stage treatment is more cost-effective than late stage 
treatment. One difference is the relatively few number of patients with stage I breast 
cancer in Ghana, which renders treatment of stage I relatively less cost-effective 
(considering the relatively large fixed cost for testing all women presenting with breast 
cancer symptoms but do not have cancer). Our results are also in line with findings by 
comparable CEA studies on cancer control. When expressed in International Dollars 
(I$), CBE screening in Ghana would cost about I$2,750 per DALY averted and is in the 
same range of cost-effectiveness as cervical (ranging I$307 to I$100,075 per DALY) 
and colorectal cancer (ranging I$336 to I$15,548 per DALY) control options in the 
African sub-region 42.
This study leads to a number of observations on breast cancer control policy 
in Ghana. First, our study suggests that biennial CBE screening in women aged 40-
69 years, combined with treatment of all stages, is economically attractive. This 
corresponds with findings from India, Egypt and Ukraine 22, 40, 43, 44. However, it should 
be taken into account that the implementation of CBE screening is highly dependent 
on the availability of human resources, facilities and devices for proper diagnosis 
and treatment. There is also a considerable uncertainty on the effectiveness of CBE 
screening interventions, particularly regarding socio-cultural barriers: although most 
CBE screening studies show positive results on stage distribution, these interventions 
can easily fail when important aspects of education and information are neglected 
6, 43, 45, 46. Furthermore, implementation of this intervention would costs around $16 
million per year, and raises concerns on affordability. With a total health expenditure 
of around $40 per capita (7.8% of total GDP) 47 the CBE screening would currently 
costs about $0.70 extra per capita (1.75 % increase) and seems only sustainable when 
combined with other programs (e.g. cervical cancer) and with long-term budgetary 
commitments. At this moment, a nationwide CBE screening program therefore seems 
a suitable option only in the long run. Pilot studies, in which the implementation of CBE 
screening is explored in e.g. the context of current primary healthcare structure, may 
be a first step. This could be followed by a phased introduction, in which the program 
is carefully monitored and evaluated. 
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Second, MAR is almost as cost-effective as CBE screening but requires a smaller budget 
(around $13 million) and could be an alternative strategy. However, there is only very 
limited evidence on intervention effectiveness, and our estimates must be interpreted 
with great caution 20, 48, 49. As for CBE screening, the implementation of MAR is highly 
dependent on the availability of human resources and treatment services and can only 
commence in the long run upon careful evaluation.
Third, although treatment interventions are, on themselves, not cost-effective, they 
are relatively affordable and deserve higher priority if only a small budget would be 
available. The annual costs for treating all stages are far lower ($12.18 million) than 
those of screening options, and scaling-up treatment of all stages to a 80% coverage 
level, would already generate an almost ten-fold gain in DALYs annually. Moreover, 
treatment is an integral component of the continuum of care and essential to be 
scaled up if any intervention for early detection is implemented. A gradual increase 
in coverage of basic treatment services, along with improvements of referral systems 
should then be simultaneously established 45, 50.
Fourth, the need for pain treatment of stage IV patient is evident 25. If management 
of stage IV patients entails basic palliative care, health effects slightly increase and 
costs slightly decrease (due to a reduction of hospitalization days). Hence, this form 
of palliative care is economically attractive and seems most meaningful. Extended 
palliative care costs much more, averts relatively few extra DALYs, and is therefore not 
recommended from an economic perspective. 
Fifth, while biennial mammography screening is proven cost-effective in high-income 
countries, our analysis suggests it is not cost-effective in Ghana. Mammography 
screening would also require huge investments in equipment and human resources, 
demanding a considerable proportion of Ghana’s health budget. Nevertheless, 
investments in mammographic services are still required for diagnostic purposes 
in Ghana, and mammography screening could become a relevant option if more 
resources would become available in the future.
Our study has a number of limitations. First, the national cancer registry in Ghana is not 
fully functional and local data on breast cancer stage distribution were derived from 
Korle Bu Teaching Hospital, Accra and Komfo Anokye Teaching Hospital, Kumasi. Since 
this is based on presenting patients rather than on all patients, this may not reflect 
reality and may have biased our estimates. Second, information on the epidemiology 
and case-fatality of breast cancer was not locally derived, but based on the GBD and 
observations in other countries. If e.g. poorer case-fatality rates would apply to Ghana, 
we expect CER estimates to worsen (Table 6). Third, in the absence of reliable data 
and following the requests from Ghanaian stakeholders, we did not include travel 
costs or productivity losses of patients seeking or undergoing care and only evaluated 
biennial screening options. Including these cost would have probably lead to increased 
cost generally, and particularly for women with advanced stage breast cancer 51, 52.
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Fourth, data on costs and treatment regimes were derived from small-scaled, 
locally available sources or expert opinion, and may not be representative for the 
whole country. Fifth, evidence on the effectiveness of awareness raising, CBE and 
mammography screening in Ghana is absent. To arrive at Ghanaian estimates we used 
a model approach that showed face validity, confirmed by the expert panel in our 
study. Despite these limitations, results of our model show similarities with results from 
other models 9, 44. Moreover, although our sensitivity analysis showed that CER ranges 
of several interventions are overlapping, our overall study conclusions remain the same. 
The above limitations fit within the overall aim of WHO-CHOICE analysis to provide 
broad indications of cost-effectiveness on a range of interventions to inform general 
policy discussions rather than to deliver precise estimates on a specific intervention. 
Nevertheless, these limitations indicate the need to improve the evidence base of 
decision-making in breast cancer control in Ghana.
In summary, our analysis suggests that breast cancer control in Ghana, in order to be 
efficient, should be oriented towards earlier detection. However, the provision of basic 
cancer diagnostic, referral, treatment and possibly palliative facilities are fundamental 
for breast cancer control along the continuum of care and should be established 
simultaneously with any intervention for early detection. A phased introduction of CBE 
screening or perhaps MAR, coupled with a careful monitoring and evaluation, could be 
a feasible option for Ghana and should be further explored.
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Abstract
Objectives
In Peru, a country with constrained health resources, breast cancer control is 
characterized by late stage treatment and poor survival. To support breast cancer 
control in Peru, this study aims to determine the cost-effectiveness of different 
breast cancer control interventions relevant for the Peruvian context. 
Methods
We performed a cost-effectiveness analysis (CEA) according to WHO-CHOICE 
guidelines, from a healthcare perspective. Different screening, early detection, 
palliative, and treatment interventions were evaluated using mathematical 
modeling. Effectiveness estimates were based on observational studies, modeling, 
and on information from Instituto Nacional de Enfermedades Neoplásicas (INEN). 
Resource utilizations and unit costs were based on estimates from INEN and 
observational studies. Cost-effectiveness estimates are in 2012 United States 
dollars (US$) per disability adjusted life year (DALY) averted.
Results
The current breast cancer program in Peru ($8,426 per DALY averted) could 
be improved through implementing triennial or biennial screening strategies. 
These strategies seem the most cost-effective in Peru, particularly when mobile 
mammography is applied (from $4,125 per DALY averted), or when both CBE 
screening and mammography screening are combined (from $4,239 per DALY 
averted). Triennially, these interventions costs between $63 million and $72 million 
per year. Late stage treatment, trastuzumab therapy and annual screening strategies 
are the least cost-effective. 
Conclusions
Our analysis suggests that breast cancer control in Peru should be oriented 
towards early detection through combining fixed and mobile mammography 
screening (age 45-69) triennially. However, a phased introduction of triennial CBE 
screening (age 40-69) with upfront FNA in non-urban settings, and both CBE 
(age 40-49) and fixed mammography screening (age 50-69) in urban settings, 
seems a more feasible option and is also cost-effective. The implementation of this 
intervention is only meaningful if awareness raising, diagnostic, referral, treatment 
and basic palliative services are simultaneously improved, and if financial and 
organizational barriers to these services are reduced. 
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Introduction
In Peru and other Latin-American countries, cancers have become a pressing health 
concern over the last decades. Cancer incidence and mortality rates have been rising 
and will probably continue to rise as a result of population growth, aging, urbanization 
and lifestyle changes 1-4.
In Peru, the highest cancer burden is currently represented by stomach, cervix, breast, 
prostate and lung cancer. Breast cancer is, together with cervical cancer, the leading 
cancer among females in terms of mortality and incidence 5, 6. Breast cancer has shown 
a persistent increase in incidence over the last decades, and many women present in 
advanced breast cancer stages. Efforts to control the disease in Peru are therefore 
essential (Table 1) 6, 7.
As a public response, the Peruvian Ministry of Health (MINSA) and allied institutions 
developed multi-sectoral cancer control strategies in 2006, focusing on prevention, 
education, early detection and expanding services for multiple cancers 8. The strategic 
program, explicitly for breast cancer, consists of group and individual counseling in 
breast cancer prevention (women aged 18 to 64 years) as well as the promotion of 
annual mammography screening (age group 40-65). Furthermore, with the goal of 
reaching universal coverage, the Peruvian government introduced a universal health 
insurance law in 2009 and has also gradually been devoting more financial resources to 
cancer control 9-11.
Despite these developments, the implementing institutions face significant problems 
with the roll out of cancer control strategies. The coverage of breast cancer services 
is only partial and unequal, partly due to a fragmented health system, decentralization, 
and the unguaranteed financial resources 12. In addition, only 51.8% of the population 
was insured (INEI 2008) and breast cancer treatment and rehabilitation, only partially 
covered by insurance, may require substantial out of pocket payments 13. This may lead 
to important financial, cultural and geographical disparities in access to breast cancer 
care for many Peruvian women 14.
With this background, and with the rising cost of cancer control to the Peruvian 
healthcare system, MINSA is facing difficult choices on which breast effective cancer 
interventions to provide and at which cost they can be sustained for the long term. 
Also, given its limited health-care resources, Peru needs to spend money wisely and 
fund interventions that provide best value for money. Cost-effectiveness analysis (CEA) 
is a tool that systematically compares costs and effects of health interventions and 
that can guide policy makers in these decisions. Results from CEAs can for example 
be used to improve the general planning of strategies, or to strengthen certain breast 
cancer strategies by demonstrating their value for money. So far, CEAs on breast 
cancer interventions have not been conducted in Peru 15, hence, important information 
on efficient breast cancer control strategies is currently lacking.
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To support breast cancer control in Peru, this study aims to explore and report the 
cost-effectiveness of different breast cancer control interventions relevant for the 
Peruvian context. In this paper, we provide an outline of the most efficient and feasible 
interventions for breast cancer control in Peru from the healthcare perspective.
Table 1. Age distribution of breast cancer incidence and mortality in Peru
Age 
groups
Female 
population 
(2005)*
Incidence 
rate per 
100.000)*
Number of 
incident cases 
(%)
Mortality 
rate (per 
100.000)*
Number of 
deaths (%)
Mortality / 
incidence 
ratio
Current stage 
distribution 
(AJCC)**
0-4 1,382,448 0.0 0 (0%) 0.0 0 (0%) n/a Stage I 
5-14 2,860,994 0.0 0 (0%)  0.0 0 (0%) n/a 7.04%
15-29 3,801,363 1.28 49 (1.4%) 0.25 10 (0.5%) 0.20 Stage II 
30-44 2,736,393 31.69 867 (24.2%) 9.66 264 (12.7%) 0.30 36.44%
45-59 1,654,473 85.79 1419 (39.6%) 46.22 765 (36.7%) 0.54 Stage III 
60-69 630,326 85.17 536 (15.0%) 64.45 406 (19.5%) 0.76 43.48%
70-79 400,815 121.59 487 (13.6%) 104.57 419 (20.1%) 0.86 Stage IV 
80+ 142,471 158.61 226 (6.3%) 153.32 218 (10.5%) 0.98 13.04%
*WHO Global Burden of Disease, 2004 update 7.
**INEN 2007-2011 12.
Methods
General approach
Our standardized CEA methods, derived from WHO-CHOICE, are described 
in detail elsewhere and build on previous regional and country specific analyses of 
interventions to control breast cancer 16-20. An important feature of this methodology is 
that all possible interventions are compared to a situation where no interventions are 
implemented. This counterfactual acts as a reference to compare the cost and effects 
of all possible interventions, and enables us to make comparisons across a wide range 
of competing interventions (e.g. tuberculosis, mental disorders, non-communicable 
diseases) 16, 21-24.
Breast cancer data and interventions 
To select a set of breast cancer interventions relevant to Peru and to identify sources 
for cost and effectiveness data, a local study team was established during a stakeholder 
meeting in 2011. The team, consisting of representatives from the Ministry of Health 
(MoH), the national cancer institute (INEN), the social security network (EsSalud), 
PATH, and the World Health Organization (WHO/PAHO), could propose any type 
of breast cancer intervention. An assessment tool, to collect information on breast 
cancer programs and their coverage, finance, and epidemiology, was developed by the 
WHO and sent to the study team leader (INEN). Its results provided key data for our 
analyses and an overview of the current breast cancer activities in Peru 12.
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From a standard set of breast cancer control interventions 17, 18, the study team 
identified a set of 15 interventions relevant to in the Peruvian context, all related 
to breast cancer treatment, early diagnosis, screening or palliative care (Table 2). 
The study team introduced a particular intervention of interest, relating to the 
diagnostic procedure of women with palpable masses detected through clinical breast 
examination (CBE) screening 25, 26. This intervention aims at improving the capacity of 
early breast cancer diagnosis (i.e. confirmation by triple test) during CBE screening, 
by using upfront fine needle aspiration (FNA) first - instead of mammography first 
- at the primary healthcare level (Figure S1). In this way, the number of (technically 
more demanding) mammograms and core biopsies at the primary healthcare level 
could be reduced. The study team also adjusted standard treatment regimes of 
previous WHO-CHOICE analyses, and added therapies for HER2neu positive women 
(Trastuzumab). Furthermore, various combinations of screening age groups (40-69/40-
64/45-69/45-64/50-69/50-64 years) and screening frequencies (annually/biennially/
triennially) were introduced for the screening interventions. Additionally, the team 
defined different screening interventions specifically for rural areas (CBE screening vs. 
mobile mammography units in 40% of the total population) and urban areas (e.g. only 
fixed mammography units in 60% of the total population) according to the Peruvian 
urbanization rate (60%).
We combined the 15 interventions to construct a total of 94 intervention scenarios. 
This includes the current Peruvian situation in which patients of stages I to IV are 
treated at a 50% coverage level, along with preventive counseling (30% coverage) 
and opportunistic screening (15% coverage) 12. Other interventions are evaluated at a 
geographic coverage level of 60%, 80% or 95% (i.e. reaching 95% of those who need 
services) according to standard CHOICE methodology.
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Table 2. Definition and classification of selected interventions for breast cancer control in Peru
Treatment of individual stages # Awareness raising† # Screening† # Palliative Care‡ #
Stage I treatment: lumpectomy with 
axillary dissection and radiotherapy 
(33 fractions).* Eligible patients 
receive tamoxifen** 18, 27 
#4 Basic Awareness Raising (BAR): commu-
nity nurses training program + opportu-
nistic outreach activities by community 
nurses to raise breast cancer awareness 
and educate on breast self examination 
techniques (BSE) + enhanced media 
activities. 28
#13 CBE screening: Clinical breast examina-
tion (CBE) screening (95% coverage) in 
asymptomatically women: community 
nurses training program + active out-
reach screening by community nurses 
+ limited media and awareness raising 
activities. 29
#15-
32
Standard Palliative Care (SPC): pain 
treatment through pain medica-
tion and anti-emetics, palliative 
radiotherapy (8 Gy in 1 boost) for 
eligible patients. Includes end of 
life hospitalization. No home based 
visits.27, 30
All 
except
#11-12, 
91-94
• ages 40-69/40-64/45-64/45-69/50-
69/50-64
• annual/biennial/triennial
Stage II treatment: lumpectomy 
with axillary dissection (70%), or 
modified radical mastectomy (30%) 
followed by adjuvant chemothera-
py*** and radiotherapy (33 or 
25 fractions)* Eligible patients 
receive tamoxifen** or 
chemotherapy. ‡ 18, 27
#5 Mass-media awareness raising (MAR): 
BAR + mass media campaign (weekly 
emissions) 28
#14 Mammography fixed screening urban 
only : Mammography screening urban 
(57% coverage by fixed mammograp-
hy units) in asymptomatic women + 
limited media and awareness raising 
activities. 17
#33-
52
Basic Palliative Care (BPC): SPC + 
palliative care-volunteers training 
program + home based visits by 
volunteers every fortnight. Includes 
end of life hospitalization. 27, 30, 31
#11, 91
• ages 40-69/40-64/45-64/45-69/50-
69/50-64
• annual/biennial/triennial
Stage III treatment: modified radical 
mastectomy followed by adjuvant 
chemotherapy*** and radiotherapy 
(25 fractions).* Eligible patients 
receive tamoxifen.** 18, 27
#6 Mammography screening fixed (urban) 
and mobile (rural): Mammography 
screening fixed (57% coverage by fixed 
mammography units + 38% coverage by 
mobile units) in asymptomatic women 
+ limited media and awareness raising 
activities. 17
#53-
70
Extended Palliative Care (EPC): 
SPC+ BPC apart from community 
nurses instead of palliative care-vo-
lunteers, medication strengthe-
ned with anti-depressants, and 
bisphosphonates. Includes end of life 
hospitalization. 27, 30-32
#12, 
92-94
• ages 40-69/40-64/45-64/45-69/50-
69/50-64
• annual/biennial/ triennialages 40
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Treatment of individual stages # Awareness raising† # Screening† # Palliative Care‡ #
Stage IV treatment: adjuvant 
chemotherapy*** and radiotherapy 
(10 whole +3 boost fractions) + 
Standard Palliative Care. Eligible 
patients receive tamoxifen **18, 27
#7 Mixed Screening: #71-
88
• Urban: Mammography screening urban 
(57% coverage by fixed mammography 
units) only in ages >50 / combined with 
CBE screening in ages <50 urban (57% 
coverage) in asymptomatic women + 
limited media and awareness raising 
activities.17
• Rural: CBE screening all ages in 
non-urban areas (38% coverage) in 
asymptomatically women: community 
nurses training program + active out-
reach screening by community nurses 
+ limited media and awareness raising 
activities.29
• ages 40-69/40-64/45-64/45-69/50-
69/50-64
• annual/biennial/ triennial
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Treatment of individual stages # Awareness raising† # Screening† # Palliative Care‡ #
Stage I to IV combined #8-
10
Upfront FNA (fine needle aspiration) 
after a positive CBE screen, only in 
combination with CBE screening: 
FNA training program for GP/medical 
officer at district hospitals + training 
of cytologists (2 per province/year). 
FNA samples are evaluated at district 
level, and eligible patients referred to 
provincial or national hospitals.33
#33-
34, 
89-
93
• without trastuzumab • Combined only with the most cost 
effective biennial and triennial CBE 
screening intervention
• with trastuzumab in all HER2 
positives (stage I to IV).with 
trastuzumab in early stage HER2 
positives (stage I and II only)
* Radiotherapy generally includes a dose of 50 Gy given in 10-33 fractions or boosts on an outpatient basis 
** Endocrine therapy consists of 20 mg. tamoxifen per day for 5 years. 
*** The (neo)adjuvant chemotherapy combination regimen consists of AC-Taxol: AC given 3-weekly for 4 cycles followed by paclitaxel given weekly for 12 weeks
† Down-staging interventions cause a shift in stage distribution and are only modeled in combination with treatment of all stages (I to IV).
‡ Palliative care interventions BPC and EPC are only applied to stage IV patients, and substitutes Standard Palliative Care.
# Scenario number in supplement (Table S2) and Figure 2
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Mathematical model
The model structure is presented in Figure 1 and includes a healthy state, a deceased 
state, and stage I to IV breast cancer states following the American Joint Committee 
on Cancer (AJCC) 18, 34. To assess health outcomes, WHO-CHOICE employs an 
epidemiological, population based approach. The national breast cancer epidemiology 
is entered into a state transition model, along with background birth, population, 
and mortality rates, to estimate the total number of disability adjusted life years 
(DALYs) experienced over the lifetime (100 years) of the Peruvian population 35. 
The effectiveness of interventions is expressed in changes in case fatality (treatment 
interventions), health state valuations (HSVs), or stage distribution (awareness raising 
and screening interventions). Interventions are taken to be implemented for a period 
of 10 years, after which epidemiological rates go back to their counterfactual level of 
no intervention. The difference in the total number DALYs lived by the population 
between each scenario and the null-scenario gives the population health gains in 
DALYs averted. Consistent with the WHO Global Burden of Disease study, DALYs are 
discounted (at 3% per year) and age weighted.
Figure 1. Graphical representation of the model 
Graphical representation of the model showing the relationships between the different health states through the incidence rates of breast cancer (Ix1–Ix4), 
the different stage specific case fatality rates (Fx1–4), and the background mortality (M). Stage specific relapse rates to stage IV were used to correct the 
disability weights (Rx1–Rx3).
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Effectiveness data
We based epidemiological data on the WHO Global Burden of Disease (GBD) 
study, applied to the population of Peru of 2011 5, 7, 36. The impact of treatment in 
Peru was estimated on the basis of stage specific survival rates (case-fatality) from 
INEN (2000-2010) and previous WHO-CHOICE analyses 18, 37, whereas the impact 
of trastuzumab on case fatality was based on the literature (Table 3) 38. Health 
state valuations originate from disability weights (DWs) of the GBD study, and we 
assumed that interventions affect DWs in stage IV only. The DW for stage I is equal 
to the GDB estimate, while for other stages the GBD long term sequel (0,09) was 
adjusted according to quality of life estimates from the literature 39, 40. The current 
stage distribution of women presenting with breast cancer in Peru was derived 
from INEN (2007-2011) 12, and the impact of the various screening interventions 
on this stage distribution was estimated on the basis of a model following Duffy et 
al. by using proportional detection rates 41. We applied a stage shift from developing 
countries 17 to the Dutch screening program 42, and corrected this shift for locally 
relevant attendance rates (72%) and the Peruvian epidemiology and demography. 
The age specific sensitivity of tests and sojourn times (CBE sojourn times are two-
third that of mammography) were based on the literature 41-43. The effectiveness of 
the awareness raising interventions are based on a study from Malaysia 28 while we 
assumed a twofold effect on stage distribution when applying a mass media campaign.
Cost data
Following standardized WHO-CHOICE methodology on CEA, we used an ingredients 
approach for our costing analysis, in which prices and quantities are separately 
reported. We distinguished patient-level and program-level costs, and to estimate the 
total patient costs of interventions we multiplied the unit costs of patient services with 
the number of patients requiring these services.
Unit costs of patient services were based on the principles of micro-costing, including 
detailed resource utilization patterns and prices for each procedure (Table S1, Table 
4). INEN provided these unit cost to a great level of detail, except for the cost of 
facilities (buildings, rooms) and the cost for the transportation of drugs and supplies. 
We derived the transportation multipliers, the size, price and annualization factors for 
facilities, from a standard WHO-CHOICE database and applied them to each eligible 
item 20. 
We estimated the costs for the FNA intervention through a patient management 
scheme from the international literature, as this data was not yet available in Peru 33. 
We then used average weighted resource patterns for FNA, based on observational 
studies from different countries 44-49, and assumed similar final outcomes for both CBE 
screening with upfront FNA and usual CBE screening (Figure S1). 
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Program-level costs capture management, administrative, media and law-enforcement 
costs, and costs for training of healthcare personnel. These costs were based on 
estimates from WHO-CHOICE and from Peruvian program managers (INEN). Media 
and operating costs (i.e. prices for broadcasting, flyers, and posters) were based on 
local inventories of prices, also provided by INEN. 
For all interventions, we also included costs of diagnostic tests for women presenting 
with initial symptoms without breast cancer (true-negatives), and assumed the ratio 
of tested negatives vs. tested positives to be 16.4:1 in non-screened populations and 
21.5:1 in screened populations 50, 51. Single treatment scenarios also include the costs of 
diagnosing all other stages, and regarding screening interventions, we included costs for 
evaluating false positives 52.
All costs were estimated in 2012 Peruvian Soles and converted to U.S. dollars (US$) 
using the 2012 exchange rate (1US$ = 2,603SOL). Both health effects (DALYs) and 
costs (US$) were discounted at an annual rate of 3%. 
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Table 3. Case fatality rates, disability weights and stage distribution used for intervention combinations in Peru
Case fatality rates* Disability weights** Stage distribution***
Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV % in 
stage I
% in 
stage II
% in 
stage III
% in stage 
IV
Untreated 0.021 0.065 0.156 0.311 0.086 0.097 0.104 0.375 7.0% 36.4% 43.5% 13.0%
Treatment only 0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 7.0% 36.4% 43.5% 13.0%
Treatment only + Trastuzumab in all HER2 
positives
0.006 0.038 0.086 0.247 0.086 0.097 0.104 0.154 7.0% 36.4% 43.5% 13.0%
Current country specific situation (50% cover-
age), annual opportunistic screening (15%) and 
free consultation (30%)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.153 7.0% 36.4% 43.5% 13.0%
Basic Palliative Care (BPC) 0.006 0.040 0.093 0.275 0.0153 13.0%
Extended Palliative Care (EPC) 0.006 0.040 0.093 0.275 0.0152 13.0%
Basic Awareness Raising (BAR) 0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 10.2% 20.1% 44.8% 24.8%
Mass media Awareness Raising (MAR) 0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 21.1% 41.5% 24.1% 13.3%
Annual CBE screening (age 40-69/40-64/45-
64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 29.2%-
15.8%
31.2%-
16.9%
30.4%-
51.5%
9.3%-
15.8%
Biennial CBE screening (age 40-69/40-64/45-
64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 26.9%-
14.0%
28.8%-
14.9%
33.9%-
54.4%
10.4%-
16.7%
Triennial CBE screening (age 40-69/40-64/45-
64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 25.4%-
12.8%
27.2%-
13.7%
36.3%-
56.2%
11.1%-
17.2%
Annual mammography screening FIXED 60% 
(age 40-69/40-64/45-64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 26.2%-
19.7%
29.7%-
22.7%
33.6%-
43.9%
10.5%-
13.7%
Biennial mammography screening FIXED 60% 
(age 40-69/40-64/45-64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 25.7%-
19.0%
29.1%-
22.0%
34.4%-
44.9%
10.8%-
14.0%
Triennial mammography screening FIXED 60% 
(age 40-69/40-64/45-64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 25.2%-
18.6%
28.6%-
21.5%
35.1%-
45.7%
11.0%-
14.3%
Annual mammography screening FIXED/MOBILE 
(age 40-69/40-64/45-64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 37.4%-
26.5%
40.0%-
28.4%
17.3%-
34.5%
5.3%-
10.6%
Biennial mammography screening FIXED/MOBI-
LE (age 40-69/40-64/45-64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 36.5%-
25.4%
39.0%-
27.2%
18.8%-
36.2%
5.7%-
11.1%
Cost-effectiveness analysis of breast cancer control interventions in Peru
1315
Case fatality rates* Disability weights** Stage distribution***
Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV % in 
stage I
% in 
stage II
% in 
stage III
% in stage 
IV
Triennial mammography screening FIXED/MOBI-
LE (age 40-69/40-64/45-64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 35.8%-
24.6%
38.3%-
26.4%
19.9%-
37.5%
6.1%-
11.5%
Annual CBE/mammography screening MIXED 
(age 40-69/40-64/45-64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 33.6%-
22.3%
36.0%-
23.8%
23.3%-
41.3%
7.1%-
12.6%
Biennial CBE/mammography screening MIXED 
(age 40-69/40-64/45-64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 32.1%-
20.9%
34.3%-
22.3%
25.7%-
43.5%
7.9%-
13.3%
Triennial CBE/mammography screening MIXED 
(age 40-69/40-64/45-64/45-69/50-69/50-64)
0.006 0.040 0.093 0.275 0.086 0.097 0.104 0.154 31.0%-
19.9%
33.2%-
21.3%
27.4%-
45.0%
8.4%-
13.8%
Current country specific situation: Current situation in Peru with treatment coverage of 50%, annual opportunistic screening (15%) and free preventive consultations (30%)12.
* Derived from Bland et al. and stage I and II corrected for the addition of chemotherapy 37. For trastuzumab CFs were multiplied with 0.66 38, for eligible patients (eligibility = 12.7% stage I, 12.07%, stage II, 22.0%, stage III, 30.4% stage IV) 53.
** The DW for stage I is equal to the GDB estimate, while for other stages the GBD long term sequel (0,09) was adjusted according to utilities from the literature [7,32,33] and corrected for relapse to stage IV. Relapse rates were derived from Adjuvant Online 54.
*** Present stage distribution is based on INEN public sector 12. Effects of MAR derived from Devi et al 28. Effects of screening interventions were based on stage shifts from baseline 17 to the stage distribution in The Netherlands42 . Stage shifts were adapted 
by calculating relative differences in detection rates between The Netherlands and Peru 41. Calculations included age specific incidence, prevalence 7, sojourn time 41, sensitivity 43 and attendance rates (72% in Peru)
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Table 4. Average utilization of main diagnostic and treatment services and unit costs per patient
Procedure Ingredients Stage I Stage II Stage III Stage IV Palliative 
(SPC)†
Unit cost per 
patient (US$)
Initial diagnosis and 
evaluation during 
treatment
Medical consultation 2 2 2 2 6.22
Core biopsy procedure 1 1 1 1 45.02
Specimen examination 1 1 1 1 9.76
Bilateral Mammography 1 1 1 1 14.24
Echo of breast 1 1 1 1 6.20
Echo of abdominal/pelvic area 1 1 1 1 10.49
Liver function tests 1 1 1 1 2.07
Chest X-ray 1 1 1 1 6.79
Bone scan 1 1 1 1 46.01
CT of chest 1 1 1 1 96.37
CT of abdominal/pelvic area 1 1 1 1 115.50
Multidisciplinary consult 1 1 1 1 100.90
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Procedure Ingredients Stage I Stage II Stage III Stage IV Palliative 
(SPC)†
Unit cost per 
patient (US$)
Treatment Pre-operative tests 1 1 1 - 86.57
Surgical risk analysis 1 1 1 - 20.18
Surgery 1 (lumpectomy) 1 (lumpectomy /modified 
radical mastectomy)
1 (modified radical 
mastectomy)
- 835.88 / 951.77
Radiotherapy consult 1 1 1 1 7.64
Radiotherapy planning & first administration* 1 1 1 1 224.20
Radiotherapy session administration* 32 29.6 24 12 23.36
AC regimen** - 4 4 4 104.00
Taxol regimen** - 12 4 4 134.47
Hepatic tests - 12 12 12 22.14
Renal tests - 12 12 12 39.38
Coagulation tests - 12 12 12 115.40
CT - 2 4 4 115.50
Bone scan - 2 2 2 46.01
% receiving endocrine treatment*** 1680 1680 336 336 0.18
% receiving pain medication 1 9136.87
% receiving emetics 1 1903.52
* Radiotherapy generally includes a dose of 50 Gy given in 10-35 fractions or boosts on an outpatient basis.
** The (neo) adjuvant chemotherapy combination regimen consists of AC-Taxol: AC given 3-weekly for 4 cycles followed by paclitaxel given weekly for 12 weeks or 4 weeks.
*** Endocrine therapy consists of 20 mg. tamoxifen per day for 5 years. 
† Palliative care is only applied to stage IV patients. Standard Palliative Care (SPC) does not include home based visits. Medication includes Tramadol 50 ml, Morphine 0.02 mg, Fentanyl 50 mg, Parecoxib 40 mg, Triamcinolone 50 mg, Diazepam, Lidocaine, 
epidural injections, Omeprazol 40 mg, Haloperidol 5mg, Levosulpiride 25mg.
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Cost-effectiveness analysis
The average cost effectiveness ratio (ACER) for each intervention is calculated by 
dividing the total costs of an intervention by its corresponding effects, relative to the 
comparator situation of no intervention. 
In addition to these ACERs, incremental cost effectiveness ratios (ICERs) are reported 
for the successive set of interventions that can be purchased at expanding levels of 
resource availability, starting with the intervention with the lowest cost per DALY 
averted, then moving to the next most cost-effective intervention. The order in 
which interventions can be selected according to their ICER is called an expansion 
path, and only interventions that are both more effective and less costly than 
other (combinations of) interventions are considered on this expansion path. The 
incremental cost-effectiveness ratios (ICERs) for those interventions are calculated by 
dividing the incremental costs by the incremental health effects.
CEA results should be furthermore interpreted according to a defined set of cost-
effectiveness thresholds. WHO-CHOICE denotes an intervention as “cost-effective” if 
it produces a healthy year of life for less than three times the gross domestic product 
(GDP) per capita, and as “very cost-effective” if it produces a healthy year of life for 
less than the GDP per capita (human capital approach) 55. In Peru, this means that 
interventions that cost less than $4,608 per DALY averted can be considered very 
cost-effective, and interventions that cost between $4,608 and $12,204 can be 
considered as cost-effective.
Sensitivity Analysis
We performed a deterministic sensitivity analysis to assess the robustness of the 
results to potential changes in key assumptions regarding the model parameters. 
Based also on the results of previous sensitivity analyses 16-18, the baseline case fatality 
rates and DWs were varied +/- 25% and we used other sources for Peru’s current 
case fatality rates 12 and current stage distribution 56. The effect of awareness raising 
interventions was reduced by 25%, and we lowered attendance rates of screening 
interventions and the sensitivity of CBE and mammography tests (-25%). Regarding 
costs, we varied the transportation multipliers (+/- 25%), and varied the unit costs of 
CBE and mammography (+/- 25%) as well as the costs for FNA (+/- 25%).
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Results
A total of 94 single and combined intervention strategies were assessed and their 
annual cost, effects, and cost-effectiveness are provided in Table S2 and shown 
graphically in Figure 2. The annual treatment costs for breast cancer stages I to IV, vary 
between 7.1 million (treatment of stage I) and 23.0 million US$ (treatment of stage II). 
Treatment of all stages costs more than $58 million (95% coverage) and expanding this 
by providing trastuzumab in all stages costs an extra $25 million ($83.8 million in total), 
while the additional cost for providing trastuzumab only in stage I&II is about $7 million 
($65.4 million in total). The additional costs for providing basic or extensive palliative 
are $1.2 million and $1.6 million ($44.4 and $59.5 million in total) respectively, whereas 
awareness raising interventions cost $59.8 million (BAR) and $56.0 million (MAR). 
The costs of screening interventions generally increase with the screening frequency, 
e.g. in age groups 40 to 69, the costs are $74.3 to $101.5 million for annual screening 
strategies and $63.4 to $71.4 for triennial screening strategies. Furthermore, when age 
group 40 to 45 is included in the screening strategy or annual screening frequencies 
are applied, costs increase relatively more as compared to age group 65 to 69 and 
triennial screening frequencies. Screening costs also increase when a mobile screening 
component is applied, i.e. the costs per mammogram or CBE with a mobile unit are 
about 20% higher.
The upfront FNA component reduces the costs of CBE screening (as compared to 
the usual CBE screening strategy) by an estimated $3.48 per women diagnosed (Figure 
S1). As a result, CBE screening interventions combined with upfront FNA have slightly 
lower patient costs but higher program and training costs.
In the individual stage I to IV treatment interventions the annual number of DALYs 
averted vary between 451 (stage IV) and 2,900 (stage II). Jointly these interventions 
can avert 6,757 DALYs. The addition of trastuzumab to eligible women in stage I&II 
only averts 313 extra DALYs (a total of 7,080 DALYs), whereas providing trastuzumab 
to eligible women in all stages can avert 1128 extra DALYs (a total of 7,895 DALYs). 
The addition of palliative care, both basic (BPC) and extended (EPC), only adds very 
few DALYs. Awareness raising interventions, combined with treatment of all stages and 
standard palliative care, avert between 5,306 (BAR) and 12,115 DALYs (MAR). 
The various screening intervention combinations avert between 6,000 and 18,000 
DALYs, generally much more than treatment interventions only. By increasing screening 
frequencies and by widening age groups, screening interventions can avert more 
DALYs. With regards to the age group of screening, including the oldest age group 
(65-69) seems to avert relatively more DALYs as compared to including the youngest 
age group (40-45). Annual screening through fixed (urban) and mobile (non-urban) 
mammography units has the most health impact, and can avert more than 18,000 
DALYs when applied in age group 40 to 69 and combined with EPC.
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Average cost-effectiveness ratios (ACERs) of the individual treatment interventions 
range between $5,406 (stage I treatment) and $48,5676 (stage IV treatment) per 
DALY averted. Treatment of all stages costs $8,605 per DALY averted costs around 
$10,000 per DALY averted when trastuzumab is added. Palliative care interventions 
costs $8,782 (BPC) and $8,832 per DALY averted (EPC).
With regards to current breast cancer program in Peru, the ACER of this scenario 
(scenario #3) is $8,426 per DALY averted. The ACER of mass media awareness raising 
(MAR) is $5,650 per DALY, yet, basic awareness raising (BAR) costs $13,713 per DALY.
Screening intervention combinations have ACERs ranging from $4,125 to $10,939 
per DALY. The most cost-effective screening intervention in our analysis is triennial 
fixed mammography screening (age 45-69) in urban areas combined with mobile 
mammography screening (age 45-69) in non-urban areas, which costs $4,125 per 
DALY averted.
Figure 2 shows the cost-effectiveness thresholds of three times ($12,204) and one 
time ($4,608) the Peruvian GDP per capita per DALY averted (dotted lines). This 
figure and Table 5 also show the expansion path for breast cancer control, i.e. the 
order in which interventions should be implemented at different levels of resource 
availability on the basis of incremental cost-effectiveness ratio (ICER). This path shows 
that triennial fixed mammography screening (age 45-69) in urban areas combined with 
mobile mammography screening (age 45-69) in non-urban areas is the optimal choice 
($4,125 per DALY averted, scenario #67), followed by triennial fixed mammography 
screening (age 40-69) in urban areas combined with mobile mammography screening 
(age 40-69) in non-urban (ICER of $5,659 per DALY averted, scenario #65). After 
that, the next best intervention that follows from this expansion path is biennial 
mammography screening (40-69 years) with fixed and mobile units (ICER $27,477 per 
DALY, scenario #59). These screening interventions are all combined with treatment 
of all stages and standard palliative care (SPC). Eventually, annual fixed and mobile 
screening combined with extended palliative care and trastuzumab (scenario #94) is 
the most extensive intervention with an ICER of $87,243 per DALY averted. 
Note that of the aforementioned interventions, the ICERs of only 2 interventions 
(scenario #67 and #65) are beneath the proposed cost-effectiveness thresholds. 
Therefore, strictly interpreted, they are the only candidates for implementation in 
Peru according to the rules of allocative efficiency. Additionally, other interventions 
(scenarios #4, #53, #55, #60, #83, #85, #90-#93) are not on the expansion path 
(i.e. dominated) and should therefore not be considered as well. However, as these 
small differences in ICERs are likely not relevant at the policy level, we nevertheless 
consider interventions on - and close to - the expansion path as potential candidates 
for implementation in Peru (Table 5). 
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Figure 2. Cost-effectiveness frontier 
Cost-effectiveness of breast cancer interventions and expansion path according to ICER (Incremental cost-effectiveness ratio). Dotted lines represent the cost-effectiveness threshold of 3*GDP/capita/DALY averted (12.204 US$/DALY) and 1* GDP/capita/
DALY (4.068 US$/DALY).
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Table 5. Recommended interventions according to their incremental cost-effectiveness ratio (ICER), position in expansion path and budget impact
Scenario 
number 
(#)
Intervention scenarios Coverage 
level (%)
Patients 
per year
Annual treat-
ment costs**
Annual 
program 
costs**
Annual 
training 
costs**
Annual total 
costs**
Cost per 
patient a 
year**
DALYs 
averted a 
year***
DALYs averted 
per patient a 
year***
ACER ICER
4 Stage I treatment & relapse 
only
95% 1,602 6,582,278 515,816 29,227 7,127,321 4,449 1,318 0,82 5,406 Dominated
85 Stage I to IV treatment 
with triennial MIXED 
screening: URBAN (45-49 
CBE) (50-69 MM FIXED) 
60%/ RURAL (CBE 45-69) 
40%*
95% 4,402 53,035,136 10,396,581 276,684 63,708,401 14,473 14,308 3,25 4,453 Dominated
83 Stage I to IV treatment 
with triennial MIXED 
screening: URBAN (40-49 
CBE) (50-69 MM FIXED) 
60%/ RURAL (CBE 40-69) 
40%*
95% 4,402 53,577,050 10,396,581 276,684 64,250,315 14,596 14,959 3,40 4,295 Dominated
89 Stage I to IV treatment 
with most efficient trienni-
al MIXED: URBAN (40-49 
CBE) (50-69 MM FIXED) 
60%/ RURAL (CBE 40-69) 
40%*+ FNA*
95% 4,402 53,557,982 11,208,251 292,272 65,058,506 14,779 14,959 3,40 4,349 Dominated
90 Stage I to IV treatment 
with most efficient trienni-
al MIXED: URBAN (40-49 
CBE) (50-69 MM FIXED) 
60%/ RURAL (CBE 40-69) 
40%* + FNA + BPC
95% 4,402 53,539,583 12,511,232 518,783 66,569,598 15,123 14,961 3,40 4,450 Dominated
67 Stage I to IV treatment 
with triennial mammograp-
hy screening (45-69 years) 
FIXED 60%/MOBILE 40%*
95% 4,402 54,944,080 13,423,175 350,727 68,717,982 15,611 16,657 3,78 4,125 4,125
91 Stage I to IV treatment 
with most efficient 
triennial FIXED/MOBILE 
screening strategy (FIXED/
MOBILE, 45-69) + BPC
95% 4,402 54,804,394 14,726,156 577,237 70,107,788 15,926 16,658 3,78 4,209 Dominated
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Scenario 
number 
(#)
Intervention scenarios Coverage 
level (%)
Patients 
per year
Annual treat-
ment costs**
Annual 
program 
costs**
Annual 
training 
costs**
Annual total 
costs**
Cost per 
patient a 
year**
DALYs 
averted a 
year***
DALYs averted 
per patient a 
year***
ACER ICER
65 Stage I to IV treatment 
with triennial mammograp-
hy screening (40-69 years) 
FIXED 60%/MOBILE 40%*
95% 4,402 57,581,446 13,423,175 350,727 71,355,347 16,210 17,123 3,89 4,167 5,659
60 Stage I to IV treatment 
with biennial mammograp-
hy screening (40-64 years) 
FIXED 60%/MOBILE 40%*
95% 4,402 62,065,226 15,710,263 370,211 78,145,701 17,752 17,338 3,94 4,507 Dominated†
59 Stage I to IV treatment 
with biennial mammograp-
hy screening (40-69 years) 
FIXED 60%/MOBILE 40%*
95% 4,402 63,804,007 15,710,263 370,211 79,884,482 18,147 17,433 3,96 4,582 27,477†
55 Stage I to IV treatment 
with annual mammography 
screening (45-69 years) 
FIXED 60%/MOBILE 40%*
95% 4,402 74,070,789 17,997,352 389,696 92,457,837 21,004 17,385 3,95 5,318 Dominated†
53 Stage I to IV treatment 
with annual mammography 
screening (40-69 years) 
FIXED 60%/MOBILE 40%*
95% 4,402 83,070,430 17,997,352 389,696 101,457,478 23,048 17,857 4,06 5,682 Dominated†
94 Stage I to IV treatment 
with most expensive 
screening strategy (annual, 
FIXED60%/MOBILE40%, 
40-69 ) + EPC + trastuzu-
mab (all stages)
95% 4,402 103,306,498 19,638,424 625,949 123,570,871 28,072 18,737 4,26 6,595 87,243†
ICER = Incremental cost effectiveness ratio, ratio of additional cost per additional life-year saved when next intervention is added to a mix (additional US$ per additional DALY saved;. ACER = Average cost-effectiveness ratio compared to the do nothing-scenario 
(US$ per DALY averted); MIXED screening: combines both CBE screening and mammography screening elements in the screening program;. URBAN: program specified for urban population, covers about 60% of the total population; RURAL: program specified 
for rural population, covers about 40% of the total population; CBE: clinical breast examination screening; MM: mammography screening; FIXED: screening program based on fixed mammography units; MOBILE: screening program based on mobile screening 
unit; FNA: upfront fine needle aspiration program; BPC: basic palliatice care program; EPC: extende palliative care program.
* These scenarios include Standard Palliative Care (SPC)
** In 2012 US$ (1 SOL = 0,384 US$)
*** DALYs, disability-adjusted life-years (age weighted, 3% discounted) . DALYs are averted over a 100 year period but attributed to the implementation period of 10 years.
† These interventions have ICERs higher than the 3 times GDP per capita per DALY threshold and can, strictly speaking, not be considered cost-effective.
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Sensitivity Analysis
Sensitivity analysis showed that our model is most sensitive to alternative assumptions 
on screening attendance and the sensitivity of screening devices. Varying the case 
fatality rates and current stage distribution also impacts our results, whereas alternative 
assumptions on unit costs for FNA or mammography, transportation multipliers or 
DW’s have less impact (Table S3). Lowering screening attendance from 72% to 54% 
(-25%) would increase the ACERs with about 26%, while lower test sensitivities of 
CBE and mammography screens (-25%) would increase the ACERs with about 24%. 
If higher case-fatality rates were assumed (+25%), representing poorer survival, the 
ACERs of the interventions in table S3 would increase about 22%. Lower case-fatality 
rates would result in a 15% decrease of these ACERs. Increased intervention costs due 
to respectively higher unit costs of FNA, mammograms and transportation multipliers 
(+25%) increase the ACERs between 0% and 9%.
Discussion
We have quantified the health effects, costs, and cost-effectiveness of a broad range 
of interventions for breast cancer control in Peru. The results were obtained by means 
of a dynamic population model, using consistent demographic and epidemiological 
data of the populations, allowing general comparisons of the costs and effects of the 
interventions studied. 
Our results provide important information on strategies for breast cancer control 
in Peru and suggest that the current situation in Peru could be improved through 
implementation of triennial or biennial mammography screening strategies, combined 
with treatment of all strategies and standard palliative care. These strategies seem the 
most cost-effective in Peru, and costs between $68 and $80 million per year. Probably 
also cost-effective, but less expensive, are triennial screening strategies through 
combining mammography and CBE screening. These strategies, combined with or 
without basic palliative care or upfront FNA, cost between $64 and $66 million per 
year. Annual screening strategies come with higher cost to the healthcare system and 
with relatively lower effects compared to tri- or biennial screening, and are therefore 
not recommended from an economic perspective.
Of the abovementioned interventions, only triennial mammography screening 
strategies can be labeled cost-effective (scenario #67 and #65). However, considering 
the uncertainty on the effectiveness of these interventions, and considering the 
inappropriateness to use this threshold as the sole criterion for choosing interventions 
at the policy level, we suggest considering all the interventions near the expansion 
path for planning (long term) strategies (Table 5). Besides the efficiency aspects of the 
studied interventions, we believe the choice of intervention should also relate to other 
aspects of the health system such as budget impact, equity and feasibility. These aspects 
are discussed below.
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First, compared to mammography screening, CBE screening with upfront FNA implies 
a simpler and technically less demanding approach at the primary healthcare level. 
Although the total costs of adding the upfront FNA component are slightly higher 
(about $240,000 per year), patient costs can be slightly reduced due to the lower 
costs of the FNA strategy ($3.48 saved per diagnosis) and the implementation of 
this intervention has been demonstrated in a very rural area 25. This intervention, 
which includes an awareness raising of signs and symptoms component, could be 
recommended above usual CBE screening strategies in Peru for feasibility reasons, 
especially in rural areas. 
Second, although treatment interventions are - on themselves - not economically 
attractive, treatment is an integral component of the continuum of care and essential 
to be scaled up if any screening intervention is implemented. Only 60% of the Peruvian 
population is currently insured, creating high barriers to accessing care for many 
Peruvians. Besides treatment interventions, awareness raising of signs and symptoms 
(particularly in areas where breast cancer is diagnosed in late stages) is imperative for 
early detection 57. Also, if any form of early detection or screening is implemented, 
patients need to be referred through to a comprehensive system with low social 
and financial barriers. This could partly be managed by reimbursing patients and their 
families for travel and accommodation. Efforts to reach universal coverage should 
therefore continue and a gradual increase in coverage of current treatment services, 
along with improvements of referral systems should first - or simultaneously - be 
established in Peru. 
Third, stage IV treatment only (including standard palliative care (SPC)) is the least 
economically attractive intervention (ACER of $48,576 per DALY), and generally 
palliative care cannot be recommended from an economic perspective. If management 
of stage IV patients entails home based visits (BPC), patient costs slightly decrease 
due to a reduction of hospitalization days. However, the extra training and program 
cost for organizing this palliative service model outweigh these savings and BPC is not 
cost-effective either. Nevertheless, this intervention costs only slightly more than the 
current SPC ($1.2 million more) and allows patients to decease at home, where family 
and friends are able to support and spend their last moments with the patient. For 
this reason, and regarding the many patients in advanced stages currently, it could be 
meaningful to provide basic palliative care in Peru.
Fourth, the addition of trastuzumab to all eligible patients (about 15% of all patients), 
is less economically attractive than treatment of all stages (ACER of $10,620 vs. ACER 
of $8,605 per DALY). Moreover, it comes with an additional cost of over $25 million 
($83.8 million in total) - almost 45% higher than the budget for treatment of all stages. 
If trastuzumab is given only to eligible patients in stage I and II, this ACER is lower 
($9,247 per DALY) and the additional costs are about 12% higher ($65.5 million in 
total). This intervention should therefore be preferred if trastuzumab is added as a 
therapeutic option for breast cancer control. The addition of trastuzumab to all eligible 
patients is not recommended for Peru.
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Fifth, breast cancer screening highly depends on the availability of human resources, 
facilities and devices for proper diagnosis and treatment. It is necessary to secure 
adequate infrastructure, equipment and human resources before any screening 
activities can commence. In addition, as the current health system in Peru is fragmented 
and in a decentralization process, it seems very difficult to achieve nationwide, 
organized screening. If screening is provided by competitive public and private actors, 
all with their own target populations in the same areas, we recommend either law 
enforcement and strong leadership to negotiate a plan with all these actors, or installing 
a separate public operation that could provide the entire screening programme. 
Attendance rates are perhaps equally important for both the success of screening and 
the equitable distribution of its health outcomes. In this, appropriate education and 
information is essential and although most screening studies show positive results on 
stage distribution in developing countries 29, 58, 59, these interventions can easily fail when 
education and information are neglected. Screening or early detection communications 
strategies should also include clear messages on the benefits and harms of the 
different early detection modalities 57. Our sensitivity analysis furthermore showed that 
if attendance rates reduce from 72% to 54%, the ACERs of screening interventions 
increase with 26%.
We therefore recommend a thorough evaluation of Peru’s current screening activities, 
so these barriers become more transparent and future screening programs can better 
guarantee adequate attendance and equal access.
Sixth, mobile screening units are generally more accessible in non-urban areas as 
opposed to fixed mammography units and therefore more effective. Mobile screening 
could also lead to a more equal distribution of health outcomes and could therefore 
be considered if screening is implemented. However, the costs for reaching out to 
the non-urban areas (30%-40% of total population) by mobile units are high as the 
cost of each screen increases with at least 20%. A combination of CBE screening and 
mammography screening (mixed screening) seems a cost-effective alternative with 
lower budget impact, and less complex to implement in non-urban areas compared to 
mobile mammography screening. Hence, we generally recommend Peru to consider 
a mixed screening strategy (CBE screening below 50 and mammography screening 
in women older than 50 for urban areas, and CBE screening in all ages for non-urban 
areas) for feasibility and budgetary reasons.
Seventh, and in general, the current budget for controlling priority cancers in 
Peru (colo-rectal, stomach, cervical, breast, prostate, lymphomas, leukemia) has 
been increased to over $25 million for 2012 11. Despite this impetus, the full 
implementation of the broad range of breast cancer interventions already requires 
more budget. Treatment of all patients with breast cancer would costs around 
$58 million per year, and screening will at least cost another $5 million per year. 
Moreover, the budget for (breast) cancer control also faces competition with other 
healthcare interventions. International literature suggests that interventions for 
communicable diseases and preventive interventions for non-communicable diseases 
are economically more attractive compared to breast cancer interventions 20, 60, 61. 
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With regards to the economic attractiveness of screening interventions for 
other non-communicable diseases, breast cancer screening seems to compare 
worse to cervical screening but better compared to colorectal screening 16. 
Yet, these international estimates should be carefully interpreted for national level 
decision making. Given these budgetary constraints, the MoH in Peru could decide to 
implement less expensive interventions such as CBE screening, mass-media awareness 
raising, or treatment only. This would however introduce an inefficient use of resources 
and instead we suggest to gradually expand the recommended screening interventions, 
starting at lower -more affordable- coverage levels. The MoH in Peru could for 
example first increase treatment coverage and select an urban area to demonstrate 
triennial CBE and mammography screening in currently targeted women (45-64 years). 
In a non-urban area, awareness raising and CBE screening could first be initiated and 
combined with upfront FNA.
Once a reasonable increase in coverage is reached, the program could expand to 
screening women 45 to 69 years, or 40-69 years old, possibly by mobile units providing 
both mammography and CBE. These mobile units could be shared for the screening 
and early detection activities of the other priority diseases. The gradual expansion will 
give extra time to train the required human resources and to negotiate more budget 
for infrastructure and equipment. 
Our study has a number of limitations. First, a national cancer registry in Peru is not 
yet available and local data on breast cancer epidemiology and patient resource 
patterns were derived from different sources. Breast cancer treatment practices 
probably differ between the many public and private institutions. Since our data was 
mostly based on composite hospital data from the urban, public sector, our results 
may not be representative for the whole country. These limitations indicate the need 
to start a national cancer registry in Peru. Second, evidence on the effectiveness 
of awareness raising, CBE and mammography screening in Peru and many other 
countries is absent. To arrive at Peruvian estimates we used a model approach that 
has previously been applied in a range of other studies and was also considered 
credible by the expert panel in our study. Also, our sensitivity analysis shows that 
using alternative assumptions on case fatality rates, attendance rates or the sensitivity 
of screening devices lead to significant differences in cost-effectiveness. A combined 
effect of these factors could change the cost-effectiveness of the interventions under 
study further. However, as these factors have a similar impact on all interventions 
under study, it is unlikely that this combined effect would change our study conclusions. 
Despite these limitations, the results of our model show similarities with results 
from other models 59, 62, 63. Third, as information on the patient resource patterns of 
the upfront FNA strategy was limited in Peru, we assumed similar final outcomes for 
both CBE screening with upfront FNA and the usual CBE screening strategy (i.e. the 
number benign or malignant outcomes in both arms in Figure S1).However, FNA 
could also cause structural distortions that may render further imaging accuracy. 
Fourth, in the absence of reliable data and following the health care perspective of the 
Peruvian MoH, we did not include travel costs or productivity losses of patients seeking 
or undergoing care.
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Including these cost would have probably led to increased cost generally, and 
particularly for women with advanced stage breast cancer 64, 65. WHO-CHOICE 
analyses aim to provide broad indications of cost-effectiveness on a range of 
interventions to inform general policy discussions rather than to deliver very precise 
estimates on a specific intervention and the above limitations are a manifestation of 
this.
Conclusions
In summary, taking in consideration cost-effectiveness and other factors, our analysis 
suggests that CBE screening with upfront FNA in non-urban settings (age 40-69), 
combined with both CBE and fixed mammography screening in urban settings (age 40-
69), could be a preliminary, cost-effective and feasible option for Peru. A combination 
of fixed and mobile mammography screening, due to its high budget impact and the 
challenging implementation characteristics, should perhaps be preferred on the long 
term when the economic and health system conditions improve. However, whichever 
screening modality is used, awareness raising of signs and symptoms, cancer diagnosis, 
cancer treatment and basic palliative care services should be improved simultaneously 
and barriers to early detection and breast cancer care along the continuum should 
also be explored and dissolved. As population based screening programs are very 
complex and resource intensive, particularly mammography screening, we suggest 
Peru to focus initially on triennial screening in women currently targeted (age 45-64) 
in urban and non-urban demonstration areas and gradually expand to the proposed 
program. Annual screening strategies, late stage treatment and trastuzumab therapy are 
generally not economically attractive.
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Supporting information
Figure S1. Comparison of usual CBE screening strategy and CBE screening with upfront FNA, and level of execution.
CBE screening with upfront FNA (fine needle aspiration): after a positive CBE screen (about 4% of the CBE screened population) women receive FNA. Depending on the FNA test results, mammo-
graphy (MM) or core needle biopsy (CNB) is performed as part of the triple test (physical examination, mammography, needle biopsy) for final breast cancer diagnosis.
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Table S1. Example of micro costing study results (i.e. core biopsy), and their modifications in Peru
CORE BIOPSY MICRO COSTING Multiplier drugs/
goods*
HUMAN RESOURCES  Time (min)  HR wage HR per min. Cost per procedure
Medical doctor  10  4,500.00 0.50000 5.00000
Nursing assistent  10  1,800.00 0.20000 2.00000
Total      7.00000
REUSABLE ITEMS  Time (min)  Buying price Useful Life Depreciation per min. Cost per procedure
Trolley   10 500.00 10 0.00010 0.00096
Metal stretcher   10 968.00 10 0.00019 0.00187
Total      0.00283
DISPOSABLE ITEMS Presentation Buying price Unit definition quantity used Price per unit Cost per procedure
1. Activity: Skin Cleaning      
Gauze (x 2 und)   Pack 3 0.45442 1.36325
Alcohol   Ml 1 0.02079 0.02079
Formaldehyde   Ml 5 0.02140 0.10700
Plaster   Cm 20 0.01067 0.21333
2. Activity: Procedure      
5cc disposable syringe. C / A 21x1 1/2"   Piece 1 0.13000 0.13000
Disposable needle 25X5/8X100   Piece 1 0.06800 0.06800
21x1 disposable needle 1/2X100   Piece 1 0.06800 0.06800
Biopsy Needle 14 x 10   Piece 1 90.25000 90.25000
25.10cm x 24.5cm Paper Towel x 175 sheets 175 6.46 Sheet 4 0.03691 0.14766
Germicidal Soap Liquid x 800ml 800 11.00 Ml 6 0.01375 0.08250
Total      92.45053 106.32366
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CORE BIOPSY MICRO COSTING Multiplier drugs/
goods*
FACILITIES** Time (min) Size Useful Life Replacement 
costs per m2
cost per m2 Cost per procedure
Examination / procedure room 12.5 12.5 15 3120 0.17265 0.44962
DRUGS & MEDICATION Presentation Buying price Unit definition quantity used Price per unit Costs per procedure
Xilocaine 2%   Fco 1 3.50000 3.50000
3.50000 5.20205
TOTAL COSTS 102.95 118.52854
This procedure does not include specimen examination.
* Drug and goods multipliers are derived from WHO-CHOICE database and are used to correct for cost of shipping and transportation. Multipliers are 1,4863 for drugs, and 1,1501 for goods.
** Details on facilities also derived from CHOICE database. Annualization (r=3%) is: A= ((1+r)^useful life-1)/(r*(1+r)^useful life). Maintenance costs for facility is 7%, capacity utilization is 240 working days for 8 hours a day 20. 
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Abstract
Objective
 This paper reports the most cost-effective policy options to support and improve 
breast cancer control in Costa Rica and Mexico. 
Methods
Total costs and effects of breast cancer interventions were estimated using the 
health care perspective and WHO-CHOICE methodology. Effects were measured 
in disability-adjusted life years (DALYs) averted. Costs were assessed in 2009 
United States Dollars (US$). To the extent available, analyses were based on locally 
obtained data.
Results
In Costa Rica, the current strategy of treating breast cancer in stages I to IV at 
a 80% coverage level seems to be the most cost-effective with an incremental 
cost-effectiveness ratio (ICER) of US$4,739 per DALY averted. At a coverage level 
of 95%, biennial clinical breast examination (CBE) screening could improve Costa 
Rica’s population health twofold, and can still be considered very cost-effective 
(ICER US$5,964/DALY). For Mexico, our results indicate that at 95% coverage a 
mass-media awareness raising program (MAR) could be the most cost-effective 
(ICER US$5,021/DALY). If more resources are available in Mexico, biennial 
mammography screening for women 50-70yrs (ICER US$12,718/DALY), adding 
trastuzumab (ICER US$13,994/DALY) or screening women 40-70yrs biennially 
plus trastuzumab (ICER US$17,115/DALY) are less cost-effective options. 
Conclusions
We recommend both Costa Rica and Mexico to engage in MAR, CBE or 
mammography screening programs, depending on their budget. The results of 
this study should be interpreted with caution however, as the evidence on the 
intervention effectiveness is uncertain. Also, these programs require several 
organizational, budgetary and human resources, and the accessibility of breast 
cancer diagnostic, referral, treatment and palliative care facilities should be 
improved simultaneously. A gradual implementation of early detection programs 
should give the respective Ministries of Health the time to negotiate the 
required budget, train the required human resources and understand possible 
socioeconomic barriers. 
Keywords
Cost-effectiveness analysis; WHO CHOICE; Breast cancer; Costa Rica; Mexico
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Introduction
Due to population ageing and changing lifestyles in low-and-middle countries (LMICs), 
breast cancer incidence rates are increasing 1,2. Given the organizational and financial 
constraints faced by the health systems in LMICs the majority of breast cancers are 
diagnosed at late stages 3. Accordingly, the majority of breast cancer deaths occur in 
LMICs 4,5. The World Health Organization (WHO) therefore states that early detection 
and implementation of cost-effective interventions should be a priority in LMICs 6. In 
an attempt to support LMICs with breast cancer control, the Susan G. Komen for 
the cure foundation provided a grant to investigate the cost-effectiveness of several 
breast cancer control interventions in 7 LMICs to a consortium of the WHO, Erasmus 
University Rotterdam (EUR) and Radboud University Nijmegen Medical Center 
(RUNMC). Cost-effectiveness analyses may support governments in deciding how to 
spend scarce resources in health care most efficiently.
In each country, during four phases, the consortium works closely with local authorities 
and experts in the fields of breast cancer, health economics, epidemiology and public 
policy. First, a three-day technical workshop is held, where the consortium explains a 
general cost-effectiveness model based on WHO-CHOICE methodology (described 
elsewhere 7,8) which is to be tailored to the country specific situation. In the second 
phase, lasting approximately six months, local authorities identify and assemble the 
(local) data required for the cost-effectiveness model. Subsequent in phase three, the 
cost-effectiveness analyses are carried out. Thereafter, a second workshop is organized. 
Here the results of the analyses are discussed among representatives of all local 
institutions involved in breast cancer care and made available for actual policy making 
by the local health authorities, i.e. the fourth phase. This paper identifies the most cost-
effective interventions for breast cancer control in both Costa Rica and Mexico from a 
health care perspective.
After presenting an overview of the situation regarding breast cancer in both Costa 
Rica and Mexico, we discuss the methods, data and interventions considered in this 
study and discuss the results.
Breast cancer in Costa Rica and Mexico
Cancer incidence and mortality rates are rising across Central America [9,10]. In Costa 
Rica and Mexico breast cancer ranks among the top-five causes of death for women 
over 25 years old 11. Between 1995 and 2003, breast cancer incidence increased 
by 32.3% to a rate of 40.07 per 100,000 women in Costa Rica 12. In Mexico, breast 
cancer incidence increased as well and in both countries breast cancer mortality 
rates have increased since the 1980s 9,13,14. In Costa Rica 13.14 breast cancer deaths 
per 100,000 women in 2006, the highest number among malignant neoplasms, are 
observed. Mortality rates per 100,000 women range from 28.19 in province ‘Dota’ to 
1.23 Guácimo, while in provinces ‘Los Chiles, ‘La Cruz’, and ‘Garabito’ no breast cancer 
related deaths were registered 12. In Mexico mortality rates doubled over the last 20 
years.
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The average mortality rate per 100,000 women in Mexico stands at 9.9 with regional 
differences from 13.2 and 11.8 respectively in the Federal District and the north to 
9.7 and 7.0 respectively in the center and the south 15. This increase caused breast 
cancer to overtake cervical cancer as the most deadly cancer among females in 2006 
14,15. Where in 1979 1,144 females died from the disease, in 2006 4,497 deaths were 
registered 15.
Although in Costa Rica and Mexico official recommendations for both breast self-
examination (BSE) and mammography screening have existed for over a decade, 
their coverage levels remain very low and the large majority of breast cancer patients 
present at the hospital with advanced disease 16-18.
In light of the above, Non-Governmental Organizations (NGOs) and the general 
public put pressure on governments in Costa Rica and Mexico to improve treatment 
and early diagnosis through screening 19,20. Hence, both countries face choices on 
efficient allocation of scarce resources for breast cancer screening. 
Materials and Methods
Methods
General approach
We used the WHO-CHOICE methodology, described in detail elsewhere 7,8, as a basis 
of our analysis. This approach compares all possible interventions in a specific disease 
area to a situation where no interventions are implemented. The latter, a counterfactual 
‘null scenario’, acts as a reference to compare the costs and effects of existing and new 
interventions. An intervention in isolation, or a combination of different interventions, 
is then implemented for 10 years in a modeled population. However, to include effects 
that occur after these 10 years, this modeled-population is tracked for 100 years. This 
approach enables us to make comparisons of the costs and health effects across a 
wide range of competing interventions, identify differences in relative cost-effectiveness 
and identify the most efficient mix of interventions to improve population health.
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Breast Cancer Model
Costs and health effects are calculated using a state transition population model 
developed and explained in detail by Groot et al. 7. Its structure is presented in Figure 
1. The model simulates the development of a national population and accounts for 
births, background mortality and breast cancer epidemiology of a country. It includes 
a healthy state, a deceased state, and stage I to IV breast cancer states following the 
classification of the American Joint Committee on Cancer (AJCC) 21. The effectiveness 
of each intervention is expressed in changes in disability weights (DWs i.e. health 
state valuations (HSVs)), case fatality rates (CFs, i.e. improved survival for treatment 
scenarios), or in more positive stage distributions (in awareness raising and screening 
interventions).
Since the interventions affect mortality (i.e., CFs) and morbidity (DWs), intervention 
effectiveness is expressed in disability adjusted life years (DALYs) averted. The 
difference in the total number of healthy years lived by the population between each 
scenario and the null-scenario gives the population health gains in DALYs averted.
Figure 1. Graphical representation of the model showing the relationships between the different health states 
through the incidence rates of breast cancer (Ix1–Ix4), the different stage specific case fatality rates (Fx1–4), and 
the background mortality (M) 7.
Stage specific relapse rates to stage IV were used to correct health state valuations only (Rx1–Rx3).
Zelle et al. 22 improved the published model 7 by correcting HSVs for relapse, assuming 
that patients could only relapse to stage IV at a constant rate 23.
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Interventions
An important element of the overall project is to select a set of appropriate 
interventions for breast cancer control in LMICs. Therefore, a study group at 
WHO-CHOICE defined a mix of 11 common and preferable practices in 2009 22. 
Participating countries can combine and adapt these practices to appropriately inform 
their specific policy questions. For Costa Rica and Mexico focus was placed on the 
cost-effectiveness of screening & treatment combinations. The most urgent policy 
questions in both countries concerned the age groups that should be targeted for 
screening and whether treating Her2/NEU+ patients with Trastuzumab (Herceptin™) 
was cost-effective. Therefore, the basic awareness raising intervention was excluded 
and different intervention scenarios, including treatment with Trastuzumab, were added. 
Combining the 11 common practices with or without Trastuzumab led to a total of 
19 scenarios. Input from local policy makers led us to model the current situations of 
breast cancer control in Costa Rica and Mexico at 80% and 70% geographic coverage 
levels (i.e. reaching 80%/70% of those people who need services) respectively. In 
line with WHO-CHOICE methodology all other interventions were evaluated at 
a geographic coverage level of 95% 8. An overview of the interventions is listed in 
table 1.
Table 1. Definition and classification of individual interventions (coverage) 22
Treatment of individual stages Down-staging interventions b Palliative care d
Stage I treatment: lumpectomy with
axillary dissection and radiotherapy. 
Eligible patients receive tamoxifen a 
or chemotherapy e [7,23,49].
Basic Awareness Raising (BAR):
community nurses training
program + opportunistic outreach 
activities by community nurses to 
raise breast cancer awareness and 
educate on breast self-examination 
techniques (BSE) + enhanced media 
activities [50].
Basic Palliative Care (BPC): palliative 
care volunteers training program 
+ home-based visits by volunteers 
every fortnight + pain treatment 
through morphine, laxatives and 
palliative radiotherapy (8 Gy in 1 
fraction) for eligible patients [49-51].
Stage II treatment: lumpectomy with 
axillary dissection and radiotherapy. 
Eligible patients receive tamoxifena 
or
Chemotherapy e [7,23,49].
Mass-media awareness raising 
(MAR): BAR + mass media campaign 
[50].
Extended Palliative Care (EPC): 
BPC apart from community nurses 
instead of palliative care volunteers, 
pain treatment strengthened with 
antidepressants, anti-emetics and 
zelodronic acid [50-54].
Stage III treatment: modified
mastectomy followed by adjuvant
chemotherapy e and radiotherapy f.
Eligible patients receive tamoxifena 
[7,49].
Biennial clinical breast examination 
(CBE) screening in asymptomatically 
women aged 40–69 years: communi-
ty nurses training program + active 
outreach screening by community 
nurses +limited media activities [50,55].
Stage IV treatment: adjuvant
Chemotherapy e and radiotherapy
(10 Gy) + end of life hospitalization.
Eligible patients receive total
mastectomy and ⁄ or tamoxifen a
[49,56].
Biennial mammography screening in 
asymptomatic women aged 50–69 
years + limited media activities [7].
Treatment of stage I – IV as listed 
above plus the addition of Trastuzu-
mab g for Her2/NEU+ patients.
Biennial mammography screening in 
asymptomatic women aged 40–69 
years + limited media activities [7].
a Endocrine therapy consists of 20 mg tamoxifen per day for 5 years; b Down-staging interventions cause a shift in stage distribution and are only modeled 
in combination with treatment of all stages (I–IV); c BAR was excluded as a standalone intervention in Costa Rica and Mexico; d Palliative care interventions 
are only applied to stage IV patients, and substitutes stage IV treatment; e The (neo)adjuvant chemotherapy combination regimen consists of 7 cycles of 
Epirubicin, Fluorouracil and cyclophosphamide (FEC regimen) Given on an outpatient basis; f Radiotherapy includes a standard dose of 50 Gy given in 25 
fractions of 2 Gy on an outpatient basis; g Trastuzumab is given for 8 months.
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Data
Effectiveness
A key factor is the stage distribution of patients presenting at the hospital, given the 
breast cancer stage determines the survival and disability of the breast cancer patients 
and the effectiveness of each intervention 21. 
In Costa Rica we obtained the current stage distribution from Ortiz 24, who studied 
breast cancer survival in Costa Rica between 2000 and 2003. Demographic data and 
incidence rates were obtained from the Statistical office of the Costa Rican Ministry 
of Health (MoH). For the prevalence we used the 2004 Global Burden of Disease 
estimates 25.
For Mexico, we used the current stage distribution from Knaul et al. 17, who studied 
1904 patients that were all treated within the Mexican Social Security Institute (IMSS, 
its abbreviation in Spanish). Demographic data were obtained from the Mexican 
National Population Council 26. For Mexico we obtained incidence rates based on 
GLOBOCAN 2008 adjusted by group of age considering the distribution from the 
Mexican Histopathology Registry 2006 27,28. For the prevalence in Mexico, as in Costa 
Rica, we used 2004 Global Burden of Disease estimates 25.
The case fatality rates for the treatment scenarios were based on Groot et al. (stage III 
& IV) and Zelle et al. (stage I & II), who corrected those from Groot et al. for the use of 
chemotherapy in stage I and II 7,22. We take these CF’s to represent technical efficiency, 
representing the maximum amount of DALYs that can be averted based on successful 
implementation of breast cancer diagnosis, treatment and follow-up. Disability weights 
were derived from the Global Burden of Disease estimates for long term sequela 25 
using quality of life literature 26,27. For stage I we took the disability estimate of 0.086 
28 and for stage IV we combined the terminal estimate of 0.75 28 with estimates from 
quality of life literature 26.
Since screening and awareness interventions as defined in international literature, 
alter the stage distribution, their effects on the stage distribution at presentation were 
estimated using the same methods applied by Zelle et al. 22. Zelle et al. use international 
study results to estimate the health effects of various screening options and account 
for the sensitivity of the screening method, attendance rates (80% in both countries), 
incidence rates and demography in target groups.
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Table 2. Analyzed interventions and the estimates used for the stage were interventions are applied to
Case Fatality Rates a Disability Weights b Stage Distribution c
Costa Rica (CR) - Intervention stage I stage II stage III stage IV stage I stage II stage III stage IV % in stage II % in stage II % in stage III % in stage IV
Untreated 0.0207 0.0654 0.1556 0.3112 0.086 0.097 0.104 0.375 14.6% 41.6% 20.4% 23.4%
Stage I treatment 0.0056 0.086 14.6%
Stage II treatment 0.0393 0.097 41.6%
Stage III treatment 0.0930 0.104 20.4%
Stage IV treatment 0.2750 0.154 23.4%
Basic Palliative Care (BPC) 0.2750 0.153 23.4%
Extended Palliative Care (EPC) 0.2750 0.152 23.4%
Current Country Situation 0.0056 0.0393 0.0930 0.2750 0.086 0.097 0.104 0.154 14.6% 41.6% 20.4% 23.4%
Mass-media Awareness Raising (MAR) 0.0056 0.0393 0.0930 0.2750 0.086 0.097 0.104 0.154 21.1% 41.5% 24.1% 13.3%
Biennial CBE screening (40-69) 0.0056 0.0393 0.0930 0.2750 0.086 0.097 0.104 0.154 32.0% 34.3% 25.8% 7.9%
Biennial mammography screening (50-69) 0.0056 0.0393 0.0930 0.2750 0.086 0.097 0.104 0.154 35.0% 37.5% 21.1% 6.5%
Biennial mammography screening (40-69) 0.0056 0.0393 0.0930 0.2750 0.086 0.097 0.104 0.154 40.0% 42.8% 13.2% 4.0%
With Trastuzumab 0.0050 0.0353 0.0835 0.2470 0.086 0.097 0.104 0.154
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Mexico(MX) - Intervention stage I stage II stage III stage IV stage I stage II stage III stage IV % in stage I % in stage II % in stage III % in stage IV
Untreated 0.0207 0.0654 0.1556 0.3112 0.086 0.097 0.104 0.375 13.8% 39.6% 33.9% 12.7%
Stage I treatment 0.0056 0.086 13.8%
Stage II treatment 0.0393 0.097 39.6%
Stage III treatment 0.0930 0.104 33.9%
Stage IV treatment 0.2750 0.154 12.7%
Basic Palliative Care (BPC) 0.2750 0.153 12.7%
Extended Palliative Care (EPC) 0.2750 0.152 12.7%
Current Country Situation 0.0056 0.0393 0.0930 0.2750 0.086 0.097 0.104 0.154 13.8% 39.6% 33.9% 12.7%
Mass-media Awareness Raising (MAR) 0.0056 0.0393 0.0930 0.2750 0.086 0.097 0.104 0.154 21.1% 41.5% 24.7% 12.7%d
Biennial CBE screening (40-69) 0.0056 0.0393 0.0930 0.2750 0.086 0.097 0.104 0.154 30.5% 32.6% 28.3% 8.7%
Biennial mammography screening (50-69) 0.0056 0.0393 0.0930 0.2750 0.086 0.097 0.104 0.154 33.9% 36.3% 22.8% 7.0%
Biennial mammography screening (40-69) 0.0056 0.0393 0.0930 0.2750 0.086 0.097 0.104 0.154 39.1% 41.8% 14.6% 4.5%
With Trastuzumab 0.0054 0.0374 0.0865 0.2569 0.086 0.097 0.104 0.154
\a Estimates for stages III and IV are from Groot et al. 7 and for stages I and II from Zelle et al 22; The CFs for the untreated patients are from Groot et al. and were corrected based on Bloom et al 57;
 b Estimates from Zelle et al. 22; c Current stage distribution CR is based on Ortiz 24, MX onKnaul et al.17, Effects of MAR derived from Devi 50, Effects of screening interventions were based on stage shifts from baseline Groot et al.7 to the stage distribution 
USA in Bland et al. 58. Stage shifts were adapted by calculating relative differences in detection rates between the USA and CR / MX from Duffy & Gabe 59. Calculations included age-specific incidence (MoH CR & Unidad Analysis Económica MX), prevalence 
(WHO 2008), sojourn time Duffy & Gabe 59, sensitivity Bobo et al. 60 and attendance rates (75% in the USA vs. 80% in Costa Rica and Mexico); d We assumed in Mexico implementing MAR could not lead to a higher proportion of stage IV patients and 
increase stage III with the difference of 0.6%.
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Costs
In line with the WHO-CHOICE approach we distinguished patient, program and 
training costs, which were calculated by multiplying quantities of applied procedures by 
their corresponding unit costs. Patient costs were dependent on patient consumption 
(utilization) of explicit resources (procedures) for diagnosis, treatment, follow-up, early 
detection and screening.
Although Costa Rica has developed several guidelines for treating breast cancer over 
the years 18,32, local specialists informed us that treatments differ somewhat across 
hospitals. Therefore, together with these specialists, we revised the entire set of 
resource items to reflect the (average) current breast cancer treatment practices in 
Costa Rica. Specialists in Mexico had a similar opinion. 
As its health care system has three main public institutions providing health care, 
treatment and reimbursement between these institutions may differ due to, for 
example, differences in salaries and drug prices. Hence we used resource utilization 
estimates of IMSS, which provides social insurance to approximately 40% of Mexico’s 
population 33.
Whenever possible we used locally obtained costing data. When not available we 
applied the original WHO-CHOICE estimates for either country. These estimates are 
based on econometric analysis of a detailed WHO-CHOICE database from South 
Africa including a set of standard salaries, drugs, outpatient visits, materials and supplies, 
capacity utilization and transportation multipliers 34. In Costa Rica, the CCSS provided 
readily available unit costs of most breast cancer procedures. For Mexico, contrary to 
Salomon et al. 35, who used the WHO-CHOICE original estimates on costs, in this 
study we used a detailed micro-costing exercise performed by IMSS 36.
Costs of the procedures used for Costa Rica and Mexico are listed in table 3. We 
also integrated evaluation costs of women presenting without breast cancer, included 
the costs of diagnosing all other stages (only for stages I-IV separately) and, regarding 
screening interventions, included costs for evaluating false positives.
For the program-level costs, which capture management, administrative, media and 
law-enforcement costs, and costs for training of healthcare personnel we used local 
salaries and WHO-CHOICE allocation rules for Costa Rica. For Mexico we used the 
standard WHO-CHOICE program cost estimates and allocation rules. Media and 
operating costs (i.e. prices for broadcasting, flyers, and posters) were provided by the 
CCSS in Costa Rica and the MoH in Mexico.
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Training costs were primarily based on training the required health care workers for 
each intervention. We maintained the allocation assumptions listed in the WHO-
CHOICE model as set by Zelle et al. 22 and used local salaries and WHO standard 
salaries for Costa Rica and Mexico respectively. In both countries all costs were 
estimated in 2009 local currency units (i.e. Costa Rican colones (CRC) and Mexican 
pesos (MXN)) and converted to U.S. dollars (US$) using the 2009 exchange rate 
(1.00US$ = 560.45CRC and 1.00US$ = 13.06MXN$) 34,35. Both health effects (DALYs) 
and costs (US$) were discounted at a rate of 3% annually, which is recommended 
by WHO-CHOICE 8. Working from a health care perspective we did not take into 
account travel and opportunity costs.
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Table 3. Average utilization of diagnosis and treatment ingredients and unit costs per patient
Procedure Ingredients Stage I Stage II Stage III Stage IV Relapse Palliative Care g 
(Extended)
Unit cost per patient 
(US$)
Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico
Initial diagnosis and 
evaluation during 
treatment
No. of health center visits 1 1 1 1 1 1 1 1 1 1 23,69 a 25,40 c
No. of hospital visits 3 2 3 2 3 2 3 2 3 2 63,187 a 80,47 c
Bilateral Mammography 1 1 1 1 2 1 - - - - 45,44 a 42,27 d
Complete blood count 7 7 7 7 7 7 7 7 6 6 17,50 b 10,34 d
FNA or core needle biopsy 1 1 1 1 1 1 1 1 - - 71,62 a 91,52 c
Liver function tests 8 8 8 8 8 8 8 8 7 7 40,31 a 10,34 d
Ultrasonography 1 1 1 1 1 1 1 1 - - 23,65 b 48,32 d
Renal function tests 8 8 8 8 8 8 8 8 7 7 9,81 a 10,34 d
Bone scan - - - - 1 1 1 1 - - 108,01 b 192,57 d
Chest X-ray 1 1 1 1 1 1 1 1 - - 16,11 a 14,93 c
ECG 1 1 1 1 1 1 1 1 - - 10,14 b 27,26 f
Her2/neu test 1 1 1 1 1 1 1 1 - - 27,73 e 32,70 d
Non-breast cancer 
evaluation
No. of health center visits 2 2 2 2 2 2 2 2 23,69 a 25,40 c
Bilateral Mammography 1 1 1 1 1 1 1 1 45,44 a 42,27 d
Ultrasonography 0.28 0.28 0.28 0.28 0.28 0.28 0.28 0.28 22,68 b 22,59 c
FNA or core needle biopsy 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 71,62 b 91,52 c
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Procedure Ingredients Stage I Stage II Stage III Stage IV Relapse Palliative Care g 
(Extended)
Unit cost per patient 
(US$)
Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico
Treatment No. of hospitalization days 2 2 2 2 2 2 6 0 6 0 6 134,55 a 292,11 c
No. of OPD visits radio-
therapy
30 0 30 0 30 0 30 0 30 0 1 0 63,16 a 80,47 c
No. of OPD visits chemo-
therapy
% receiving surgical inter-
vention
6 7 6 7 6 7 6 7 6 7 - 63,16 a 80,47 c
Lumpectomy Lumpectomy Lumpectomy Lumpectomy Lumpectomy Lumpectomy 239,33 b 805,59 c
60% 80% 60% 0,40% 20% 0% - - - - - -
Mastectomy Mastectomy Mastectomy Mastectomy Mastectomy Mastectomy 243,27 b 857,34 d
40% 20% 40% 60% 80% 30% 10% - 10% - 5% -
% receiving anesthesia 60% 70% 90% 5% - 5% - 5% - 61,22 b 76,68 c
% receiving radiotherapy h 70% 86% 70% 80% 100% 100% 30% 0% 30% 0% - - 500,52 b 438,20 c
% receiving endocrine 
treatment i
61% 50% 61% 40% 61% 65% 61% 40% 61% 40% 61% 50% 0,04/day a 0,51 d
% receiving chemotherapy j 0% 80% 20% 100% 60% 100% 60% 90% 80% 0% - 1469,97 a 2327,20c
% receiving boost radio-
therapy k
41% 65% 71,23 b 106,16 c
% receiving home based 
visits
75% 75% 23,69 a 25,40 c
% receiving morphine l 84% 100% 0,59/day a 1,12 c
% receiving laxative m 50% 47% 0,10/day a 0,03 c
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Procedure Ingredients Stage I Stage II Stage III Stage IV Relapse Palliative Care g 
(Extended)
Unit cost per patient 
(US$)
Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico Costa 
Rica
Mexico
% receiving Ondansetron n 36% 60% 2,80/day a 1,72 c
% receiving Amitriptyline o 41% 100% 0,04 a 0,37 c
% receiving Zelodronic 
Acid p
30% 30% 30% 30% 30% 200,00 a 260,18 d
% receiving Trastuzumab 30% 11% 30% 14% 30% 21% 30% 19% 30% 7% 1800 a 1610 c
a Based on estimates by Costa Rican CCSS; b Unit costs WHO-CHOICE database in 2000 US$. Corrected for inflation: 2000-2009 (2.81 in CR & 1.66 in MX). 2009 exchange rates were used (560.45 CRC/US$ & 13.06 MXN/US$); c Based on values of 
IMSS; d Based on communication with Unidad de Análisis Económico of MoH; e Based on Norum et al. 61; f Based on Knaul et al. 11; 
g palliative care (substitutes stage IV treatment); h 50 Gy given in 25 fractions of 2 Gy.; i daily dose of 20 mg. Tamoxifen for 5 years; j 7 cycles of Epirubicin, Fluorouracil and cyclophosphamide (FEC regimen); k 1 fraction of 10 Gy.;. l 40ml/54sdays; m 35mg/54 
days; n 8mg/day; o 75mg/day; p 5 mg/day.
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Cost-effectiveness analysis
The average cost-effectiveness ratio (ACER) of each intervention is calculated by 
dividing the average costs of the intervention by average number of DALYs averted. 
These ACERs provide information on the set of interventions a region should finance 
to maximize health gains. The incremental cost-effectiveness ratios (ICERs) are 
calculated in relation to the last intervention purchased in each country, by dividing the 
incremental costs by the incremental health effects. These ICERs are used to establish 
an expansion path which shows the order in which the various interventions should 
be introduced if cost-effectiveness is the only consideration 39. Only interventions with 
the lowest cost for additional effects are considered on this expansion path. WHO-
CHOICE defines interventions that have a cost-effectiveness ratio of less than one 
times the gross domestic product (GDP) per capita as very cost-effective, and those 
with a ratio that falls between one and three times the GDP per capita as cost-effective 
40. In Costa Rica, this means that interventions that cost less than US$6,629 per DALY 
averted can be considered very cost-effective, and interventions that cost between 
US$6,629 and US$19,888 per DALY averted can be considered cost-effective. For 
Mexico these thresholds are US$8,416 and US$25,249 per DALY averted, respectively.
Sensitivity analysis
In line with Zelle et al. we performed a deterministic sensitivity analysis for both Costa 
Rica and Mexico to assess the impact of key parameters on our cost-effectiveness 
estimates 22. In both countries we increased the DW’s with 10%. Whereas costs of 
outpatient visits were increased by 25%, we raised the costs of mammography with 
200%. In estimating the impact of various screening interventions we decreased 
the sensitivity of CBE and mammography by 25% and assumed attendance rates of 
screening of 60%. When available we also used alternative stage distributions for the 
current situation and different CFs. The unit costs for surgical procedures Costa Rica 
were much lower than those of Mexico. To test the impact of this we substituted these 
costs with the Mexican values. 
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Results
Table 4 shows the results for Costa Rica (panel A) and Mexico (panel B). Both costs, 
effects and cost-effectiveness are presented. In Figure 2 these results are presented 
graphically and the expansion paths are shown as black lines.
Costa Rica
Table 4 panel A shows the annual number of DALYs averted in treating the individual 
stages I-IV to vary between 193 (stage III) and 573 (stage II). Jointly these interventions 
in each stage can avert almost 1,400 DALYs per year. Adding palliative care only averts 
a small number of DALYs. The costs of treating the individual stages range between 
approximately US$4 million and US$5 million per year. Adding basic and extensive 
palliative care programs to stage IV treatment adds approximately US$0.1 and US$1 
million to the yearly costs of stage IV treatment. At the 80% coverage level the current 
country situation in Costa Rica is highly cost-effective with an ICER below the country’s 
GDP per capita, i.e. US$4,739/DALY. In expanding Costa Rica’s breast cancer services, 
our analysis shows that treatment of all stages plus a CBE screening program targeting 
women between 40 and 70 years of age (I-IV + CBE (40-70)) is the next best option. 
At a total yearly cost of almost US$13 million, CBE averts 2,381 DALYs per year. This 
can be considered a very cost-effective intervention as the ICER of this intervention is 
below one time Costa Rica’s GDP per DALY. 
From figure 2 it follows that although the ACER of implementing mammography 
screening for women between 50-70 years is still below Costa Rica’s GDP per capita 
per DALY, the ICER (as compared to CBE screening) is not lower than this threshold 
(i.e. the slope of the expansion path is steeper than US$6,629/DALY). While still 
considered a cost-effective intervention, mammography screening in age group 50-
69 averts 2,619 DALYs per year at a yearly cost of US$16 million. Increasing the age 
group for mammography screening to women between 40-70 years shows a similar 
trend, i.e. averting 3,015 DALYs at an annual cost of US$21 million can be considered 
cost-effective. Adding Trastuzumab to this intervention, while resulting in the highest 
number of DALYs averted per year, i.e. 3,274 DALYs at a total yearly cost of US$29 
million, is not considered cost-effective as its ICER is above the three times GDP per 
DALY threshold. 
The combinations of various interventions are all close to the expansion path meaning 
they avert DALYs at a slightly less favorable ICER but could nevertheless be meaningful 
to implement. For example, expanding the current program’s coverage to reach 95% 
or implementing a Mass-media Awareness Raising program (MAR), could be interesting 
options if the available budget is not sufficient to implement a screening strategy.
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Mexico
Table 4 panel B shows that the annual number of DALYs averted in the individual 
stages I-IV varies between 1,503 (stage IV) and 10,629 (stage II). Jointly these 
interventions in each stage avert approximately 26,000 DALYs per year. The addition 
of palliative care does not gain much health. 
With an ACER of US$5,715 the current situation with 70% coverage is very cost-
effective. The analysis shows it is better to increase the coverage level of the current 
intervention to 95% instead of adding Trastuzumab. In our analysis, implementing a 
program of Mass-media awareness raising (MAR) buys health most efficiently. Our 
results show that MAR averts 32,908 DALYs per year at a yearly cost of US$165 
million, which leads to an ACER of US$5,021 per DALY averted. When a higher 
budget would be available, implementing mammography screening for women 
aged 50-70 would be the first next step. This intervention averts 44,192 DALYs per 
year at an estimated yearly cost of US$310 million. Even more resources would 
allow to subsequently add Trastuzumab and increase the age group to 40-70. These 
interventions fill out the expansion path and avert 47,616 and 50,714 DALYs per year 
at an estimated yearly cost of US$358 and US$471 million respectively. It should be 
noted that a CBE screening program, with an expected health gain of 39,769 DALYs 
averted at a cost of US$260 million, could be an interesting ‘in-between’ option. 
Chapter 6
170
Table 4. Average costs (US$), effects and cost-effectiveness of breast cancer control scenarios per year
Panel A: Costa Rica
No. Description of intervention Patients Annual Annual Annual Annual DALYs ACERc ICERd
per year patient costsa program costs training costs total costs averted per yearb
1 Current country specific situation (80%) 940 4,569,310 646,358 6,660 5,222,329 1,102 4,739 4,739
2 Stage I to IV treatment (current) + Trastuzumab (80%) 940 11,708,670 646,358 6,660 12,361,689 1,347 9,180 NA
3 Stage I treatment + relapse (95%) 163 2,862,111 854,431 7,439 3,723,980 404 9,218 NA
4 Stage II treatment + relapse (95%) 464 4,303,195 854,431 7,439 5,165,065 573 9,007 NA
5 Stage III treatment + relapse (95%) 235 3,884,520 854,431 7,439 4,746,390 193 24,587 NA
6 Stage IV treatment (95%) 261 3,107,345 854,431 7,439 3,969,215 162 24,559 NA
7 Basic Palliative Care (BPC) (95%) 261 2,466,328 1,583,922 27,897 4,078,147 163 25,078 NA
8 Extended Palliative Care (EPC) (95%) 261 3,160,703 2,022,956 27,897 5,211,556 164 31,852 NA
9 Stage I to IV treatment combined (current 95%) 1,116 5,659,297 1,421,412 7,439 7,088,148 1,309 5,417 NA
10 Biennial mammography screening (50-70) + treatment of stage I to IV 
(95%)
1,116 12,498,059 3,792,653 22,317 16,313,029 2,619 6,228 NA
11 Biennial mammography screening (50-70) + treatment of stage I to IV + 
Trastuzumab (95%)
1,116 20,438,042 3,792,653 22,317 24,253,012 2,886 8,402 NA
12 Biennial mammography screening (40-70) + treatment of stage I to IV 
(95%)
1,116 17,546,792 3,792,522 22,317 21,361,632 3,015 7,085 13,426
13 Biennial mammography screening (40-70) + treatment of stage I to IV + 
Trastuzumab (95%)
1,116 25,401,093 3,792,522 22,317 29,215,932 3,274 8,924 30,352
14 Basic awareness outreach program + Mass-media Awareness Raising 
(MAR) + treatment of stage I to IV (95%)
1,116 6,158,209 4,519,154 11,159 10,688,521 1,825 5,857 NA
15 Biennial Clinical Breast Examination (CBE) screening (40-70) + treat-
ment of stage I to IV (95%)
1,116 9,255,065 3,576,629 20,086 12,851,779 2,381 5,397 5,964
16 MAR + BPC + treatment of stage I to III (95%) 1,116 6,262,398 4,733,109 39,055 11,034,563 1,826 6,044 NA
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Panel A: Costa Rica
No. Description of intervention Patients Annual Annual Annual Annual DALYs ACERc ICERd
per year patient costsa program costs training costs total costs averted per yearb
17 Biennial CBE Screening + BPC + treatment of stage I to III (95%) 1,116 9,422,391 3,426,610 47,982 12,896,984 2,382 5,415 NA
18 Biennial mammography Screening (40-70) + BPC + treatment stage I 
to III (95%)
1,116 17,578,700 4,170,935 50,214 21,799,850 3,016 7,229 NA
19 Biennial mammography Screening (50-70) + EPC + treatment of stage 
I to III (95%)
1,116 12,620,626 4,215,537 50,214 16,886,376 2,621 6,444 NA
a All costs in this table are in 2009 US$ (1CRC = 0,001784 US$); b DALYs, disability-adjusted life-years (age weighted, discounted); c ACER = average cost-effectiveness ratio compared to the do nothing-scenario (US$ per DALY averted); d ICER = Incremental 
cost effectiveness ratio, ratio of additional cost per additional life-year saved when next intervention is added to a mix on the intervention path (additional US$ per additional DALY saved).
Panel B: Mexico
No. Description of intervention Patients Annual Annual Annual Annual DALYs ACERc ICERd
per year patient costsa program costs training costs total costs averted per yearb
1 Current country specific situation (80%) 940 4,569,310 646,358 6,660 5,222,329 1,102 4,739 4,739
2 Stage I to IV treatment (current) + Trastuzumab (80%) 940 11,708,670 646,358 6,660 12,361,689 1,347 9,180 NA
3 Stage I treatment + relapse (95%) 163 2,862,111 854,431 7,439 3,723,980 404 9,218 NA
4 Stage II treatment + relapse (95%) 464 4,303,195 854,431 7,439 5,165,065 573 9,007 NA
5 Stage III treatment + relapse (95%) 235 3,884,520 854,431 7,439 4,746,390 193 24,587 NA
6 Stage IV treatment (95%) 261 3,107,345 854,431 7,439 3,969,215 162 24,559 NA
7 Basic Palliative Care (BPC) (95%) 261 2,466,328 1,583,922 27,897 4,078,147 163 25,078 NA
8 Extended Palliative Care (EPC) (95%) 261 3,160,703 2,022,956 27,897 5,211,556 164 31,852 NA
9 Stage I to IV treatment combined (current 95%) 1,116 5,659,297 1,421,412 7,439 7,088,148 1,309 5,417 NA
10 Biennial mammography screening (50-70) + treatment of stage I to IV 
(95%)
1,116 12,498,059 3,792,653 22,317 16,313,029 2,619 6,228 NA
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Panel B: Mexico
No. Description of intervention Patients Annual Annual Annual Annual DALYs ACERc ICERd
per year patient costsa program costs training costs total costs averted per yearb
11 Biennial mammography screening (50-70) + treatment of stage I to IV + 
Trastuzumab (95%)
1,116 20,438,042 3,792,653 22,317 24,253,012 2,886 8,402 NA
12 Biennial mammography screening (40-70) + treatment of stage I to IV 
(95%)
1,116 17,546,792 3,792,522 22,317 21,361,632 3,015 7,085 13,426
13 Biennial mammography screening (40-70) + treatment of stage I to IV + 
Trastuzumab (95%)
1,116 25,401,093 3,792,522 22,317 29,215,932 3,274 8,924 30,352
14 Basic awareness outreach program + Mass-media Awareness Raising 
(MAR) + treatment of stage I to IV (95%)
1,116 6,158,209 4,519,154 11,159 10,688,521 1,825 5,857 NA
15 Biennial Clinical Breast Examination (CBE) screening (40-70) + treat-
ment of stage I to IV (95%)
1,116 9,255,065 3,576,629 20,086 12,851,779 2,381 5,397 5,964
16 MAR + BPC + treatment of stage I to III (95%) 1,116 6,262,398 4,733,109 39,055 11,034,563 1,826 6,044 NA
17 Biennial CBE Screening + BPC + treatment of stage I to III (95%) 1,116 9,422,391 3,426,610 47,982 12,896,984 2,382 5,415 NA
18 Biennial mammography Screening (40-70) + BPC + treatment stage I 
to III (95%)
1,116 17,578,700 4,170,935 50,214 21,799,850 3,016 7,229 NA
19 Biennial mammography Screening (50-70) + EPC + treatment of stage 
I to III (95%)
1,116 12,620,626 4,215,537 50,214 16,886,376 2,621 6,444 NA
a All costs in this table are in 2009 US$ (1MXN = 0,0765697 US$); b DALYs, disability-adjusted life-years (age weighted, discounted); c ACER= Average cost-effectiveness ratio compared to the do nothing-scenario (US$ per DALY averted). d ICER = 
Incremental cost effectiveness ratio, ratio of additional cost per additional life-year saved when next intervention is added to a mix on the intervention path (additional US$ per additional DALY saved).
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Figure 2. Cost-effectiveness of breast cancer interventions and expansion path according to Incremental Cost-Effectiveness Ratios for Costa Rica
Dotted lines represent cost-effectiveness threshold of 1 and 3 times 2009 GDP/capita, i.e. 6,629 US$/DALY and 19,888 US$/DALY 37, 38.
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Figure 3. Cost-effectiveness of breast cancer interventions and expansion path according to Incremental Cost-Effectiveness Ratios for Mexico.
Dotted lines represent cost-effectiveness threshold of 1 and 3 times 2009 GDP/capita, i.e. 8,416 US$/DALY and 25,249 US$/DALY 37, 38.
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Sensitivity analysis
Sensitivity analysis showed our results to be particularly sensitive to different 
assumptions on stage distribution at presentation and case fatality rates (Table 5). The 
Costa Rican CFs we obtained from Ortiz 24 differed strongly from those we deem 
to reflect technical efficiency 7,22. Using these CFs causes the ACERs to vary between 
minus 82.7% for stage I and plus 65.5% for stage II. With regards to the current 
stage distribution, for Costa Rica we used the distribution from Groot et al. 7. With 
this less favorable stage distribution, the current country situation was not part of the 
expansion path anymore. Rather, the CBE screening program now became the most 
cost-effective.
For Mexico we ran the model with three different current stage distributions obtained 
from different studies 7,41,42. These different stage distributions caused the ACERs to 
increase between 0 – 15%. When using the higher CFs from Salomon et al. 35 for the 
intervention scenarios, the ACERs increased to a larger extent (34.7% for the current 
country situation). 
For both countries, changes in the other parameters also led to different outcomes 
although their impact was smaller. For example, in Costa Rica the WHO default unit 
costs for a mastectomy or a lumpectomy were relatively low. Unable to obtain these 
unit costs from Costa Rica, using the higher Mexican unit costs showed their impact on 
the ACERs to be marginal.
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Table 5. Results of sensitivity analysis on average cost-effectiveness ratio (ACER)
Panel A: Costa Rica
Intervention scenarios ACER Alternative 
stage dis-
tributiona
Case 
fatality 
ratesb
Disability 
weights 
+10%
Costs 
outpatient 
visits +25%
Costs mam-
mography 
+200%
Costs mas-
tectomy 
Mexico
Costs lum-
pectomy 
Mexico
Capacity 
utilization 
equipment 
25%c
Sensitivity of 
CBE and 
mammo- 
graphy -25%d
Attendance 
rates screening 
program 60%
1 Current country specific situation 
80%
4,739 5,519 4,447 5,132 4,882 6,218 4,931 4,901 4,739
2 Stage I to IV treatment combined 
(current 80%) + Trastuzumab
9,180 9,838 8,226 9,796 9,325 10,402 9,337 9,313 9,180
3 Stage I treatment 9,218 11,569 53,348 13,846 9,690 13,096 9,308 9,340 9,218
4 Stage II treatment 9,007 16,395 5,442 9,605 9,369 12,032 9,183 9,250 9,007
5 Stage III treatment 24,587 7,630 19,686 26,352 25,608 33,092 25,133 24,709 24,587
6 Stage IV treatment 24,559 29,195 25,869 26,307 25,774 33,715 24,646 24,559 24,559
7 Basic Palliative Care (BPC) 25,078 30,875 26,412 26,833 26,248 34,179 25,121 25,078 25,078
8 Extended Palliative Care (EPC) 31,852 38,068 33,542 34,044 33,245 40,897 31,895 31,852 31,852
9 Stage I to IV treatment combined 
(current 95%)
5,417 6,254 5,082 5,866 5,592 6,895 5,609 5,579 5,417
10 Biennial mammography scree-
ning (50-70 years) + Stage I to IV 
treatment 
6,228 4,464 7,060 6,565 6,538 10,589 6,336 6,330 6,228 7,535 7,723
11 Biennial mammography screening 
(50-70 years) + Stage I to IV treat-
ment + Trastuzumab
8,402 6,251 9,013 8,807 8,684 12,365 8,501 8,495 8,402 9,856 10,058
12 Biennial mammography scree-
ning (40-70 years) + Stage I to IV 
treatment
7,085 5,216 8,069 7,433 7,496 13,203 7,174 7,182 7,085 7,677 8,114
13 Biennial mammography screening 
(40-70 years) + Stage I to IV treat-
ment + Trastuzumab
8,924 6,769 9,674 9,322 9,303 14,562 9,006 9,014 8,924 9,566 10,031
14 Mass media awareness raising (MAR) 
+ treatment of stage I to IV
5,857 3,965 5,947 6,247 6,017 7,232 6,010 5,987 5,857
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Panel A: Costa Rica
Intervention scenarios ACER Alternative 
stage dis-
tributiona
Case 
fatality 
ratesb
Disability 
weights 
+10%
Costs 
outpatient 
visits +25%
Costs mam-
mography 
+200%
Costs mas-
tectomy 
Mexico
Costs lum-
pectomy 
Mexico
Capacity 
utilization 
equipment 
25%c
Sensitivity of 
CBE and 
mammo- 
graphy -25%d
Attendance 
rates screening 
program 60%
15 Biennial clinical breast examination 
(CBE) screening (40–69) + treat-
ment of stage I to IV
5,397 3,794 6,095 5,710 5,916 5,977 5,520 5,503 5,397 6,881 7,028
16 MAR + BPC + Stage I to III treat-
ment
6,044 4,092 6,137 6,446 6,206 7,418 6,195 6,174 6,044
17 Biennial CBE screening (40–69) + 
BPC + treatment of stage I to III
5,415 3,806 6,115 5,728 5,934 5,994 5,537 5,520 5,415 6,919 7,068
18 Biennial mammography screening 
(40–69) + BPC + treatment of stage 
I to III
7,229 5,323 8,232 7,583 7,641 13,345 7,318 7,326 7,229 7,836 8,284
19 Biennial mammography screening 
(50–69) + EPC + treatment of stage 
I to III
6,444 4,619 7,304 6,792 6,756 10,803 6,551 6,545 6,444 7,815 8,013
Panel A. (Costa Rica). Alternative stage distribution = 9.4% stage I, 14.2% stage II, 58.0% stage III, 18.4% stage IV[7]; b Alternative Case Fatality rates = 0,0174 stage I, 0,0284 stage II, 0,0832 stage III, 0,2855 stage IV 24; c Mechanical equipment (e.g. 
mammography machines, CT, X-ray); d Alternative assumptions on effectiveness of awareness interventions (-25%), sensitivity of CBE, and stage shifts of CBE screening.
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Panel A: Costa Rica
Intervention scenarios ACER Alternative 
stage dis-
tributiona
Case 
fatality 
ratesb
Disability 
weights 
+10%
Costs 
outpatient 
visits +25%
Costs mam-
mography 
+200%
Costs mas-
tectomy 
Mexico
Costs lum-
pectomy 
Mexico
Capacity 
utilization 
equipment 
25%c
Sensitivity of 
CBE and 
mammo- 
graphy -25%d
Attendance 
rates screening 
program 60%
1 Current country specific situation 
70%
5,715 6,081 6,576 5,742 7,696 7,764 5,865 6,861 5,713
2 Stage I to IV treatment combined 
(current 70%) + Trastuzumab
7,344 7,405 7,330 7,513 9,031 8,768 7,482 8,400 7,342
3 Stage I treatment 8,541 11,835 11,407 9,745 19,263 11,997 8,933 11,407 8,534
4 Stage II treatment 10,021 9,613 9,026 16,334 11,433 14,721 10,326 12,416 10,014
5 Stage III treatment 14,960 12,661 15,139 9,786 18,509 31,038 15,515 19,071 14,950
6 Stage IV treatment 49,231 55,817 169,157 37,773 46,698 52,548 51,336 63,668 49,192
7 Basic Palliative Care (BPC) 45,609 53,896 195,026 31,995 43,268 48,621 47,661 59,946 45,569
8 Extended Palliative Care (EPC) 77,813 85,844 229,906 62,358 73,858 82,886 80,085 92,056 77,774
9 Stage I to IV treatment combined 
(current 95%)
5,796 6,168 6,673 5,820 7,804 7,874 5,946 6,942 5,793
10 Biennial mammography scree-
ning (50-70 years) + Stage I to IV 
treatment 
7,025 5,703 8,161 4,043 9,059 7,649 7,397 11,541 7,023 10,041 10,567
11 Biennial mammography screening 
(50-70 years) + Stage I to IV treat-
ment + Trastuzumab
7,526 6,261 8,495 4,607 9,462 8,108 7,526 7,526 7,526 10,051 10,460
12 Biennial mammography scree-
ning (40-70 years) + Stage I to IV 
treatment
8,339 6,992 9,425 5,169 10,572 8,945 8,863 15,109 8,338 9,525 10,509
13 Biennial mammography screening 
(40-70 years) + Stage I to IV treat-
ment + Trastuzumab
8,659 7,377 9,599 5,602 10,859 9,226 9,148 14,974 8,658 9,821 10,688
14 Mass media awareness raising (MAR) 
+ treatment of stage I to IV
5,021 3,656 6,503 2,293 6,604 5,799 5,172 6,186 5,019
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Panel A: Costa Rica
Intervention scenarios ACER Alternative 
stage dis-
tributiona
Case 
fatality 
ratesb
Disability 
weights 
+10%
Costs 
outpatient 
visits +25%
Costs mam-
mography 
+200%
Costs mas-
tectomy 
Mexico
Costs lum-
pectomy 
Mexico
Capacity 
utilization 
equipment 
25%c
Sensitivity of 
CBE and 
mammo- 
graphy -25%d
Attendance 
rates screening 
program 60%
15 Biennial clinical breast examination 
(CBE) screening (40–69) + treat-
ment of stage I to IV
6,550 5,149 7,837 3,510 8,579 7,246 7,218 7,097 6,549 11,097 11,711
16 MAR + BPC + Stage I to III treat-
ment
6,522 4,751 8,452 2,981 8,661 7,531 6,671 7,613 6,520
17 Biennial CBE screening (40–69) + 
BPC + treatment of stage I to III
7,021 5,519 8,402 3,763 9,195 7,766 7,690 7,568 7,019 12,194 12,893
18 Biennial mammography screening 
(40–69) + BPC + treatment of stage 
I to III
8,701 7,296 9,836 5,394 11,023 9,333 9,226 15,490 8,700 10,010 11,103
19 Biennial mammography screening 
(50–69) + EPC + treatment of stage 
I to III
7,634 6,200 8,874 4,395 9,844 8,312 8,009 12,149 7,633 11,152 11,765
Panel B (Mexico). Unidad de Análisis Económico - 8.4% stage I, 38.5% stage II, 42.5% stage III, 10.6% stage IV [42]; b 9.7% stage I, 52.7% stage II, 34.8% stage III, 2.8% stage IV 41; c 9.4% stage I, 14.2% stage II, 58.0% stage III, 18.4% stage IV 7; d 
Alternative Case Fatality rates: 0,013 stage I, 0,042 stage II, 0,102 stage III, 0,266 stage IV 35; e Mechanical equipment (e.g. mammography machines, CT, X-ray); f Alternative assumptions on effectiveness of awareness interventions (-25%), sensitivity of 
CBE, and stage shifts of CBE screening. 
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Discussion
Our results indicate that in both Costa Rica and Mexico treating stage IV disease only, 
or treating stage IV and providing basic or extended palliative care is not cost-effective. 
In general, interventions ensuring more patients to present at the hospital in earlier 
stages seem the most cost-effective. 
These results are in line with other studies which find mammography screening for 
women aged 50-70 to be cost-effective in sub-Saharan Africa and South East Asia 
7,43. Although Ginsberg et al. did not study the cost-effectiveness of clinical breast 
examination or other awareness raising programs, they acknowledge less expensive 
means of early detection in limited resource settings could be cost-effective in LMICs 
43. When modeling the expected outcomes of such strategies - though based on 
limited evidence - Zelle et al. find that CBE screening or mass media awareness raising 
interventions seem indeed cost-effective in Ghana 22.
Although mammography interventions can be considered cost-effective, their total 
annual costs (budget impact) are high and may therefore not be appropriate for wide 
scale implementation. 
If the necessary resources are not available both countries could choose to lower 
coverage levels or implement interventions with comparable ACERs (buying health just 
as efficiently) but with lower budget impact. For Costa Rica, our analysis shows the 
most cost-effective option for expanding the current breast cancer services would be 
a CBE screening program combined with treatment of all stages. The yearly costs of 
this program are about US$12 million. In 2009, the per capita health expenditure in 
Costa Rica was US$660 (10.3% of total GDP) 37. With a population of approximately 
4.5 million, implementing a CBE screening program would add US$2.82 to this amount 
(0.43% increase). Although this increase may seem feasible, the implementation and 
effectiveness of this program is highly dependent on the availability of human resources 
and the capacity of the healthcare system to refer and treat all new-found cases 44-46. 
Also, if the implementation of a CBE screening program would be unfeasible, MAR 
could be an interesting option as it is slightly less cost-effective but has a smaller yearly 
budget impact (US$10 million). Yet, the very limited evidence on MAR’s effectiveness 
requires our estimates to be interpreted with caution. Implementing a screening 
program for which the evidence base is stronger (e.g. mammography for women 
between 50-70 years of age) could be recommended if the yearly costs of US$16 
million are affordable. Mammography screening in age group 40-70 costs much more 
(about US$21 million) and is therefore less economically attractive.
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The Mexican MoH already decided to start increasing the use of the available 
infrastructure and mammography equipment for the population most at risk (women 
50 to 70 years old and women with more than two risk factors). The gradual expansion 
will give enough time to train the required human resources. From our analysis the 
yearly costs of a mammography screening program for women 50-70 years of age at 
95% coverage eventually would be US$310 million per year, a threefold increase over 
the current scenario. Next, once a reasonable increase on coverage would be reached 
the Mexican MoH plans to increase the coverage rate to women between 40-49 years 
of age 47. According to our estimates the yearly costs of implementing such a program 
would be US$422 million. With approximately 110 million inhabitants and a per 
capita health expenditure of US$525 in 2009 (6.43% of total GDP) 37, implementing 
these programs would add US$2.82 (0.54% increase) and US$3.84 (0.72% increase) 
respectively to per capita health expenditure. 
However, our analysis shows perhaps that strengthening actual MAR or CBE screening 
programs to be a more attractive first step in improving breast cancer services from 
an economic perspective. With yearly costs of US$165 and US$260 million if started 
from zero, the strengthening of existing programs is more affordable and more 
politically feasible as it would represent modest increases to existing budgets.
One of the principal questions we received from policy makers in both Costa Rica and 
Mexico concerned the addition of Trastuzumab to the treatment regimens. In Costa 
Rica we assumed 30% of the breast cancer patients have overexpression of the HER2/
neu+ gene and are eligible for Trastuzumab 48. As a result of adding Trastuzumab, in 
Costa Rica between 230 – 270 extra DALYs/year are averted at an additional cost of 
approximately US$7 million per year. For Mexico we obtained the actual proportion of 
patients receiving Trastuzumab in IMSS. Here the health gains comprise between 2,800 
and 3,400 extra DALYs/year averted and the additional costs fall between US$45 – 51 
million. It is worth noting that in Mexico Trastuzumab is already provided as part of the 
treatment for all eligible women in stages I to IV. Our analysis shows the addition of this 
bio-pharmaceutical to increase the cost of treatment of stages I to IV by more than 
48%, generating the need of developing public policies focused on negotiating price 
reductions that can contribute to the mid- and long-term financial sustainability. The 
use of tools as the ones presented in this paper can provide technical evidence on the 
benchmark price that the Mexican health system could use in negotiations considering 
the threshold of one times the GDP per capita.
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The limitations regarding the model are essentially the same as those reported in 
previous studies 7,22. First, as evidence on the effectiveness of awareness raising, CBE 
and mammography screening in Costa Rica and Mexico were absent, we relied on the 
same model approach as used by Zelle et al. 22. Second, when calculating unit costs 
for Mexico we did not account for the mark up of transportation costs (as generally 
recommended by WHO-CHOICE) and did not include the costs of facilities. Including 
these costs would have probably resulted in slightly higher unit costs. Third, in adopting 
a health care perspective we did not take into account travel and opportunity costs. 
Including these costs would probably have increased costs generally. Fourth, we did 
not carry out a probabilistic sensitivity analysis. Carrying out such analysis would have 
shown worse ACERs when parameters are jointly changed in the negative direction 
(i.e. higher CFs and costs / worse stage distribution). Nonetheless, our deterministic 
sensitivity analysis shows the direction in which ACERs would change is clear and 
our general conclusions remain the same although the ranges of several ACERs are 
overlapping. The limitations fit within the overall goal of WHO-CHOICE which is to 
provide general indications of cost-effectiveness, i.e. not precise estimates of specific 
interventions. 
In summary, for improving their current breast cancer control programs, our analysis 
suggests that both Costa Rica and Mexico would benefit from implementing strategies 
that advance early detection. For these countries, a mass-media awareness raising 
program and/or a CBE screening program coupled with treatment of all stages and 
careful monitoring and evaluation could be feasible options. If these strategies are 
implemented, the provision of breast cancer diagnostic, referral, treatment and, 
when possible, basic palliative care services is essential and should be facilitated 
simultaneously.
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Abstract
Background
Breast cancer in India in an increasing public health problem. Costs of breast cancer 
treatment, in particular costs of systemic therapy, play an increasingly important 
role and this is accompanied by high out-of-pocket expenditure. As India has low 
financial resources, it is important to select cost-effective interventions. Our aim is 
to assess the cost-effectiveness of breast cancer treatment, with the focus on the 
impact of systemic therapy prices on this, and to investigate which price reductions 
are required for breast cancer treatment to be considered cost-effective.
Methods
We performed cost-effectiveness analysis from a health care perspective according 
to WHO-CHOICE standardised methods with costs expressed in United States 
Dollars (US$) and effects in disability adjusted life years (DALYs) averted. We 
used the BRC PopMod v4 model to simulate costs and effects for 21 different 
treatment scenarios. Analyses were based on demographic, epidemiological, 
economic and breast cancer specific data specific for the region Maharashtra, to 
the extent they were available.
Results
Treatments including only chemotherapy and hormone therapy cost annually 416 
million to 689 million US$ and can avert up to 262,776 DALYs per year. Scenarios 
including a combination of chemotherapy, hormone therapy and taxanes avert 
maximal 268,173 DALYs per year and annual cost vary from 675 to 943 million 
US$. Interventions including trastuzumab (and taxanes) are most expensive and 
can costs up to 2.5 billion a year, but avert less DALYs per year, e.g. 248,088.
Conclusions
Only AC combined with tamoxifen and secondly, CAF combined with tamoxifen, 
can be considered cost-effective (ICERs are 1,840 and 5,102 US$ per DALY 
averted respectively). Interventions including taxanes and/or trastuzumab are not 
recommended for implementation. Trastuzumab prices need to be a 50 fold lower 
to be considered cost-effective. Achieving these reductions could be considered 
by the Indian government, as it is able to influence the drug market through policy 
making.
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Introduction
Breast cancer is an increasing public health problem in India and has emerged as the 
leading type of female cancer in most urban populations in India 1. Trend evaluations 
have shown a significant increase of breast cancer incidence from 1976 to 2005 
and in 2008 incidence was 162 cases per 100,000 females (Table 1) 2. Moreover, 
approximately 666.000 disability adjusted life years (DALYs) are lost every year due to 
breast cancer in India 3. 
Causes for these increasing numbers and the high amount of burden of disease (BOD) 
in India are transitions in (socio-)economic factors, urbanization, modernization and 
change of diet. These transitions may lead to a lifestyle entailing more risk factors for 
breast cancer. High burden of disease is caused by poor breast cancer outcomes, 
due to advanced clinical stage at diagnosis 4-7. Additionally, the costs of breast cancer 
treatment play an increasingly important role. Not only is the economic burden of 
breast cancer considerably high, in addition to this, 59% from the total expenditure 
on health care is out-of-pocket in India 8, 9. The largest cost are represented by drugs 
for systemic treatment and these are, hence, less accessible to Indian breast cancer 
patients.
In response to these high drug prices and the high burden of disease, the Indian 
government eliminated patents on drugs by introducing the Indian Patent Act in 1970, 
enabling the country to produce generic drugs at low cost. When India joined the 
World Trade Organisation in 1995, it was forced to adjust national laws and practices 
to the terms of the Agreement on Trade Related Aspects of Intellectual Property 
Rights (TRIPS). Currently, pharmaceutical companies can be forced by the Indian 
government to grant compulsory licenses to generic drug manufacturers, which 
enables these companies to produce drugs at low costs 10-12.
Besides controlling the costs of drugs for systemic therapy, given the impact of breast 
cancer on health care utilization and the financial constraints in India, it is necessary to 
identify cost-effective interventions that reduce the burden of breast cancer. However, 
economic evidence on breast cancer treatment in low- and middle-income countries 
such as India is currently lacking, as it has poor availability, quality and comparability 13. 
The aim of this study is to provide evidence based information on the cost-
effectiveness of breast cancer treatment in Maharashtra, India. We focus on the impact 
of systemic drug prices on this cost-effectiveness. This information can be used to 
investigate which price reductions are required to make breast cancer treatment more 
cost-effective. The results could be important for the Indian government, since it is able 
to influence the drug market through policy making and law-enforcement.
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Table 1. Age distribution of breast cancer incidence and mortality India
Age 
groups
Female population* Incidence 
(/100.000)
Number of incident 
cases (%)
Mortality 
(/100.000)
Number of 
deaths (%)
Mortality/incidence 
ratio
0-14 178,622,740 0.0 5 (0.0%) 0.0 0
(0.0%)
n/a
15-29 149,709,824 1.0 1,505 (1.7%) 0.3 392
(0.7%)
0.26
30-44 106,264,174 19.2 20,380 (22.8%) 6.1 6,437 
(11.4%)
0.32
45-59 68,440,591 42.4 29,037 (32.4%) 25.2 17,264 
(30.7%)
0.59
60-69 25,953,999 69.2 17,971 (20.1%) 52.6 13,643 
(24.3%)
0.76
70-79 13,681,782 94.7 12,954 (14.5%) 79.2 10,829 
(19.3%)
0.84
80+ 4,111,983 187.3 7,701 (8.6%) 186.5 7,669 
(13.6%)
1.00
Source: WHO Global Burden of Disease data 2004 update 3
* Based on UN population 2005 14
Methods
General approach
We performed cost-effectiveness analyses using WHO-CHOICE standardised 
methods. This approach compares the costs and effects of all possible existing and new 
intervention scenarios to a counterfactual null, which is defined as a reference situation 
in which no interventions are available 15. 
Interventions/scenarios
An expert panel, including representatives of the Tata Memorial Centre (TMC), the 
World Health Organization (WHO), and the Radboud University Nijmegen Medical 
Centre, defined 21 intervention scenarios for the systemic treatment of breast 
cancer in women. These intervention combinations include chemotherapy (CMF/AC/
CAF and/or taxanes and/or trastuzumab), endocrine therapy (tamoxifen, aromatase 
inhibitors and switch therapy) and additional drugs, such as biphosphanates (Table 2). 
Following several breast cancer treatment guidelines 16-18 and data on average age 6, 
weight and height, we determined the dosage of each drug for the average Indian 
female breast cancer patient (Table 2). The scenarios are evaluated at 95% coverage 
level (i.e. reaching 95% of those who need the service) according to standard CHOICE 
methodology.
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Mathematical model
The BRC PopMod v4 model was used to conduct the analysis. Demographic and 
epidemiological data, breast cancer specific data and data on costs and effects were 
entered into the model to calculate the cost-effectiveness ratios of the 21 scenarios.
The model structure is presented in Figure 1 19, 20. The model simulates the 
development of the Indian population in terms of births, background mortality and 
breast cancer epidemiology. The structure is built up from several components, which 
represent the sick population (AJCC breast cancers stages I-IV) 21, healthy population 
and a deceased state (death).
Figure 1. Graphical representation of the model
Graphical representation of the model. showing the relationships between the different health states through the incidence rates of breast cancer (ix1–ix4), 
the different stage-specific case-fatality rates (corrected for progression) (Fx1–4) and the background mortality (M). Stage-specific disability weights 
(Rx1–Rx3) are equal for all intervention scenarios and patients have relapse to stage IV at a constant rate 19, 20.
The effectiveness of the intervention scenarios is based on case fatality and disability 
weights. All interventions are implemented for a period of 10 years, after which 
epidemiological rates return to their counterfactual level of no intervention. The 
model’s population, however, is followed for another 90 years (100 years total), as the 
health effects of interventions are visible years after the period of implementation. 
Population health gains in DALYs averted are calculated as the difference in total 
number of healthy life years lived by the population between each treatment scenario 
and the null scenario after a 100 years 19. DALYs were age-weighted and both DALYs 
and costs were discounted at an annual rate of 3%. 
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Data sources on effects
Main components of the mathematical model are demography, breast cancer 
epidemiology, stage distribution, case fatality rates and disability weights.
Demographic and epidemiological data were both derived from Global Burden of 
Disease (GBD) estimates of the WHO for India 3. Information on stage distribution 
was adapted from Groot et al. 20.
Survival and relapse estimates for hormone therapies, i.e. tamoxifen, aromatase 
inhibitors (AIs) and switch therapy, in combination with chemotherapy, were based on 
calculations with Adjuvant! Online 22. Survival and relapse estimates for trastuzumab 
(stage I-IV) and taxanes (stage I-III) were derived from Slamon et al. 23, Smith et al. 
24 and the Early Breast Cancer Trialists’ Collaborative Group 25, respectively. As AIs 
are associated with bone loss, biphosphonates, which prevent these side-effects, are 
added to the regimen, but do not have a significant effect on survival or relapse 26. All 
drugs, except for trastuzumab, are assumed to have no significant effect on survival 
and relapse in stage IV 17. All effects were eventually combined to calculate case fatality 
rates and relapse rates (Table 2). We assumed that stage specific disability weights are 
equal for all intervention scenarios and that all patients will have relapse to stage IV at 
a constant rate.
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Table 2. All 21 scenarios with stage specific case fatality rates, relapse rates and disability weights
Intervention scenario Case fatality rates (10 years) Relapse rates Disability weights
Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV
0 Null scenario 0.01413 0.04655 0.11702 0.27567 0.02506 0.06710 0.15640 0.00000 0.068 0.071 0.073 0.090
1 CMF + tamoxifen 0.01110 0.02873 0.05454 0.27567 0.01341 0.03222 0.06135 0.00000 0.068 0.070 0.072 0.073
2 CMF + tamoxifen + AI + biphosphonates 0.01110 0.02873 0.05454 0.27567 0.01245 0.02997 0.05764 0.00000 0.068 0.070 0.072 0.073
3 CMF + tamoxifen + AI + biphosphonates 0.01110 0.02873 0.05454 0.27567 0.01245 0.02997 0.05764 0.00000 0.068 0.070 0.072 0.073
4 CAF + tamoxifen 0.01002 0.02432 0.04475 0.27567 0.01109 0.02706 0.05432 0.00000 0.068 0.070 0.072 0.073
5 CAF + tamoxifen + taxanes 0.00941 0.02315 0.04384 0.27567 0.01083 0.02556 0.05039 0.00000 0.068 0.070 0.072 0.073
6 CAF + tamoxifen + AI + biphosphonates 0.01002 0.02432 0.04475 0.27567 0.01033 0.02525 0.05063 0.00000 0.068 0.070 0.072 0.073
7 CAF + tamoxifen + switch therapy + biphosphonates 0.01002 0.02432 0.04475 0.27567 0.01033 0.02525 0.05063 0.00000 0.068 0.070 0.072 0.073
8 CAF + tamoxifen + AI + biphosphanates + taxanes 0.00941 0.02315 0.04384 0.27567 0.01007 0.02375 0.04681 0.0000 0.068 0.070 0.072 0.073
9 CAF + tamoxifen + switch therapy + biphosphonates + 
taxanes
0.00941 0.02315 0.04384 0.27567 0.01007 0.02375 0.04681 0.0000 0.068 0.070 0.072 0.073
10 AC + tamoxifen 0.01110 0.02873 0.05454 0.27567 0.01341 0.03222 0.06135 0.00000 0.068 0.070 0.072 0.073
11 AC+ tamoxifen + taxanes 0.01049 0.02756 0.05362 0.27567 0.01315 0.03071 0.05749 0.00000 0.068 0.070 0.072 0.073
12 AC + tamoxifen + AI + biphosphonates 0.01110 0.02873 0.05454 0.27567 0.01245 0.02997 0.05764 0.00000 0.068 0.070 0.072 0.073
13 AC + tamoxifen + switch therapy + biphosphanates 0.01110 0.02873 0.05454 0.27567 0.01245 0.02997 0.05764 0.00000 0.068 0.070 0.072 0.073
14 AC + tamoxifen + AI + biphosphonates + taxanes 0.01049 0.02756 0.05362 0.27567 0.01219 0.02846 0.05379 0.00000 0.068 0.070 0.072 0.073
15 AC + tamoxifen + switch therapy + biphosphonates + 
taxanes
0.01049 0.02756 0.05362 0.27567 0.01219 0.02846 0.05379 0.00000 0.068 0.070 0.072 0.073
16 AC + tamoxifen + trastuzumab 0.01033 0.02675 0.05077 0.25664 0.01341 0.03222 0.06135 0.00000 0.068 0.070 0.072 0.073
17 AC+ tamoxifen + taxanes + trastuzumab 0.00976 0.02566 0.04992 0.25664 0.01315 0.03071 0.05749 0.00000 0.068 0.070 0.072 0.073
18 AC + tamoxifen + AI + biphosphonates + trastuzumab 0.01033 0.02675 0.05077 0.25664 0.01245 0.02997 0.05764 0.00000 0.068 0.070 0.072 0.073
19 AC + tamoxifen + switch therapy + biphosphonates + 
trastuzumab
0.01033 0.02675 0.05077 0.25664 0.01245 0.02997 0.05764 0.00000 0.068 0.070 0.072 0.073
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Intervention scenario Case fatality rates (10 years) Relapse rates Disability weights
Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV
20 AC + tamoxifen + AI + biphosphonates + taxanes + 
trastuzumab
0.00976 0.02566 0.04992 0.25664 0.01219 0.02846 0.05379 0.00000 0.068 0.070 0.072 0.073
21 AC + tamoxifen + switch therapy + biphosphonates + 
taxanes + trastuzumab
0.00976 0.02566 0.04992 0.25664 0.01219 0.02846 0.05379 0.00000 0.068 0.070 0.072 0.073
Chemotherapies: CMF consist of cyclophosphamide (PO), methotrexate and 5-fluorouracil (both IV), AC of cyclophosphamide and doxorubicin (both IV) and CAF of cyclophosphamide (PO), doxorubicin and 5-fluoracil. Dosages 18, 27: Cyclophosphamide PO 
2.5 mg/kg bodyweight and IV 13.5 mg/kg bodyweight. Doxorubicin 1.8 mg/kg bodyweight. 5-fluorouracil 12 mg/kg bodyweight. Methotrexate 40 mg/m2 body surface. Tamoxifen 30 mg/day. Aromatase inhibitors; anastrozole 1 mg/day, letrozole 2.5 mg/day 
and exemestane 25 mg/day. Switch therapy (combination of tamoxifen and aromatase inhibitors) is dosed similarly. Start dosage for trastuzumab 4 mg/kg bodyweight, maintenance dosage 2 mg/kg. Taxanes; paclitaxel 90 mg/m2 body surface and docetaxel 
175 mg/m2 body surface. Biphosphonates as a single dose of 4. We assumed the average height to be 1.66 meters, average weight 60 kg and body surface 1.62 m2. 
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Data on immunohistochemical characteristics of breast cancer patients (ER- and HER2 
status), lymph node status and menopausal status were based on the literature 28-34. 
Datasets on these characteristics were derived from multiple studies. All data were 
weighed for the sample size of the corresponding study and eventually combined to 
form the weighting factors (Table 3). These data were used to calculate the overall 
effect of each regimen on survival or relapse, since eligibility for drugs is determined 
by patients’ immunohistochemical profile, nodal- and menopausal status (Table 2). 
Each separate effect of one drug was weighted for the percentage of patients who are 
eligible for these drugs within the regimen (e.g. the effect of scenario 1 is calculated by 
combining the effect of CMF, which all patients receive, with the effect of tamoxifen, 
which 52% of all patients receive). 
We did not discriminate between the prescription of different types of AIs (i.e. 
anastrozole, letrozole and exemestane) and taxanes (i.e. paclitaxel and docetaxel) as 
they do not show a significant difference in effect on survival and relapse 22. Therefore, 
we used the terms ‘aromatase inhibitors’ and ‘taxanes’ within the regimen, indicating all 
subtypes of the concerning drug.
Table 3. Weighting factors for effects and costs
Weighting factor Stage Value Data sources
ER+ All stages 52.0% (default) Ambroise et al. 28, Munjal et al. 32, Ghosh et al. 30 and Verma et 
al. 34
HER2+ All stages 20.3% (default) Ambroise et al. 28, Ghosh et al. 30, Kumar et al. 31 and Verma et 
al. 34
Node+ I 25.0% Tata Memorial Centre
II 65.0%
III 100.0%
IV 90.0%
Postmenopausal All stages 63.9% (default) Ambroise et al. 28, Gadgil et al. 29, Kumar et al. 31, Munjal et al. 32, 
Sandhu et al. 33 and Verma et al. 34
Data sources on costs
The costs of the chemotherapy regimens were derived from the Indian drug price 
index 35 and the literature 36, 37. We also did not make a distinction between the 
prescription of different types of AIs and taxanes to calculate the costs. To calculate the 
unit costs for systemic treatment of each regimen (all stages), costs were weighted for 
patients’ eligibility for drugs and we used the same allocation rules as explained before 
for calculating the effects (Table 4).
Total unit costs for breast cancer diagnosis, treatment (except for systemic therapy) 
and follow-up derived from standard WHO-CHOICE database and corrected for 
inflation to 2011 (Table 4) 3, 38. All drug costs were estimated in 2013 Indian Rupees 
and converted to US dollars (US$) using a currency exchange rate of 1US$:59.53 
Indian Rupees (2013).
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Cost-effectiveness analysis
Average cost-effectiveness ratios (ACERs) were calculated for each intervention by 
dividing the total costs by the total of effects. To assess the expansion path, defined as 
the order in which interventions should be chosen according to their incremental cost-
effectiveness ratio (ICER), we calculated the ICERs of each intervention by dividing 
incremental costs of each intervention by their incremental health effects. Solely 
interventions that are both more effective and less costly in comparison to other 
scenarios are included in the expansion path.
Results of CEA should be interpreted according to a certain cost-effectiveness 
threshold. The WHO-CHOICE defines an intervention as very cost-effective when the 
costs of one DALY averted are less than the gross domestic product (GDP) per capita 
and cost-effective when these costs are below 3 times GDP per capita 15. The GDP 
per capita in Maharashtra was 1,681 US$ in 2012, resulting in a threshold value for 
interventions of 5,044 US$ per DALY averted.
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Table 4. Average utilisation of diagnosis and treatment services and unit costs per patient
Procedure Ingredients Stage I Stage II Stage III Stage IV Relapse Unit costs per patient (US$)
Initial diagnosis and lab tests 1 1.1 2.1 1.8 0.7 166.42
Radiotherapy Radiotherapy planning 0.4 0.3 1.0 0.1 0.6 21,16
Radiotherapy 0.4† 0.3† 1.0† 0.1† 0.6† 2,12 (per fraction)
Surgery Partial mastectomy 0.4 0.3 0.1 0 0 180.35
Modified radical mastectomy 0.6 0.7 0.9 0.05 0.05 183.96
General anaesthesia 1 1 1 0.05 0.05 42.95
Hospitalization days for surgery 2 2 6 6 6 12.83
Chemotherapy CMF/AC/CAF 1 1 1 1 1 457.93 / 170.13 / 819.75‡
Taxanes 25.0% 65.0% 100.0% 90.0% 90.0% 1,008.50
Trastuzumab 20.3% 20.3% 20.3% 20.3% 20.3% 29,865.71‡
Endocrine therapy Tamoxifen 52.0 / 18.8%* 52.0 / 18.8%* 52.0 / 18.8%* 52.0 / 18.8%* 52.0 / 18.8%* 554.49 (5 years)
Aromatase inhibitors 33.2%* 33.2%* 33.2%* 33.2%* 33.2%* 1,367.28 (5 years)
Switch therapy 33.2%* 33.2%* 33.2%* 33.2%* 33.2%* 960.88 (5 years)
Additional drugs Biphosphonates 33.2%* 33.2%* 33.2%* 100%** 100%** 45.27
† Radiotherapy for stage I is given in 10 fractions, stage II in 7.5 fractions, stage III in 25 fractions, stage IV in 25 fractions and for relapse in 15 fractions (2 Gy, by linear accelerator).
‡ Costs for intravenous administration of the drug are included 
* If an intervention scenario only includes the hormone therapy tamoxifen, the effect and costs of tamoxifen were only weighted for the patients who are ER-positive, and therefore eligible for tamoxifen (i.e. 52.0%). If a scenario also includes aromatase 
inhibitors or switch therapy, we made the distinction between patients who are eligible for tamoxifen (premenopausal, 36.1%) and eligible for aromatase inhibitors/switch therapy (postmenopausal, 63.9%). We assumed that all patients who are ER+ and 
premenopausal receive tamoxifen and all patients who are ER+ and postmenopausal receive AIs or switch therapy. 
** All patients in stage 4 and those with relapse receive bisphosphonates, regardless if they receive AIs/switch therapy or not.
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Sensitivity analysis
We performed a deterministic one-way sensitivity analysis to assess the impact of drug 
prices on the results of the cost-effectiveness analysis by varying their price values. 
Input values on drug prices were varied using average, minimal and maximal prices, 
derived from the national price index 35 and other literature 36, 37. 
Results
Results on annual costs, effects (DALYs averted per year) and cost-effectiveness for 
three different drug price levels are shown in table 5 and graphically in figure 2. All 21 
scenarios also include the diagnosis, treatment and follow-up for breast cancer stages 
I to IV, as described by Zelle et al. 19. Programme and training costs were kept at the 
same level for all scenarios.
Annual total costs for treatment, including only chemotherapy and any type of 
hormone therapy (i.e. tamoxifen, aromatase inhibitors or switch therapy) vary from 
416 million to 689 million US$, with treatment scenarios including AIs being the most 
expensive. Adding taxanes to these regimens leads to annual total treatment costs 
that range between 675 million to 943 million US$. Treatment scenarios including 
trastuzumab (with or without taxanes) are the most expensive, as the total treatment 
costs vary from 2.2 billion to 2.5 billion US$ per year.
Intervention scenarios consisting of CAF, hormone therapy and taxanes avert the most 
DALYs per year, i.e. 268,173. AC combined with hormone therapy and taxanes averts 
less DALYs per year ; 230,981. Intervention scenarios including only chemotherapy and 
hormone therapy avert 225,912 (CMF and AC) to 262,776 (CAF) DALYs per year. 
The amount of DALYs averted per year by regimens including AC, hormone therapy, 
trastuzumab (and taxanes) avert 243,238 and 248,088 DALYs per year, respectively.
The average cost-effectiveness ratios (ACERs) of intervention scenarios which include 
chemotherapy and hormone therapy vary from 1,840 to 2,624 US$ per DALY 
averted. Adding taxanes leads to slightly higher ACERs, i.e. 2,924 to 3,516 US$ per 
DALY averted. Cost-effectiveness ratios of treatment scenarios increase even more 
when including trastuzumab (and taxanes); these ACERs vary from 9,143 to 10,272 
US$ per DALY averted respectively.
Figure 2 shows the expansion path, i.e. the order in which interventions should be 
implemented according to their ICER. The upper line represents the cost-effectiveness 
threshold of three times GDP per capita per DALY averted, the lower line one time 
GDP per capita per DALY. When comparing all interventions to the null-scenario, AC 
combined with tamoxifen is the most cost-effective and costs 1,840 US$ per DALY 
averted. The next best scenario to implement is CAF combined with tamoxifen (ICER 
= 5,102 US$ per DALY averted), followed by CAF combined with tamoxifen and 
taxanes (ICER = 47,343 US$ per DALY averted).
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According to the set threshold value of 3x GDP per capita per DALY averted (i.e. 
5,044 US$ per DALY averted), only AC combined with tamoxifen can be considered 
cost-effective. However, the ICER of CAF combined with tamoxifen is only slightly 
higher than this cut-off point and could still be recommended if this threshold is not 
strictly interpreted. When using the average drug prices, all other intervention scenarios 
(i.e. all scenarios including CMF, CAF combined with AIs or switch therapy, and 
scenarios including AC combined with AIs, switch therapy, taxanes and/or trastuzumab) 
are dominated. Nevertheless, these interventions could still be considered based on 
criteria other than cost-effectiveness. Moreover, CMF combined with tamoxifen could 
be the most cost-effective if lower drugs prices are used. Intervention scenarios that 
include trastuzumab cannot be considered cost-effective (ICERs vary from 9,143 to 
10,272). 
We investigated how much the price of trastuzumab should decline to be included in 
the expansion path, i.e. to become cost-effective and considered for implementation. 
When the price of trastuzumab is 50 times lower than its original price of 
approximately 30,000 US$ per patient per year, intervention scenarios including 
trastuzumab become cost-effective. After lowering the price of trastuzumab to circa 
590 US$, the first intervention that should be implemented according to the expansion 
path is AC combined with tamoxifen, followed by AC combined with tamoxifen and 
trastuzumab (ICER is 2,916 US$ per DALY averted). Interventions scenarios consisting 
of AC, hormone therapy, trastuzumab and taxanes are dominated by CAF combined 
with tamoxifen and CAF in combination with tamoxifen and taxanes, the third and 
fourth best option, respectively.
Sensitivity analysis
We explored the impact of different prices for drugs for systemic treatment on cost-
effectiveness by using average prices, minimum and maximum prices. This analysis 
showed that our outcomes and conclusions change when using different prices. 
When using average and maximum prices, AC combined with tamoxifen is most cost-
effective, followed by CAF combined with tamoxifen and CAF in combination with 
tamoxifen and taxanes. However, as Table 5 shows, when using minimum prices, CMF 
combined with tamoxifen is the most cost-effective (incremental CER is 1,406 US$ 
per DALY averted), dominating AC combined with tamoxifen. The second best option 
to implement is CAF with tamoxifen, followed by CAF combined with tamoxifen and 
taxanes.
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Table 5. Annual patient and total costs (US$), effectiveness (DALYs averted per year), cost-effectiveness ratios using average, minimum and maximum prices per scenario for systemic therapy 
as a part of breast cancer treatment in Maharashtra, India
Intervention scenario Annual patient 
costs (US$) a
Annual total 
costs (US$) a
Effectiveness 
(DALYs averted 
per year) b
ACER 
(average 
prices) c
ICER 
(average 
prices) d
ICER 
(minimum 
prices) d
ICER (maxi-
mum prices) d
1 CMF + tamoxifen 465,744,621 500,637,748 225,912 2,216 Dominated 1,406 Dominated
2 CMF + tamoxifen + AI + biphosphanates 552,984,203 587,877,329 225,912 2,602 Dominated Dominated Dominated
3 CMF + tamoxifen + AI + biphosphanates 513,237,542 548,130,668 225,912 2,426 Dominated Dominated Dominated
4 CAF + tamoxifen 568,839,951 603,733,077 262,776 2,298 5,102 2,372 8,427
5 CAF + tamoxifen + taxanes 824,374,849 859,267,975 268,173 3,204 47,343 38,441 58,664
6 CAF + tamoxifen + AI + biphosphanates 654,502,251 689,395,377 262,776 2,624 Dominated Dominated Dominated
7 CAF + tamoxifen + switch therapy + biphosphanates 615,210,426 650,103,552 262,776 2,474 Dominated Dominated Dominated
8 CAF + tamoxifen + AI + biphosphanates + taxanes 908,009,448 942,902,574 268,173 3,516 Dominated Dominated Dominated
9 CAF + tamoxifen + switch therapy + biphosphanates + taxanes 868,944,773 903,837,899 268,173 3,370 Dominated Dominated Dominated
10 AC + tamoxifen 380,756,145 415,649,271 225,912 1,840 1,840 Dominated 3,276
11 AC+ tamoxifen + taxanes 640,521,721 675,414,847 230,981 2,924 Dominated Dominated Dominated
12 AC + tamoxifen + AI + biphosphanates 468,501,068 503,394,194 225,912 2,228 Dominated Dominated Dominated
13 AC + tamoxifen + switch therapy + biphosphanates 428,754,407 463,647,533 225,912 2,052 Dominated Dominated Dominated
14 AC + tamoxifen + AI + biphosphanates + taxanes 726,140,842 761,033,968 230,981 3,295 Dominated Dominated Dominated
15 AC + tamoxifen + switch therapy + biphosphanates + taxanes 686,622,874 721,516,000 230,981 3,124 Dominated Dominated Dominated
16 AC + tamoxifen + trastuzumab 2189,077,647 2,223,970,773 243,238 9,143 Dominated Dominated Dominated
17 AC + tamoxifen + taxanes + trastuzumab 2438,474,224 2,473,367,350 248,088 9,970 Dominated Dominated Dominated
18 AC + tamoxifen + AI + biphosphanates + trastuzumab 2266,074,173 2,300,967,300 243,238 9,460 Dominated Dominated Dominated
19 AC + tamoxifen + switch therapy + biphosphanates + trastuzumab 2,226,325,788 2,261,218,914 243,238 9,296 Dominated Dominated Dominated
20 AC + tamoxifen + AI + biphosphanates + taxanes + trastuzumab 2,513,381,586 2,548,274,712 248,088 10,272 Dominated Dominated Dominated
21 AC + tamoxifen + switch therapy + biphosphanates + taxanes + trastuzumab 2,473,861,917 2,508,755,043 248,088 10,112 Dominated Dominated Dominated
a Costs in this table are in 2013 US$ (1 INR = 0,01679 US$); b DALYs, disability-adjusted life-years (age weighted, discounted); c ACER= Average cost-effectiveness ratio compared to the do nothing-scenario (US$ per DALY averted). d ICER = Incremental 
cost effectiveness ratio, ratio of additional cost per additional life-year saved when next intervention is added to a mix on the intervention path (additional US$ per additional DALY saved).
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Figure 2. Expansion path of systemic drug interventions according to their incremental cost-effectiveness
The threshold values are based on the gross domestic product (GDP) of Maharashtra in 2012 41, 42. The upper dotted line represents the threshold value of 3 times GDP per capita per disability adjusted 
life year (DALY) averted (5,044 US$ per DALY averted). The lower dotted line represents a value of 1 times GDP per capita per disability adjusted life year (DALY) averted (1,681 US$ per DALY averted). 
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Discussion
We have investigated the cost-effectiveness of several interventions for breast cancer 
treatment in India and focussed on the impact of systemic drug treatment on cost-
effectiveness. This is the first article to provide economic evidence on the cost-
effectiveness of breast cancer treatment, and the impact of systemic therapy on this 
cost-effectiveness, in India. Our results show that AC combined with tamoxifen is most 
cost-effective intervention costing 415 million US$ (ICER 1,840 per DALY averted). 
CAF together with tamoxifen is the second most cost-effective intervention and CAF 
in combination with tamoxifen and taxanes the third best option when assuming 
average prices. Trastuzumab is not cost-effective and prices need to be approximately 
50 times lower to be considered cost-effective.
Our analyses show that the treatment scenario AC combined with tamoxifen is 
the most cost-effective and costs 1,840 US$ per DALY averted, which is below the 
threshold value of 5,044 US$ per DALY averted. Other treatment scenarios including 
AC or CMF combined with any type of hormone therapy (tamoxifen, AIs or switch 
therapy), all have the same effect on survival and/or relapse, but are slightly more 
costly and therefore dominated on the expansion path. However, as these small 
differences are likely not clinically and policy relevant and the selection of specific 
therapies depends on patient preferences and patient characteristics, we recommend 
all intervention scenarios that include AC or CMF combined with any type of hormone 
therapy for implementation in India.
The second best option according to the expansion path is CAF combined 
with tamoxifen ($5,102 per DALY averted). This value is slightly higher than the 
threshold value of 3 times GDP per capita, but nevertheless can be considered for 
implementation if sufficient resources are available in India. If even more resources are 
available in India, CAF combined with AIs or switch therapy might also be considered 
for implementation. Intervention scenarios consisting of CAF and AIs or switch therapy 
have the same health effects as CAF combined with tamoxifen, but have higher total 
costs (85.7 million US$ and 46.4 million US$ extra per year respectively) and relatively 
higher ICERs ($7,426 and $6,360 per DALY averted respectively). 
The third best option, CAF combined with tamoxifen and taxanes costs $47,343 
per DALY averted. This value exceeds the threshold value and therefore, CAF 
in combination with tamoxifen and taxanes cannot be considered cost-effective. 
Comparable interventions with taxanes, CAF combined with AIs or switch therapy 
and taxanes, are also not cost-effective, as they have even higher ICERs. All scenarios 
including AC, hormone therapy and taxanes are dominated and therefore also not 
recommended for implementation. 
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As our results indicate, intervention scenarios including trastuzumab are not cost-
effective despite the results of other studies, showing that regimens including 
trastuzumab are cost-effective 39, 40. However, these studies are mostly conducted in 
developed countries, where the threshold values, defined by 3 times GDP per capita 
or willingness to pay (WTP), lies much higher. The GDP per capita in a developing 
country such as India is quite low in comparison to most developed countries and 
therefore, when the WHO-CHOICE methodology is applied, the GDP limits 
interventions to be considered cost-effective. Moreover, trastuzumab is supplied by 
Western companies, with western prices, and are thus very expensive in comparison 
to other drugs, that are produced by generic drug manufacturers in India for much 
lower prices. Our analysis showed that the price of trastuzumab needs to be 50 times 
lower to be considered cost-effective in Maharashtra, India. Achieving these price 
reductions could be considered by the Indian government, as it is able to influence the 
drug market through policy making. Reduced trastuzumab prices could improve access 
and therefore the scope of breast cancer treatment, since approximately 20% of all 
female breast cancer patients are eligible for trastuzumab.
Our sensitivity analysis showed that the order of the expansion path changes when 
varying drug prices between minimum, average and maximum prices. AC combined 
with tamoxifen was most-cost-effective using average and maximum prices, however, 
when using minimum prices CMF combined with tamoxifen is the most cost-effective. 
This can be explained by the price ranges of AC and CMF. AC has a much smaller 
price range and a minimum price of approximately 28 US$ compared to CMF, which 
has a minimum price of circa 3 US$. As this analysis shows that the outcome of our 
CEA is sensitive to different assumptions on drug prices, and therefore influences the 
choice of selecting the most cost-effective intervention, it seems important for the 
Indian government to apply drugs with the lowest prices, while maintaining quality.
There are some limitations of our study. First, demographic and epidemiological data 
and data on stage distribution were derived from WHO and UN datasets specific for 
India and from 2005, and therefore do not entirely represent the current population of 
Maharashtra. 
Second, calculations for effects were based on using Adjuvant! Online. As this program 
makes several assumptions on the effectiveness and the difference in effectiveness 
between several types of chemotherapy and hormone therapy, correct administration 
of drugs and the best possible surgery and radiotherapy, the used effectiveness 
estimates might not represent the actual effectiveness of these therapies. Also, we 
did not perform sensitivity analysis to investigate whether our model is sensitive to 
alternative assumptions on effectiveness.
Third, data on nodal status per stage were adapted from expert opinion and probably 
do not represent the entire population in Maharashtra. Data on other eligibility factors, 
i.e. HER2-, ER- and menopausal status were derived from literature. Some studies 
had a considerably small sample size, and more importantly, these data was not stage 
specific. Different distribution could influence the overall effect of an intervention and 
total patient costs due to different percentages of eligibility.
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Fourth, we did not discriminate between the prescription of different types of taxanes 
(i.e. paclitaxel and docetaxel) and AIs (i.e. anastrozole, letrozole and exemestane) and 
used averaged prices. However, in reality, not all types might be available or some types 
might be prescribed more often than others. These variations could influence the unit 
costs per patients, as some types are more expensive than others (e.g. docetaxel is 
more expensive than paclitaxel). 
 
Fifth, input data on GDP per capita was available until 2012 and data on the GDP per 
capita in PPP and the PPP exchange rate was available until 2011. Moreover, for non-
drug costs, we were only able to correct for inflation from 2000 to 2012. However, we 
used drug prices from 2013 and these discrepancies could have led to relatively high 
drug costs compared to for example GDP per capita, resulting in an overestimation of 
costs.
Sixth, as stated before, out-of-pocket expenditure on health care is very high in India 
(59%). The impact of this financial burden might be stronger in some subpopulations, 
and consequently might have high impact on the access and adherence to treatment 
and the degree of benefit from breast cancer treatment. However, we performed our 
analyses from a health care perspective, and therefore did not include opportunity 
costs and travel costs for patients. Analysis from a societal perspective could give a 
more detailed evaluation of the cost-effectiveness of breast cancer treatment and the 
financial burden for specific subpopulations, and for this reason lead to more targeted 
policy.
Seventh, all interventions were modelled at a geographical coverage level of 95%. 
In reality, however, these high levels of population and treatment coverage are not 
reached in India due to barriers in access and compliance and this could have led 
to a general overestimation of both effects and costs. However, the above limitations 
fall within the aim of WHO-CHOICE to provide generalized and comparable cost-
effectiveness estimates of public health strategies.
Despite these limitations, we can conclude that treatment consisting of AC or CMF 
combined with hormone therapy can be considered cost-effective in India according 
to WHO-CHOICE standardised methods. When more resources become available 
for breast cancer control in India, CAF combined with hormone therapy could be 
considered for implementation as their ICERs are slightly above the threshold value. 
However, cost-effectiveness should not be the only criterion for decisions on breast 
cancer treatment and decisions should also depend on patients’ characteristics and 
preferences. Treatment scenarios that include taxanes are generally not considered 
cost-effective because their ICERs are above the proposed threshold value and 
therefore not recommended. Treatments comprising trastuzumab are also not cost-
effective and trastuzumab prices should be 50 fold lower to be considered cost-
effective.
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Abstract
Objective
To determine the costs and health effects of interventions to combat breast, cervical 
and colorectal cancers in order to guide resource allocation decisions in developing 
countries.
Setting
Two sub-regions of the world: countries in Sub-Saharan Africa with very high adult 
and high child mortality; and countries in Southeast Asia with high adult and high 
child mortality. 
Design
Cost-effectiveness analysis of prevention and treatment strategies for breast, cervical 
and colorectal cancer, using mathematical modelling based on a lifetime population 
model. 
Data sources
Demographic and epidemiological data were taken from the WHO mortality and 
global burden of disease databases. Estimates of intervention coverage, effectiveness 
and resource needs were based on clinical trials, treatment guidelines and expert 
opinion. Unit costs were taken from the WHO-CHOICE price database.
Main outcome measures
Cost per disability adjusted life year (DALY) averted, expressed in international 
dollars (I$) for the year 2005.
Results
In both regions, certain interventions in cervical cancer control (i.e. screening 
through Pap smears or visual inspection with acetic acid (VIA) in combination with 
treatment) and colorectal cancer control (i.e. increasing the coverage of treatment 
interventions) cost less than I$ 2,000 per DALY averted and can be considered 
highly cost-effective. In the Sub-Saharan African, screening for colorectal cancer (i.e. 
by colonoscopy at age 50 in combination with treatment) costs between IS2,000 
and I$ 6,000 per DALY averted and can be considered cost-effective. In both 
regions, certain interventions in breast cancer control (treatment of all stages in 
combination with mammography screening) cost between I$ 2,000 and I$ 6,000 
per DALY averted and can also be considered cost-effective. Other interventions, 
such as fruit and vegetable campaigns or subsidies in colorectal cancer control, are 
not cost-effective according to the criteria defined. 
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Conclusion
A number of highly cost-effective interventions to combat cervical and colorectal 
cancer are available in the African and Asian sub-regions. In cervical cancer control, 
these include screening through Pap smear or VIA, in combination with treatment. 
In colorectal cancer, increasing treatment coverage is highly cost-effective (screening 
through colonoscopy is cost-effective in the African sub-region). In breast cancer 
control, mammography screening in combination with treatment of all stages is 
cost-effective.
Keywords
Cost-Utility Analysis, Breast Cancer, Cervical Cancer, Colorectal cancer. 
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Introduction
Malignant neoplasms are responsible for nearly 7.5 million deaths, representing some 
13% of all mortality and 5% of the global burden of disease in terms of DALYs lost 1. 
Leading contributors to global cancer mortality include tracheal, bronchial and lung 
cancer (18%), stomach cancer (11%), colorectal cancer (9%), liver cancer (8%), breast 
cancer (7%), oesophageal cancer (7%), lymphomas (5%), oral cancers (5%), prostate 
cancer (4%), leukaemia (4%), pancreatic cancer (4%) and cervical cancer (4%) 1.
This study evaluates a set of 240 interventions (and intervention combinations) for 
prevention, screening and treatment in breast, cervical and colorectal cancer control. 
The cost-effectiveness of interventions against tracheal, bronchial and lung cancer in the 
context of tobacco use is presented in a companion article in this series 2.The study 
does not evaluate interventions for stomach cancer due to the absence of known 
efficacious interventions. Likewise, it does not evaluate interventions against liver 
cancer: although preventive interventions exist, only part of their impact is captured 
by reductions in liver cancer (Hepatitis B vaccination has a more direct impact on 
hepatitis B and cirrhosis, and interventions to reduce alcohol use are considered within 
the context of neuropsychiatric conditions in this series 3).
Breast cancer incidence varies considerably between world regions, incidence rates can 
be up to eight times higher in high-income than in low-income regions, such as South-
Asia 1. Similarly, colorectal cancer incidence rates are five to ten times higher in high-
income compared to low-income regions. Conversely, the burden of cervical cancer is 
inversely related to economic development, with 300-400 disability-adjusted life years 
(DALYs) per million people in high-income regions, rising to 800-1,250 in low-income 
regions 1.
This paper provides indications on the cost-effectiveness of prevention, screening 
and treatment strategies for reducing the burden associated with leading causes of 
cancer in developing countries. It draws on previously undertaken analyses of each of 
the three selected cancers 4-6, here updated to the year 2005 and brought together 
in order to elicit key insights into the comparative costs and effects of different 
intervention strategies across and beyond individual cancer entities. In common with 
other papers in this series, we evaluated interventions for two major global regions 
using a standardized analytical approach. The two regions are referred to as Sub-
Saharan Africa, including those African countries with very high adult and high child 
mortality (referred to as Afr-E in the WHO classification) and Southeast Asia including 
those countries in Asia with high adult and high child mortality (referred to as Sear-D). 
The use of the standardized WHO-CHOICE framework allows the comparison of the 
cost-effectiveness of interventions within cancer control, but also in a broader respect 
with intervention in non-communicable disease control as presented in this series, and 
with interventions on infant and infectious diseases as reported earlier 7.
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Table 1. Epidemiology of breast, cervical, and colorectal cancer in WHO sub-Saharan African sub-region AfrE and South East Asian sub-region SearD*
Age group (years) African region Afr-E South-East Asian region Sear-D
Breast cancer (women) Cervical cancer (women) Colorectal cancer Breast cancer (women) Cervical cancer (women) Colorectal cancer
Men Women Men Women
Incidence (per 1000 population)
15–29 0.02 0.23 0.02 0.00 0.01 0.18 0.01 0.00
30–44 0.38 0.27 0.05 0.04 0.21 0.12 0.02 0.02
45–59 0.82 1.58 0.31 0.20 0.45 0.75 0.12 0.09
60–69 1.79 3.46 0.91 0.49 0.79 1.21 0.35 0.23
70–79 2.44 3.95 1.59 0.83 0.95 0.99 0.42 0.30
≥80 3.01 3.56 3.36 1.61 2.18 1.61 0.83 0.89
Prevalence (per 1000 population)
15–29 0.07 0.08 0.07 0.02 0.18 8.44 0.11 0.11
30–44 1.44 0.76 0.20 0.12 2.40 3.29 0.24 0.43
45–59 3.03 3.83 0.89 0.45 3.43 11.00 0.81 0.87
60–69 6.43 7.45 3.50 1.55 3.48 9.32 2.14 1.46
70–79 7.60 5.72 5.16 2.08 2.28 2.85 1.40 1.15
≥80 8.60 4.26 9.48 3.48 3.58 2.63 1.50 1.68
Mortality (per 1000 population)
15–29 0.01 0.05 0.01 0.00 0.00 0.03 0.00 0.00
30–44 0.13 0.09 0.05 0.02 0.07 0.04 0.02 0.01
45–59 0.47 0.69 0.13 0.07 0.28 0.33 0.04 0.03
60–69 1.26 2.27 0.41 0.26 0.65 0.84 0.20 0.12
70–79 2.04 3.61 1.23 0.58 0.85 1.93 0.32 0.21
≥80 3.01 3.55 3.20 1.44 2.18 1.61 0.78 0.80
*Data source: WHO Global Burden of Disease 1.
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Methods
This section outlines the main principles of WHO-CHOICE analysis, and its application 
to the cost-effectiveness analysis of breast, cervical and colorectal control. Further 
details on WHO-CHOICE are presented in detail in the General Appendix A and 
other documents 8,9. Details on the disease-specific analysis are reported in Appendices 
1-3. 
Intervention effects
WHO-CHOICE employs an epidemiological, population-based approach to the 
assessment of health outcomes. Along with background demographic rates, observed 
rates of cancer incidence, prevalence, remission and case-fatality (Table 1) - primarily 
drawn from the global burden of disease database 1 - are represented as parameters 
in a state-transition model in order to establish the total number of years of healthy 
life experienced over the lifetime of a defined population (see General Appendix 
A, 8,9). The model is successively run for each intervention scenario and compared to 
the baseline of no interventions for the disease in question. Thus, the health effects of 
a range of preventive, screening and treatment strategies for cancer are considered, 
with effectiveness expressed as a reduction in epidemiological rates such as incidence 
or case-fatality. We followed standardized WHO-CHOICE methodology to the 
identification of best available evidence on the (clinical or population) effectiveness of 
interventions – in the ideal case, this evidence is retrieved from systematic reviews. In 
other instances, evidence is based on individual studies. In the extreme case where no 
evidence is available, estimates are based on expert opinion. We used evidence on 
intervention effectiveness pertaining to the regions under study, or extrapolated this 
from western settings where meaningful. Evaluated interventions are listed in Table 2 
and their data sources for intervention effectiveness in Tables 3-5. DALYs averted were 
discounted at 3% per annum and age-weighted. Interventions were analyzed at WHO-
CHOICE standardized geographic coverage levels of 50%, 80%, and 95%, referring to 
the percentage of eligible cases receiving treatment.For breast cancer, we evaluated 
lumpectomy with auxiliary dissection supplemented with external radiotherapy to 
the breast for stage I and II breast cancer. For stage III breast cancer, we evaluated 
neo-adjuvant chemotherapy followed by mastectomy with auxiliary dissection 
supplemented with adjuvant chemotherapy including external breast radiotherapy. For 
stage IV breast cancer, we evaluated systemic chemotherapy. All interventions include 
endocrine therapy for eligible patients. We also considered combinations of treatment 
strategies, both with and without the implementation of a breast awareness program 
and early case finding through biannual mammography screening in women age 50–70 
years. Details on assumptions on intervention effectiveness are provided in Table 3, 
whereas the modeling design is provided in Appendix 1. 
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Table 2. Evaluated interventions for breast, cervical, and colorectal cancer control in WHO sub-Saharan African 
sub-region AfrE and South East Asian sub-region SearD. All interventions were evaluated at 50%, 80%, and 95% 
coverage
Intervention Abbreviation
Breast cancer
1: Stage I treatment (Lumpectomy with auxiliary dissection supplemented with external 
radiotherapy to breast. Eligible patients also receive endocrine therapy)
Stage I treatment
2: Stage II treatment (Lumpectomy with auxiliary dissection supplemented with external 
radiotherapy to breast. Eligible patients also receive endocrine therapy)
Stage II treatment
3: Stage III treatment (neo-adjuvant chemotherapy followed by mastectomy with auxiliary 
dissection supplemented with adjuvant chemotherapy. External radiotherapy to the breast. 
Eligible patients receive endocrine therapy)
Stage III treatment
4: Stage IV treatment (systemic chemotherapy supplemented with endocrine therapy for 
eligible patients)
Stage IV treatment
5: Combination treatment (treatment of all stages) Combination treatment
6: Optimal programme (treatment of all stages plus biannual mammographic screening in 
women aged 50–70 years)
Optimal programme
Colorectal cancer
1: Annual faecal occult blood tests FOB1
2: Biennial faecal occult blood tests FOB2
3: Sigmoidoscopy every 5 years SIG5
4: Colonoscopy every 10 years COL10
5: Annual faecal occult blood test + sigmoidoscopy every 5 years FOB1SIG5
6: Faecal occult blood test at age 50 years FOB50
7: Sigmoidoscopy at age 50 SIG50
8: Colonoscopy at age 50 COL50
9: Faecal occult blood test + sigmoidoscopy at age 50 FOBSIG50
10: Medical treatment of cancers RX
11: Annual faecal occult blood tests + medical treatment FOB1RX
12: Biennial faecal occult blood tests + medical treatment FOB2RX
13: Sigmoidoscopy every 5 years + medical treatment SIG5RX
14: Colonoscopy every 10 years + medical treatment COL10RX
15: Annual faecal occult blood test + sigmoidoscopy every 5 years + medical treatment FOB1SIG5RX
16: Faecal occult blood test at age 50 + medical treatment FOB50RX
17: Sigmoidoscopy at age 50 + medical treatment SIG50RX
18: Colonoscopy at age 50 + medical treatment COL50RX
19: Faecal occult blood test + sigmoidoscopy at age 50 + medical treatment FOBSIG50RX
20: Fruit and vegetables campaign FVCAMP
21: Fruit and vegetables campaign + medical treatment FVCAMPRX
22: Annual digital rectal examination DRE1
23: Annual digital rectal examination + medical treatment DRE1RX
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Intervention Abbreviation
Cervical cancer
1: Annual screening by cervical smear test for ages 20–65 years (with removal of lesions) Pap (1,20,65)*
2: Triennial screening by cervical smear test for ages 20–65 (with removal of lesions) Pap (3,20,65)*
3: Screening by visual inspection with acetic acid at age 40 years (with removal of lesions) VIA (40)*
4: Treatment of invasive cancer (including chemotherapy, radiotherapy, and/or surgery) Rx
5: Annual smear test for ages 20–65 years + cancer treatment Pap (1,20,65)* + Rx
6: Triennial smear test for ages 20–65 years + cancer treatment Pap (3,20,65)* + Rx
7: Visual inspection with acetic acid at age 40 + cancer treatment VIA (40)* + Rx
8: Screening by smear test every five years for ages 20–65 (with removal of lesions) Pap (5,20,65)*
9: Smear test every five years for ages 20–65 + cancer treatment Pap (5,20,65)* + Rx
10: Annual screening by smear test for ages 20–30 years, then annual smear test with HPV 
vaccination for ages 30–65 years
Pap (1,20,30) then Pap 
& HPV (1,30,65)
11: Annual smear test for ages 20–30 then annual smear test with HPV vaccination for 
ages 30–65 + cancer treatment
Pap (1,20,30) then Pap 
& HPV (1,30,65) + Rx
12: Triennial smear test for ages 20–30 then triennial smear test with HPV vaccination for 
ages 30–65
Pap (3,20,30) then Pap 
& HPV (3,30,65)
13: Triennial smear test for ages 20–30 then triennial smear test with HPV vaccination for 
ages 30–65 + cancer treatment
Pap (3,20,30) then Pap 
& HPV (3,30,65) + Rx
14: Smear test every five years for ages 20–30 then smear test with HPV vaccination 
every five years for ages 30–65
Pap (5,20,30) then Pap 
& HPV (5,30,65)
15: Smear test every five years for ages 20–30 then smear test with HPV vaccination 
every five years for ages 30–65 + cancer treatment
Pap (5,20,30) then Pap 
& HPV (5,30,65) + Rx
16: Screening by smear test at ages 35, 40, and 45 years (with removal of lesions) Pap (35,40,45)*.
17: Smear test at ages 35, 40, and 45 + cancer treatment Pap (35,40,45)* + Rx.
18: HPV vaccination at ages 35, 40, and 45 years (with removal of lesions) HPV (35,40,45) *.
19: HPV vaccination at ages 35, 40, and 45 + cancer treatment HPV (35,40,45) * + Rx
20: Screening by visual inspection with acetic acid at ages 35, 40, and 45 years VIA (35,40,45) 
21: Visual inspection with acetic acid at ages 35, 40, and 45 + cancer treatment VIA (35,40,45) * + Rx 
22: Screening by smear test at age 40 years (with removal of lesions) Pap (40) *
23: Smear test at age 40 + cancer treatment Pap (40) * + Rx
24: HPV vaccination at age 40 (with removal of lesions) HPV (40) *
25: HPV vaccination at age 40 + cancer treatment HPV (40) * + Rx
26: HPV vaccinations starting at age 12 at cost of US$0.60 per vaccine HPVAC(12), $0.60/dose 
27: HPV vaccinations starting at age 12 at US$0.60 + cancer treatment HPVAC (12), $0.60/
dose + Rx
28: HPV vaccinations starting at age 12 at cost of US$2.00 per vaccine HPVAC (12), $2.00/
dose 
29: HPV vaccinations starting at age 12 at US$2.00 + cancer treatment HPVAC (12), $2.00/
dose + Rx
30: Annual smear test for ages 20–65 years + HPV vaccinations starting at age 12 at cost 
US$0.60
Pap(1,20,65)*+HPVAC 
(12,$.60)
31: Triennial smear test for ages 20–65 years + HPV vaccinations starting at age 12 at cost 
US$0.60
Pap(3,20,65)*+HPVAC 
(12,$.60)
32: Visual inspection with acetic acid at age 40 + HPV vaccinations starting at age 12 at 
cost US$0.60
VIA(40)*+HPVAC (12), 
$.60)
33: Annual smear test for ages 20–65 years + HPV vaccinations starting at age 12 at cost 
US$0.60 + cancer treatment
Pap(1,20,65)*+HPVAC 
(12, $.60) + Rx
34: Visual inspection with acetic acid at age 40 + HPV vaccinations starting at age 12 at 
cost US$0.60 + cancer treatment
VIA(40)*+HPVAC (12, 
$.60) + Rx
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Intervention Abbreviation
35: Smear test every five years for ages 20–65 + HPV vaccinations starting at age 12 at 
cost US$0.60
Pap(5,20,65)*+HPVAC 
(12, $.60)
36: Smear test every five years for ages 20–65 + HPV vaccinations starting at age 12 at 
cost US$0.60 + cancer treatment
Pap(5,20,65)*+HPVAC 
(12, $.60) + Rx
37: Annual smear test for ages 20–30 then annual smear test with HPV vaccination for 
ages 30–65 + HPV vaccinations starting at age 12 at cost US$0.60
Pap (1,20,30) & Pap/
HPV(1,30,65)*+HPVAC 
(12,$.60)
38: Annual smear test for ages 20–30 then annual smear test with HPV vaccination for 
ages 30–65 + HPV vaccinations starting at age 12 at cost US$0.60 + cancer treatment
Pap (1,20,30) & Pap/
HPV(1,30,65)*+HPVAC 
(12,$.60)+Rx
39: Triennial smear test for ages 20–30 then triennial smear test with HPV vaccination for 
ages 30–65 + HPV vaccinations starting at age 12 at cost US$0.60 
Pap (3,20,30) & Pap/
HPV(3,30,65)*+HPVAC 
(12,$.60)
40: Triennial smear test for ages 20–30 then triennial smear test with HPV vaccination for 
ages 30–65 + HPV vaccinations starting at age 12 at cost US$0.60 + cancer treatment
Pap (3,20,30) & Pap/
HPV(3,30,65)*+HPVAC 
(12,$.60)+Rx
41: Smear test every five years for ages 20–30 then smear test with HPV vaccination 
every five years for ages 30–65 + HPV vaccinations starting at age 12 at cost US$0.60 
Pap (5,20,30) & Pap/
HPV(5,30,65)*+HPVAC 
(12,$.60)
42: Smear test every five years for ages 20–30 then smear test with HPV vaccination 
every five years for ages 30–65 + HPV vaccinations starting at age 12 at cost US$0.60 + 
cancer treatment
Pap (5,20,30) & Pap/
HPV(5,30,65)*+HPVAC 
(12,$.60)+Rx
43: Smear test at ages 35, 40, and 45 + HPV vaccinations starting at age 12 at cost 
US$0.60
Pap (35,40,45)* +HP-
VAC (12,$.60)
44: Smear test at ages 35, 40, and 45 + HPV vaccinations starting at age 12 at cost 
US$0.60 + cancer treatment
Pap (35,40,45)* +HP-
VAC (12,$.60)+Rx
45: HPV vaccination at ages 35, 40, and 45 + HPV vaccinations starting at age 12 at cost 
US$0.60
HPV (35,40,45)* +HP-
VAC (12,$.60)
46: HPV vaccination at ages 35, 40, and 45 + HPV vaccinations starting at age 12 at cost 
US$0.60 + cancer treatment
HPV (35,40,45)* +HP-
VAC (12,$.60)+Rx
47: Visual inspection with acetic acid at ages 35, 40, and 45 + HPV vaccinations starting at 
age 12 at cost US$0.60
VIA (35,40,45)* +HP-
VAC (12,$.60)
48: Visual inspection with acetic acid at ages 35, 40, and 45 + HPV vaccinations starting at 
age 12 at cost US$0.60 + cancer treatment
VIA (35,40,45)* +HP-
VAC (12,$.60)+Rx
49: Smear test at age 40 + HPV vaccinations starting at age 12 at cost US$0.60 Pap (40)* +HPVAC 
(12,$.60)
50: Smear test at age 40 + HPV vaccinations starting at age 12 at cost US$0.60 + cancer 
treatment
Pap (40)* +HPVAC 
(12,$.60)+Rx
51: HPV vaccination at age 40 + HPV vaccinations starting at age 12 at cost US$0.60 HPV (40)* +HPVAC 
(12,$.60)
52: HPV vaccination at age 40 + HPV vaccinations starting at age 12 at cost US$0.60 + 
cancer treatment
HPV (40)* +HPVAC 
(12,$.60)+Rx
HPV= human papillomavirus.
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Table 3. Model inputs for cost effectiveness analysis of breast cancer control in WHO sub-Saharan African sub-regi-
on AfrE and South East Asian sub-region SearD
Variable Assumption Data source
Distribution of prevalent cases (2005) and incident cases 
(2005–14) without breast cancer control programme:
Sankaranarayanan et al10*
 Stage I 9.4%
 Stage II 14.2%
 Stage III 58.0%
 Stage IV 18.4%
Distribution of incident cases (2005–14) in presence of 
optimal breast cancer programme:
Bland et al11†
 Stage I 49.0%
 Stage II 37.4%
 Stage III 8.6%
 Stage IV 5.0%
Case fatality rate of untreated patients (2005–14): Sankaranarayanan et al10*
 Stage I 0.020
 Stage II 0.063
 Stage III 0.150
 Stage IV 0.300
Case fatality rate of treated patients (2005–14): Bland et al11†
 Stage I 0.006
 Stage II 0.042
 Stage III 0.093
 Stage IV 0.275
Disability weight: Murray and Lopez12; Norum et al13; 
Launois et al14; de Koning et al15‡
 Stage I 0.068
 Stage II 0.070
 Stage III 0.072
 Stage IV treated 0.073
*Combined data on breast cancer survival and disease staging from studies in Bombay, Bangalore, Barshi, Madras, Rizal, Chiang Mai, and Khon Kaen. 
These data, collected at International Agency for Research on Cancer (IARC), give the best available overview of survival and cancer stage distributions in 
Asian countries. Because of lack of similar data in sub-Saharan Africa, we assumed the IARC data to represent this region as well. These data represent 
the absence of breast cancer control strategies.
†Data on breast cancer survival and disease staging based on a large sample size and specific per treatment. These data represent the presence of an 
optimal breast cancer control programme. 
‡Health state valuation were based on the Burden of Disease study following standard WHO-CHOICE methods. Since only a single health state valuation 
is available for breast cancer, other studies were used to develop health state valuations for each cancer stage. The referred studies are the only studies 
that differentiate health state valuations for breast cancer by stage.
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Table 4. Model inputs for cost effectiveness analysis cervical cancer control in WHO sub-Saharan African sub-region 
AfrE and South East Asian sub-region SearD
Variable Assumption Data source
Efficacy of HPV vaccination against HPV genotypes 16 and 18 100% Kim et al17 
Cervical smear test: Goldie et al21 
 Sensitivity of detecting low grade lesions 0.60
 Specificity of detecting low grade lesions 0.95
HPV DNA testing: Goldie et al21 
 Sensitivity of detecting low grade lesions 0.84
 Specificity of detecting low grade lesions 0.88
Visual inspection with acid (VIA): Goldie et al21 
 Sensitivity of detecting low grade lesions 0.68
 Specificity of detecting low grade lesions 0.85
Cervical smear + HPV DNA tests combined: Kim et al22 
 Sensitivity of detecting low grade lesions 0.94
 Specificity of detecting low grade lesions 0.93
Disability weight for cervical cancer 0.075 Murray and Lopez12 
HPV= human papillomavirus; Estimates of incidence and case fatality reductions derived from modelling the above data are listed in table A3.1 in 
appendix 3 on bmj.com.
Table 5. Model inputs for cost effectiveness analysis of colorectal cancer control in WHO sub-Saharan African 
sub-region AfrE and South East Asian sub-region SearD
Variable Assumption Data source
Faecal occult blood test: Wagner et al23*
 Sensitivity for detecting polyps 0.1
 Specificity for detecting polyps 0.9
 Sensitivity for detecting cancer 0.6
 Specificity for detecting cancer 0.9
Sigmoidoscopy: Wagner et al23*
 Sensitivity for detecting polyps and cancers 0.4
 Specificity for detecting polyps and cancers 0.9
Colonoscopy: Wagner et al23*
 Sensitivity for detecting polyps and cancers 0.9
 Specificity for detecting polyps and cancers 1.0
Digital rectal examination: Herrinton et al24†
 Sensitivity for detecting polyps and cancers 0.04
 Specificity for detecting polyps and cancers 1.0
Eat more fruit and vegetables campaign:
 Increased consumption 12.4% Dixon et al25‡
 Decrease in cancer risk per 80 mg increase 0.01 Lock et al26§
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Variable Assumption Data source
Disability weights for colorectal cancer: Murray and Lopez12¶
 Diagnosis and treatment 0.08
 Watchful waiting 0.08
 Metathesis 0.75
 Terminal 0.81
Estimates of incidence and case fatality reductions were derived from modelling the above data and are listed in table A3.1 in appendix 3 on bmj.com.
*Consensus values from systematic literature reviews for the US Office of Technology Assessment.
†Highest available level of evidence, from a single case-control study.
‡Largest available health promotion campaign, in state of Victoria, Australia.
§Meta-analysis of available literature.
¶Burden of Disease study following standard WHO-CHOICE methods.
For cervical cancer, screening interventions(plus removal of lesions as required) 
included Pap smears (Pap), HPV-DNA testing, visual inspection with acid (VIA) and 
combinations of Pap with HPV-DNA testing at various frequencies. Vaccination against 
the human papillomavirus (HPV) in a scenario where a booster dose is required every 
ten years 5, 16 assumed an efficacy of 100% against genotypes 16 and 18 17, which 
together account for around two-thirds of cervical cancers in low-income countries 
18-20. Treatment of cervical cancer included chemotherapy, radiotherapy and surgery. 
Details on assumptions on intervention effectiveness are provided in Table 4, whereas 
the modeling design is provided in Appendix 2.
For colorectal cancer, a range of one-off (at age 50) and repeated (every 5 or 10 
years) screening strategies were assessed, including faecal occult blood test (FOBT), 
sigmoidoscopy, colonoscopy and - despite uncertain evidence as to its efficacy - digital 
rectal examination (DRE) with subsequent removal of polyps and cancerous lesions as 
needed. The estimated impact of these strategies on the incidence of colorectal cancer 
ranged from 2.6% (i.e. one-off FOBT aged 50) to over 50% (e.g. colonoscopy every 10 
years; annual FOBT plus sigmoidoscopy every 5 years) 6. Treatment strategies included 
radiotherapy, chemotherapy and surgery. In addition, the preventive effect of a mass 
media campaign focused on higher fruit and vegetable consumption was considered. 
Details on assumptions on intervention effectiveness are provided in Table 5, whereas 
the modeling design is provided in Appendix 3.
At present, cancer control strategies in many Sub-Saharan African and Southeast Asian 
countries mainly rely on treatment of - often - advanced cases in referral hospitals, 
with treatment availability varying widely in and among countries in the regions under 
study. At present, there is low to very low coverage of cervical cancer vaccination 
or screening programs in the regions under study 27 – in South-Africa, coverage of 
screening by Pap smear is around 10%, while in India, this is less than 1% 28. However, 
screening by VIA is likely to be more common. Screening programs for colorectal or 
breast cancer are virtually absent 29. 
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Intervention costs 
WHO-CHOICE employs an ingredients approach to costing, such that resources used 
in the implementation of an intervention (e.g. outpatient visits or diagnostic tests) are 
specified in detail and the unit costs of these resources are determined separately. For 
example, for the breast cancer analysis, patient-level patterns of resource use (i.e. initial 
evaluation, local treatment and follow-up) were based on clinical practice guidelines 30, 
31, and are summarized in Groot et al 4. Since only a small proportion of all presenting 
women are diagnosed with breast cancer, most of the resources used for initial 
evaluation correspond to women diagnosed as not having breast cancer. Screening 
in the extensive cancer programme included mammographic screening of women 
aged 50–70 years, with further diagnostic tests on referral. Stage-specific treatment 
protocols for treating cervical cancer were based on standard practice in high-income 
countries 32, 33. Resource quantities for the delivery of screening tests and treatment 
procedures for cervical and colorectal cancer (salaries, room use, drugs and disposable 
and reusable equipment) were retrieved from a South African database 34. Over and 
above these facility-level resources, estimates of the resources needed to set up and 
maintain screening programmes were generated, based on a standardized procedure 
35 and predicted numbers of human and other resources required to implement 
the programmes (e.g. 4-5 administrative posts per million population for notification, 
coordination, follow-up and monitoring activities 5, 6. Details on resource use patterns 
are provided in Appendices 1-3.
Unit costs of non-traded goods - including salaries of health and administrative 
workers, as well as inpatient and outpatient services - were retrieved from the WHO-
CHOICE database (http://www.who.int/choice/costs), which reports region-specific 
values derived from econometric estimation 36. Drug prices were obtained from 
the International Drug Price Indicator Guide, marked up for international and local 
transportation costs 37,38. Unit costs of laboratory, diagnostic and screening tests, as 
well as surgical procedures, derived on the basis of the aforementioned South African 
database, are provided in Appendices 1-3. 
Unit costs were combined with resource-use patterns (described in more detail 
in Appendix 2b) to estimate costs per patient treated. Total patient costs in the 
population were then calculated as the cost per patient treated multiplied by the 
number of patients treated (calculated from the modelled annual incidence of disease 
multiplied by the coverage level and the proportion of cases diagnosed and treated in 
the covered population). All costs were reported in year 2005 international dollars (I$) 
to facilitate more meaningful comparisons across regions (I$1 buys the same quantity 
of health care resources in the Sub-Saharan African and Southeast Asian regions as 
it does in the United States. Cost estimates in Sub-Saharan Africa in I$ should be 
divided by a factor 2.3 to obtain US$ cost estimates for Kenya (in, Southeast Asia cost 
estimates should be divided by a factor 3.1 to obtain US$ cost estimates for India) 8. 
All costs and effects are discounted at 3%, following standardized WHO-CHOICE 
analysis 9. 
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Cost-effectiveness
Dividing total implementation costs of each intervention by its effects generates 
a simple average cost-effectiveness ratio (ACER), relative to a comparator situation 
of no intervention. In addition to average CERs, incremental cost-effectiveness ratios 
(ICERs) are reported for the successive set of interventions that would be selected at 
expanding levels of resource availability, starting with the intervention with the lowest 
cost per DALY averted, then moving to the next most cost-effective combination 
intervention out of the remaining available set of interventions. An intervention that is 
more costly and/or less effective than other more efficient interventions is denoted as 
‘dominated’.
Uncertainty 
Estimating the cost-effectiveness of interventions is inherently uncertain. To deal 
with this, we plot results on a double-logarithmic scale, so as to ascertain order-of-
magnitude differences (e.g. I$ 10-100 versus I$ 100-1,000 per DALY averted). Second, 
we classify results according to defined cost-effectiveness thresholds:  WHO-CHOICE 
calls an intervention yielding a healthy year of life for less than three times gross 
domestic product (GDP) per capita ‘cost-effective’, and an intervention yielding a 
healthy year of life for less than one times GDP per capita, ‘very cost-effective’. In the 
sub-regions considered here, an intervention yielding a DALY for less than I$ 2,000 
is considered highly cost-effective. Interventions yielding a DALY at a cost greater 
than three times GDP per capita (i.e. > I$ 6,000) are considered ‘not cost-effective’, 
while those with a cost-effectiveness ratio falling between I$ 2,000 and I$ 6,000 are 
considered ‘cost-effective’ in these sub-regions 39. Finally, for the subset of interventions 
that are not dominated and therefore fall on the cost-effectiveness frontier, we 
undertook a probabilistic uncertainty analysis using the MCLeague software program 
40. We also assessed the impact of removing age-weights or discounting on baseline 
results via one-way sensitivity analysis for interventions with 95% coverage.
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Results
Cost, effects and cost-effectiveness of interventions are listed in Table 6 (Sub-Saharan 
Africa) and Table 7 (Southeast Asia), and rank ordered on the basis of their ICER (the 
Tables do not include dominated interventions, i.e. those that are more costly and less 
effective than (combinations of) other interventions). The focus here is on determining 
the most efficient set of interventions, first within and then across the disease-specific 
groups (cost, effect and cost-effectiveness of all interventions are listed in appendix 
table 4, 5 and 6 for respectively cervical, colorectal and breast cancer control). 
In both regions, certain interventions in cervical cancer control (i.e. screening through 
Pap smears or VIA in combination with treatment) and colorectal cancer control (i.e. 
increasing the coverage of treatment interventions) cost less than I$ 2,000 per DALY 
averted and can thus be considered highly cost-effective. In the African sub-region, 
screening for colorectal cancer (i.e. by colonoscopy at age 50 in combination with 
treatment) costs less than I$ 6,000 per DALY averted and can be considered cost-
effective. In both regions, certain interventions in breast cancer control (treatment of 
all stages in combination with mammography screening) cost between I$ 2,000 and 
I$ 6,000 per DALY averted and can be considered cost-effective. Below we discuss the 
findings in detail. 
In breast cancer control, treatment of all stages in combination with mammography 
screening costs between I$ 2,248-4,596 per DALY averted in both regions. At an 
optimal coverage level of 95%, this optimal program would avert 381 and 595 DALYs 
per one million population in Southeast Asia and Sub-Saharan Africa respectively, at 
a cost of between I$ 1.38 and I$ 1.68 per capita (i.e. around US$ 0.45-0.55). In both 
regions, treatment of stage I costs between I$ 3,800 and I$ 4,548 per DALY averted, 
whereas treatment of stage IV costs more than I$ 49,000 per DALY averted, and is the 
least cost-effective option (these interventions are less effective and/or more costly 
than other combination in breast cancer control, and therefore not reported in Tables 
6 and 7). 
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For cervical cancer, screening 50% of the target population through a one-off Pap 
smear at age 40, with lesion removal and treatment as required, represents the single 
most cost-effective strategy in both Sub-Saharan Africa and Southeast Asia (I$ 307 
and 142 per DALY averted, respectively). In both regions, the next most cost-effective 
cervical cancer intervention is treatment of invasive cancer with an appropriate 
combination of surgery, chemotherapy and radiotherapy. Also, in both regions, 
screening by means of VIA instead of Pap is slight more effective, but also more costly, 
and therefore less cost-effective. In Sub-Saharan African, adding a HPV vaccination 
program to the provision of Pap smears at age 40 and treatment as required can be 
considered very cost-effective if a cost per dose of US$ 0.60 cents can be realized. In 
the Southeast Asia, a HPV vaccination program is not cost-effective even at the same 
low vaccine price. Adding a booster vaccination every 10 years in addition to such 
strategies has a negligible impact on health outcomes but substantially increases costs 
and hence incremental cost-effectiveness values.
In colorectal cancer control, the most cost-effective strategy is the increased coverage 
of treatment interventions – at 95% coverage this would yield 792 and 868 DALYs 
per one million people in Southeast Asia and Sub-Saharan Africa respectively, at a cost 
of around I$ 0.30 per capita in both regions (i.e. around US$ 0.10). Once treatment 
has been scaled up, it would still be cost-effective to introduce colonoscopy screening 
at age 50 in the Sub-Saharan Africa. The incremental cost and cost-effectiveness of all 
other assessed interventions makes them much less attractive options. 
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Table 6. Costs, effects, and cost effectiveness of interventions to combat breast, cervical, and colorectal cancer in WHO sub-Saharan African sub-region AfrE
Intervention Coverage (%) Annual cost per 
capita ($Int)
Annual DALYs averted 
per million population
Cost effectiveness ratio Rank*
Average Incremental
Breast cancer
BRE-6: Optimal programme (treatment of stages I–IV cancer, plus biannual mammographic scree-
ning)
50 0.68 313 2248 2248 8
BRE-12: Optimal programme 80 1.09 501 2253 2261 9
BRE-18: Optimal programme 95 1.34 595 2323 2696 10
Cervical cancer
ALIGN TO MARGINCVC-129: Smear test at age 40 (with lesion removal) + cancer treatment 50 0.14 462 307 307 1
CVC-4: Treatment of invasive cancer (by surgery, chemotherapy, and/or radiotherapy) 95 0.24 606 401 702 4
CVC-51: Smear test at age 40 + HPV vaccinations starting at age 12 at cost of US$0.60 per vaccine 
dose + cancer treatment
95 0.41 829 497 756 5
CVC-35: VIA at age 40 + HPV vaccine from age 12 at US$0.60 per vaccine dose + cancer treatment 95 0.42 834 500 972 6
CVC-49: VIA at ages 35, 40, 45 + HPV vaccine from age 12 at US$0.60 per vaccine dose+ cancer 
treatment
95 0.48 872 550 1675 7
CVC-37: Smear test every five years for ages 20–65 + HPV vaccine from age 12 at US$0.60 per 
vaccine dose+ cancer treatment
95 0.72 934 772 3906 12
CVC-34: Smear test every three years for ages 20–65 + HPV vaccine from age 12 at US$0.60 per 
vaccine dose+ cancer treatment 
95 0.92 950 970 12 425 14
CVC-43: Smear test every five years for ages 20–30 then smear test with HPV vaccination every 
five years for ages 30–65 + HPV vaccine from age 12 at US$0.60 per vaccine dose + cancer 
treatment
95 1.00 956 1048 13 705 15
CVC-33: Annual smear test for ages 20–65 + HPV vaccine from age 12 at US$0.60 per vaccine 
dose+ cancer treatment
95 1.41 971 1456 27 139 17
CVC-39: Annual smear test for ages 20–30 + then annual smear test with HPV vaccination every 
five years for ages 30–65 + HPV vaccine from age 12 at US$0.60 per vaccine dose+ cancer treat-
ment
95 2.73 984 2773 100 075 18
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Intervention Coverage (%) Annual cost per 
capita ($Int)
Annual DALYs averted 
per million population
Cost effectiveness ratio Rank*
Average Incremental
Colorectal cancer
CRC-35: Cancer treatment (by surgery, chemotherapy, and/or radiotherapy) 80 0.27 792 336 336 2
CRC-10: Cancer treatment 95 0.35 1031 336 337 3
CRC-18: Colonoscopy at age 50 (with surgical removal of polyps) + cancer treatment 95 0.65 1115 585 3630 11
CRC-14: Colonoscopy screening every 10 years + cancer treatment 95 0.87 1138 766 9598 13
CRC-15: Annual faecal occult blood test + sigmoidoscopy every 5 years (with surgical removal of 
polyps) + cancer treatment
95 1.10 1153 952 15 548 16
HPV=human papillomavirus, VIA=visual inspection with acetic acid.
*Rank ordered on the basis of incremental cost effectiveness ratios.
Table 7. Costs, effects, and cost effectiveness of interventions to combat breast, cervical, and colorectal cancer in WHO South East Asian sub-region SearD
Intervention Coverage (%) Annual cost per 
capita ($Int)
Annual DALYs averted 
per million population
Cost effectiveness ratio Rank*
Average Incremental
Breast cancer
BRE-6: Optimal programme (treatment of stages I–IV cancer plus biannual mammographic scree-
ning)
50 0.87 201 4338 4338 8
BRE-12: Optimal programme 80 1.40 321 4362 4401 9
BRE-18: Optimal programme 95 1.68 381 4399 4596 10
Cervical cancer
CVC-129: Smear test at age 40 (with lesion removal) + cancer treatment 50 0.19 1327 142 142 1
CVC-4: Treatment of invasive cancer by surgery, chemotherapy, and/or radiotherapy 95 0.27 1507 182 477 3
CVC-23: Smear test at age 40 + cancer treatment 95 0.46 1755 264 757 4
CVC-7: VIA at age 40 (with lesion removal) + cancer treatment 95 0.48 1765 269 1240 5
CVC-21: VIA at ages 35, 40, and 45 (with lesion removal) + cancer treatment 95 0.53 1796 294 1719 6
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Intervention Coverage (%) Annual cost per 
capita ($Int)
Annual DALYs averted 
per million population
Cost effectiveness ratio Rank*
Average Incremental
CVC-17: Smear test at ages 35, 40, and 45 (with lesion removal) + cancer treatment 95 0.55 1803 303 2886 7
CVC-34: Triennial smear test for ages 20–65 + HPV vaccinations starting at age 12 at cost of 
US$0.60 per vaccine dose+ cancer treatment
95 0.85 1822 467 16 051 13
CVC-41: Triennial smear test for ages 20–30 then triennial smear test with HPV vaccination for 
ages 30–65+ HPV vaccinations starting at age 12 at cost of US$0.60 per vaccine dose + cancer 
treatment 
95 1.41 1837 770 36 764 15
CVC-39: Annual smear test for ages 20–30 then annual smear test with HPV vaccination for 
ages 30–65+ HPV vaccinations starting at age 12 at cost of US$0.60 per vaccinedose + cancer 
treatment 
95 2.77 1854 1493 81 629 17
Colorectal cancer
CRC-10: Cancer treatment by surgery, chemotherapy, and/or radiotherapy 95 0.31 868 362 362 2
CRC-17: Sigmoidoscopy at age 50 (with removal of polyps) + cancer treatment 95 0.51 891 574 8291 11
CRC-18: Colonoscopy at age 50 (with removal of polyps) + cancer treatment 95 0.73 914 794 9318 12
CRC-14: Colonoscopy screening every 10 years + cancer treatment 95 1.04 926 1124 28 017 14
CRC-15: Annual faecal occult blood test + sigmoidoscopy every 5 years (with surgical removal of 
polyps) + cancer treatment 
95 1.63 939 1735 42 940 16
VIA=visual inspection with acetic acid, HPV=human papillomavirus.
*Rank ordered on the basis of incremental cost effectiveness ratios.
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The incremental cost and cost-effectiveness of these interventions are illustrated in 
Figure 1 and Figure 2, which include only interventions considered cost-effective (i.e. 
with a cost per DALY below I$ 6,000). These graphs reveal the cost implications of 
adding in successively less cost-effective or more comprehensive interventions, showing 
for example the cumulative cost per capita associated with the provision of one of the 
more cost-effective interventions for each of the three cancers is less than I$ 1 in both 
regions.
Figure 1. Incremental cost and cost effectiveness of interventions to combat breast, cervical, and colorectal cancer 
in WHO sub-Saharan African sub-region AfrE
See table 6 for explanation of intervention codes.
Figure 2. Incremental cost and cost effectiveness of interventions to combat breast, cervical, and colorectal cancer 
in WHO South East Asian sub-region SearD. 
See table 7 for explanation of intervention codes.
Cost, effects and cost-effectiveness of strategies to combat breast, cervical and colorectal cancer in Sub-
Saharan Africa and Southeast Asia: a mathematical modelling study
229
8
Figure 3. Probabilistic uncertainty analysis of interventions to breast, cervical and colorectal cancer in WHO sub-Sa-
haran African sub-region Afr-E. 
See table 6 for explanation of intervention codes.
Figure 4. Probabilistic uncertainty analysis of interventions to breast, cervical and colorectal cancer in WHO South 
East Asian sub-region Sear-D
See table 7 for explanation of intervention codes.
Chapter 8230
The probabilistic uncertainty analysis depicted in Figures 3 and 4 shows the impact 
of plausible variations in total costs and total effects and shows that the average cost-
effectiveness ratio of most interventions would retain a classification of ‘highly cost-
effective’ and ‘cost-effective’, respectively, after taking into account such uncertainty. 
A similar logic would apply to the incremental cost-effectiveness ratios. One-way 
sensitivity analysis (Appendices 7-8) shows that for both sub-regions and all three 
diseases, removing age weights in the calculation of DALYs has a moderate impact on 
cost-effectiveness (CER rising slightly or falling by up to 20%). Removing discounting 
as well as age weighting had a far larger influence, increasing health outcomes and 
thereby lowering (i.e. improving) cost-effectiveness values markedly (by 45%-90%). 
In addition, we performed sensitivity analysis on the price of HPV vaccines: the 
approximate threshold price for HPV vaccine to become very cost-effective is US$ 6 
in Sub-Saharan Africa and US$9 in Southeast Asia. If booster doses are required every 
10 years, a cost as low as US$ 1.30 in Sub-Saharan Africa and US$ 0.90 in Southeast 
Asia is required to render the intervention cost-effective (not in Table).
Discussion
Principal findings
Our analyses suggest that a number of highly cost-effective interventions to combat 
cervical and colorectal cancer are available in Sub-Saharan Africa and Southeast Asia. 
In cervical cancer, these include screening through Pap smear or visual inspection with 
acetic acid, in combination with treatment. In colorectal cancer, increasing treatment 
coverage is highly cost-effective (screening through colonoscopy is cost-effective in the 
African sub-region). In breast cancer control, mammography screening in combination 
with treatment of all stages is cost-effective.
Policy implications
In breast cancer control, our analyses have shown that treating early stage breast cancer 
is more cost-effective than treating late-stage disease. Results indicate that priorities in 
national breast cancer control programs would be the implementation of an extensive 
cancer control program (including active mammography screening and treatment of 
all stages). Although such a program reflects the economic attractiveness of diagnosing 
breast cancer at an earlier stage, many developing countries may not be able to meet 
its total costs (including the required infrastructure, logistics, and expertise). Given the 
limited available resources, priorities are probably best directed at treatment of early 
stage disease and at developing a less expensive means of early diagnosis. We did not 
evaluate clinical breast examination or breast self-examination because currently there 
is no consensus on their value alone or in addition to mammography. Nevertheless, 
together with other ways of raising awareness, clinical breast examination and breast 
self-examination could be a cost-effective means by which to diagnose breast cancer 
earlier in resource-poor settings.
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In cervical cancer control, an increased coverage of treatment services and low-cost 
screening programs like Pap smears or VIA are both economically very attractive in 
both regions. Increasing treatment coverage is a challenging task, and requires ample 
investments in hospital infrastructures (especially in rural areas) along with the 
training of staff in surgery, chemotherapy and radiotherapy. Also the implementation 
of screening through Pap smears is complex, and requires the routine availability of 
laboratory facilities. In that respect, the implementation of screening by means of VIA, 
which does not require laboratory facilities, may be relatively less complex. In Sub-
Saharan Africa, an HPV vaccination program could also be considered if vaccine prices 
are very low. However, analyses on HPV vaccines involve a greater level of uncertainty 
41,42 – for example, there is no observational evidence on the duration of efficacy 
(conservatively assumed to be 10 years in our analysis) and the price is unknown. 
We assumed a vaccine price as low as US$ 0.60 based on a figure twice that of the 
current yellow fever vaccine cost and the precedent of falling hepatitis B vaccine costs 
in the 1990s. At the current price (over US$100 per dose in developed countries), the 
vaccine is unlikely to be cost effective in developed, let alone in developing, countries; 
in the latter, it will also be highly unaffordable. An additional question is the acceptability 
of a vaccination to prevent cervical cancer initially aimed at twelve-year old girls, 
especially in religious cultures 43. However, it should be noted that the reported cost-
effectiveness ratios for HPV vaccination are upwardly biased in the sense that our 
model did not take into account the burden of condyloma 44 or recurrent respiratory 
papillomatosis 45 on health systems, nor the potential cost savings or DALY reductions 
when a quadravalent vaccine is used 46,47. Targeting screening and vaccinations at HIV 
positive persons could be a way of improving cost-effectiveness, since HIV infection is 
associated with elevated cervical cancer levels 48. A more sensitive but less specific HPV 
test (carelHPV) will soon be available in developing countries at a far lower cost than 
the Hybrid Capture II test 49 - this is likely to improve the relative cost-effectiveness of 
HPV-DNA testing against other PAP,  VIA (and vaccine-based) interventions and in turn 
improve the relative effectiveness of PAP and HPV-DNA combinations against other 
interventions. 
In colorectal cancer control, increasing the low level of treatment coverage is the 
most cost-effective intervention in both the regions considered here. Screening by 
colonoscopy at age 50 in combination with treatment is also cost-effective in the Sub-
Saharan Africa. The use of DRE is not cost-effective despite its low cost as only a very 
small percentage of polyps can be detected. However the cost-effectiveness ratio of 
DRE is overestimated as the model did not include the potential effects of reducing 
mortality from prostate cancer. We also evaluated the introduction of a fruit and 
vegetable campaign, and the provision of price subsidies to fruit and vegetables, but 
these are only able to avert a very modest level of disease burden and are accordingly 
not cost effective in relation to their effect on colorectal cancer alone. However fruit 
and vegetable campaigns could be cost-effective when possible protective effects on 
other diseases are taken into account. 
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Comparison with other studies
Several studies have reported on the global and regional cost-effectiveness of 
interventions targeting breast, cervical and colorectal cancer 4-6. However, studies have 
been carried out in isolation, which prevents the cost-effectiveness of the different 
interventions in cancer control being directly compared. In addition, these studies 
have been analyzed using year 2000 demographics and price levels. This study directly 
compares cost and effects of interventions targeting breast, cervical and colorectal 
cancer, using more recent price levels. This allows the identification of most efficient 
strategies to improve cancer control in the regions considered. For example, our 
analyses show that certain interventions in cervical cancer and colorectal cancer 
control are more cost-effective than others in breast cancer control, in both regions 
considered. 
Strengths and limitations
Over and above the limitations of these cancer-specific models, a number of more 
general shortcomings need to be mentioned. Firstly, our analysis considers costs and 
effectiveness of interventions, but does not address health systems constraints making 
implementation of the interventions difficult. For cancer control strategies constraints 
may be in terms of infrastructure, logistics, and expertise, and these factors should 
be taken into account when making actual programme decisions. For example, the 
expansion of colonoscopy services in colorectal cancer control or mammography 
screening in breast cancer control will be constrained by lack of trained health 
personnel. Likewise, the successful implementation of Pap and HPV-DNA interventions 
will depend on laboratory capacity. Also, issues of acceptability may play a role – e.g. 
of the HPV vaccine 50. We therefore stress that cost-effectiveness analysis should only 
be considered as one input in the decision-making process, and should not be used in 
a formulaic way. Second, for some interventions, assumptions on effectiveness were 
based on studies in other (high-income) settings (many under trial conditions) in the 
absence of local evidence. This may overestimate the effectiveness that can be achieved 
in the regions of analysis, and therefore the economic attractiveness of interventions. 
However, our uncertainty analysis indicates that study results are robust to alternative 
assumptions. Third, and closely related, patterns of resource utilization were sometimes 
based on clinical practice guidelines in western settings, e.g. in the cost analysis of 
breast cancer treatment. The relevance of these guidelines was then carefully assessed 
and adjusted where necessary (see Groot et al. 4 for more detail). Fourth, we did not 
evaluate all possible interventions in cancer control, and our selection of interventions 
for analysis was pragmatic and somewhat arbitrary. Policy makers should be aware of 
this, and should not limit their choice of interventions to those included in this analysis. 
Fifth, the analyses did not include economies of scale resulting from the joint provision 
of breast, cervical or colorectal cancer interventions. In reality, cost saving may be 
realized when breast and cervical cancer screening activities are jointly organized. 
Sixth, in the absence of reliable data, the analyses did not include costs of patients 
seeking or undergoing care, not did it include changes in productivity as a result of the 
interventions 51-53. Seventh, the analysis evaluates interventions at 50%, 80% and 95% 
geographic coverage levels, following standardized WHO-CHOICE methodology.
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The higher coverage levels may not be achievable in the short term but are included 
to indicate the long-term efficiency resulting from economies of scale as more people 
are reached 54. Eight, analyses are carried out at the regional level but important 
differences in costs and/or effectiveness of interventions may exist between countries 
in the same region. Since decision making is made at the country (as opposed to 
regional) level, more refined estimates of costs, effects and cost-effectiveness should 
be made at the county-level, based on country specific data. A good example is the 
contextualization of WHO-CHOICE regional results to the country-level in Mexico, as 
reported in this series 55. The above limitations should be considered in the overall aim 
of WHO-CHOICE analysis to provide broad indications, i.e. a crude bird’s eye view, on 
the cost-effectiveness of a range of interventions to inform general policy discussions 
rather than to deliver precise estimates on a specific intervention 7-9. 
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1. What is already known on this topic
• Several studies have reported on the global and regional cost-effectiveness of 
interventions targeting breast, cervical and colorectal cancer.
• However, studies have been carried out in isolation, which prevents the cost-
effectiveness of the different interventions in cancer control being directly 
compared.
• In addition, these studies have been analyzed using year 2000 demographics and 
price levels
2. What this study adds
• This study directly compares cost and effects of interventions targeting breast, 
cervical and colorectal cancer, using more recent price levels.
• Analyses show that a number of highly cost-effective interventions to combat 
cervical and colorectal cancer are available in Sub-Saharan Africa and Southeast 
Asia. In cervical cancer control, these include screening through Pap smear or 
VIA, in combination with treatment. In colorectal cancer, increasing treatment 
coverage is highly cost-effective (screening through colonoscopy is cost-effective 
in the African sub-region). In breast cancer control, mammography screening in 
combination with treatment of all stages is cost-effective.
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Abstract
Background
The objective of this study was to develop a rating tool for policy makers to 
prioritize breast cancer interventions in low- and middle- income countries 
(LMICs), based on a simple multi-criteria decision analysis (MCDA) approach. The 
definition and identification of criteria play a key role in MCDA, and our rating 
tool could be used as part of a broader priority setting exercise in a local setting. 
This tool may contribute to a more transparent priority-setting process and fairer 
decision-making in future breast cancer policy development.
Methods
First, an expert panel (n=5) discussed key considerations for tool development. A 
literature review followed to inventory all relevant criteria and construct an initial 
set of criteria. A Delphi study was then performed and questionnaires used to 
discuss a final list of criteria with clear definitions and potential scoring scales. For 
this Delphi study, multiple breast cancer policy and priority-setting experts from 
different LMICs were selected and invited by the World Health Organization. 
Fifteen international experts participated in all three Delphi rounds to assess and 
evaluate each criterion.
Results
This study resulted in a preliminary rating tool for assessing breast cancer 
interventions in LMICs. The tool consists of 10 carefully crafted criteria 
(effectiveness, quality of the evidence, magnitude of individual health impact, 
acceptability, cost-effectiveness, technical complexity, affordability, safety, 
geographical coverage, and accessibility), with clear definitions and potential 
scoring scales. 
Conclusions
This study describes the development of a rating tool to assess breast cancer 
interventions in LMICs. Our tool can offer supporting knowledge for the use or 
development of rating tools as part of a broader (MCDA based) priority setting 
exercise in local settings. Further steps for improving the tool are proposed and 
should lead to its useful adoption in LMICs. 
Keywords
Multi-criteria decision analysis, priority setting, breast cancer 
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Introduction
As the second most common cancer in the world and the most common cancer 
in women, breast cancer is an important health problem globally 1. Although it was 
originally considered to be a disease of the developed world, low- and middle-income 
countries (LMICs) are experiencing large increases in incidence 2. Mortality-to-
incidence rates remain relatively high in these areas 3, possibly due to relatively poor 
breast cancer control strategies (e.g.  awareness raising, early detection, treatment) and 
differences in cultural beliefs 2-4. Because strong early detection programs are beneficial, 
the World Health Organization (WHO) seeks to improve appropriate breast cancer 
control programs in LMICs. 
Cost-effectiveness analyses (CEAs), based on the maximization of health benefits, 
have often been used for the selection of breast cancer control strategies. To provide 
an evidence base for the cost-effectiveness of breast cancer interventions in LMICs, 
a consortium of the WHO, Erasmus University Rotterdam, the Radboud University 
Nijmegen Medical Center, and the Susan G. Komen for the Cure foundation initiated 
an international study in 2010 5. Such CEAs may help governments decide how to 
spend scarce health care resources more efficiently. However, decision-makers often 
deviate from CEA results because other principles such as equal treatment and priority 
to the worst-off 6-8 and other factors like feasibility or acceptability influence decisions, 
as well 9-11. Ignorance about these criteria may induce implementation problems or 
inequality among certain patient groups 12-14. 
Multi Criteria Decision Analysis (MCDA) is a well-accepted framework that can 
simultaneously assess multiple criteria for priority setting of interventions 15. Different 
approaches of MCDA are proposed but contain at least the following elements: 1) 
selection of relevant interventions, 2) selection of criteria for priority setting, 3) 
collecting evidence and rating the performance of interventions on selected criteria, 4) 
deliberation on the evidence and performance of interventions with the aim to select 
the best interventions for implementation 16-19.
Several studies have shown the potential of MCDA in prioritizing health interventions, 
however, it has not yet been applied for the selection of breast cancer control 
interventions 20-23. Recently, MCDA has been criticized for being technocratic and 
conceptually challenging for local decision makers 21. Therefore, the development of a 
tool to support local policy makers in selecting criteria and in rating the performance 
of interventions on these criteria is warranted. 
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The objective of this study is to develop a rating tool to assess breast cancer 
interventions along the continuum of care, within the context of the overarching 
breast cancer CEA project 5. The rating tool will be composed of criteria, criteria 
definitions, criteria weights and rating scales to measure the overall impact of breast 
cancer interventions and support the priority setting process. Such a rating tool can 
be used in a broader, MCDA based, priority setting process to develop cancer control 
strategies in a local setting. 
Methods
To develop the rating tool we established an expert panel (n=5) of breast cancer and 
priority-setting experts from WHO and the Radboud University Nijmegen Medical 
Centre. The expert panel consisted of two health economists, a scientific researcher, 
a public health specialist and a student on health technology assessment. Three of 
the experts are co-authors of this article (KV, SZ and JL). A detailed overview of 
the considerations made by the expert panel in the development of the rating tool 
is provided as additional information (additional file 1). Below we describe the most 
important steps that were taken to develop the tool.
A literature search using PubMed and Google Scholar was performed for the 
identification of a first set of predefined criteria. Different combinations of the terms 
‘criteria’, ‘values’, ‘factors’, ‘priority setting’, ‘decision making’, and ‘policy making’ were 
used as the query. The expert panel discussed the list in order to avoid overlap among 
the criteria. For the remaining criteria, clear definitions were defined with the help of 
glossaries and documents published by the WHO 25-27.
To develop the scoring scales, another literature study was performed for each 
criterion of this predefined list. When no or little information was available, scoring 
scales were mainly based on discussions with the expert panel.  
The Delphi study
The list of predefined criteria and scoring scales was further refined by the opinion of 
experts from all over the world. A Delphi study was chosen because of the anonymity 
of participants, the opportunity to include participants globally, and the time and 
money available to conduct the study 28. Delphi studies have proven to be appropriate 
for finding a core list of evaluation criteria 29. 
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Participants 
Experts were selected following WHO selection criteria that include a balanced 
geographical and gender representation, expertise in the technical area (particularly 
in LMICs), and absence of any relevant interest in the personal declaration of interest 
form. Twenty-nine experts with expertise in priority setting or breast cancer policies in 
LMICs were involved, ensuring methodological as well as substantive quality. Experts 
were identified by approaching authors of relevant articles and by snowball sampling. 
Among the experts there were epidemiologists, cancer survivors, pathologists, 
guideline-developers, public health specialists, radiotherapists, surgeons, researchers, 
managers, strategists and ethicists.
First round
In this round, the list with criteria based on the performed literature study was 
presented to the participants. The participants were asked to score the criteria on five-
point Likert scales, according to whether they agreed that interventions scoring high 
on the criterion should be more prioritized (1= strongly disagree, 2= disagree, 3= 
neutral, 4= agree, 5= strongly agree). The experts could give comments on the list 
and mention whether important criteria were missing. In addition, the definitions and 
scoring scales of the criteria were presented and participants were asked to provide 
comments. Likert scales were chosen for this first round because this method is 
reviewed as acceptable for a Delphi study and is simple and easy to perform 30. 
Chapter 9
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Figure 1.  Overview of the development of the criteria list.
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Table 1. Initial criteria including Likert scores and important comments given in the Delphi study
Average 
Likert 
scores
Median 
Likert 
scores
Range 
of Likert 
scores
Most important comments 
Effectiveness 4.75 5 4-5 -Effectiveness is covered by its components. Effectiveness should therefore be removed and its components should be indepen-
dent criteria, otherwise they will overlap.
-No important comments.
-Not related to effectiveness only. The strength of the evidence varies by criterion for any given intervention. Much simpler and 
effective to include considerations of certainty of evidence in assigning scores for all given criterion. 
-Time preference for immediate effects goes against principles of intergenerational equity, and is especially inappropriate for 
preventive services. Therefore this criterion should be removed. 
- Size of effectiveness 4.70 5 3-5
- Certainty of the evidence 4.35 5 1-5
- Time until the effect emerges 3.09 3 1-5
Cost-effectiveness 4.25 4.5 1-5 -MCDA might replace C/E. We can have costs but "effectiveness" is defined by the sum of the criteria so adding this criterion 
introduces double-counting. 
-Efficiency cannot be replaced by costs since higher costs do not per se mean lower efficiency as the effectiveness may be higher.
Feasibility 4.23 4 2-5 -This should be four different criteria, otherwise they will overlap each other.
-See comments accessibility.
-No important comments.
-This criterion should not be limited to capital costs but also explicitly include operating costs required from the health system. 
-No important comments.
- Reach 4.46 5 2-5
- Technical complexity 3.5 3.5 1-5
- Capital intensity 3.75 4 1-5
- Cultural acceptability 4.13 4.5 1-5
Safety 4 4 2-5 -The importance of safety may vary with respect to whose safety (provider vs. patient) and what is at stake, while the level of 
acceptability may remain the same. Therefore acceptability and safety should be kept separated.
Accessibility 4.33 4.5 1-5 -Accessibility due to geographical coverage of an intervention (‘Reach’) is not the same as accessibility due to socio-economic 
status. Therefore this criterion should be about equal access for patients with different socio-economic status, while geographical 
coverage should be covered by another criterion (‘Reach’).
Severity of breast cancer 3.26 3 1-5 -Of course I think that palliative care is very important. On the other hand, if you do nothing for all the people with earlier stage 
cancer, the cancer will progress and they will all need palliative care. So you could treat people with stage 1 or 2 cancer and most 
of them will not experience late stage cancer, therefore will not need palliative care. I guess I don't find this a useful way to think 
about breast cancer.
Age 3.29 3.5 1-5 -Ages of patients with breast cancer don't seem appropriate even if one wanted to create prioritized age groups, which I wouldn't.
Magnitude of individual health 
impact
3.83 4 1-5 -No important comments.
Catastrophic health expen-
ditures
4.17 5 1-5 -Affordability is about whether the health system can afford an intervention and catastrophic health expenditures is about 
whether patients can afford it. Extreme health expenditures might however be covered by accessibility, because patients with 
lower socio-economic status cannot afford high health expenditures.
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Second round
This second round showed the scores and comments given in the first round, together 
with the adaptations to which they had led. Subsequently, participants were asked 
whether they agreed on the adaptations and if they could clarify their answers. 
Third round
Based on the proportion of participants agreeing on the adaptations made after the 
first round and on the comments provided, some final changes were made to the 
criteria list. These final criteria and their definitions and scoring scales were shown to 
the participants, who were asked whether they agreed that this final list contained the 
most relevant criteria for the prioritization of breast cancer interventions. Furthermore, 
participants were asked to divide 100 points over the criteria according to their 
relative importance for the evaluation of breast cancer interventions.
The analysis
The analysis of the answers was both quantitative and qualitative. After the first Delphi 
round, mean and median scores on the Likert scales for “the importance” of criteria 
were calculated. The second round resulted in a percentage of participants who 
agreed with the suggested adaptations. After the third round, the mean and median 
weights given according to the importance of criteria were calculated. All participant 
comments were quantitatively analyzed. 
Results
The literature search on criteria resulted in a total of 33 criteria (Figure 1). After the 
expert panel discussed these criteria, nine criteria remained for the Delphi study. Two 
criteria, effectiveness and feasibility, were divided into three and four subcomponents. 
For each of these nine criteria and the subcomponents, a definition and a potential 
scoring scale were defined.
Participants
Out of 72 experts who were asked, 29 were willing to participate. Of these, 17 were 
experts on priority setting, and 12 were experts on breast cancer policies. The first 
questionnaire was completed by 23 participants, the second questionnaire by 19 
participants, and the third questionnaire by 15 participants. Reasons for not completing 
a questionnaire were private circumstances and disagreement with the aim of this 
research (n=1). Most participants, however, gave no reason.
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First round
Based on the results of the first round, two criteria (‘Severity of breast cancer’ and 
‘Age’) and one of the components (‘The time until the effect emerges’) were 
suggested for removal; two of the components were suggested to be combined 
with two criteria; and all the other components were suggested for separation into 
different criteria. Also, a new criterion was suggested (‘Political will’), two definitions 
were refined, and four scoring scales were adapted. These adaptations led to a list of 
10 criteria. For all criteria, except for the criterion ‘Effectiveness’, there was divergence 
in Likert scale scores. The average and median Likert scale values and most important 
comments on the criteria are shown in Table 1.
Second round
Based on the results of the second round, the new suggested criterion (‘Political will’) 
was removed again because participants argued that political will would also depend 
on the results of interventions on the other criteria; political will changes too often; and 
MCDA aims at a more fair priority-setting process while political will might even be 
clearly unfair. Two criteria (‘Equal access’ and ‘Acceptability’) were separated into two 
different criteria (‘Geographical coverage’ and ‘Accessibility’; ‘Acceptability’ and ‘Safety’); 
two criteria were combined (‘Catastrophic health expenditures’ and ‘Acceptability’); 
and some small refinements to most of the definitions and scoring scales were made. 
An overview of the changes made in the criteria list is shown in Figure 1. The second 
round resulted in a final list of 10 criteria (Table 4). 
Third round
All participants agreed that the list after the second round covered the most relevant 
criteria for the prioritization of breast cancer interventions. Three participants 
mentioned, however, that some criteria might be still overlapping. As one participant 
noted: “Doing the relative weighting exercise above, I realized that some criteria 
are overlapping and it was difficult to assess independent relative weights to them; 
for example, ‘effectiveness’ and ‘quality of the evidence’ are inseparable whereas we 
would not perhaps say something is effective if the quality of the evidence is weak.” 
There were also doubts about ‘cost-effectiveness’ being covered by the ‘affordability’ 
and ‘effectiveness’ and about ‘safety’ being covered by ‘effectiveness’ and ‘geographical 
coverage’ being covered by ‘effectiveness’. The criterion ‘geographical coverage’ was 
rated relatively low in its importance for the evaluation of breast cancer interventions, 
followed by ‘safety’ and ‘affordability’, respectively. The importance of the criterion 
‘Effectiveness’ was rated highest (Table 2).
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Table 2. Final criteria list for the prioritization of breast cancer interventions including weights
Definition Potential scoring scales Average weight* 
(min-max)
Median weight
Effectiveness 31-35 Effectiveness is the extent to which an intervention impacts the most 
relevant health-related outcomes (e.g. time to recurrence or healthy 
life years gained). In comparison of effectiveness of interventions, it 
is important to note that the most relevant health-related outcome 
should be consistent for all interventions under consideration 25. 
Size of the effect (e.g. in a population of 1 million people):
0 less effective (e.g. < 50 healthy life years gained a year)
1 effective (e.g. ≥ 50 < 100 healthy life years gained a year)
2 very effective (e.g. ≥ 100 healthy life years gained a year) 30
17.33 
(5 - 50)
15
Quality of the 
evidence 31, 32, 
35, 37, 38
The risk of bias and the extent of the confidence that the evidence is 
adequate to support a particular decision or recommendation 39. 
0 very little or limited confidence in the evidence: the estimated 
values may be substantially different from the outcomes in reality
1 moderately confident about the evidence: The estimated values are 
likely to be close to the outcomes in reality, but there is a possibility 
that it is different
2 very confident that the estimated values lie close to the outcomes 
in reality 33
11.93
(0 - 20)
12
Magnitude of 
individual health 
impact 32, 38
Interventions offering small benefits for many may be viewed diffe-
rently from those offering large benefits for a few. When one of the 
two is preferred above the other, interventions providing the prefer-
red effect (concentrated or dispersed) might be more prioritized 32.
0 the intervention is not accepted by some people and it is not 
likely that this can be changed
1 the intervention is not accepted by some people but it is likely 
that this can be changed with some extra effort (e.g. special educa-
tion)
2 the intervention is accepted by almost all people
8.67
(5 - 15)
10
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Definition Potential scoring scales Average weight* 
(min-max)
Median weight
Acceptability 26, 
35, 35, 38
The extent to which the intervention is judged as suitable, satisfying 
or attractive by different stakeholder groups (e.g. patients, providers 
or politicians). The acceptability depends on people their norms, 
beliefs and values 26, 40.
0 poor affordability (e.g. costs > 1 US$ per capita)
1 moderate affordability (e.g. costs > 0.50 ≤ 1 US$ per capita)
2 good affordability (e.g. costs ≤ 0.50 US$ per capita) 20
8.47
(0 - 20)
15
Cost-effective-
ness 31, 32, 35, 37, 40 
The capacity to produce the maximum output for a given monetary 
input 25. 
0 there is a risk of severe adverse effects (life threatening) to pa-
tients or a risk of adverse effects (of any kind) to providers
1 there is a risk of mild adverse effects to patients
2 there is no risk or a risk of very mild adverse effects (adverse 
effects which will completely recover within a month) to patients 
7.87
(0 - 15)
10
Technical com-
plexity 26, 34
Other types of inputs required in addition to monetary inputs to 
implement and to keep providing the intervention. (These include 
human resource requirements, both quantitative and qualitative, and 
organizational requirements. The potential to integrate the interven-
tion into an already existing health system should also be taken into 
account 26.
0 the intervention does not cover (most) people who live far away 
from cities. 
1 the intervention does not cover some people who live far away 
from cities.
2 the intervention covers (almost) all people
5.47
(0 – 13)
10
Affordability 26, 31, 
34, 35, 38 
The monetary input (e.g. capital investments and operational costs) 
required from the health system to implement and to keep providing 
the intervention 26.
0 poor affordability (e.g. costs > 1 US$ per capita)
1 moderate affordability (e.g. costs > 0.50 ≤ 1 US$ per capita)
2 good affordability (e.g. costs ≤ 0.50 US$ per capita) 20
8.47
(0 - 20)
10
Safety 31, 34 Safety is the practical certainty that adverse effects to patients or 
providers will not result from exposure to an intervention under 
defined circumstances 27.
0 there is a risk of severe adverse effects (life threatening) to pa-
tients or a risk of adverse effects (of any kind) to providers
1 there is a risk of mild adverse effects to patients
2 there is no risk or a risk of very mild adverse effects (adverse 
effects which will completely recover within a month) to patients 
7.87
(0 - 15)
5
Geographical 
coverage 26, 
32, 34, 35
The ability of the intervention to be reached by the target population, 
independent of their living place 26.
0 the intervention does not cover (most) people who live far away 
from cities. 
1 the intervention does not cover some people who live far away 
from cities.
2 the intervention covers (almost) all people
5.47
(0 – 13)
13
Accessibility 31, 37 Patients with a different socioeconomic status or a different income 
should be able to make equal use of the intervention 32.
0 the intervention is not accessible to many patients
1 the intervention is not accessible to some patients
2 the intervention is accessible to (almost) all patients
10.6
(0 – 20)
NOTE: References were used to identify the criteria in first instance. The Delphi study may have resulted in adaptations in definitions or scoring scales than originally found in the literature
* weights were calculated by asking  participants to divide 100 points over the criteria according to their relative importance for the evaluation of breast cancer interventions.
* weights were calculated by asking  participants to divide 100 points over the criteria according to their relative importance for the evaluation of breast cancer interventions.
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Discussion
This study describes the development of a rating tool to measure the impact of 
breast cancer interventions based on multiple criteria in LMICs. Ten criteria, including 
definitions and potential scoring scales, have been indicated. The results of this study 
show that effectiveness, quality of the evidence, magnitude of individual health impact, 
acceptability, cost-effectiveness, technical complexity, affordability, safety, geographical 
coverage, and accessibility seem to be important principles in the selection of breast 
cancer control strategies. Although selecting and defining interventions and criteria for 
breast cancer control is context specific, we think that this rating tool can be a starting 
point for local policy makers as part of a broader, MCDA based, priority setting 
process. 
Use of the tool in a LMIC
The tool could be used as part of the integrated MCDA and accountability for 
reasonableness (A4R) approach for priority setting, recently proposed by Baltussen et 
al. 16 (Figure 2). This new approach combines strong components of both frameworks 
and requires a set-up of a multi-stakeholder consultation panel (step one). In this way 
a democratic learning process is started in which stakeholders are involved in all steps 
of the priority setting. Compared to the stand-alone MCDA framework, this combined 
approach may increase the acceptance of decisions among stakeholders and the 
likelihood of implementation of prioritized programs. The rating tool can be part of 
step two and three (Figure 1) of the approach that aim to identify criteria for priority 
setting and assess (i.e. rate) the performance of interventions on the selected criteria.
An important next step in the local use of the rating tool is to investigate how the 
tool and its components are understood in LMICs in a pilot study. Users of the tool 
could for example select relevant stakeholders (e.g. patients, lay-people policy makers, 
caregivers, public health specialists) and establish a consultation panel (step 1). These 
stakeholders could discuss the interventions, criteria, the attitude of decision-makers 
against the criteria and scoring scales using democratic elements (e.g. Nominal Group 
Technique) (step 2). After the collection of all relevant (local) evidence, the users could 
use our tool as an input for a performance matrix (step 3), and then interpret and 
deliberate on the results of this matrix (step 4 and 5). Users should be well informed 
and plan enough time for this process, and should try to ensure that the tool is 
perceived as a simple and legitimate way to frame policy discussions in a more rapid 
and balanced manner. The potential of this tool could also be investigated for other 
cancers.
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Figure 2. Elements of a priority setting process based on MCDA 16
Limitations of the study
Our study has a number of limitations. First, prior to the Delphi study, the expert panel 
made a selection of 9 criteria out of 33 criteria. This selection was based on overlap 
between criteria and whether criteria would be appropriate for the selection of breast 
cancer interventions. However, there is no certainty that personal preferences did not 
lead to bias in this selection. 
Second, we used Delphi studies to define a list with core criteria including definitions 
and scoring scales. The Delphi method ensures participant anonymity and provides 
enough time to properly consider one’s own answers and those of others. However, 
the Delphi questionnaire may not allow for adequate elaboration on difficult concepts 
such as equity and social welfare. Also, Delphi questionnaires can be relatively time 
consuming, which may have partly caused 14 participants to withdraw from this study. 
We do not expect that these withdrawals biased the results because they varied 
in gender and type of expert and the number of comments remained high in each 
questionnaire. 
Third, the wide variety of comments and views of the participants made us aware 
of the difficulties in developing a clear, consensus-based, non-overlapping criteria list 
and scoring scales. There are many possible compositions and definitions of criteria 
31-33. Besides there are many ways to divide a scoring scale into different categories 
and this also depends on the variability of the interventions that are considered (i.e. 
discriminative power of the scoring scale). Further research should focus on more 
informed contextualized categories for scoring scales.
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The difficulty of avoiding overlap between criteria may be explained by a lack of a 
broader theory on the relationship between criteria. Some disagreement between 
participants remained until the end of the process, and some overlap was still 
suspected in the final criteria list. These potential overlaps will need attention in the 
further development of this tool because criteria should preferentially be independent 
from each other 15, 42. Especially effectiveness has a risk of overlap with other criteria, 
like cost-effectiveness, safety and geographical coverage. Further overlap between 
criteria should be identified and distinctions should be made and clearly described in 
the definitions.
Limitations of the tool
The tool also has some practical limitations that one should be aware of. First, the tool 
does not provide guidance to convert the performance matrix into a final prioritization 
of interventions. This tool stops at rating interventions after which a choice should be 
made based on a democratic learning process (figure 1). This tool does not facilitate a 
democratic learning process, which makes it less likely that good rated interventions 
are implemented. The accountability for reasonableness framework (A4R) is successful 
in introducing such a learning process 43. We recommend making the tool part of the 
integrated MCDA A4R approach for priority setting in health as proposed by Baltussen 
et al. 16, however local capacity should be present or established to facilitate such a 
complete process. 
Second, the proposed rating tool is based on decision-maker values and preferences 
while the views of other stakeholder groups are also considered important in priority 
setting exercises. Different stakeholder groups are likely to have different preferences 
for criteria 22, 44. This limitation of the tool could be solved while applying the tool in a 
local setting. At that stage, other stakeholder groups (like patients, the public, and health 
care workers) can be asked to comment on the relevance of the criteria included in 
the tool and the relative importance and the tool can be adapted accordingly. 
Third, there are limitations to the collection of information, and it may sometimes be 
difficult to assess interventions on certain criteria. This is however a problem across the 
field of health priority setting and we recommend to be transparent on the available 
evidence and its quality. A sensitivity analysis may help to give insight in the uncertainty 
of the scoring performances of intervention options. In this way, quality of evidence is 
not used as a single criterion but as an uncertainty factor per criterion per intervention 
45. 
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Conclusion
This study describes the development of a rating tool to assess the impact of breast 
cancer interventions on multiple criteria. This tool may be a starting point for local 
decision makers that would like to conduct multi criteria decision analysis to set 
priorities for breast cancer control.
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Thesis rationale 
The general objective of this thesis is to improve the knowledge base on the 
cost-effectiveness of interventions for breast cancer control in LMICs. Evidence-
based information on interventions that provide the greatest value for money can 
support LMICs in improving their national breast cancer control programs. To meet 
this objective, the research question addressed in this thesis is: What is the cost-
effectiveness of a range of breast cancer control interventions along the continuum of 
care in a number of LMICs? 
To answer this research question, this thesis first provides a systematic review of 
available cost-effectiveness estimates for breast cancer control in LMICs (Chapter two). 
It then demonstrates a method to predict the stage distribution of different breast 
cancer screening options, which can be used to estimate the effectiveness of screening 
interventions (Chapter three). 
Next, a number of case studies are discussed that provide the costs, effects, and cost-
effectiveness of breast cancer control interventions in five LMICs (Chapters four to 
seven). These case studies only include the individual perspectives of countries, and a 
more global perspective is also taken in this thesis (Chapter eight). 
To comprehensibly guide LMICs in improving breast cancer control, this thesis also 
focuses on other considerations next to cost-effectiveness. The last study presented 
in this thesis therefore includes a generic rating tool that can be used in a broader 
priority-setting process (Chapter nine). This tool considers multiple other criteria, 
including cost-effectiveness, to support comprehensive breast cancer control strategies 
in LMICs.
The next section summarizes and further elaborates on the available cost-effectiveness 
evidence of five countries - Ghana, Mexico, Costa Rica, India, and Peru - to which this 
thesis contributes. Then, the global evidence used in this thesis will be considered using 
the results from Chapter eight and supplementary analyses. In the subsequent sections, 
the policy implications (exemplified by a case study from Colombia), limitations, and 
suggestions for future research that follow from this thesis will be discussed. 
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Interventions that provide the greatest health for 
money
Contributions of this thesis on individual countries 
Our systematic review (Chapter two) shows that not many health economic studies 
on breast cancer control have been conducted in LMICs. A search of the international 
literature in January 2013 yielded 24 economic studies that evaluated different kinds 
of screening, diagnostic, and therapeutic interventions in various age and risk groups 
in LMICs 1. However, out of these 24 studies, only seven presented functional cost-
effectiveness results - these are studies from which cost-effectiveness ratios could be 
determined. In addition to the functional cost-effectiveness studies from our systematic 
review, cost-effectiveness estimates from five individual countries (Costa Rica, Ghana, 
India, Mexico, and Peru) are presented in this thesis (Chapters four to seven). 
Table 1 provides an overview of the most cost-effective interventions based on the 
studies presented in this thesis. The interventions can be considered cost-effective 
if their incremental cost-effectiveness ratio (ICER) is less than three times the GDP 
per capita, which is a generic decision rule recommended by the World Health 
Organization.
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Table 1. Overview of the reported cost-effectiveness estimates of breast cancer control interventions in individual LMICs in this thesis.
Country Base 
year
GDP in per 
capita in 
base year
Number of 
interventi-
ons analyzed
Model used Control component of 
recommended intervention
Cost-effective-
ness estimates
(ICER min-max)
Most cost-effective intervention based on ICER
Results from systematic review in this thesis
Brazil 5 2005 $4,739 2 Markov model Treatment 
(Hormonal therapy)
$11,193
per LYS
Anastrozole, in relation to tamoxifen ($11,193/LYS)
China 6 2012 $6,093 2 Markov model Treatment 
(Radiotherapy)
$328 - 577 
per QALY
Radiotherapy, in relation to no radiotherapy after breast conserving 
therapy ($233/LYS) and ($421/QALY)
China 7 2008 $3,414 2 Markov model Treatment 
(Chemotherapy)
$4,892 
per QALY
TC, in relation to AC ($5,383/LYS) and ($4,892/QALY)
India 8 2001 $466 11 MISCAN-model Early detection 
(Population based screening)
$793 - $19257 
per LYS
Single CBE screen at age 50 ($793/LYS)
Mexico 9 2005 $7,824 101 WHO-CHOICE 
model
Early detection 
(Population based screening)
$1,625 - $21,983 
per DALY
Treatment of all stages plus mammography screening ($21,983/DALY)
Morocco 10 - $2,861 2 - Treatment 
(trastuzumab)
$663,000 
per LYS
Treatment with trastuzumab for HER2 over expressing patients 
($663,000/LYS)**
Vietnam 11 - $1,232 2 - Treatment 
(Surgery)
$351 
per LYS
Adjuvant oophorectomy and tamoxifen for hormone receptor posi-
tive operable breast cancer, compared to standard treatment ($351/
LYS)
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Country Base 
year
GDP in per 
capita in 
base year
Number of 
interventi-
ons analyzed
Model used Control component of 
recommended intervention
Cost-effective-
ness estimates
(ICER min-max)
Most cost-effective intervention based on ICER
Results from original work in this thesis
Costa Rica 1 2009 $6,629 19 WHO-CHOICE 
model
Early detection 
(Population based screening)
$4,739 - $30,352
per DALY
Biennial CBE screening ($5,964/DALY)
Ghana 2 2009 $649 17 WHO-CHOICE 
model
Early detection 
(Population based screening)
Early detection 
(Breast health awareness)
$1,299 - 
$553,616 
per DALY
Biennial CBE screening ($1,299/DALY)
or mass media awareness raising (MAR) ($1,364/DALY)
Maharashtra, 
India 3
2013 $3,650 21 WHO-CHOICE 
model
Treatment (Chemotherapy) $1,406 - $58,664 
per DALY
AC regimen combined with tamoxifen ($1,840/DALY)
or CAF regimen combined with tamoxifen ($5,102/DALY)
Mexico 1 2009 $8,416 19 WHO-CHOICE 
model
Early detection
(Breast health awareness)
Early detection
(Population based screening)
$5,021 - $13,994 
per DALY
Mass media awareness raising (MAR) ($5,021/DALY) or biennial 
mammography screening (age 50-70) ($12,718/DALY)
Peru 4 2012 $4,068 94 WHO-CHOICE 
model
Early detection
(Population based screening)
$4,125 - $87,243
per DALY
Triennial screening by CBE in rural areas (age 40-69) + triennial 
screening by CBE (age 40-49) and fixed mammography (age 50-69) in 
urban areas ($4,349/DALY)*
*Next to the ICER, affordability and complexity were considered as criteria. 
** Cannot be considered cost-effective based on the WHO-CHOICE decision rule on cost-effectiveness analysis.
QALY = Quality Adjuste Life Year; LYS = Life Year Saved; DALY = Disability Adjusted Life Year; ICER = Incremental cost effectiveness ratio, ratio of additional cost per additional life-year saved when next intervention is added to a mix on the intervention 
path (additional US$ per additional DALY saved). CBE = Clinical breast examination; AC = cyclophosphamide and doxorubicin ; CAF = cyclophosphamide ,doxorubicin and 5-fluoracil; TC = docetaxel, cyclophosphamide.; HER2 = human epidermal growth 
factor receptor.
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Many of the breast cancer interventions in Table 1 relate to early detection or 
treatment strategies, and the cost-effectiveness estimates of these interventions vary 
greatly per country (ranging from $233 to $633,000 per life-year saved). Concerning 
early detection strategies for breast cancer control, the cost-effectiveness estimates for 
population-based screening are $793 per life-year saved (CBE screening, India), $1,299 
(CBE screening, Ghana), $4,125 (mixed screening, Peru), $4,739 (CBE screening, 
Costa Rica), $5,021 (MAR, Mexico), and $21,983 per DALY averted (mammography 
screening, Mexico). The cost-effectiveness estimates for treatment interventions for 
breast cancer are $233 (radiotherapy, China) and $4,892 per QALY (chemotherapy, 
China) and $351 (oophorectomy, Vietnam), $1,406 (chemotherapy, India), $11,193 
(hormonal therapy, Brazil), and $633,000 per life-year saved (trastuzumab, Morocco). 
Treatment with trastuzumab in Morocco cannot be considerd cost-effective according 
to the proposed threshold.
Some of the variation in these cost-effectiveness estimates can be explained by the 
many differing factors in these countries, including disease epidemiology, population 
structure, wages of healthcare personnel, inflation rates, drug costs, practice variation, 
utilization rates of equipment, and health financing system. However, it seems that 
most of the variation can be explained by differences in study characteristics and study 
objectives. Prior studies recommending treatment interventions did not include any 
early detection or palliative care interventions and used different comparator scenarios 
from studies recommending screening interventions. For example, the Brazilian study 
included only two hormonal treatment interventions, one of which served as a 
comparator scenario, whereas the Peruvian study included 94 interventions along the 
continuum of care for which “do nothing” served as the comparator scenario. Even 
the six WHO-CHOICE studies shown in Table 1 have differing study characteristics, 
mostly relating to the interventions analyzed. For example, the Indian study did not 
analyze early detection or palliative care interventions at all. The first Mexican study 
(base year 2005) did not analyze CBE screening or palliative care interventions. The 
second Mexican study (base year 2009) did not analyze opportunistic screening, mixed 
forms of screening (fixed vs. mobile), or upfront FNA.
Therefore, if recommendations are to be made for individual countries purely on 
the basis of cost-effectiveness, a closer look at the results for each study by control 
component is necessary. These components, which were described in the introduction 
section of this thesis, consist of early detection (breast health awareness, population 
based screening, opportunistic screening), diagnosis (clinical, pathological, lab/
radiological), treatment (surgery, radiotherapy, chemotherapy, hormonal, and other 
therapy), follow-up and rehabilitation, and palliative care (Table 2). 
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Cost-effectiveness estimates for the early detection component of breast cancer 
control indicate that CBE screening (ages 40–69) may be recommended for most 
countries. Mass media awareness-raising (MAR) could also play an important role 
in most countries, especially in countries with relatively poor stage breast cancer 
distributions and relatively inexpensive media costs. Mammography screening (ages 
50–69), on the other hand, may only be recommended for countries with a relatively 
high GDP per capita (over $4,000) and relatively low mammography procedure 
costs. Mixed screening programs, such as CBE screening in rural areas and fixed 
mammography screening in urban areas, were only analyzed for Peru but could be 
important for all countries with a relatively high GDP per capita and relatively high 
urbanization rates.
Cost-effectiveness estimates for the treatment component of breast cancer control 
show that adjuvant radiotherapy and surgery are highly cost-effective. Treatment 
schedules that include standard radiotherapy, surgery, chemotherapy (AC regimen), 
and tamoxifen are also cost-effective. However, the results show that treatment of 
stages I to IV breast cancer only is less cost-effective than when treatment is combined 
with early detection strategies. More advanced treatment regimens that include CAF 
or aromatase inhibitors may only be recommended for countries with a relatively high 
GDP per capita (over $4,000), whereas treatment regimens that include taxanes may 
only be recommended for countries with a GDP per capita over $6,000. Trastuzumab 
therapy may only be recommended for countries with a GDP per capita above $8,000 
dollars and seems not to be appropriate for most LMICs. 
Remarkably, no cost-effectiveness research has been performed on interventions 
relating to diagnosis or to follow-up and rehabilitative breast cancer control 
components. This is remarkable, particularly for follow-up, since the cost of follow-up 
can account for 35% of the total healthcare costs per breast cancer patient.
The few estimates for the palliative care component of breast cancer control generally 
indicate that palliative care interventions are not cost-effective for most countries. 
More efficient palliative care strategies are those that comprise less expensive 
elements, such as oral morphines and home-based visits by volunteers. These strategies 
seem to be still relatively cost-effective in Peru and Costa Rica and could be important 
in LMICs were patients arrive mostly in advanced breast cancer stages.
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Table 2. Overview of recommended breast cancer interventions by control component based on cost-effectiveness 
estimates only
Recommended, intervention costs less than 1 times the GDP per capita, per health outcome
Optional, intervention costs between 1 and 3 times the GDP per capita, per health outcome
Not recommended, intervention costs more than 3 times the GDP per capita, per health outcome
Country
(GDP per capita in US$,
in base year of study) G
ha
na
 (
64
9)
   
V
ie
tn
am
 (
1,
23
2)
 
M
or
oc
co
 (
2,
86
1)
In
di
a 
(3
,6
50
)
Pe
ru
 (
4,
06
8)
Br
az
il 
(4
,7
39
)
C
hi
na
 (
6,
09
3)
C
os
ta
 R
ic
a 
(6
,6
29
)
M
ex
ic
o 
(8
,4
16
)
 MAR*
CBE screening*
CBE and MM screening*
MM screening*
Surgery, radiotherapy, AC regimen, tamoxifen
Adjuvant oophorectomy
CMF regimen*
CAF regimen*
Aromatase Inhibitors*
Taxanes*
Trastuzumab*
Basic palliative care*
Standard palliative care*
Extended palliative care*
MAR = Mass media awareness raising of breast cancer signs and symptoms; CBE = Clinical breast examination; MM = mammography; AC = cyclophosp-
hamide and doxorubicin ; CMF = cyclophosphamide, methotrexate, fluorouracil; CAF = cyclophosphamide ,doxorubicin and fluoracil; Basic palliative care 
= only morphines and home based care by volunteers; Standard palliative care = only morphines and treatment of bone metastasis; Extended palliative 
care = morphines, treatment of metastases, home based care by professionals. 
*Includes treatment of all stages (sugery, radiotherapy, AC regimen, tamoxifen).
Global contributions of this thesis
Our results on the cost-effectiveness of breast cancer control in the African sub-region 
E (Afr-E) and Southeast Asian sub-region D (Sear-D) (Chapter eight) demonstrated 
that interventions combining mammography screening and treatment of all breast 
cancer stages can have a cost-effectiveness ratio equal to or less than the GDP per 
capita and are thus cost effective. The estimated cost-effectiveness ratios were 2,696 
(Afr-E) and 4,596 (Sear-D) per DALY for mammography screening in the 50–69 age 
group with treatment of all stages.
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The analysis in Chapter eight includes only two high-mortality world sub-regions; 
however, the analysis does not include estimates of CBE screening or breast health 
awareness raising strategies and we furthermore have estimates for the other 12 
world sub-regions. These estimates can be used as a starting point for making choices 
on the wide spectrum of breast cancer control in countries for which country-specific 
estimates are currently unavailable. Pooling the results of all these sub-regions gives 
the rough average global costs and rough average global effectiveness estimates per 
patient (Figure 1). 
Figure 1. Global costs (US$) and effects (DALYs) per patient for breast cancer (2005 estimates)
From this figure, rough global cost-effectiveness estimates can also be derived. Costs 
for treatment of stage I, II, III, and IV breast cancer are about $558, $1,011, $2,864, and 
$26,850 per DALY, respectively; globally, late-stage breast cancer management (stages 
III and IV) is twice as expensive as early-stage breast cancer management (stages I and 
II). Treatment of all stages comes at a global cost of roughly $2,260 per DALY averted. 
For early detection strategies, the rough breast health awareness costs are $2,297 
(BAR) and $1,555 (MAR) per DALY. Population-based screening costs are $1,146 
(biennial CBE), $1,071 (triennial CBE), $1,398 (triennial mammography), and $1,574 
(biennial mammography) per DALY averted. 
Figure 1 shows that early detection strategies can improve the cost-effectiveness of 
healthcare spending globally. However, early detection strategies may require additional 
investments that are higher than the resources required for only the treatment 
of breast cancer (treatment of all stages, no early detection). From a healthcare 
perspective, investments in early detection strategies are not cost saving. Using 2005 
estimates, these additional investments range between $0.11 per capita (mass media 
awareness in Afr-E) and $5.26 per capita (biennial mammography screening in Western 
Pacific sub-region A). 
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Although additional investments for implementing early detection strategies can be 
substantial and may double breast cancer control expenditures, the health benefits 
to society that would accrue from these strategies - if implemented well and 
followed by appropriate treatment - would generally outweigh the additional costs. 
The average cost per unit of health spent will decrease because of early detection, 
allowing resources to be allocated more efficiently. Globally, in the absence of early 
detection strategies and when only treatment was available, about three DALYs 
would be averted per breast cancer patient. When early detection strategies would 
be implemented in combination with treatment the number of DALYs averted could 
increase threefold, to about 10 per breast cancer patient (Figure 1).
Implications for policymakers: Interventions that 
provide the greatest value for money
In LMICs, many breast cancer patients typically present with locally advanced 
or metastatic tumors. Shifting the stage distribution of the disease downward 
seems to be a necessary step toward improving health outcomes for these patients. 
The previous section argued that early detection strategies may increase the health 
of breast cancer populations threefold and that the cost per unit of health accrued 
by these strategies was lower than that of treatment only. Early detection strategies 
linked to appropriate treatment can therefore be considered relatively more cost-
effective than treatment only, and investments in early detection most likely ensure that 
resources are allocated more efficiently. 
From the perspective of cost-effectiveness, policymakers from LMICs should include 
early detection strategies in their national breast cancer control programs. Available 
diagnosis, treatment, and follow-up interventions are warranted, as these components 
are essential for the effectiveness of the entire breast cancer control program. 
In addition, screening interventions should always include an awareness-raising 
component to ensure an informed target population, proper breast health education 
for the general population, and adequate attendance rates. In general, all of these 
control components should be in place, and the lack of any component or referral 
system between these components could decrease the efficiency of the entire control 
program. 
Whether to choose MAR, CBE screening, mammography screening, or mixed screening 
for early detection in a specific LMIC or whether to provide aromatase inhibitors, 
taxanes, or trastuzumab seems to depend on the many country-specific inputs that 
affect the cost-effectiveness of these interventions. The previous section showed 
that CBE screening strategies (ages 40–69) seem cost-effective in most LMICs and 
mammography screening (ages 50–69) is only cost-effective in those countries with 
sufficient resources (GDP per capita over $4,000). Early detection linked to essential 
treatment (surgery, radiotherapy, AC chemotherapy, tamoxifen) seems cost-effective in 
all LMICs, and could be complemented by aromatase inhibitors.
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Providing taxanes or trastuzumab is generally not economically attractive unless 
LMICs have a GDP per capita over $6,000 or $8,000, respectively. Nevertheless, 
although the research presented in this thesis indicates that early detection strategies 
are cost-effective in a selection of LMICs, the current knowledge base for the costs 
and effects of breast cancer control strategies in many other LMICs is still inadequate. 
It is currently uncertain how early detection strategies will perform and how much 
they will cost if implemented in a specific LMIC. For example, important indicators 
such as attendance rates and sensitivity rates are often unavailable, but are essential 
in estimating the performance of screening programs (Chapter three). Hence, policy 
recommendations for specific LMICs based on the current cost-effectiveness evidence 
should be developed carefully and should account for some degree of uncertainty. 
Decision makers often base their choices on the cost-effectiveness of interventions, 
for which this thesis provides evidence. In addition to this efficiency consideration, 
a policy maker will need to carefully consider the financial burden of interventions, 
especially in resource-poor settings. Which breast cancer control strategies to provide 
in a particular LMIC seems to depend predominantly on the amount of resources 
available in a particular country. The previous sections showed that the economical 
attractiveness of breast cancer control interventions relates to the GDP per capita. 
These sections also showed that additional investments are required to implement 
early detection strategies linked to appropriate treatment, which may double current 
spending on breast cancer control. In particular, screening strategies may be considered 
too expensive in LMICs; thus, in the decision-making process, the budget impact of 
breast cancer control strategies should always be considered.
Furthermore, in addition to affordability considerations, other factors can be of 
significant importance in considering certain breast cancer control strategies. One 
of the most fundamental problems for policymakers in LMICs is the lack of good 
surveillance and monitoring systems to provide accurate data on the burden of breast 
cancer and its risk factors. Another problem is the lack of various system-level factors, 
such as a lack of trained personnel and cancer services to support early detection 
services. In addition, communicable diseases tend to be prevalent in LMICs, and it 
can be difficult for policymakers to divert resources from communicable diseases to 
non-communicable diseases. Moreover, early detection strategies may be unethical in 
countries in which treatment is unaffordable or inaccessible or is only accessible to a 
small affluent part of the population 12. 
In Chapter nine of this thesis, we explored the range of considerations for selecting 
breast cancer control strategies with international experts 13. Ten criteria, including 
definitions and potential scoring scales, were selected: effectiveness, quality of the 
evidence, magnitude of individual health impact, acceptability, cost-effectiveness, 
technical complexity, affordability, safety, geographical coverage, and accessibility. The 
most important outcome of this study for policymakers is a rating tool to measure the 
impact of breast cancer interventions based on all these criteria simultaneously. This 
type of approach, which is called multi-criteria decision analysis (MCDA), is known for 
its potentially broader application in setting priorities in healthcare 14,15. 
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Hence, what LMICs should provide in their breast cancer control programs should not 
only be based on the interventions that provide the greatest health for money but also 
the interventions that provide the greatest value for money. This means maximizing 
the utility of breast cancer control programs using a broader trade-off process that 
includes all valuable criteria. Although selecting and defining interventions and criteria 
for breast cancer control based on MCDA should be context-specific, our proposed 
rating tool can be a starting point for local policy makers in LMICs as part of a broader 
priority-setting process. 
Using more criteria than just cost-effectiveness; 
example for policymakers 
To demonstrate the use of our developed rating tool, a short implementation 
experiment was performed in Colombia. The approach used and the results from this 
experiment are discussed in Box 1 and could be useful to policymakers from other 
LMICs. 
Box 1. MCDA in practice: The case of Colombia
In this experiment, we estimated the value for money of fifteen breast cancer control interventions. The experiment 
was conducted in Colombia during a three-day cost-effectiveness policy workshop with a number of important 
Colombian policymakers, health professionals, and researchers. In the steps below we explain how the experiment 
was conducted.
Step 1: Fifteen breast cancer interventions were selected during a three-day cost-effectiveness workshop in Bogota 
(25 participants). Participants selected interventions form a predefined list that included early detection strategies 
as discussed in this thesis. Other interventions were added at the recommendation of a clinical expert group with 
experience on evidence-based guidelines for breast cancer. Next, relevant criteria were selected from a predefined 
list of 10 criteria as defined by our rating tool 13. The 25 participants selected eight criteria through an individual 
ranking exercise in which participants could distribute 100 points over 10 criteria. Two criteria (required budget and 
confidence in evidence) were excluded because the participants found these criteria stringent and wanted to use 
them in a later stage of the experiment.
Step 2: Using the Nominal Group Technique (25 participants), the definitions of the eight criteria and their scoring 
scales were improved. Each participant was provided with a sheet of paper with the preliminary definitions of the 
eight criteria and their scoring scales. Participants were asked to write down everything that came to mind when 
considering these definitions and to provide improved definitions. Then, all alternative definitions were recorded on 
a flip chart and discussed after all alternatives were listed. Participants were invited to provide verbal explanation or 
further details for any of the definitions their colleagues produced. This was eventually followed by an anonymous 
voting process in which each participant could vote for the best definition.
Step 3: To obtain the weights of each criterion, a discreet choice experiment was performed with 18 participants 
using software from 1000 Minds 16,17. Each participant was asked to answer a range of questions through the online 
environment, from which weights (utilities) for each criterion were automatically derived. The final criteria, definiti-
ons, scoring scales, and their weights are presented in Appendix Table A1; these could be used by other LMICs.
Step 4: Evidence was collected to analyze the extent of performance of the 15 interventions on each of the eight se-
lected criteria. Most of the evidence was derived from reviewing the international literature; where possible, Colom-
bian scientific literature was used. The evidence for all 15 interventions was analyzed by criterion by two researchers 
and summarized using a performance matrix. This performance matrix was completed through the online 1000 Minds 
environment to identify the interventions with the most value relative to other interventions17.
A visual representation of the results of the Colombian performance matrix (Figure 3) shows the total value 
(utility) of each intervention according to its performance on all eight criteria simultaneously (y-axis). These values 
are plotted along the required budget of each intervention (x-axis). The size of each bubble represents the level of 
uncertainty of each intervention’s total value; hence, interventions with overlapping bubbles could have similar values, 
making it unclear as to which intervention is preferable.
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Figure 3 shows that treatment interventions a1 to a4 (aromatase inhibitors or switch therapy in stages I and II) 
have the greatest value for money. Since the bubbles of these interventions overlap, it is difficult to distinguish the 
values of these interventions, and all of them could be recommended. The figure also shows that with regard to early 
detection interventions, biennial CBE screening in women aged 40–49 provides the greatest value for money (a5). 
Intervention a6 (triennial CBE screening in women aged 40–49 + mammography screening in women aged 50–69) is 
the second-best option.
Hence, when more criteria than just cost-effectiveness are considered simultaneously in Colombia, this experiment 
indicates that CBE screening strategies (ages 40–69) should receive even greater priority in LMICs and that aromata-
se inhibitors could be provided in addition to essential treatment. Providing mammography screening, taxanes, and 
trastuzumab should be given less priority in LMICs. The total value for money was based on eight relevant criteria: 
cost-effectiveness, number of potential beneficiaries, safety, acceptability, effectiveness, geographical coverage, severity 
of the health condition, and technical complexity. This proposed MCDA approach could therefore be more realistic, 
integrated, and useful in practice for decision making on breast cancer control.
Figure 2. Values (utilities) of 15 breast cancer interventions based on the proposed MCDA approach in Colombia.
a1:Treatment + aromatase inhibitors for hormonal positive women in stage I a2: Treatment + aromatase inhibitors for hormonal positive women in 
stage II a3: Treatment + switch therapy for hormonal positive women in stage I a4: Treamtent + switch therapy for hormonal positive women in stage II 
a5: Biennial CBE screening in women aged 40-69 + treatment of all stages a6: Triennial CBE screening in women aged 40-69 + mammography scree-
ning in women aged 50-69 + treatment of all stages a7: Biennial CBE screening in women aged 40-49 + mammography screening in women aged 
50-69 + treatment of all stages  a8: Biennial mammography screening in women aged 50-69 + treatment of all stages a9: Treamtent + trastuzumab 
for HER2 positive breast cancer in stage I  a10: Treatment + trastuzumab for HER2 positive breast cancer in stage IIa  a11: Biennial mammography 
screening in women aged 40-69 + treatment of all stages a12: Opportunistic mammography screening in women aged 50-69 + treatment of all 
stages a13: Treatment + trastuzumab for HER2 positive breast cancer in stage IV a14: Treament + Lapatinib + Trastuzumab for HER2 positive breast 
cancer in stage IV a15: Treatment + Lapatinib for HER2 positive breast cancer in stage IV
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The arguments and the proposed approach in this section indicate that cost-
effectiveness analyses based on the maximization of health benefits may help 
governments select breast cancer control strategies. However, policymakers often 
deviate from CEA results because other principles and (ignorance of) these principles 
may lead to sub-optimal priorities. The results from Chapter nine showed that cost-
effectiveness is as important as the effectiveness criterion. The results from our 
Colombian experiment show that cost-effectiveness is less important than two other 
criteria, number of potential beneficiaries and safety (Appendix Table A1). This confirms 
that more criteria should be considered than just cost-effectiveness in deciding which 
breast cancer control interventions should be given the highest priority. The approach 
proposed above and the tools presented in this thesis should be used as one part 
of a broader priority setting approach in a local setting (Figure 4, steps 2 and 3). This 
broader approach requires the setup of a multi-stakeholder consultation panel and a 
democratic learning process in which local stakeholders are involved in all the priority-
setting steps 13,18. This broader approach fosters broad acceptance of the prioritized 
intervention among all stakeholders and the actual implementation of the intervention.
Figure 3. Broader MCDA apporoach for priotiry setting of breast cancer control interventions 18
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Limitations of this thesis and future research
The studies presented in this thesis have a number of limitations, and future research 
should try to address these. First and most important, evidence from high-quality 
experimental studies on the costs and effectiveness of early detection strategies 
is currently lacking in most LMICs 1,12. At present, only one randomized controlled 
trial has investigated an early detection strategy for breast cancer control in a LMIC 
19. Observational studies are available but are difficult to interpret. To arrive at the 
cost-effectiveness estimates in this thesis, we used a model approach that only has a 
theoretical proof of concept, and the extrapolation of our model to other settings 
(external validity) is not yet proven (Chapter three). The economic evidence provided 
in this thesis is therefore subject to many assumptions, and this may have biased our 
estimates. There seems to be a general lack of evidence on (less established) early 
detection interventions such as awareness-raising and screening by tactile imaging, 
ultrasound, breath tests, or CBE screening. However, there is also a lack of studies on 
shorter follow-up and diagnostic work-up management schemes as well as preventive 
and palliative interventions. It is necessary to evaluate these types of interventions, 
particularly in LMICs, as they have the potential to be economically attractive 12,20–22.
Second, national cancer registries in the LMICs for which cost-effectiveness estimates 
are provided in this thesis were often unavailable or not fully functional (for Ghana, 
Peru, India, and Mexico). Local data on breast cancer epidemiology, survival, and breast 
cancer stage distributions were derived from different sources, although often from 
composite hospital data from the (urban) public sector. Likewise, practice and unit cost 
variation are very likely within our analyzed countries and were also often derived 
from the public sector. For example, within Peru, there are noticeable variations in 
breast cancer treatment procedures, which differed by hospital or health maintenance 
organization. Since our data is based on patients and practices in urban areas and the 
public sector rather than on all patients, our cost-effectiveness estimates may not be 
representative of the whole country. As cancer registries provide essential information 
on the cancer burden, understanding the causes of cancer, the prospects for cancer 
control, and potentially costs, these limitations indicate the need to start national 
functional, population-based cancer registries in LMICs. Support could, for example, be 
offered by the Global Initiative for Cancer Registry Development 23,24.
Third, a key aspect in the WHO-CHOICE models applied in our cost-effectiveness 
studies is the relationship between early detection and improved breast cancer stage 
distributions (and eventual health outcomes). A proof of concept of the relationship 
between early detection strategies and breast cancer stage distribution is presented 
in Chapter three. However, there currently is no external validation of the proposed 
model in this chapter and it is therefore uncertain whether the model can be applied 
to LMICs. Also, in the relationship between early detection and breast cancer stage 
distribution we did not account for the effects of early detection strategies on (stage-
specific) incidence rates.
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Other modeling studies have indicated that the observed breast cancer incidence will 
significantly increase as a result of breast cancer screening, and this is likely also true 
for other early detection strategies. This increase in breast cancer incidence can be 
the result of diagnosing additional stage-I cancers, but it does not necessarily mean a 
reduction of the absolute numbers of stages III and IV cancers and, correspondingly, 
improved breast cancer stage distribution. The cost-effectiveness estimates presented 
in this thesis could therefore be biased and could be too optimistic in general. 
Despite these limitations, the results of our model show similarities with results from 
other models 8,25,26, and these limitations fit with our overall aim to inform general 
policy discussions by proving the broad cost-effectiveness indications of a range of 
comprehensive interventions. More precise estimates of the effectiveness of breast 
cancer screening interventions through more detailed breast cancer models are 
important 27,28. This could, for example, be achieved by linking our detailed WHO-
CHOICE costing estimates with the MISCAN model. 
Fourth, a healthcare perspective has been used in the cost-effectiveness analyses in this 
thesis, and the travel costs or productivity losses of patients seeking or undergoing care 
were not included. The healthcare perspective is the most commonly used perspective 
in economic evaluations presented in this thesis. Including these costs would probably 
lead to increased costs and savings generally and different cost patterns 29. Although 
cost-effectiveness analyses using a health care perspective contribute very important 
information, productivity losses for patients suffering from breast cancer (and, most 
likely, other non-communicable diseases) are substantial 29,30. Previous studies have 
indicated that healthcare costs account for 45% of the total costs associated with 
breast cancer. Non-healthcare costs seem to be generally larger (about 55%) 
compared to healthcare costs since breast cancer commonly occurs in women during 
their reproductive lifespan, especially in LMICs 31,32. Future research should be more 
inclusive by using a societal perspective and investigating productivity losses.
Fifth, the recommendations in the presented cost-effectiveness studies are subject 
to a hypothetical cost-effectiveness threshold that is not fully relevant in LMICs. The 
proposed threshold value is very generic (three times the GDP per capita per DALY) 
and does not apply to a specific context, to a specific moment in time, or under 
specific conditions. In reality, the threshold value is dynamic, and hence, the proposed 
cost-effectiveness threshold values should not be interpreted strictly. Although these 
thresholds can be still useful as a criterion in many decision-making processes, the 
results of cost-effectiveness studies should be presented in disaggregated form. Instead 
of concentrating on threshold values, future cost-effectiveness analyses should strive for 
transparency by presenting all input information used in a way that allows policymakers 
to verify the assumptions, view the uncertainties, and weigh the importance of the 
assumptions and uncertainties. 
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Sixth, as previously discussed, recommendations that are based solely on the 
cost-effectiveness of breast cancer interventions fall short to adequately inform 
policymakers. Future cost-effectiveness analyses should therefore be extended with 
broader types of analysis, such as MCDA. This broader approach could foster the 
broad acceptance of decisions and increase the likelihood that prioritized breast cancer 
control strategies will be implemented.
Concluding remarks
Breast cancer and other cancers affect many people worldwide. Breast cancer kills 
women, men, and even children and tears apart millions of families, particularly in 
LMICs. Because of a lack of access to early detection and treatment facilities, breast 
cancer is considered a death sentence in LMICs, and although much has been learned 
about the disease, little has been done for the thousands of women diagnosed each 
year with breast cancer in these countries. Women in LMICs could be saved if early 
detection linked to appropriate treatment were offered. 
This thesis provides recommendations on the types of early detection and treatment 
strategies that should be provided in these countries. It suggests that CBE screening 
strategies (ages 40–69) are cost-effective and can be recommended for LMICs. 
Breast health awareness-raising is an important component, although it could also 
be an economically attractive early detection strategy in itself. Even though additional 
investments for implementing these early detection strategies can be substantial, the 
health benefits to society will generally outweigh the additional costs.
This thesis confirms that when criteria beyond affordability and cost-effectiveness 
are considered, CBE screening strategies should be given priority in LMICs and 
aromatase inhibitors could be provided in addition to essential treatment. Providing 
mammography screening, taxanes, and trastuzumab should be given less priority in 
LMICs.
However, such interventions in LMICs require a great deal of time and money, and 
there seems to be enormous distance between the goal of saving thousands of women 
suffering from breast cancer each year and the reality of the limited possibilities in 
LMICs. This thesis propagates the message that progress in breast cancer control in 
LMICs lies not in an extension of state-of-the-art interventions, but in the knowledge 
of the limitations that LMICs face. Small steps should be taken in the right direction, 
and affordable and comprehensible interventions such as breast health awareness-
raising, CBE screening, surgery, radiotherapy and basic palliative care should be given 
first priority. 
General discussion 273
10
References
1.  Zelle SG,Baltussen RM. Economic analyses of breast 
cancer control in low- and middle-income coun-
tries: a systematic review. Syst Rev. 2013;2:20. Epub 
2013/04/10.
2. Niens LM, Zelle SG, Gutierrez-Delgado C, Rivera 
Pena G, Hidalgo Balarezo BR, Rodriguez Steller E, et al. 
Cost-effectiveness of breast cancer control strategies 
in Central America: the cases of Costa Rica and Mexi-
co. PLoS One. 2014;9(4):e95836. Epub 2014/04/29.
3. Zelle SG, Nyarko KM, Bosu WK, Aikins M, Niens LM, 
Lauer JA, et al. Costs, effects and cost-effectiveness of 
breast cancer control in Ghana. Trop Med Int Health. 
2012;17(8):1031-43. Epub 2012/07/20.
4. Zelle SG, Vidaurre T, Abugattas JE, Manrique JE, Sarria 
G, Jeronimo J, et al. Cost-effectiveness analysis of 
breast cancer control interventions in Peru. PLoS 
One. 2013;8(12):e82575. Epub 2013/12/19.
5. Fonseca M, Araujo GT,Saad ED. Cost-effectiveness of 
anastrozole, in comparison with tamoxifen, in the ad-
juvant treatment of early breast cancer in Brazil. Rev 
Assoc Med Bras. 2009;55(4):410-5. Epub 2009/09/15.
6. Bai Y, Ye M, Cao H, Ma X, Xu Y,Wu B. Economic eval-
uation of radiotherapy for early breast cancer after 
breast-conserving surgery in a health resource-limited 
setting. Breast Cancer Res Treat. 2012;136(2):547-57. 
Epub 2012/10/12.
7. Liubao P, Xiaomin W, Chongqing T, Karnon J, Gannong 
C, Jianhe L, et al. Cost-effectiveness analysis of adju-
vant therapy for operable breast cancer from a Chi-
nese perspective: doxorubicin plus cyclophosphamide 
versus docetaxel plus cyclophosphamide. Pharma-
coeconomics. 2009;27(10):873-86. Epub 2009/10/07.
8. Okonkwo QL, Draisma G, der Kinderen A, Brown 
ML,de Koning HJ. Breast cancer screening policies in 
developing countries: a cost-effectiveness analysis for 
India. J Natl Cancer Inst. 2008;100(18):1290-300. Epub 
2008/09/11.
9. Salomon JA, Carvalho N, Gutierrez-Delgado C, 
Orozco R, Mancuso A, Hogan DR, et al. Intervention 
strategies to reduce the burden of non-communicable 
diseases in Mexico: cost effectiveness analysis. BMJ. 
2012;344:e355. Epub 2012/03/06.
10. Boutayeb S, Boutayeb A, Ahbeddou N, Boutayeb 
W, Ismail E, Tazi M, et al. Estimation of the cost of 
treatment by chemotherapy for early breast cancer 
in Morocco. Cost Eff Resour Alloc. 2010;8:16. Epub 
2010/09/11.
11. Love RR, Duc NB, Allred DC, Binh NC, Dinh NV, Kha 
NN, et al. Oophorectomy and tamoxifen adjuvant 
therapy in premenopausal Vietnamese and Chinese 
women with operable breast cancer. J Clin Oncol. 
2002;20(10):2559-66. Epub 2002/05/16.
12. Dey S. Preventing breast cancer in LMICs via 
screening and/or early detection: The real and the 
surreal. World J Clin Oncol. 2014;5(3):509-19. Epub 
2014/08/13.
13. Venhorst K, Zelle SG, Tromp N,Lauer JA. Multi-cri-
teria decision analysis of breast cancer control in 
low- and middle- income countries: development of 
a rating tool for policy makers. Cost Eff Resour Alloc. 
2014;12:13. Epub 2014/05/24.
14. Baltussen R,Niessen L. Priority setting of health inter-
ventions: the need for multi-criteria decision analysis. 
Cost Eff Resour Alloc. 2006;4:14. Epub 2006/08/23.
15. Ghandour R, Shoaibi A, Khatib R, Abu Rmeileh N, Unal 
B, Sozmen K, et al. Priority setting for the prevention 
and control of cardiovascular diseases: multi-criteria 
decision analysis in four eastern Mediterranean coun-
tries. Int J Public Health. 2014. Epub 2014/06/01.
16. Johnson SR, Naden RP, Fransen J, van den Hoogen F, 
Pope JE, Baron M, et al. Multicriteria decision analysis 
methods with 1000Minds for developing system-
ic sclerosis classification criteria. J Clin Epidemiol. 
2014;67(6):706-14. Epub 2014/04/12.
17. 1000 minds. Available from: http://www.1000minds.
com. Accessed 12 December 2014.
18. Baltussen R, Mikkelsen E, Tromp N, Hurtig A, Byskov 
J, Olsen O, et al. Balancing efficiency, equity and feasi-
bility of HIV treatment in South Africa - development 
of programmatic guidance. Cost Eff Resour Alloc. 
2013;11(1):26. Epub 2013/10/11.
19. Mittra I, Mishra GA, Singh S, Aranke S, Notani P, 
Badwe R, et al. A duster randomized, controlled trial 
of breast and cervix cancer screening in Mumbai, 
India: methodology and interim results after three 
rounds of screening. International Journal of Cancer. 
2010;126(4):976-984.
20. Al-Foheidi M, Al-Mansour MM,Ibrahim EM. Breast 
cancer screening: review of benefits and harms, and 
recommendations for developing and low-income 
countries. Medical Oncology. 2013;30(2).
21. Moss S. Screening for breast cancer in India - Is 
it an appropriate strategy? J Natl Cancer Inst. 
2008;100(18):1270-U3.
22. Sankaranarayanan R,Boffetta P. Research on cancer 
prevention, detection and management in low- and 
medium-income countries. Annals of Oncology. 
2010;21(10):1935-1943.
23. Global Initiative for Cancer Registry Development. 
Available from: http://gicr.iarc.fr/. Accessed 10 Decem-
ber 2014.
24. Bray G, Znaor A, Cueva P, Korir A, Swaminathan R, Ull-
rich A, et al. Planning and developing population-based 
cancer registration in low- and middle-income set-
tings. 2014.
25. Brown ML, Goldie SJ, Draisma G, Harford J,Lipscomb 
J, Health Service Interventions for Cancer Control in 
Developing Countries, in Disease Control Priorities in 
Developing Countries, D.T. Jamison, J.G. Breman, A.R. 
Measham, G. Alleyne, M. Claeson, D.B. Evans, et al., 
Editors. 2006: Washington (DC).
26. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de 
Koning HJ, Draisma G, et al. Effects of mammography 
screening under different screening schedules: model 
estimates of potential benefits and harms. Ann Intern 
Med. 2009;151(10):738-47. Epub 2009/11/19.
27. Habbema JD, Schechter CB, Cronin KA, Clarke 
LD,Feuer EJ. Modeling cancer natural history, epi-
demiology, and control: reflections on the CISNET 
breast group experience. J Natl Cancer Inst Monogr. 
2006(36):122-6. Epub 2006/10/13.
Chapter 10274
28. Karnon J, Goyder E, Tappenden P, McPhie S, Towers 
I, Brazier J, et al. A review and critique of modelling 
in prioritising and designing screening programmes. 
Health Technol Assess. 2007;11(52):iii-iv, ix-xi, 1-145. 
Epub 2007/11/23.
29. Broekx S, Den Hond E, Torfs R, Remacle A, Mertens 
R, D’Hooghe T, et al. The costs of breast cancer 
prior to and following diagnosis. Eur J Health Econ. 
2011;12(4):311-7. Epub 2010/03/23.
30. Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel 
S, Bloom LR,Fathima S. The Global Economic Burden 
of Non-communicable Diseases. Available from: www.
weforum.org/EconomicsOfNCD. Geneva: 2011.
31. Luengo-Fernandez R, Leal J, Gray A,Sullivan R. Eco-
nomic burden of cancer across the European Union: 
a population-based cost analysis. Lancet Oncology. 
2013;14(12):1165-1174.
32. Breakaway: The global burden of cancer - challenges 
and opportunities. A report from the Economist 
Intelligence Unit. 2009. Available from: http://graphics.
eiu.com/upload/eb/EIU_LIVESTRONG_Global_Can-
cer_Burden.pdf.
General discussion 275
10
Appendix of general discussion
Appendix Table A1. Criteria definitions, scoring scales and weights developed during the Colombian experiment. 
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1. Number of potential beneficiaries
Definition Levels Weight 
(as %)
The number of people with the health 
condition that are eligible for the inter-
vention. Per 100.000 of the Colombian 
populations.
0 <2 per 100.000 (per year) 0.0%
1 2 >< 5 per 100.000 (per year) 5.3%
2 5 >< 10 per 100.000 (per year) 9.1%
3 10 >< 15  per 100.000 (per year) 12.5%
4 > 15 per 100.000  in population per year) 16.7%
2. Safety
Definition Levels Weight 
(as %)
Safety is the practical certainty that 
adverse effects to patients or providers 
will not result from exposure to an 
intervention under defined circum-
stances.
0 there is a risk of severe adverse effects (life 
threatening) to patients or a risk of adverse 
effects (of any kind) to providers
0.0%
1 there is a risk of mild adverse effects to patients 
and/or to providers.
10.0%
2 there is no risk or a risk of very mild adverse 
effects (adverse effects which will completely 
recover within a month) to patients and/or to 
providers
15.6%
3. Cost-effectiveness
Definition Levels Weight 
(as %)
The capacity to produce the maximum 
output for a given monetary input.
0 not cost-effective (e.g. costs per gained healthy 
life year are above 3*Gross Domestic Product 
(GDP) per capita)
0.0%
1 cost-effective (e.g. costs per gained healthy life 
year are below 3*GDP per capita)
10.4%
2 highly cost-effective (e.g. costs per gained healt-
hy life year are below 1*GDP per capita)
15.1%
5. Effectiveness
Definition Size of the effect Weight 
(as %)
Effectiveness is the extent to which 
an intervention restores the health 
gap caused by the condition (e.g. the 
number of DALYs without the inter-
vention/number of DALYs with the 
intervention)
0 less effective (e.g. < 5% reduction of DALYs in a 
single patient)
0.0%
1 Moderate (e.g. 5><10% reduction of DALYs in 
a single patient)
6.9%
2  Very effective (e.g. >10% reduction of DALYs in 
a single patient)
12.2%
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6. Geographical coverage/area of living
Definition Levels Weight 
(as %)
The ability of the intervention to be 
reached by the target population, inde-
pendent of their living place or income 
(includes out of pocket expenditures)
0 the intervention does not cover or is too 
expensive to reach, for (most) people who live 
outside cities. More than 20% of the Colombian 
population
0.0%
1 the intervention does not cover or is too 
expensive to reach, for some people who live 
outside cities. Between 10% and 20% of the 
Colombian population
5.0%
2 the intervention covers (almost) all people in 
Colombia
11.3%
7. Severity of the health condition of patients targeted by intervention
Definition Levels Weight 
(as %)
The degree to which the condition 
affects a person's health lifetime by 
causing death, handicap, disability, any 
kind of suffering or pain. This includes 
emotional, mental, social and/or physio-
logical factors for both the patient and 
her family
0 not severe (healthy or including risk factors) 0.0%
1 severe (e.g. stage I or II breast cancer) 5.7%
2 very severe advanced breast cancer (e. g. stage 
III or IV breast cancer)
8.3%
8. Technical complexity
Definition Ability to train and deliver all clinical and organi-
zational requirements to run the intervention.
Weight 
(as %)
Other types of inputs required in addi-
tion to monetary inputs to implement 
and to keep providing the interven-
tion (These include human resource 
requirements, both quantitative and 
qualitative, and organizational require-
ments. The potential to integrate the 
intervention into an already existing 
health system should also be taken into 
account).
0 poor ability 0.0%
1 moderately good ability 4.5%
2 good ability 8.3%
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Thesis rationale
Breast cancer and other cancers are now leading causes of death and disability in 
low- and middle-income countries (LMICs). Although cancers were thought to be 
a problem almost exclusive to high-income countries (HICs), the breast cancer 
incidence is increasing in LMICs and the associated mortality is relatively high. While 
LMICs now bear the majority of the burden of breast cancer, their health systems 
are predominantly ill prepared to meet this challenge and there is an urgent need to 
identify cost-effective and affordable breast cancer control strategies in LMICs.
HICs have made major improvements in the fight against breast cancer, particularly 
in the past three decades. Much is known about the disease, and there has been a 
substantial increase in medical interventions, mostly in HICs, where more resources 
and infrastructure are available. Both breast cancer incidence and mortality have 
declined in HICs because of these interventions, which include enhanced awareness 
of signs and symptoms, earlier detection, and the availability of new and more effective 
treatment. Women in HICs who are diagnosed with breast cancer in an early stage of 
the disease can now reasonably expect to be cured and to live a disease-free life. 
Although much has been learned about breast cancer, little has been done for the 
thousands of women diagnosed with breast cancer each year in LMICs, where the 
disease is still considered a death sentence. These women could be saved if early 
detection linked to appropriate treatment were offered. However, this requires 
a well-functioning health system, skilled personnel, and modern equipment, and the 
interventions available in HICs cannot simply be realized in LMICs. Because of the 
different dynamics in population and the epidemiology of breast cancer, the relative 
effectiveness of these interventions is also unknown in LMICs. Moreover, the costs 
of breast cancer control interventions are a major constraint, adding to the complex 
discussion on how best to control the disease in LMICs.
Cost-effectiveness analysis (CEA) systematically compares the costs and effects of 
health interventions and can be a useful guiding tool in health care spending. CEAs 
can assist policymakers in LMICs with their decisions on national breast cancer control 
strategies by identifying which interventions provide the greatest value for money. 
This information is particularly important in LMICs, which often have fragile health 
systems and lack sustainable resources. Since this information is currently insufficient, 
the general objective of this thesis is to improve the knowledge base for the cost-
effectiveness of interventions for breast cancer control in LMICs. 
This thesis addresses a single research question (Chapter one) to reach this objective: 
What is the cost-effectiveness of a range of breast cancer control interventions along 
the continuum of care in a number of LMICs? 
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To answer this research question, this thesis presents eight scientific studies. This thesis 
first provides a systematic review of available cost-effectiveness estimates for breast 
cancer control in LMICs (Chapter two). It then demonstrates a method to predict the 
stage distribution of different breast cancer screening options, which can be used to 
estimate the effectiveness of screening interventions (Chapter three). Four case studies 
are then presented that provide the costs, effects, and cost-effectiveness information 
of breast cancer control interventions in Ghana, Peru, Mexico, Costa Rica, and India 
(Chapters four to seven). More global cost-effectiveness estimates are presented in 
Chapter eight. To comprehensibly guide LMICs in improving breast cancer control, 
this thesis also focuses on other considerations next to cost-effectiveness. The last 
scientific study in this thesis therefore reflects on multiple relevant criteria, including 
cost-effectiveness, to support comprehensive breast cancer control strategies in LMICs 
(Chapter nine). These studies are discussed together in Chapter ten of this thesis.
Interventions that provide the greatest health for 
money: Contributions of this thesis
This thesis starts with a systematic review on available cost-effectiveness estimates for 
breast cancer control in LMICs (Chapter Two). Our review confirms that few health 
economic studies on breast cancer control have been conducted in LMICs and that 
this type of research in LMICs is still in its infancy. The results indicate the need for 
more economic analyses that are uniform and of better quality, analyses that cover 
a comprehensive set of interventions and result in clear policy recommendations. 
The review identified 24 economic studies that evaluated different kinds of screening, 
diagnostic, and therapeutic interventions in various age and risk groups in LMICs. Of 
these 24 studies, only seven presented functional cost-effectiveness results (from which 
cost-effectiveness ratios could be determined). These studies suggest that radiotherapy 
and surgery are very cost-effective ($233 and $351 per life-year saved, respectively) 
and that screening strategies may be economically attractive in LMICs (i.e., in India and 
Mexico, but not Morocco). However, these studies present very little evidence upon 
which to provide specific recommendations (on screening by mammography vs. clinical 
breast examination, the frequency of screening, or the target population). 
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As the current knowledge on the costs and effects of breast cancer control strategies 
in LMICs is limited, it is uncertain how early detection strategies will perform and 
how much they will cost in a specific LMIC. Chapter three therefore demonstrates 
a theoretical method to predict the stage distribution of different breast cancer 
screening options in LMICs. The amount of stage shift is an essential early detection 
indicator and an important proxy for the performance of screening programs and 
their possible further impact. The model can (in theory) be used to estimate the 
potential effect on the stage distribution of screening interventions in LMICs, and it 
uses default estimates for indicators such as attendance rates and sensitivity rates. 
The results of this chapter show that our model can be used to estimate the stage 
shifts of the Nijmegen Screening Program and provides proof of concept that it could 
also be adapted to other settings with different characteristics. Using hands-on data 
and formulas (i.e., y =0.45 + 0.9349*index Z), this model could provide important 
information on the performance of the breast cancer screening programs that LMICs 
consider implementing.
Chapter four presents a case study performed in Ghana. Studies on breast cancer 
in Ghana typically report poor stage distribution, survival, and awareness of breast 
cancer symptoms. The knowledge, beliefs, and social stigma of Ghanaians are important 
determinants of the late-stage presentation of breast cancer. These poor conditions 
highlight the need to improve breast cancer control policy in Ghana and address the 
needs of Ghana’s relatively young female population. Our analysis suggests that to be 
efficient, breast cancer control in Ghana should be oriented toward earlier detection. 
Biennial screening by clinical breast examination (CBE) of women aged 40–69 years, 
in combination with treatment of all stages, seems to be the most cost-effective 
intervention (costing $1,299 per DALY averted). Mass media awareness-raising 
(MAR) is the second-best option (costing $1,364 per DALY averted). Mammography 
screening of women aged 40–69 years (costing $12,908 per DALY averted) cannot be 
considered cost-effective.
Another case study was performed in Peru (Chapter five), where breast cancer has 
shown a persistent increase in incidence over the last decades and where many 
women present in advanced breast cancer stages. This detailed case study indicates 
that triennial screening strategies are the most cost-effective in Peru, particularly 
when a combination of fixed and mobile mammography screening is applied (from 
$4,125 per DALY averted). However, because of its high budget impact and challenging 
implementation characteristics, a combination of fixed and mobile mammography 
screening will only be preferable when Peru’s economic and health system conditions 
improve. CBE screening with upfront fine needle aspiration (FNA) in non-urban 
settings (age 40–69), combined with both CBE and fixed mammography screening in 
urban settings (age 40–69) could be a cost-effective and more feasible option for Peru 
in the near future (from $4,239 per DALY averted). Late-stage treatment, trastuzumab 
therapy, and annual screening strategies are the least cost-effective in Peru. 
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Chapter six reports on our analysis in Costa Rica and Mexico, two Central American 
countries. To improve their current breast cancer control programs, our analysis 
suggests that both Costa Rica and Mexico would benefit from implementing strategies 
that advance early detection. In Costa Rica, the current strategy of treating breast 
cancer in stages I to IV at an 80% coverage level seems to be the most cost-effective 
($4,739 per DALY averted). CBE screening could improve Costa Rica’s population 
health twofold and can would be very cost-effective ($5,964 per DALY averted). For 
Mexico, our results indicate that a mass media awareness raising program (MAR) 
could be most cost-effective ($5,021 per DALY averted). If more resources become 
available in Mexico, biennial mammography screening for women (age 50–70) would 
be recommended ($12,718 per DALY averted).
Breast cancer is an emerging public health problem in India and already causes a high 
burden of disease in this country. Costs of breast cancer treatment play an increasingly 
important role in India, as 59% of the total expenditure on health care is paid out 
of pocket. The largest costs are represented by drugs for systemic treatment; these 
are less accessible to Indian breast cancer patients. Thus, in Chapter seven, this 
thesis focused only on the impact of systemic drug prices on cost-effectiveness. This 
information can be used for drug price reductions to make breast cancer treatment 
more cost-effective and accessible. The results of this study suggest that AC1 or 
CMF1 chemotherapy regimes, combined with tamoxifen, can be cost-effective in 
India (from $1,840 per DALY averted). When more resources become available for 
breast cancer control in India, CAF1 combined with tamoxifen could be considered 
for implementation, as their ICERs are only slightly above the suggested threshold 
value ($5,102 per DALY averted). Trastuzumab prices need to decrease fifty-fold to be 
considered cost-effective in India.
Chapter eight reports on the cost-effectiveness of interventions to combat breast, 
cervical, and colorectal cancers in two world sub-regions with very high adult and child 
mortality. This study takes a wider (sectoral) and more global perspective and finds 
that a number of highly cost-effective interventions to combat cervical and colorectal 
cancer are available in Sub-Saharan Africa (AFR-E) and Southeast Asia (SEAR-D). 
For cervical cancer, these include screening through Pap smears or visual inspection 
with acetic acid in combination with treatment (from I$142 per DALY averted). For 
colorectal cancer, increasing treatment coverage is highly cost-effective (below I$2,000 
per DALY averted). For breast cancer control, mammography screening in combination 
with treatment of all stages is cost-effective (I$2,248–4,596 per DALY averted). It 
seems that screening for breast cancer control is relatively more cost-effective than 
screening for colorectal cancer but less cost-effective than cervical cancer screening.
1 AC = cyclophosphamide and doxorubicin; CMF = cyclophosphamide, methotrexate, fluorouracil; 
CAF = cyclophosphamide ,doxorubicin and fluoracil
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When the study in chapter eight is extended to all 14 world sub-regions, rough 
global cost-effectiveness ratios can be estimated (Chapter ten). These estimates can 
be used as a starting point for countries for which country-specific estimates are 
currently unavailable. Treatment of stage I, II, III, and IV breast cancer only about $558, 
$1,011, $2,864, and $26,850 per DALY averted, respectively. Globally, late-stage breast 
cancer management (stages III and IV) is twice as expensive as early-stage breast 
cancer management (stages I and II). Treatment of all stages comes at a global cost 
of roughly $2,260 per DALY averted. Early detection strategies trough breast health 
awareness raising costs $2,297 (BAR) and $1,555 (MAR) per DALY. Population-based 
screening costs of $1,146 (biennial CBE), $1,071 (triennial CBE), $1,398 (triennial 
mammography), and $1,574 (biennial mammography) per DALY averted.
If only treatment were available worldwide and early detection strategies were absent, 
the number of DALYs saved would be about three per breast cancer patient. When, 
next to treatment, early detection strategies are implemented, the number of DALYs 
may increase threefold, to about 10 per breast cancer patient. Although additional 
investments for implementing early detection strategies can be substantial and may 
double breast cancer control expenditures, the health benefits to society that would 
accrue from these strategies would outweigh the additional costs. The average cost 
per unit of health will decrease because of early detection, allowing resources to be 
allocated more efficiently. 
Interventions that provide the greatest value for 
money: Implications for policymakers
Whether to choose MAR, CBE screening, mammography screening, or mixed screening 
for early detection in a specific LMIC or whether to provide aromatase inhibitors, 
taxanes, or trastuzumab, seems to depend on the many country-specific inputs that 
define the cost-effectiveness of these interventions. CBE screening strategies (ages 
40–69) seem to be cost-effective in most LMICs and mammography screening (ages 
50–69) seems to be cost-effective only in those countries with sufficient resources 
(GDP per capita over $4,000). Early detection linked to essential treatment (surgery, 
radiotherapy, AC chemotherapy, tamoxifen) seems to be cost-effective in all LMICs and 
could be complemented with aromatase inhibitors. Providing taxanes or trastuzumab is 
generally not economically attractive unless LMICs have a GDP per capita over $6,000 
or $8,000, respectively.
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Information from CEAs may help governments select breast cancer control 
strategies to maximize health benefits. However, policymakers often deviate from 
CEA results because of other principles that are valuable to society. National breast 
cancer control programs should therefore not only be based on interventions that 
provide the greatest health for money but on those that provide the greatest value 
for money. This means maximizing the utility of breast cancer control programs on 
the basis of a broader trade-off process that includes all valuable criteria. This type of 
approach is called multi-criteria decision analysis (MCDA); Chapter nine of this thesis 
explored a range of considerations for selecting breast cancer control strategies with 
international experts. The results from this study confirm that effectiveness, quality of 
the evidence, magnitude of individual health impact, acceptability, cost-effectiveness, 
technical complexity, affordability, safety, geographical coverage, and accessibility are 
also important. Furthermore, a rating tool for policy makers to prioritize breast cancer 
interventions is proposed in this study.
To demonstrate the use of this rating tool, a short implementation experiment was 
performed in Colombia (Chapter ten). The value for money of fifteen Colombian 
breast cancer control interventions was estimated based on eight relevant criteria: 
cost-effectiveness, number of potential beneficiaries, safety, acceptability, effectiveness, 
geographical coverage, severity of the health condition, and technical complexity. This 
proposed MCDA approach could be more realistic, integrated, and useful in practice 
for decisions on breast cancer control. The most value for money is provided by 
aromatase inhibitor therapy or switch therapy in early-stage breast cancer. With regard 
to early detection interventions combined with treatment, biennial CBE screening in 
women aged 40–49 provides the most value for money. Triennial CBE screening in 
women aged 40–49 combined with mammography screening in women aged 50–69 is 
the second-best option for early detection in Colombia.
Conclusions
In an effort to reduce the high number of breast cancer deaths in LMICs, this thesis 
provides careful recommendations on the types of early detection and treatment 
strategies that should be provided in these countries. It finds that CBE screening 
strategies (ages 40–69) are cost-effective and can be recommended for LMICs. In 
this, breast health awareness raising is an important component, although it could also 
be an economically attractive early detection strategy in itself. Even though additional 
investments for implementing early detection strategies can be substantial, the health 
benefits to society will generally outweigh the additional costs and resources are 
allocated more efficiently.
Summary 285
When, in addition to affordability and cost-effectiveness, other criteria are considered 
simultaneously, this thesis confirms that CBE screening strategies should be given 
priority in LMICs and that aromatase inhibitors could be provided in addition to 
essential treatment. Providing mammography screening, taxanes, or trastuzumab should 
be given less priority in LMICs.
Nevertheless, all breast cancer control components - early detection, diagnosis, 
treatment, follow-up and palliative care - should be made available in LMICs because 
they are essential for the functioning of the breast cancer control program. If access 
to any of these components is lacking or if proper referral systems between these 
components are lacking, the quality and effectiveness of breast cancer control will 
decrease. This leaves societies in LMICs with the challenge of synchronously improving 
all these essential control components and keeping breast cancer services accessible to 
those who need them. These improvements require a great deal of time and money 
and are thus especially challenging for LMICs.
Thus there seems be a distance between the goal of saving thousands of women 
suffering from breast cancer each year and the reality of the limited possibilities 
in LMICs. Small steps should be taken in the right direction, and affordable and 
comprehensible interventions, such as breast health awareness-raising, CBE screening, 
surgery, radiotherapy and basic palliative care should first be given priority. Life is 
not always a matter of holding good cards, but sometimes of playing a poor hand well. 
The global community should now support these small steps, as the futures of many 
women living in LMICs and their families depends on what we do today. 
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Aanleiding van dit proefschrift
Borstkanker en andere vormen van kanker zijn een belangrijke oorzaak van ziekte 
en sterfte in lage- en middeninkomenslanden (LMIL’s). Hoewel kanker altijd is gezien 
als een probleem van hoge inkomenslanden (HIL’s), is het aantal borstkankergevallen 
in LMIL’s inmiddels fors toegenomen en is de sterfte aan borstkanker in deze landen 
onevenredig hoog. Tegenwoordig kennen LMIL’s daarmee de grootste ziektelast door 
borstkanker, maar zijn de gezondheidszorgsystemen in deze landen slecht voorbereid 
op de uitdagingen die deze ziekte stelt. Het is daarom de hoogste tijd dat deze landen 
kosteneffectieve en betaalbare strategieën voor het bestrijden van borstkanker 
vaststellen.
De HIL’s, waar meer financiële middelen en voorzieningen aanwezig zijn, hebben 
in de afgelopen drie decennia al grote sprongen vooruit kunnen maken in de strijd 
tegen borstkanker. Men is veel over de ziekte te weten gekomen en sindsdien 
is er een substantiële toename van medische interventies geweest. Door deze 
medische interventies, zoals onder andere het verbeteren van het bewustzijn van 
borstkankersignalen en symptomen, vroegtijdige opsporing, en het beschikbaar komen 
van verbeterde behandelmethoden, zijn zowel het aantal nieuwe borstkankergevallen 
en de sterfte aan borstkanker afgenomen. Vrouwen in HIL’s die de diagnose 
borstkanker krijgen in een vroegtijdig stadium, mogen tegenwoordig redelijkerwijs 
genezing van de ziekte verwachten.
Hoewel er veel kennis is vergaard over borstkanker, is er nog maar erg weinig gedaan 
voor de duizenden vrouwen die ieder jaar de diagnose borstkanker krijgen in LMIL’s, 
waar de ziekte nog steeds als een doodstraf geldt. Deze vrouwen kunnen worden 
gered van een gewisse dood als zou worden voorzien in een vroegtijdige opsporing 
gelinkt aan passende behandelingen. Echter, dit vereist een goed functionerend 
gezondheidszorgsysteem, competent personeel en moderne voorzieningen. De in 
HIL’s beschikbare interventies om borstkanker te bestrijden, kunnen niet zomaar in 
LMIL’s worden geïmplementeerd. Gezien de populatiedynamiek en de epidemiologie 
van borstkanker anders zijn in HIL’s, is de relatieve effectiviteit van deze interventies 
onbekend in LMIL’s. Bovendien kunnen de kosten van deze interventies een groot 
struikelblok vormen voor LMIL’s. Naast de overwegingen ten aanzien de effectiviteit van 
borstkankerinterventies, moeten kostenoverwegingen absoluut worden toegevoegd 
aan de lijst met lastig af te wegen criteria omtrent borstkankerbestrijding in LMIL’s.
In kosteneffectiviteitsanalyses (KEA’s), worden de kosten en effecten van interventies 
systematisch vergeleken. KEA’s kunnen daarom een erg nuttig en sturend instrument 
zijn in beslissingen rondom gezondheidszorguitgaven. KEA’s kunnen beleidsmakers in 
LMIL’s handvatten bieden voor beslissingen rondom borstkankerbestrijding, omdat 
ze de interventies aanwijzen die het meeste rendement (value for money) genereren. 
Juist in LMIL’s is deze informatie belangrijk, omdat deze landen vaak zeer fragile 
gezondheidszorgsystemen en een structureel gebrek aan financiële middelen hebben. 
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Omdat de informatie ten aanzien van de kosten en effecten van borstkankerbestrijding 
op dit moment ontbreekt, is dit proefschrift gericht op het vergroten van de kennis 
over de kosteneffectiviteit van borstkankerbestrijding in LMIL’s. Dit proefschrift richt 
zich derhalve op één onderzoeksvraag (hoofdstuk één): Wat is de kosteneffectiviteit 
van een aantal borstkankerbestrijdingsinterventies binnen het complete zorgcontinuüm, 
in een reeks LMIL’s?
Er worden in dit proefschrift acht wetenschappelijke studies gepresenteerd om 
deze onderzoeksvraag te beantwoorden. Allereerst wordt er een systematisch 
overzicht gegeven van de reeds beschikbare kosteneffectiviteitschattingen van 
borstkankerbestrijdingsinterventies in LMIL’s (hoofdstuk 2). Vervolgens wordt er een 
methode gepresenteerd om de stadiumdistributie van borstkanker te voorspellen, 
in het kader van verschillende opties voor borstkankerscreening (hoofdstuk 3). In 
hoofdstuk vier tot en met zeven worden vier casestudies beschreven met informatie 
over de kosten, effecten en kosteneffectiviteit van borstkankerbestrijdingsinterventies 
in Ghana, Peru, Mexico, Costa Rica en India. Meer globale kosteneffectiviteitsschattingen 
worden vervolgens aangeboden in hoofdstuk acht. Om LMIL’s op een allesomvattende 
manier te helpen met een verbetering van de borstkankerbestrijding, gaat 
dit proefschrift ook in op andere criteria naast kosteneffectiviteit. De laatste 
wetenschappelijke studie in dit proefschrift reflecteert daarom op meerdere relevante 
criteria voor het verbeteren van borstkankerbestrijdingsstrategieën in LMIL’s, waarvan 
kosteneffectiviteit er één van is (hoofdstuk 9). Alle bovenstaande studies worden 
gezamenlijk bediscussieerd in hoofdstuk 10.
Interventies die het meeste 
gezondheidsrendement (health for money) 
opleveren: bijdragen van dit proefschrift
Hoofdstuk twee van dit proefschrift geeft een systematisch overzicht van reeds 
beschikbare kosteneffectiviteitsschattingen voor borstkankerbestrijding in LMIL’s 
(hoofdstuk 2). Het systematische overzicht bestaat uit 24 economische studies 
die verschillende soorten screening, diagnostische en therapeutische interventies 
evalueerden in LMIL’s, binnen een verscheidenheid aan leeftijdsgroepen en 
risicogroepen. Uit slechts zeven van deze 24 studies konden functionele 
kosteneffectiviteitsresultaten worden afgeleid. Deze zeven studies suggereerden dat 
radiotherapie en chirurgie zeer kosteneffectief zijn (respectievelijk $233 en $351 per 
gewonnen levensjaar) en dat borstkankerscreening economisch aantrekkelijk kan zijn in 
LMIL’s (wel in India en Mexico, maar in Marokko niet).
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Deze studies leverden echter weinig bewijs op om specifieke aanbevelingen te 
doen voor borstkankerscreening in LMIL’s. Zo is het niet duidelijk of mammografie 
dan wel klinisch borstonderzoek (KBO) moet worden ingezet, of wat de frequentie 
van screening of de leeftijd van de doelpopulatie in deze landen moet zijn. Het 
overzicht bevestigt het heersende beeld dat er maar erg weinig gezondheids-
economische studies op het gebied van borstkankerbestrijding in LMIL’s zijn 
uitgevoerd, en ook dat dit type onderzoek nog in de kinderschoenen staat. Deze 
resultaten geven de noodzaak weer om meer economische studies uit te voeren in 
LMIL’s die meer uniform en van betere kwaliteit zijn. Daarnaast zouden deze studies 
een meer uitgebreide reeks aan interventies moeten analyseren en ook concretere 
beleidsboodschappen moeten genereren.
Gezien het feit dat de huidige kennis ten aanzien van de kosten en effecten van 
borstkankerbestrijdingsstrategieën beperkt is, blijft het onduidelijk wat de impact is 
van de vroegtijdige opsporing van borstkanker in LMIL’s en wat dit kost. In hoofdstuk 
drie leggen we daarom een theoretische methode voor om de stadiumdistributie, ten 
gevolge van verschillende borstkankerscreeningsopties, in LMIL’s te voorspellen. De 
mate van verandering in stadiumdistributie (stage shift) is een essentiële graadmeter 
in de vroegtijdige opsporing van borstkanker. Bovendien is deze stage shift een 
belangrijke voorwaarde voor het slagen van screeningsprogramma’s en hun mogelijke 
verdere impact. In theorie kan de voorgestelde methode worden gebruikt om het 
potentiele effect van screeningsinterventies op de stage shift in LMIL’s te schatten. Het 
model gebruikt ook waardevolle standaardwaarden, zoals waarden voor de opkomst 
en sensitiviteit van een screeningsprogramma, die ook gebruikt kunnen worden in 
andere studies. De resultaten van dit hoofdstuk laten zien dat ons model gebruikt kan 
worden om de stage shift van het Nijmeegse screeningsprogramma te bepalen, en 
laten daarnaast conceptueel bewijs zien dat het model ook gebruikt kan worden in 
landen met andere karakteristieken. Met direct te gebruiken data en formules (y =0.45 
+ 0.9349*index Z), kan ons model belangrijke informatie verschaffen wat betreft het 
potentiële vermogen van screeningsprogramma’s die LMIL’s overwegen in te zetten in 
de strijd tegen borstkanker.
Hoofdstuk vier van dit proefschrift beschrijft een casestudy die uitgevoerd is in 
Ghana. Studies naar borstkanker in Ghana typeren zich door het rapporteren van 
een slechte stadiumdistributie, slechte overlevingskansen en een laag bewustzijn ten 
aanzien van borstkankersignalen en symptomen. De kennis, overtuigingen en het 
sociale stigma van Ghanezen zijn belangrijke determinanten voor het late stadium 
waarin vrouwen met borstkanker zich presenteren. Deze slechte omstandigheden 
onderstrepen de noodzaak het borstkankerbeleid in Ghana te verbeteren en te 
voorzien in de behoeften van de relatief jonge, vrouwelijke bevolking van Ghana. 
Onze analyse suggereert dat, om efficiënt te zijn, borstkankerbestrijding in Ghana 
gericht moet worden op vroegtijdige opsporing van de ziekte. Tweejaarlijkse screening 
door middel van klinisch borstonderzoek (KBO) van vrouwen van 40 tot en met 69 
jaar, in combinatie met de behandeling van alle borstkanker gevallen, lijkt de meest 
kosteneffectieve interventie ($ 1,299 per vermeden Disablity Adjusted Life Year 
[DALY]).
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Bewustmaking door middel van massamedia daarna de beste optie ($ 1,364 per 
vermeden DALY). Screening van vrouwen in de leeftijdsgroep 40-69 door middel van 
mammografie kan niet beschouwd worden als kosteneffectief ($ 12,908 per vermeden 
DALY).
De volgende casestudy is uitgevoerd in Peru (hoofdstuk vijf). Peru is een land waarin 
een hardnekkige groei van het aantal borstkankergevallen zichtbaar is geworden in 
de afgelopen decennia, en waar veel vrouwen in een laat stadium gediagnosticeerd 
worden. Deze gedetailleerde casestudy geeft aan dat driejaarlijkse screeningsstrategieën 
het meest kosteneffectief zijn in Peru, vooral wanneer een combinatie van vaste en 
mobiele mammografie units wordt ingezet (vanaf $4,125 per vermeden DALY). Echter, 
door de hoge budgetvereisten en de uitdagende implementatie, zullen combinaties 
van vaste en mobiele mammografie-screeningsstrategieën pas aan te bevelen zijn 
wanneer de economische- en gezondheidszorgvoorwaarden van Peru verbeterd zijn. 
In de nabije toekomst zou een meer kosteneffectieve en haalbare optie voor Peru zijn: 
KBO screening voorafgaand met fijne naald aspiratie (FNA), in niet-stedelijke gebieden 
(leeftijdsgroep 40-69). Dit in combinatie met zowel KBE en vaste mammografie 
units in stedelijke gebieden (leeftijdsgroep 40-69). Het minst kosteneffectief in Peru 
zijn behandelingen met trastuzumab, het behandelen van patiënten in late stadia, of 
jaarlijkse screeningsstrategieën.
Hoofdstuk zes van dit proefschrift heeft betrekking op onze analyses in Costa Rica en 
Mexico. De analyses suggereren dat, om de huidige borstkankerbestrijdingsprogramma’s 
van deze landen te verbeteren, zowel Costa Rica en Mexico zouden kunnen profiteren 
van strategieën die de vroegtijdige opsporing van borstkanker bevorderen. In Costa 
Rica lijkt de huidige strategie, de behandeling van borstkanker in stadium I tot en 
met IV bij een 80% dekkingsgraad, het meest kosteneffectief te zijn ($ 4,739 per 
vermeden DALY). KBO screening zou de gezondheid van Costa Rica’s borstkanker 
patiënten echter kunnen verdubbelen en dit zou nog steeds zeer kosteneffectief zijn 
($ 5,964 per vermeden DALY). Onze resultaten laten zien dat voor Mexico mogelijk 
een massamediale bewustmakingscampagne het meest kosteneffectief is ($ 5,021 
per vermeden DALY). Als in de toekomst meer financiële middelen beschikbaar 
zouden komen in Mexico, kan tweejaarlijkse mammografiescreening voor vrouwen 
(leeftijdsgroep 50-70) worden aanbevolen ($ 12,718 per vermeden DALY).
Borstkanker is ook een opkomend probleem in India en veroorzaakt al een hoge 
ziektelast in dit land (hoofdstuk zeven). Kosten van de behandeling van borstkanker 
spelen een steeds belangrijkere rol in India, gezien 59% van de totale uitgaven aan 
gezondheidszorg wordt betaald door patiënten zelf (out of pocket). De grootste 
kostenpost voor borstkanker wordt bepaald door medicijnen voor systemische 
behandeling. Deze medicijnen zijn dan ook minder toegankelijk voor Indiase 
borstkankerpatiënten. In hoofdstuk zeven van dit proefschrift richten we ons daarom 
op de invloed van prijzen van systemische geneesmiddelen op de kosteneffectiviteit 
van borstkankerbehandelingen in India. Deze informatie zou kunnen worden gebruikt 
om de medicijnprijzen voor het behandelen van borstkanker te reduceren, ze meer 
toegankelijk en kosteneffectief te maken.
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De resultaten van deze casestudy geven aan dat AC1 of CMF1 chemotherapie 
kuren, gecombineerd met tamoxifen, kosteneffectief zijn in India (vanaf $ 1,840 
per vermeden DALY). Als er meer financiële middelen beschikbaar komen voor 
borstkankerbestrijding in India, kan CAF1 gecombineerd met tamoxifen overwogen 
kunnen worden voor implementatie ($ 5,102 per vermeden DALY). Trastuzumab 
prijzen moeten wel 50 keer goedkoper worden eer ze beschouwd kunnen worden als 
kosteneffectief in India.
In hoofdstuk acht behandelen we de kosteneffectiviteit van interventies voor de 
bestrijding van borstkanker, baarmoederhalskanker en dikke darmkanker. Deze studie 
is uitgevoerd voor Sub-Sahara Afrika (AFR-E) en Zuidoost-Azië (SEAR-D), twee sub 
regio’s van de wereld met een hoge kind- en volwassenensterfte. Dit onderzoek heeft, 
in vergelijking met de andere casestudies in dit proefschrift, een breder (sectoraal) en 
mondialer perspectief en laat zien dat er een aantal zeer kosteneffectieve interventies 
voor het bestrijden van kanker beschikbaar zijn in de onderzochte sub-regio’s. Voor 
baarmoederhalskanker is screening door middel van uitstrijkjes of visuele inspectie 
met azijnzuur, in combinatie met behandeling, zeer kosteneffectief (vanaf I$ 142 
per vermeden DALY). Voor dikke darmkanker is het uitbreiden van de dekking van 
behandelingen zeer kosteneffectief (minder dan I$ 2,000 per vermeden DALY). Voor 
borstkanker blijkt mammografiescreening in combinatie met de behandeling van alle 
stadia kosteneffectief te zijn (I$ 2,248-4,596 per vermeden DALY). Uit deze studie blijkt 
dat borstkankerscreening relatief kosteneffectiever is dan dikke darmkankerscreening, 
maar minder kosteneffectief dan baarmoederhalskankerscreening. 
In hoofdstuk 10 is de analyse uit hoofdstuk acht uitgebreid naar alle 14 wereld sub-
regio’s en zijn grove kosteneffectiviteitsratio’s geschat. Deze schattingen kunnen 
gebruikt worden als uitgangspunt voor landen waarvoor nauwkeurige schattingen 
op dit moment niet beschikbaar zijn. Uit onze analyses blijkt dat het behandelen van 
stadium I, II, III en IV borstkanker wereldwijd respectievelijk ongeveer $558, $1,011, 
$2,864, en $26,850 per vermeden DALY kost. De behandeling van borstkanker 
patiënten in een laat stadium (stadium III en IV) kost twee tot drie keer zoveel als 
het behandelen van patiënten in een vroeg stadium van de ziekte (stadium I en II). 
Het behandelen van alle stadia kost wereldwijd ongeveer $2,260 per vermeden 
DALY. Strategieën voor het vroegtijdig opsporen van borstkanker met behulp van 
bewustwordingscampagnes kosten ongeveer $2,297 (basic awareness raising) and 
$1,555 (mass-media awareness raising) per vermeden DALY. Het screenen van 
populaties op borstkanker kost ongeveer $1,146 (tweejaarlijkse KBO), $1,071 
(driejaarlijkse KBO), $1,398 (driejaarlijkse mammografie) en $1,574 (tweejaarlijkse 
mammografie) per vermeden DALY.
1  AC = cyclofosfamide en doxorubicine; CMF = cyclofosfamide, methotrexaat, fluorouracil;
CAF= cyclofosfamide, doxorubicine en fluorouracil
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Als er alleen borstkankerbehandeling beschikbaar zou zijn in de wereld zijn en er 
geen vroegtijdige opsporingsstrategieën aanwezig zouden zijn, dan zou het aantal 
vermeden DALYs per borstkankerpatiënt ongeveer op drie uitkomen. Als hieraan een 
vroegtijdige opsporingsstrategie zouden worden toegevoegd, zou het aantal vermeden 
DALYs in drievoud toenemen naar ongeveer 10 per patiënt. Hoewel investeringen 
in het vroegtijdig opsporen van borstkanker aanzienlijk kunnen zijn en hierdoor 
de uitgaven aan borstkankerbestrijding kunnen verdubbelen, wegen de voordelen 
voor de gezondheid die voortvloeien uit vroegtijdige opsporing op tegen de extra 
investeringskosten. Er kan dus wereldwijd worden vastgesteld dat door vroegtijdige 
opsporing van borstkanker, de gemiddelde kosten per gezondheidseenheid omlaag 
worden gebracht en het geld efficiënter wordt besteed.
Interventies die het meeste waarde rendement 
(value for money) opleveren: implicaties voor 
beleidsmakers
Het kiezen van massamedia campagnes, KBO screening, mammografiescreening voor 
de vroegtijdige opsporing van borstkanker, of het kiezen van aromataseremmers, 
taxanen, of trastuzumab voor borstkanker behandeling, lijkt af te hangen van de vele 
specifieke karakteristieken die LMIL’s hebben. Deze land-specifieke karakteristieken 
bepalen in grote mate de kosteneffectiviteit van borstkankerbestrijdingsinterventies. Zo 
lijkt in de meeste LMIL’s KBO screening (leeftijdsgroep 40-69) het meest kosteneffectief 
te zijn en lijkt mammografiescreening (leeftijdsgroep 50-69) alleen kosteneffectief te 
zijn in landen met voldoende financiële middelen (BBP per inwoner meer dan $ 4,000). 
Vroegtijdige opsporingsstrategieën gekoppeld aan essentiële behandeling (chirurgie, 
radiotherapie, AC chemotherapie, tamoxifen) lijkt kosteneffectief te zijn in alle LMIL’s 
en hier kunnen eventueel, afhankelijk van het beschikbare budget van het land, kuren 
met aromataseremmers aan worden toegevoegd. Het verstrekken van taxanen of 
trastuzumab is over het algemeen niet economisch aantrekkelijk, tenzij het BBP per 
inwoner van een LMIL meer telt dan respectievelijk $ 6,000 of $ 8,000.
Informatie van KEA’s kunnen overheden helpen om borstkankerbestrijdingsstrategieën 
te kiezen op basis van gezondheidsrendement (health for money). Beleidsmakers 
wijken echter vaak af van de resultaten van KEA’s, vanwege andere basisprincipes 
die waarde hebben voor de samenleving die ze vertegenwoordigen. 
Borstkankerbestrijdingsstrategieën moeten daarom niet alleen maar bestaan uit 
interventies die zorgen voor het meeste gezondheidsrendement, maar bestaan 
uit interventies die het meeste waarde-rendement genereren (value for money). 
De waarde van borstkankerbestrijdingsprogramma’s zou eigenlijk gemaximaliseerd 
moeten worden op basis van een breder afwegingsproces, dat rekening houdt met 
alle existerende, waardevolle criteria in de samenleving. Dit proces wordt ook wel een 
multi-criteria besluitvormingsanalyse (MCBA) genoemd. 
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In hoofdstuk negen van dit proefschrift zijn daarom met internationale experts een 
aantal criteria voor het kiezen van borstkankerbestrijdingsstrategieën onderzocht. 
De resultaten van deze studie bevestigen dat er, naast kosteneffectiviteit, andere 
belangrijke criteria een rol spelen het afwegingsproces, namelijk: effectiviteit, sterkte 
van het bewijs, omvang van de individuele gezondheidswinst, aanvaardbaarheid, 
kosteneffectiviteit, technische complexiteit, betaalbaarheid, veiligheid, geografische 
dekking en toegankelijkheid. Om borstkankerinterventies te kunnen prioriteren op hun 
volledige waarde-rendement, is er ook een waarderingsinstrument voor beleidsmakers 
ontwikkeld in deze studie. 
Om het gebruik van dit waarderingsinstrument te testen is er bovendien 
een kort onderzoek in Colombia uitgevoerd (hoofdstuk 10). Tijdens dit 
onderzoek zijn de kosten-waardeverhoudingen van vijftien Colombiaanse 
borstkankerbestrijdingsinterventies geschat, op basis van acht relevante criteria 
(kosteneffectiviteit, aantal begunstigden, veiligheid, aanvaardbaarheid, effectiviteit, 
geografische dekking, ernst van de gezondheidstoestand, en technische complexiteit). 
Deze MCBA aanpak zou tot meer realistische, geïntegreerde en praktisch bruikbare 
beslissingen over borstkankerbestrijding kunnen leiden. Uit dit onderzoek blijkt dat 
het meeste waarde-rendement kan worden toegekend aan behandeling in een vroeg 
stadium van borstkanker met aromataseremmers of switch therapie. Wat betref 
vroegtijdige opsporingsinterventies gecombineerd met behandeling, biedt tweejarige 
KBO screening (vrouwen 40-69 jaar) de meeste waarde voor geld. Driejaarlijkse KBO 
screening (vrouwen 40-49 jaar) in combinatie met mammografie (vrouwen 50-69 
jaar) is daarna de meest (waarde-)renderende vroegtijdige opsporingsinterventie in 
Colombia.
Conclusies
In een poging om de hoge ziektelast van borstkanker in LMIL’s te verminderen, 
worden er in dit proefschrift zorgvuldige aanbevelingen gedaan omtrent 
borstkankerbestrijdingsinterventies die in deze landen geïmplementeerd kunnen 
worden. De bevindingen van dit proefschrift laten zien dat screeningsinterventies 
door middel van klinisch borstonderzoek (KBO) kosteneffectief zijn (leeftijdsgroep 40-
69) en voor de meeste LMIL’s aan te bevelen zijn. Een belangrijk onderdeel van deze 
screeningsinterventies is het bewustmaken van borstkankersignalen en symptomen 
bij de te bereiken doelgroep. Om borstkanker vroegtijdig op te sporen, kan dit 
echter ook een economisch aantrekkelijke interventie op zichzelf zijn. Hoewel de 
extra investeringen voor het uitvoeren van deze vroegtijdige opsporingsinterventies 
aanzienlijk kunnen zijn, zijn de gezondheidsvoordelen voor de samenleving in het 
algemeen omvangrijker dan de extra kosten. Door deze interventies in LMIL’s toe te 
passen, worden de beschikbare middelen in deze landen dus efficiënter ingezet.
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Wanneer naast betaalbaarheid en kosteneffectiviteit, tegelijkertijd ook andere criteria 
worden meegenomen in het afwegingsproces, bevestigt dit proefschrift nogmaals dat 
screeningsinterventies door middel van KBO, in combinatie met de behandeling van 
borstkanker, prioriteit zouden moeten krijgen in LMIL’s. Aromataseremmers kunnen 
eventueel ook worden ingezet bij borstkankerbehandelingen. Borstkankerscreening 
door middel van mammografie, het inzetten van taxanen of trastuzumab bij 
borstkankerbehandelingen, zou minder prioriteit moeten krijgen in LMIL’s.
Desondanks zouden alle bouwstenen van borstkankerbestrijding (vroegtijdige 
opsporing, vroegtijdige diagnose, behandeling, follow-up en palliatieve zorg) voldoende 
beschikbaar moeten zijn in LMIL’s, gezien al deze bouwstenen essentieel zijn voor 
het functioneren van borstkankerbestrijdingsprogramma’s. Als de toegang tot één 
van deze bouwstenen ontoereikend is, of als adequate doorverwijzing tussen deze 
bouwstenen ontbreekt, zullen zowel de kwaliteit als de effectiviteit van het gehele 
borstkankerbestrijdingsprogramma afnemen. 
Deze aanbevelingen stellen LMILs voor de uitdaging om al deze onmisbare bouwstenen 
te verbeteren en tegelijkertijd de essentiële borstkanker services toegankelijker te 
maken voor degenen die ze nodig hebben. Dit kost veel tijd en geld en vraagt dus 
bijzonder veel van LMIL’s. Er lijkt dus een behoorlijke afstand te zijn tussen het doel 
om de duizenden vrouwen die ieder jaar weer sterven aan borstkanker te redden, en 
de realiteit van de beperkte mogelijkheden die er zijn in LMIL’s. Het enige dat LMIL’s 
kunnen doen, is om kleine stappen te nemen in de juiste richting en eerst prioriteit 
te geven aan betaalbare en integrale borstkankerinterventies zoals het bewustmaken 
van borstkankersignalen en symptomen, KBO screening, chirurgie, radiotherapie 
en eenvoudige palliatieve zorg. Life is not always a matter of holding good cards, but 
sometimes of playing a poor hand well. De internationale gemeenschap zou onmiddellijk 
moeten beginnen met het ondersteunen van deze kleine stappen, omdat de toekomst 
van vele vrouwen en hun families in LMIL’s afhangt van wat we vandaag de dag doen. 
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Alles komt terecht.
We zijn er nog niet,
maar we zijn onderweg
(Huub van der Lubbe)
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Het schrijven van het dankwoord van mijn proefschrift is een bijzonder moment. 
In 2010 ben ik begonnen met dit onderzoeksavontuur, een ontdekkingsreis naar 
onbekende oorden. Dit dankwoord betekent het einde van mijn avontuur. Ik heb nooit 
getwijfeld over deze ontdekkingsreis, omdat het mij kansen bood om aan de diepe 
behoefte naar het onbekende te voldoen. Bovendien ben ik er aan begonnen met de 
overtuiging om een positieve uitwerking op de bezochte landen te hebben op het 
gebied van borstkanker. 
Tijdens mijn reis viel het me zwaar deze uitwerking niet te voelen en me te wijden 
aan een wereld die soms alleen in je hoofd bestaat. Dat besef maakt het promoveren 
zwaar, laat je nietig voelen, als een religie waar elke bevestiging voor ontbreekt. Ook 
tijdens eerdere reizen merkte ik dat willekeur lijkt te regeren in de wereld en dat geen 
enkel individu hier echt invloed op lijkt te hebben. De Palestijnse taxichauffeur, de 
Colombiaanse indiaan, de Peruviaanse politieman en de Ghanese dominee hebben dit 
nogmaals bevestigd. Andere woorden in een andere taal, gloednieuwe beelden voor 
een heel ander verhaal. Waarom in deze jungle nog een wetenschappelijke waarheid 
verkondigen? 
Ondanks dit besef ben ik gelukkig de uitdagingen van deze ontdekkingsreis in 2010 
aangegaan en is het me gelukt een perspectief op de waarheid te vinden (slechts 
binnen het kader van borstkanker) en dit te verwerken in een proefschrift. Het is het 
resultaat van een succesvolle internationale samenwerking en was er niet geweest 
zonder de bijdrage van veel mensen. Deze mensen hebben mij allemaal, op hun eigen 
manier, vertrouwen en inzichten gegeven waarvoor ik ze erg dankbaar ben. Enkelen 
van hen wil ik graag in het bijzonder bedanken.
Mijn dank gaat allereerst uit naar mijn copromotor Dr. Rob Baltussen. Beste Rob, ik 
heb het geluk gehad je tegen te komen op het juiste moment en had me geen betere 
wetenschappelijke ‘vader’ kunnen voorstellen. Ik kan me ons eerste (serieuze) gesprek 
in de kantine nog goed herinneren. In die tijd was ik nog een los projectiel en jou 
komt alle eer toe dat je toen mijn interesse hebt weten te wekken voor dit avontuur 
en het lef hebt gehad om met mij in zee te gaan. Ik heb ontzettend veel opgestoken 
van je en waardeer het ontzettend dat je me hoge kwaliteit en frequente begeleiding 
hebt gegeven. Nog meer waardeer ik de menselijkheid die je uitdraagt en je kwetsbare 
opstelling, waardoor ik heb kunnen inzien dat mijn ontdekkingsreis er niet één is met 
slechts fysieke en intelligente uitdagingen. Je hebt me vaak richting gegeven wanneer 
ik op een zijspoor belandde en je stuitte dan vaak op de nodige weerstand. Ondanks 
mijn weerstand heb je me de ruimte gegeven om af en toe van het pad af te wijken, 
maar heb je me voor het diep verdwalen in het wetenschappelijke woud weten te 
behoeden. Al die tijd heb je me het gevoel gegeven dat het thuisfront en het trouw 
blijven aan jezelf, minstens zo belangrijk zijn als wetenschappelijke zorgvuldigheid. Je 
bent een aangename reisgenoot van me geworden in letterlijke zin in Geneve, Ghana, 
Jordanië, maar bent daarnaast ook een wegwijzer in de reis naar het ouder worden. 
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Prof. van der Velden, mijn promotor, beste Koos, het was fijn om ook een niet-
inhoudelijke gids te hebben. Ik doe je kennis op het gebied van borstkanker nu 
waarschijnlijk te kort, maar onze gesprekken gingen vooral over het wel en wee van 
de Nederlandse publieke gezondheidszorg, vakanties, de wetenschapsbijlage van het 
NRC en het gezinsleven. Ik begrijp nu nog steeds niet hoe je het doet, maar altijd als 
we elkaar spraken nam je uitgebreid de tijd voor mij, mijn ideeën en soms balorige 
opmerkingen. Toch lijkt tijd niet te bestaan in jouw aanwezigheid. Ik heb zeer veel 
waardering voor je flexibele, niet hiërarchische omgang en heb ook veel respect voor 
je vakkundigheid als ‘hoogwaardigheidsbekleder’. Bedankt voor de fijne gesprekken en 
je vrije geest.
Dr. Lauer, dear Jeremy, let me start with thanking you for your supervision in Geneva 
in 2009 (I never formally did this). It was the start of a very enjoyable relationship and, 
since then, we have been in contact almost every month. The two of us have been 
travelling to all countries in the Komen project and I really liked your presence during 
these country visits. Most of all, I enjoyed your appreciation for local food, liquors, 
dancing and ladies. I have also learned lots from your management skills, your talent for 
bridging problems and expressing yourself in charmingly formal language. 
Dr. Sepulveda, dear Cecilia, thank you for the very pleasant collaboration. I’ve never 
met someone with a greater public health mind and I am very grateful that I have had 
the chance to work with you. During our travels and the workshops you could always 
turn very technical or narrow minded conversations into conversations with heart, and 
you were able to bring up valuable examples from your rich background. I also have 
great respect for your attention to complications in the personal lives of people, I was 
often moved by that.
I want to thank the members of the manuscript committee, prof dr. Verbeek, prof 
dr. Smits and prof. dr. Anderson for the rapid and positive assessment of this thesis. 
Special thanks to prof. dr. Anderson, dear Ben, it has been a privilege working with you. 
Thank you very much for inviting me to Ghana for sharing your field experiences and 
network. This trip to Ghana was the start of my journey and has been a real revelation. 
Without your global contributions and your support to the international breast cancer 
community, this thesis would have probably looked quite different. I am very grateful to 
you for continuing to provide me with positive feedback and look forward to working 
with you in the future.
I am very thankful to all the investigators, doctors, ministry officials and WHO 
staff who have contributed to any of the studies in this thesis. Many of them have 
welcomed me to their departments, offices, hospitals and houses. Special thanks to 
Dr. Kofi Nyarko and Dr. Baffour Awuah from Ghana for their tireless efforts. Tatiana 
El-Kour from Jordan and the entire Jordan Breast Cancer Program team for keep on 
fighting. Dr. Oscar Boggia, Dr. Gustavo Sarria, Dr. Sonia Tavares, Dr. Julio Monreal, and 
Dr. Luis Medina Fernández from Peru for their great hospitality and delicious dinners! 
Dr. Monica Ortegon and Erika Leon from Colombia for taking the initiative. Dr. Aakash 
Raikwar from India for the (ongoing) pleasant Skype meetings.
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Beste Laurens, dr. Niëns, hoe uniek dat twee totaal onbekenden zich vijf weken lang 
zonder problemen kunnen begeven in luizige hotels zonder water en een eenpersoons 
bed. Bij het horen van de stem van Roy Orbison moet ik daar vaak aan terugdenken. 
Bedankt voor je geduld en je gastvrijheid al die jaren!
Natuurlijk zou ik ook graag mijn paranimfen willen bedanken. Dirk, dikke, wat een geluk 
dat je ook in Nijmegen bent gaan studeren en dat we, ondanks onze verschillen (je 
basisschool was immers Katholiek), zoveel kunnen delen. Onze hunker naar de Dijk, 
speklappen, voetbal, fietsen, de eeuwige twijfel en tegenwoordig ook ons nageslacht. 
Bedankt dat je van jongs af aan mijn reisgenoot bent geweest en dat je mijn paranimf 
wilt zijn! Dr. Viergever, beste Rik, wat fijn dat we ons in Geneve opgebouwd avontuur in 
Nijmegen konden voortzetten. Ik heb genoten van je werklust, je sociale houding ten 
opzichte van iedereen, je intelligentie en je neiging om iedere dag te borrelen. Het was 
heel goed om jou in de buurt te hebben op zware dagen!
Mijn directe collega’s bij NICHE met wie ik mijn reiservaringen heb mogen delen, 
Ernst Spaan, heel erg bedankt voor je persoonlijke aandacht en je invulling van feestjes 
met muziek, reisverslagen en Sumatraanse rendang. Francoise Barten, dank voor het 
verbinden van uiteenlopende personen en hun projecten, en voor je verhalen uit 
Suriname. Leon Bijlmakers, bedankt voor je initiatief en ervaring, je gastvrijheid en 
natuurlijk voor je groenten uit eigen tuin. Evelinn Mikkelsen, takk for being a great 
Viking and for your banana Amarula dishes. Noor Tromp, ontzettend bedankt voor 
je oprechte belangstelling en innemende persoonlijkheid. Het was heel fijn om af en 
toe mijn problemen te kunnen luchten en onze twijfels te constateren. Het was ook 
fantastisch om je te mogen bezoeken in Bandung. Bedankt daarvoor, je ben je een 
dierbare reisgenoot van me geworden. 
Special thanks to all NICHE ex-PhD students and affiliated staff. Sitaporn, Adi, Dereck, 
Mariana, Genevieve, Caroline, Filip, Jari, Jan, Evert, Henri, Francis, and Felix, for all the fun 
and dinners we had together. It was great to be surrounded by such many different 
cultures and minds during the course, and I hope to be seeing you in the future!
Mijn dank gaat ook uit naar Kristie Venhorst, Keyang Li en Julie van de Haterd. Jullie 
inzet tijdens diverse stageprojecten hebben een nadrukkelijke bijdrage geleverd 
aan dit proefschrift. Ik ben blij dat ik jullie begeleider heb mogen zijn. Daarnaast wil 
ik graag Nathalie Donders en Judith Bos bedanken voor de vele diners, feestjes, 
afdelingsweetjes en borrels (met name speciaalbiertjes). Jammer dat jullie nu weer zijn 
verhuisd. 
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Ik wil graag alle collega’s van AMPHI bedanken met wie ik de afgelopen jaren heb 
samengewerkt of een kamer heb gedeeld. Met name Helen, Stijn, Olga, Tamara, Sandra, 
Gerda, Jenneke, Guido, Kristine, Joni, Anne, Sietske, Gerard en Gerdine, bedankt 
voor jullie gemakkelijke omgang, oprechte aandacht en de leercurves die ik heb 
meegekregen. Eva en Emilie, bedankt voor het vaak aanhoren van mijn klaagzang, de 
gesprekken over kleine kinderen en voor het mij motiveren om te gaan hardlopen 
tijdens de lunchpauze. Minder dank voor het tarten van mijn eetlust met chocolade, 
cake en andere lekkernijen. Alma, John en Jeanine, ik vond het altijd erg prettig om af 
en toe adviezen te kunnen vragen aan jullie, te borrelen, te praten over onderwijs of 
onze internationale avonturen. Joris, ik ben erg blij dat ik jou al tijdens het begin van 
mijn promotie heb leren kennen en dat we nog steeds collega’s zijn. Wat ik vooral fijn 
vind is je attente en integere houding, maar natuurlijk blijven me ook de uitgestorven 
vrijdagen waarop we ons hebben vermaakt met borrels en lange gedachtewisselingen 
bij.
Tijdens mijn werkzaamheden heb ik me altijd erg goed vermaakt met alle promovendi 
en collega’s bij de afdeling Eerstelijnsgeneeskunde. Alle AIOTHO’s, Wouter, Hiske, Inge, 
Rhona, Karin, Willemijn, Jaap, Stephanie, Sabine, Franca, Claudia, Geertje, Maartje en 
Annette, heel hartelijk dank voor de refereeravonden, diners en kraamvisites. In het 
bijzonder wil ik Saskia, Vincent en Elza bedanken voor de band die we de afgelopen 
jaren hebben opgebouwd. Dank voor de vele conversaties over het leven, sport, 
verhuizingen, muziek, het delen van je auto en het nut van afval. Ook wil ik Tim olde 
Hartman, Kees de Kock, Erik Teunissen, Peter Lucassen, Lea Peters, Greetje Sagasser, 
Margret, en Fred Tromp bedanken voor hun fijne ‘ganggenootschap’ en de gesprekken 
over voetbal en kinderen bij de printer of de koffiemachine. Mijn overige ELG collega’s, 
Toine Lagro-Janssen, Henk Schers, Tjard Schermer, Lisette van den Bemt, Hans Bor, 
Reinier Akkermans, Waling Tiersma, Marion Biermans, Sharif Wardak, Earl Kortram, 
Sandra Boersma, Marianne Nicolasen, Chris van Weel en Pim Assendelft, bedankt voor 
jullie leiderschap, statistische inzicht, praatjes op symposia en de ruimte die jullie aan 
onderzoekers hebben geven. 
Een speciaal woord van dank aan het ELG secretariaat waar ik erg veel aan heb gehad. 
Twanny, Loes, Marike, Tilly en Caroline, ontzettend bedankt voor jullie slagvaardigheid 
en hulpvaardigheid al die jaren! Marike, ook heel erg bedankt voor alle tijd die je hebt 
gestopt in dit proefschrift. 
Mijn collega’s van Uniting Streams, Matthew, Linda, Anne, Guido, Remco en Joyce wil 
ik graag bedanken voor hun enthousiasme en bereidheid om het jaarlijkse congres te 
organiseren en iets van de grond te krijgen bij de altijd rondtrekkende achterban. 
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Wat ben ik blij dat ik tijdens deze ontdekkingsreis het genoegen heb gehad om altijd 
vrienden in de buurt te hebben. Vrienden om op bepaalde momenten je gevoelens 
mee te delen, je batterij op te laden, of gewoon helemaal lam mee te worden. Het 
is prachtig om het gevoel te hebben dat je niet alleen bent, je altijd wel iemand kunt 
bellen en er een soort onvoorwaardelijke band bestaat die lang geleden is gesmeed. 
Meer dan genoeg gelegenheden hebben zich voor gedaan om het leven te vieren, 
zoals optredens (Earring, de Dijk, Normaal), fustfeesten, verjaardagen, festivals, 
housewarmings, sportieve uitspattingen, spelletjesavonden, wintersport, weekendjes 
weg en kraamvisites. Jongens van de Eibergse Alliantie, Dirk, Jordey, Arend, Daniël, 
Jan-Willem, Bram, Dennis en Bart, heel erg bedankt dat jullie sinds jaar en dag een 
vriendengroep zijn waar ik altijd op kan terugvallen ondanks mijn vele afwezigheid. 
Inmiddels is ons aantal bijna verdubbeld en mogen we ons, ondanks onze soms 
ongezonde leefstijl (de 30 hebben we gelukkig allemaal gehaald), rijk rekenen met een 
omvangrijk nageslacht! Mijn oud-huisgenoten, Jelte, Arno, Vincent en Bram, met name 
bedankt voor het verruimen van mijn lichaam en geest met diverse genotmiddelen, 
filosofische gesprekken, en fysieke uitdagingen zoals hardlopen en boksen. Het is 
erg bijzonder dat we onze kwetsbaarheden zo goed van elkaar kennen na zo lang 
een studentenhuis gedeeld te hebben. Dat schept een hechte band en vormt een 
goede basis tegen het ‘zuur waarmee het leven soms beproefd wordt’. Ivo, onze reis 
naar Libië is er helaas nooit van gekomen. Met een beetje geluk hebben we in de 
toekomst een lange oprijlaan en kunnen we daar gewoon met onze Jeeps crossen. 
Ik heb genoten van je levenslust, je onnozele streken en je eigen gebrouwen bier. Rik, 
Sanne en Esther, wat fantastisch dat we met elkaar zijn beland in Geneve. We hebben 
daar een gouden tijd gehad maar zijn nu allemaal ineens in het lijzige academische 
circuit beland. Na onze promoties hoop ik graag de gouden tijden weer met jullie 
op te pakken. Dorothea en Max, bedankt voor jullie gezellige Indische etentjes en het 
beleven van ‘tempo doeloe’. Heren van UNIZVV, Kevin, Jasper, Hub, Jeroen, Michael en 
Wouter, heel hartelijk dank voor alle avondjes bij de ‘Chinees’, Maxim en de Extase. 
Ik vind het erg jammer dat ik heb moeten stoppen na al die jaren. Speciale dank aan 
Wouter, die als collega op de afdeling, geruime tijd gefungeerd heeft als mijn ‘geweten’. 
Gelukkig zijn de meeste e-mails van jou al in het archief beland en hoef ik er niet meer 
door afgeleid te worden. 
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Een bijzonder aandeel in mijn ontdekkingsreis heeft mijn familie en schoonfamilie. Mijn 
lieve familie Gunthardt, tante Mien en Joop, Tieken en Sjaak, Inez, Egbert en Dustin, 
tante Greet, Ed, Marlous en Jesper, Theo, Taew en Ginger, Henri, tante As en André, 
Meilyn en Lydia, Astrid(je), Vincent, Eva en Alice, oom Joos en oom Cor, en niet te 
vergeten oom Johan, Adrienne en mijn neefje Niels. We blijven een hechte familie met 
voorspoed en tegenslagen. Bedankt voor jullie warme gezelligheid en alle Indische 
lekkernijen. Familie Zelle, oom Johan, oom Herman en tante Anneke, oom Jacob en 
oom Rimmert, jullie ook erg bedankt voor jullie interesse en zorgzaamheid. Petra en 
Kees, Michelle en Joost, Midas en Felix, Walter en Marleen, Mees en Fien, Annemiek, 
Annemarie en de jongens. Met jullie heb ik er een geweldig lieve familie bij gekregen. 
Dankzij jullie ben ik gaan beseffen dat de ontwikkeling van een persoon in een nieuw 
en levendig seizoen belandt als je de dertig bent gepasseerd. De vele verjaardagen, 
paasbrunches, baabekjoes, zeiksnorverhalen en weekendjes weg hebben me altijd veel 
goed gedaan, dank daarvoor. 
Lieve zus, ik ben ontzettend blij dat ik zo’n goede band heb met jou. Deze band begon 
natuurlijk al in de wieg, lang voordat ik met dit avontuur begon. Je bazige buien als kind 
heb ik al lang niet meer meegemaakt en ik weet nog maar al te goed hoe jij, toen we 
ouder waren, pap en mam altijd probeerde af te leiden als ik weer eens boven de wc 
hing na een avondje stappen. Ik ben trots op je zuster! Je bent soms een voorbeeld 
voor me om sterk en opportuun te blijven maar daarnaast ben je ook een zorgzame 
moeder en gastvrouw. Ik ben ook supertrots op mijn lieve nichtjes Feere en Mae en 
hun vader Abe, mijn anti-tomaten werpende breur, en wil jullie graag zeggen dat ik het 
fantastisch vind om bij jullie te zijn. 
Pap en Mam, heel veel van wat ik heb bereikt heb ik aan jullie te danken. Jullie bijzijn bij 
mij als baby, kind, puber, student en vader zijn onmisbaar geweest. Ik begrijp nu pas een 
beetje wat het ouderschap inhoud en vind oprecht dat jullie het heel goed hebben 
gedaan met zijn tweeën! Jullie hebben de basis gegeven van mijn leven en me, naast 
alle flappen geld, al die tijd liefde en steun gegeven. Ik ben blij dat ik jullie zoon ben.
Lieve Othin, mijn kleine ventje, vergeef me alsjeblieft vast voor de fouten die ik ga 
maken. Door je aanstekelijke gebrabbel, gestuiter, snoekduiken en gelach, kan ik mijn 
enthousiasme voor jou soms moeilijk bedwingen. Ik zal je ooit nog wel eens vertellen 
over deze dag en zal je dan nog eens zeggen hoe blij ik ben met jou en je toekomstige 
zusje!
Lieve Bri. Het allermooiste dat ik heb overgehouden aan mijn promotie ben jij. Tijdens 
de cursus Academic Writing in het kasteeltje heb jij mij de liefde weer opnieuw 
ingeblazen. Wie had vijf jaar geleden ooit durven denken dat onze levens nu voor altijd 
verbonden zijn in Othin, onze prachtige zoon, en onze toekomstige dochter? Bedankt 
voor je ongelofelijke grote steun, vertrouwen en liefde. Al lijkt ons ‘paradijs’ soms erg 
ver weg, met jou aan mijn zij kan ik de hele wereld aan. Je tempert mijn bevliegingen, 
mijn fanatisme en mijn onredelijkheid en aanvaard mijn valse beschuldigingen en 
bromtorrenhumeur. Maar meer dan dat alles, laat jij me stilstaan bij waar het om gaat. 
Ik hoop dat mijn ontdekkingsreis met jou nooit een einde heeft. 
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